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Abstract 
The greatest challenge confronting effective tuberculosis (TB) eradication is the time to 
diagnosis, and duration of treatment of chronically infected individuals which represent a pool 
of infection. In an attempt to help limit the spread of TB in New Zealand, a fast SNP based 
diagnostic test was developed, to quickly identify the highly transmissible and virulent endemic 
Rangipo strain. The role of VapBC toxin-antitoxin systems in M. tuberculosis has been the 
subject of great interest recently, due to their expanded number in the genome and links with 
virulence and the regulation of cell growth in response to environmental stress. Their ability to 
regulate growth under adverse conditions for presumed survival advantages possibly leading 
to dormancy or persistence, make them ideal candidates for the development of new M. 
tuberculosis treatments. To establish differential expression of vapC, and therefore identify 
possible pathways and functions of the VapBC proteins, RT-qPCR was used to assess the 
expression levels of vapB and vapC in M. smegmatis under conditions of stress. No consistant 
changes in vapC mRNA levels were observed, resulting in the hypothesis that it is not the 
transcriptional differences which are important in the regulation of VapC, but post-
transcriptional factors. In order to investigate the function(s) of M. tuberculosis VapBCs, these 
VapBC proteins were expressed and purified in M. smegmatis, and the VapC toxin tested for 
RNase activity. The purification, expression, RNase testing and bioinformatic analysis of M. 
tuberculosis VapCs suggested that VapCRv2530c, VapCRv0065 and VapCRv0617 may all target the 
same recognition sequence, UA*GG. Bioinformatic analysis revealed an abundance of this 
target sequence in horizontal gene transfer and TA genes, raising the possibility that VapC 
toxins could be functioning as selfish elements, or initiating transcriptional regulation cascades 
when a rapid change in the proteomic response and metabolic state of the cell is required. It is 
intriguing that the three M. tuberculosis VapC proteins tested thus far appear to target the 
same recognition sequence, possibly suggesting that all 47 VapCs are RNases and are 
targeting the same sequence. Alternatively; VapCs may belong to sub-groups targeting 
different sequences, allowing M. tuberculosis to exude both gross and fine metabolic control; 
or, they may share the same target, but are regulated by different activators triggered in 
response to different environmental stimuli. 
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1 Chapter One: 
An Introduction to 
Tuberculosis and Toxin-
Antitoxin systems  
1.1 The Pathology of Disease 
Tuberculosis (TB) is an ancient disease responsible for the death of 1.3 million people in 2012 
(WHO 2013). Approximately one-third of the world’s population are thought to be infected with 
the tubercle bacilli, though only 5 – 10 % of infected individuals will develop active TB disease 
during their lives, in 2012 there were an estimated 8.6 million cases of active TB (WHO 2013). 
Most infected individuals will be asymptomatic, experiencing latent tuberculosis infection 
(LTBI), from which reactivation may occur at a later date, except in certain geographical areas 
where the risk of developing active disease is greatly increased due to HIV co-infection 
(Harries & Dye 2006). 
 
The rate of TB incidence at country level varies enormously, as illustrated in Figure 1.1. In 
2012, 58 % of the world’s TB cases occurred in the South-East Asia and Western Pacific 
regions, and approximately one quarter were from the African region. While India and China 
had the largest number of cases (26 % and 12 % of the global total, respectively), the African 
region contained the highest numbers of cases and deaths relative to population size 
(averaging 255 incident cases per 100,000, approximately double the global average of 122), 
with South Africa and Swaziland having the highest incidence rate per capita (approximately 
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1,000 per 100,000) (WHO 2013). The 2012 TB incidence rate in New Zealand (7.6 per 
100,000) was similar to other developed regions in parts of the Americas, several countries in 
western Europe, Japan and Australia, which all had fewer than 10 per 100,000 population 
(WHO 2013). 
 
 
Figure 1.1: Global estimated TB incidence rates for 2012. Figure obtained from the WHO Global 
Tuberculosis Report 2013. 
 
There are many factors which influence a person’s susceptibility to TB disease including poor 
living conditions, drug and alcohol abuse and immunosuppression, but non more so than the 
HIV pandemic. HIV infected individuals accounted for an estimated 13 % of the 8.6 million 
cases of TB in 2012 (with approximately 75 % of those occuring in the African Region) (WHO 
2013), and are more than 20 times more likely to reactivate TB than HIV negative individuals 
(Girardi et al. 2000).  
 
TB is an airborne disease which typically affects the lungs (pulmonary), but can infect most 
sites in the body (extrapulmonary) such as the central nervous system, lymph nodes, urinary 
tract, bones and joints. TB is caused primarily by the bacterium, Mycobacterium tuberculosis. 
M. tuberculosis is a member of the M. tuberculosis complex (MTBC), along with the very 
 3 
 
closely related mycobacterial species M. bovis, M. africanum, M. microti, M. caprae, M. 
pinnipedii, M. canetti and M. mungi which all cause tuberculosis in humans or animals. 
1.2 Organism 
M. tuberculosis is a Gram-positive, rod-shaped, non-motile aerobe of the order 
Actinomycetales. This bacterium has a characteristic hydrophobic cell wall which renders it 
acid-fast, and hinders the transfer of nutrients and waste into and out of the cell resulting in an 
extremely slow generation time of 15 - 20 hours. The impressively thick and complex cell wall 
(Figure 1.2) is composed of an inner plasma membrane, a unique large cell wall core, and an 
outer layer or capsule. The cell wall core structure contains layers of covalently linked 
peptidoglycan, arabinogalactan and mycolic acids which result in a hydrophobic permeability 
barrier making the mycobacteria resistant to detergents and a wide variety of antimicrobial 
agents. The outer part of the cell-wall core contains multiple free lipids including cord factor, 
and is covered by the capsule which consists mainly of polysaccharides (Brennan 2003;  
Zuber et al. 2008). 
 
 
 
Figure 1.2: Schematic of the M. tuberculosis cell wall structure. The cell wall is composed mainly of a 
large cell-wall core flanked on either side by an inner membrane, and a polysaccharide based outer 
capsule. The cell wall core is comprised of three covalently linked structures: peptidoglycan (grey), 
arabinogalactan (green) and mycolic acids (blue), covered by a layer of multiple free lipids including cord 
factor.  
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The bacilli vary in their size and shape from coccobacilli to long rods of 1 - 10 µm in length 
(generally 3 - 5 µm), and 0.2 - 0.6 µm in width (Velayati et al. 2009). Morphological variations 
such as: round, oval, V and Y-shape; stunted or extremely long bacilli; or bacilli with extra-
ordinary thick cell walls occur under conditions of stress such as starvation, hypoxia and old 
age, as well as in un-stressed but drug resistant strains (Ntolosi et al. 2001;  Velayati et al. 
2009;  Farnia et al. 2010;  Shleeva et al. 2011).  
 
Initial infection is caused by inhalation of bacilli which have been aerosolized by an infected 
person. The bacilli are engulfed by alveolar macrophages from where the majority of the bacilli 
are destroyed or inhibited. Some bacilli remain however, replicating intracellularly and are 
released when the macrophages die, spreading by way of the lymphatic system or 
bloodstream to other organs. Activation of the immune response however, slows replication of 
the bacilli within macrophages and in turn the bacilli become walled off within developing 
granulomas where they can persist for long periods of time. This is referred to as latent 
tuberculosis infection (LTBI). If a host’s immune system is compromised (by factors such as 
old age, malnutrition or co-infection with HIV), containment fails and the granulomas progress 
towards disease, becoming necrotic and eventually collapsing, in turn releasing the infectious 
bacilli into the airways (Russell 2007). 
 
Globally, there has been an increase in the number of cases of multidrug-resistant tuberculosis 
(MDR-TB), which have a much higher morbidity outcome than non-MDR-TB. In 2012 the 
morbidity outcome for MDR-TB cases was 37 % with an estimated 450,000 cases of MDR-TB 
and 170,000 deaths (WHO 2013) compared to 14.6 % for non-MDR-TB. 
 
1.3 Evolution of the M. tuberculosis genome 
The first Mycobacterium isolated was Mycobacterium leprae, and was done so almost 150 
years ago by Hansen, eight years before Robert Koch discovered the tubercle bacillus, M. 
tuberculosis in 1882. It was originally thought all mammalian tubercle bacilli originated from the 
same source, until in 1898 when Theobald Smith showed that bacilli isolated from humans 
were different morphologically to those isolated from cattle, and those isolated from swine, 
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horse and cat were “either identical with the bovine bacilli or very closely resembled them” 
(Smith 1898). M. tuberculosis was later designated as the typical human pathogen and M. 
bovis the animal pathogen, which is now believed to consist of a series of host-adapted 
ecotypes (Smith et al. 2006a;  Smith et al. 2006b) affecting animals such as seals (M. 
pinnipedii), mongooses (M. mungi), voles (M. microti) and goats (M. caprae). 
 
The MTBC is comprised of the typical human-associated pathogens M. tuberculosis and M. 
africanum, the so-called ‘smooth TB bacilli’ (including M. canettii), and the host-adapted 
ecotype lineages including M. bovis, M. microti, M. caprae, M. orygis, and M. pinnipedii. While 
M. tuberculosis has been isolated from other mammals, it has not been shown to be able to 
sustain its population (by animal-to-animal transmission) in any of these species, and similarly, 
while M. bovis can cause infection in humans, it does not readily transmit between them 
(Gagneux 2012). It was originally assumed that human TB strains had evolved from an animal 
origin (M. bovis) due to the expanded host range of the animal-associated MTBC. However, 
comparative genomic analyses has shown that the animal MTBC strains fit within the more 
diverse human MTBC strains, advocating the alternative scenario of animal MTBC strains 
evolving from a human origin (Gagneux et al. 2006;  Smith et al. 2006b;  Coscolla et al. 2013). 
 
One unique member of the MTBC is M. canettii. Along with the other ‘smooth TB bacilli’, M. 
canettii produces smooth and shiny colonies (not rough, characteristic of the rest of the MTBC) 
and is more genetically diverse. Unusually, M. canettii shows evidence of recombination via 
horizontal gene transfer - a trait considered not to occur for the rest of the M. tuberculosis 
complex (Supply et al. 2003;  Hirsh et al. 2004). Recombination was proposed as one possible 
explanation for an unusually high synonymous divergence rate observed between M. 
tuberculosis strains in one study, and homoplasies present within the intergenic regions in 
another study analysing single-nucleotide mutations (Gutacker et al. 2006), however these 
occurances on their own were not considered definitive evidence of recombination within 
strains belonging to the MTBC (Smith et al. 2006a), so as such M. tuberculosis is considered 
clonal and not to undergo recombination. A consequence of clonality is reduced diversity. 
Despite the MTBC adapting to different host species, these mycobacteria are extremely closely 
related displaying 99.9 % similarity at the nucleotide level, and possessing almost identical 
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16S rRNA sequences (Brosch et al. 2002). In fact, the MTBC bacilli exhibit such low sequence 
diversity they have been referred to as ‘genetically monomorphic’ along with other pathogenic 
bacteria such as Bacillus anthracis (anthrax), Yersinia pestis (the plague), and Salmonella 
enterica serovar Typhi (typhoid fever) (Achtman 2008).  
 
H37Rv and H37Ra are ‘virulent’ (Rv) and ‘avirulent’ (Ra) M. tuberculosis strains derived (in 
1934) from the original human-lung H37 strain which was isolated in 1905, and are used 
extensively worldwide as reference strains (Bifani et al. 2000). The first M. tuberculosis 
genome sequenced was H37Rv in 1998 (Cole et al. 1998). The H37Rv genome is 4.41 Mb in 
size, contains approximately 4000 genes, and as with other mycobacteria and closely related 
Actinomycetales it has an unusually high genomic DNA GC content of 65.6 %.  
Another mycobacterium widely used in mycobacteriological studies is Mycobacterium 
smegmatis, a fast-growing opportunistic mycobacteria with a much larger genome of 6.99 Mb. 
M. smegmatis was initially isolated from syphilitic chancres and normal genital secretions in 
1885 (Talaat et al. 1999) and is now considered an environmental saprophyte (common in soil 
and water) which rarely causes skin and soft-tissue lesions (Brown-Elliott & Wallace 2002). M. 
smegmatis mc2155 is a non cell clumping, high transformation efficiency mutant strain 
originally isolated from its ‘wild type’ progenitor mc26, which is a single colony isolate of the M. 
smegmatis reference strain, ATCC 607 (Snapper et al. 1990). Because it is non-pathogenic, 
fast growing and easily transformed M. smegmatis mc2155 is used extensively as a model 
organism in mycobacteriological studies. The frequent use of M. smegmatis mc2155 as a 
surrogate host is not always fully considered however, as it also contains an expansion in the 
copy number of IS1096 (containing 13 extra) as well as a large duplicated fragment (56 kb) 
and deletions (Wang et al. 2008) which may have an effect on the outcome of the study. As 
long as these differences are taken into consideration, M. smegmatis mc2155 can be 
immensely valuable in the analysis of mycobacterial gene function, expression and replication. 
 
1.3.1 Virulence 
Virulence, by Medical Subject Headings (MeSH) definition, is “the degree of pathogenicity 
within a group or species of microorganisms or viruses as indicated by case fatality rates 
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and/or the ability of the organism to invade the tissues of the host. The pathogenic capacity of 
an organism is determined by its virulence factors”. Virulent MTBC species have acquired 
virulence factors and developed strategies to evade altogether, or alter the host immune 
response in their favour. Much research is focussing on determining what these virulence 
factors are (for review, see Forreland et al. (2013)), so as to better understand the 
mechanisms involved, and to aid in the development of improved vaccines and antimicrobial 
therapies. There is no universally accepted definition of what constitutes a virulence gene, but 
it is generally considered that its loss reduces the virulence of the pathogen, without affecting 
the growth rate. 
 
Genes or proteins associated with virulence have been identified in the following categories: 
lipid and fatty acid metabolism, cell envelope proteins, proteins inhibiting antimicrobial effectors 
of the macrophage, protein kinases, proteases, metal-transporter proteins, gene expression 
regulators, proteins of unknown function, and other virulence proteins (Forrellad et al. 2013). 
An area of particular interest is virulence factors which are involved in the interaction of M. 
tuberculosis with the host macrophage. Many mycobacterial species have adapted to survive 
and replicate inside amoebae and macrophages (Zhang et al. 1999;  Greub & Raoult 2004), 
which is one of the reasons M. tuberculosis is able to persist inside its host for such extended 
periods. Human alveolar macrophages (which are the primary host cell for inhaled M. 
tuberculosis) infected with M. tuberculosis undergo apoptosis in vitro (Keane et al. 1997;  
Danelishvili et al. 2003). This cell death removes an environment conducive for bacterial 
growth, therefore limiting the growth of the intracellular pathogen and ultimately benefiting the 
host. It has been demonstrated however, that there are mycobacterial virulence determinants 
which reduce the apoptotic response of alveolar macrophages to intracellular infection, in order 
to evade this host defense mechanism (Keane et al. 2000;  Danelishvili et al. 2003). This 
negative correlation between mycobacterial virulence and the ability to induce apoptosis 
explains why the majority of M. tuberculosis infections cause necrosis, while attenuated mutant 
infections mainly induce apoptosis (Forrellad et al. 2013). Virulence factors have also been 
implicated in the switching and regulation of carbon metabolism which must occur when M. 
tuberculosis resides inside the nutrient poor host macrophage (Forrellad et al. 2013). The 
toxin–antitoxin (TA) genes were identified during the course of this research as playing an 
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important role in the regulation of carbon metabolism in mycobacteria (McKenzie et al. 2012b). 
These genes have also been linked with virulence (Arcus et al. 2005). 
 
1.4 Toxin-Antitoxin Systems 
1.4.1 History and Function of Toxin-Antitoxin systems 
TA systems were originally discovered in the 1980’s on plasmids, where they acted to maintain 
the plasmids by post-segregational killing of plasmid-free cells (Gerdes et al. 1986). They have 
since been found to be highly abundant on the chromosomes and plasmids of Eubacteria and 
Archaea (Pandey & Gerdes 2005;  Fozo et al. 2010). A TA system is comprised of two genes 
in an operon: one encodes a stable toxic protein, and the other a labile but neutralising 
antitoxin. Due to the relative stability of the toxin compared with the antitoxin, the antitoxin 
must be continually expressed to maintain its neutralising effect on the toxin and prevent cell 
stasis or death. 
 
Early research on TA systems was predominantly performed with Escherichia coli where their 
function has been linked to the response to environmental stress, programmed cell death and 
bacterial persistence as well as plasmid and gene stabilisation (Korch et al. 2003;  Hazan et al. 
2004;  Gerdes et al. 2005;  Szekeres et al. 2007;  Maisonneuve et al. 2011). It has also been 
suggested that TA loci may simply be selfish genetic elements with no biological function, 
functioning just to maintain their presence in a genome (Mine et al. 2009). The role of TA 
systems in other organisms, however, has not been studied as intensively and many questions 
remain over their physiological function in these microbes, especially M. tuberculosis. 
 
TA systems, while not generally essential for normal cell growth, are widely prevalent in 
bacterial pathogens, often in expanded numbers and closely linked to mobile genetic elements 
(Pandey & Gerdes 2005). The number of TA systems in M. tuberculosis are massively 
expanded, suggesting they perform roles which are advantageous for cell survival in its many 
and varied environments, and may be involved in M. tuberculosis pathogenesis (Ramage et al. 
2009). 
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There are five types of TA systems, classified by the nature and mode of action of the 
antitoxin: type I and III where the antitoxins are small RNAs, and types II, IV and V which utilise 
protein antitoxins (the toxins are proteins for all TA system types). Type I antitoxin RNAs 
function by binding to toxin-encoding mRNA, thereby suppressing toxin translation, while type 
III antitoxins inhibit their cognate protein by binding to it directly (Fineran et al. 2009). Type II 
antitoxin proteins bind directly to the toxin causing its inactivation, type IV antitoxin proteins 
compete with the toxin for the same binding target, and the type V antitoxin proteins cleave the 
toxin-encoding mRNA (Short et al. 2013). Type II TA systems were the first TA systems 
discovered and are the most prevalent (Yamaguchi & Inouye 2011). They are believed to 
move from one genome to another by horizontal gene transfer (Pandey & Gerdes 2005) and 
are the focus of research in this thesis.  
 
Type II TA systems were initially classified into TA system families but bioinfomatic approaches 
have since predicted many more novel putative families of toxins and antitoxins, and examples 
of ‘hybrid’ TAs (where the toxin belongs to one family and the antitoxin to another) have since 
been characterised (Schmidt et al. 2007). Therefore, the practice is to now classify the 
antitoxin and toxin families independently (Leplae et al. 2011). Toxins belonging to type II TA 
systems have been sub-divided into at least 12 super-families based on similarities of the toxin 
sequences and three-dimensional structure prediction, and antitoxins into 20 super-families 
(Leplae et al. 2011). Most of the characterised type II toxins are translation inhibitors (Doc, 
HicA, HipA, MazF, RelE, VapC, YafO and GinA,B,C and D), although there are a number of 
exceptions:  ζ toxins inhibit peptidoglycan synthesis, and CcdB and ParE toxins inhibit 
chromosome replication through inhibition of DNA gyrase (Korch & Hill 2006;  Hayes & Van 
Melderen 2011).  Table 1.1 summarises the type II toxin super-families and their targets. 
Phylogenetic distribution of the toxin super-families varies from one super-family to another. 
ParE/RelE, Zeta, VapC, Doc, CcdB/MazF, HipA and GinB are all distributed across a wide 
range of bacterial phyla (Proteobacteria, Firmicutes (except GinB), Cyanobacteria and 
Actinobacteria), while other toxin super-families are only present in one or two phyla (Leplae et 
al. 2011).  
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Table 1.1: The super-families of type II toxins, their targets, activities and cellular process they affect. 
 
Super-family Target Activity Cellular process 
CcdB/MazF DNA gyrase/mRNAs 
Generates DS breaks/ 
Endoribonuclease 
Replication/Translation 
Doc Translating ribosome Induces mRNA cleavage Translation 
Gin families ND ND Translation 
HipA EF-Tu Protein kinase Translation 
HicA* ND mRNA cleavage Translation 
ParE/RelE 
DNA gyrase/Translating 
ribosome 
Generates DS breaks/ 
Induces mRNA cleavage 
Replication/Translation 
VapC mRNAs Endoribonuclease Translation 
VapD ND ND ND 
YafO ND mRNA cleavage** Translation 
ζ ND Phosphotransferase Peptidoglycan synthesis 
Table adapted from (Van Melderen & Saavedra De Bast 2009) and (Hayes & Van Melderen 2011), * = 
(Jørgensen et al. 2009), ** = (Zhang et al. 2009). Abbreviations: ND, not determined; Ccd, coupled cell division; 
Doc, death on curing; Gin, growth inhibition; Hic, Haemophilus influenzae (hif) contiguous; Hip, high persistence; 
Par, partitioning; Vap, virulence associated protein. ParE/RelE includes the HigB, PasB, StbE, Txe, YoeB and 
YafQ subfamilies, and CcdB/MazF includes the YdcE, PemK and ChpBK subfamilies (Leplae et al. 2011).  
 
Of the type II TA systems, RelBE and MazEF have been studied in the most detail. Both the 
RelE and MazF toxins inhibit translation by cleaving mRNA, as does VapC, however only RelE 
requires the ribosome for RNA cleavage (Pedersen et al. 2003;  Zhang et al. 2003;  Arcus et 
al. 2004;  Daines et al. 2007). VapBC is the largest of the type II toxin and antitoxin 
superfamilies (Gerdes et al. 2005;  Van Melderen & Saavedra De Bast 2009), but the least well 
characterised. vapBC loci account for approximately one third of TA loci identified in a study 
involving 900 prokaryotic genomes (Shao et al. 2011), and are over-represented in the M. 
tuberculosis genome where they account for 47 of the (at least) 88 type II TA loci (Ramage et 
al. 2009;  Ahidjo et al. 2011). So why are there so many TA systems, in particular vapBCs, in 
M. tuberculosis? The majority of TA systems found in M. tuberculosis are only found in other 
pathogenic mycobacteria (Ramage et al. 2009), implying they play a fundamental role in the 
diversification and evolution of the pathogenic M. tuberculosis species from its non-pathogenic 
relatives. One theory proposed is that obligate host-associated organisms do not keep their TA 
systems, while they are beneficial to free-living organisms. This trend is supported by 
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Mycobacterium leprae (an obligate intracellular pathogen) having no functional TA loci and M. 
tuberculosis (which has extra- and intracellular growth phases) having many. Similarly the free-
living spirochetes Leptospira interrogans and Treponema denticola have five and 33 TA 
systems, respectively, while the obligate parasitic spirochetes Treponema 
pallidum and Borrelia burgdorferi have none (Pandey & Gerdes 2005;  Mitchell et al. 2010). 
Another trend observed by Pandey and Gerdes (2005) was that almost all free-living bacteria 
living in varied and changing environments contained TA systems as well as having a 
propensity for dormancy or slow growth, so they postulated that the number of TA loci may be 
correlated with the cell growth rate. This is supported by M. tuberculosis having large numbers 
of TA systems but a slow growth rate, while the related  but non-pathogenic species, M. 
smegmatis has only three TA systems (Robson et al. 2009) and is relatively fast growing. The 
function of TA systems in microbial physiology is still unknown and remains the subject of great 
debate, although the ability of pathogenic bacteria to slow or regulate growth in order to 
survive in stressful environments is an appealing hypothesis for the function of TA systems. 
 
1.4.2 Mechanism of Action and the Regulation of Type II TA 
Systems 
The toxin and antitoxin genes constituting the type II TA systems are small in all prokaryotic 
species. The antitoxins are usually shorter than their partnered toxin (approximately 210 to 450 
and 270 to 900 bp long respectively (Pandey & Gerdes 2005)) and are located upstream of the 
toxin (Yamaguchi & Inouye 2011). Exceptions to this general arrangement are the higBA, 
hicAB and mqsRA loci where they are in the reverse order, and the HigBA toxin which is 
unusually large (1320 bp) (Tian et al. 1996;  Brown et al. 2009;  Gerdes 2012). The TA genes 
are arranged in an operon with the start and stop codons usually overlapping by a few bases 
(reflecting translational coupling which is common in prokaryotes), although sometimes instead 
with a spacer region of up to 30 nucleotides (Sevin & Barloy-Hubler 2007;  Goulard et al. 
2010). The toxin and its cognate antitoxin form a stable TA complex, which inhibits toxicity. 
Generally antitoxin proteins contain unstructured regions and, as such, are unstable and more 
prone to proteolysis by cellular proteases than the toxins. Therefore, an antitoxin must be 
constantly expressed to neutralise the effect of the toxin which is most likely why antitoxins are 
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arranged (and therefore produced) first in the TA operon. In cases where the antitoxin is 
located downstream of the toxin, the antitoxin and toxin levels are balanced by rare start 
codons or an additional promoter. Antitoxins are subject to degradation by one of the cytosolic 
ATP-dependent proteases (Lon, ClpPX or ClpPA), assumed to be induced by various 
environmental stresses (Christensen et al. 2003;  Buts et al. 2005;  Gerdes et al. 2005;  Wang 
& Wood 2011). Dissociation of the TA complex results in the release of free toxin which is then 
able to bind a divalent metal ion, leading to metal-ion dependent nuclease activity which slows 
the metabolism of the cell ultimately leading to cell growth arrest (Bunker et al. 2008;  
Yamaguchi & Inouye 2009). 
 
The TA complex also functions to autoregulate the TA operon via an N-terminal DNA binding 
domain in the antitoxin which binds to a repeat sequence in the promoter region, repressing 
transcription of the TA operon (Yamaguchi & Inouye 2011). Therefore, expression of the TA 
operon is activated as the antitoxin is degraded and this drives the production of more toxin 
and antitoxin causing autoregulation of TA expression once again. During this process, free 
toxin is released into the cell where it is able to act on its molecular target (Figure 1.3). 
 
 13 
 
 
Figure 1.3: General set up of a TA loci. TA loci are organised in an operon, usually overlapping by a few 
bases but sometimes with a spacer region instead. The stable TA complex binds to the promoter region 
to autoregulate transcription, while the labile antitoxin is subject to degradation by ATP-dependant 
proteases leaving the toxin free to act on cellular targets. 
 
The M. smegmatis vapBC and N. gonorrhoeae fitAB operons have been shown to be subject 
to auto-regulation through binding of these TA complexes to inverted repeats in their promoter 
regions (Wilbur et al. 2005;  Robson et al. 2009). The inverted repeat sequence bound by 
VapBC in the M. smegmatis vapBC promoter (IR-1), overlaps the -35 and -10 sequences. 
Binding of the VapBC complex here interferes with RNA polymerase binding, as seen by a 
threefold increase in the transcriptional activity of the vapBC promoter of M. smegmatis 
ΔvapBC compared to that of wildtype M. smegmatis mc2155 (Robson et al. 2009). The FitAB 
complex (VapBC from N. gonorrhoeae) binds an inverted repeat in its promoter with high 
affinity via a ribbon-helix-helix (RHH) DNA binding motif in FitA (Mattison et al. 2006). RHH 
domains are similar to transcription factors and function to aid sequence-specific DNA binding. 
Electrophoretic mobility shift assays (EMSAs) with purified M. tuberculosis VapBC TA complex, 
Rv0617/0616 has shown that Rv0617/0616 also binds the inverted repeat in its promoter 
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region (Abby Sharrock, unpublished data), corroborating the proposed autoregulation function 
of TA complexes. The first prokaryotic VapBC structure was published in 2009 by Miallau et al. 
involving VapC-5 (Rv0627) from M. tuberculosis in complex with a fragment of VapB-5 
(Rv0626) (the missing residues were part of the N-terminal region predicted to bind DNA). 
Recently, another M. tuberculosis VapBC structure was solved, Rv0301/0300 (Min et al. 2012), 
supporting the proposed mechanisms for VapCs RNase activity, its inhibition by a cognate 
antitoxin, and its ability to bind promoter DNA (in this case, via RHH motifs like for the FitAB 
system). Both the Rv0301/0300 and VapBC-5 TA complexes from M. tuberculosis show 
similarity to the FitAB system from N. gonorrhoeae (Min et al. 2012). The structural homologue 
for VapC-5 is FitB, however their partners (VapB-5 and FitA, respectively) do not show the 
same degree of similarity, and structural comparisons suggest the VapBC interaction to be 
tighter than that for FitAB (Miallau et al. 2009). This strong binding of VapB and VapC reaffirms 
the need for exacting control of toxic VapC proteins in M. tuberculosis. 
 
1.4.3 Targets of TA Toxin Proteins 
The diverse range of targets for E.coli TA toxins include mRNA, tRNA, ribosomes, DNA 
replication machinery and cytoskeletal proteins (Yamaguchi & Inouye 2011), and many more 
are likely to emerge in the future from as yet uncharacterised TA systems. The majority of type 
II TA toxin proteins (including RelE, HigB, MazF, HicA, MqsR, Doc, HipA and VapC) inhibit 
translation by targeting the translation machinery. The target with the greatest representation is 
mRNA, and those proteins which inhibit translation via mRNA cleavage either in a ribosome-
dependent or ribosome-independent manner, are called mRNA interferases (Yamaguchi & 
Inouye 2009). Ribosome-independent mRNA interferases can cleave mRNA directly in the 
cytoplasm as the RNA does not have to be undergoing translation for cleavage to occur. 
Ribosome-independent mRNA interferases include the MazF, ChpBK, MqsR, VapC, YhaV and 
HicA toxins. Ribosome-dependent mRNA Interferases cleave mRNAs at the ribosomal A site 
and include RelE, YoeB, YafO, YafQ and HigB. 
 
The cellular targets and causes of induction of toxin proteins are highly diverse, suggesting 
these proteins play diverse roles in bacterial organisms. While a lot is known about the targets 
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in E. coli, there is still much debate about the function and targets of toxins in M. tuberculosis. 
As M. tuberculosis has so many TA systems and the number of systems possibly relates to 
pathogenicity (Pandey & Gerdes 2005), it is proposed TA systems may play a role in the ability 
of M. tuberculosis to persist, effectively dormant, within macrophages for long periods, and 
have been implicated in the metabolic switch from the replicative state to dormancy under 
nutrient stress (Albrethsen et al. 2013). Identifying the targets of M. tuberculosis toxins will 
provide a better understanding of their function in bacterial physiology and pathogenicity, and 
therefore the ability to develop novel antimicrobial therapies to target these persistent bacteria. 
 
1.4.4 Physiological Function and Roles of Toxin–Antitoxin 
Systems 
1.4.4.1 The Role of Toxin-Antitoxin Systems in the Stress Response 
MazF expression is induced by a number of stresses (nutrient starvation, antibiotics, DNA 
damage and heat) once the MazE antitoxin has been degraded by either of the ATP-
dependent serine proteases, ClpA–ClpP or Lon (Aizenman et al. 1996;  Christensen et al. 
2003). This leads to cell growth arrest or “quasi-dormancy”, and programmed cell death in E. 
coli (Aizenman et al. 1996;  Hazan et al. 2004;  Suzuki et al. 2005;  Kolodkin-Gal et al. 2007). 
MazF can induce cells into a quasi-dormant state where they are metabolically active, still 
producing RNA and protein (so long as the encoding mRNA is devoid of the MazF target 
sequence ACA) but are resistant to antibiotics (Suzuki et al. 2005;  Yamaguchi & Inouye 
2011). Cell growth can be recovered by the production of MazE antitoxin but only up to a point, 
at which stage mazEF-mediated cell death may occur and cannot be rescued (Amitai et al. 
2004) although this was found to normally occur only during the exponential phase of growth 
(Kolodkin-Gal & Engelberg-Kulka 2009). The involvement of MazF in programmed cell death is 
suggested to occur via a quorum sensing mechanism whereby the altruistic suicide of some 
cells furnishes the remaining population with nutrients during times of stress (Engelberg-Kulka 
et al. 2006). Other groups have not observed this same mazEF-mediated cell death 
phenomenon (Gerdes et al. 2005;  Van Melderen 2010), instead postulating that MazF induces 
a reversible bacteriostatic state (Pedersen et al. 2002). These differing theories as to the exact 
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role of MazEF highlight the extent to which our knowledge of these TA systems is limited, 
especially given that the MazEF system is one of the best characterised TA systems. 
 
The other well characterised TA system is RelBE, which is involved in the stringent response 
induced under conditions of amino acid starvation. RelB (as with MazF) is also degraded by 
Lon protease, releasing RelE which inhibits translation, in turn activating RelA to synthesise 
guanosine tetraphosphate (ppGpp) synthase and therefore, stringent control of RNA synthesis 
(Figure 1.4) (Gerdes et al. 2005). The mazEF operon lies downstream of relA, so is also 
considered to be related to the stringent response (Yamaguchi & Inouye 2011). RelE not only 
causes inhibition of protein synthesis, but also a reduction in colony forming units which can 
then be revived by expression of RelB (Christensen et al. 2001). The ability of RelB to 
resuscitate RelE-inhibited cells suggests these cells are not dead, but in a state of stasis, 
corroborating Gerdes’ hypothesis that these TA systems are involved in the stress response 
where they inhibit growth, directing cells into reversible bacteriostasis (Pedersen et al. 2002;  
Gerdes et al. 2005). 
 
The two higBA loci from Vibrio cholera are hypothesised to function as stress response 
elements during the change in growth rate from fast (in the human intestine) to slow or 
dormant (in its aquatic environment) (Christensen-Dalsgaard & Gerdes 2006). Both HigB 
toxins are activated by amino acid starvation resulting in inhibition of protein synthesis and cell 
growth in E. coli, which can be reversed by expression of HigA (Christensen-Dalsgaard & 
Gerdes 2006;  Gupta 2009).  
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Figure 1.4: Model for relBE regulation in the context of the stringent response. RelE activation 
reduces translation (but does not completely inhibit it) which reduces the level of charged tRNAs, 
activating RelA to synthesise ppGpp and therefore stringent control of gene expression. Figure adapted 
from Gerdes et al. (2005). 
 
In a recent study, multiple TA systems were also implicated with the switch into dormancy of 
M. tuberculosis, by the detection of TA system members in larger quantities in nutrient starved 
cultures, strengthening the role for these systems in the metabolic switch from the replicative 
to dormant state (Albrethsen et al. 2013). In total, 15 TA members were shown to be increased 
(VapC4, VapC27, VapC5, VapB32, VapC13, MazF6, VapC37, ParE2, VapC38, VapC39, 
VapC19, VapC41, VapC22, RelE2 and VapC44), of which two are antitoxins and 13 toxins, 
and the majority (11) belong to the VapBC family of TA systems. This was the first 
demonstration of M. tuberculosis TA proteins being induced during the same conditions of 
stress which may be experienced during latent infection. 
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1.4.4.2 The Role of Toxin-Antitoxin Systems in Bacterial Persistence 
Bacterial persister cells are a small subpopulation of dormant variants that become highly 
tolerant to antibiotics without undergoing genetic change, and arise primarily in biofilms and in 
stationary-phase cultures (Lewis 2008). Most of the antimicrobials available for use today 
require bacteria to be actively growing to cause cell death, so the dormant or non-replicating 
persistent bacteria are likely to be tolerant to treatment (Gomez & McKinney 2004). This 
antibiotic-tolerant state has been shown to be induced by TA system activation in E.coli (Keren 
et al. 2004), strengthening the view that the TA systems in M. tuberculosis may also have this 
effect, contributing to the extended period which is currently required for effective antibiotic 
treatment of this disease. HipA of the E.coli HipBA TA locus induces growth arrest leading to a 
persistent multidrug-resistant state once cellular HipA toxin levels reach a certain threshold 
(Rotem et al.). This threshold allows part of the population to enter a dormant state without 
affecting the growth of the remaining cells. Phosphorylation of the essential translation factor 
EF-Tu is the proposed mechanism for HipA induced growth arrest (Schumacher et al. 2009). 
 
The first direct evidence of a TA operon affecting cell persistence upon deletion was found 
with mqsRA, a member of the RelBE TA family (Brown et al. 2009). Deletion of 
mqsRA or mqsR alone decreases persister formation, and production of MqsRA increases 
persistence (Kim & Wood 2010); mqsR is also one of the most highly induced genes in E. coli 
persister cells (Shah et al. 2006). Transcription of mqsRA is activated by amino acid and 
glucose starvation, and after MsqA degradation, MsqR is proposed to interact with Hha and 
CspD (Kim & Wood 2010) as well as cleave RNA in a ribosome independent fashion 
(Christensen-Dalsgaard et al. 2010). Induction of relE, higB, mazF, yafQ, and yoeB have also 
been implicated in persister cells, however the MqsRA TA system remains the only TA system 
affecting persistence upon deletion where the antitoxin is a protein (Shah et al. 2006;  Wang & 
Wood 2011). 
 
1.4.4.3 The Role of Toxin-Antitoxin Systems in Biofilm Formation 
Biofilms are dense, multicellular communities of bacteria formed in liquid environments by 
attaching to the air-liquid interface, submerged surfaces or to each other (Kolter & Losick 
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1998). Initially, it was thought that TA systems were not involved in biofilm formation as mazF 
and relE toxin knockouts had shown no difference in biofilm formation compared to wildtype 
strains (Lemos et al. 2005), but since then a number of studies have suggested a role for TA 
systems in biofilm formation. MqsRA was the first TA system to be linked to biofilm formation 
and the autoinducer-2 quorum sensing system, where MqsR in E.coli was induced in biofilm 
cells and enhanced cell motility, and the deletion of mqsR inhibited biofilm formation (González 
Barrios et al. 2006). MqsR has also been linked to biofilm formation via its association with 
QseB, an important protein in biofilm formation, as QseB levels were reduced in a mqsR 
deletion mutant (González Barrios et al. 2006). 
 
Additional evidence that TA pairs affect biofilm formation came from a mutant strain lacking the 
five TA systems MazF/MazE, RelE/RelB, YoeB/YefM, and YafQ/DinJ and ChpB (of which the 
toxins all inhibit translation by cleaving RNAs). This mutation had no impact on the stress 
response of cells (Tsilibaris et al. 2007), but biofilm formation was reduced during the first 8 hr 
before recovering after 24 hr (Kim et al. 2009). Transcriptome profiling of these biofilm cultures 
to determine the mechanism by which the TA systems were affecting biofilm formation found 
differential expression of a single gene, yjgK. Induction of YjgK decreased biofilm formation at 
8 hr (by repressing fimbria genes as bacteria use fimbriae for adherence) and increased it at 
24 hr, while deleting yjgK had the reverse effect corroborating the complex phenotype 
observed in the five deletion TA systems mutant (Kim et al. 2009). Another group confirmed 
this phenomenon and found the initial biofilm formation defect was mainly due to deleting 
mazF and yafQ  which decreased cell lysis (Kolodkin-Gal et al. 2009). Deletion of yafQ showed 
no effect on biofilm formation but elevated levels of cell death under exposure to some 
bactericidal antibiotics during biofilm formation, while overproduction of YafQ increased biofilm 
formation substantially (Harrison et al. 2009). These results suggest cell growth inhibition or 
lysis caused by the TA system toxins affects biofilm formation. 
 
1.4.4.4 Other Roles of Toxin-Antitoxin Systems 
TA systems have also been postulated to function in other diverse roles such as DNA damage-
independent replication arrest (MazF and RelE), the SOS response (YafON and YafQ–DinJ) 
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(Yamaguchi & Inouye 2011), and stabilising integrons (HigBA) (Christensen-Dalsgaard & 
Gerdes 2006), as well as interacting within a network of TA systems. Interaction between TA 
systems in a network is supported by examples of noncognate toxin-antitoxin associations, 
even among different families both in vivo and in vitro (Figure 1.5) (Zhu et al. 2010). Zhu et al. 
(2010) showed that expression of M. tuberculosis VapB-25 can neutralize the toxicity of M. 
tuberculosis MazF-3 in E. coli, but that interactions detected in vivo may not be as stable under 
nonphysiological conditions. The suggestion of cross talk between TA systems is controversial, 
as two other studies have found no such phenomenon in the M. tuberculosis TA systems 
which they investigated (Ramage et al. 2009;  Ahidjo et al. 2011). These results using M. 
tuberculosis TAs challenge the general consensus of ‘one toxin for one antitoxin’ rule 
established from studies in other bacteria (usually E.coli), and suggest the possibility of the 
combined action of multi-TA system toxins functioning so as M. tuberculosis can adapt and 
survive in the diverse environmental conditions encountered. 
 
 
Figure 1.5: Summary of possible TA system networks in M. tuberculosis.  Coloured lines represent 
interactions between cognate TA pairs, black lines between non-cognate pairs. Dashed lines indicate 
weaker interactions based on partial rescue of toxicity. Figure adapted from Zhu et al.  (2010). 
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The role TA systems play in response to antibiotic, nutrient, temperature, oxidative or other 
stressors caused by the extreme environments which they encounter is still under intense 
investigation, and while there is a wealth of information regarding the function of TA systems 
in E. coli, their role in other microbes, especially M. tuberculosis, remains largely unexplored. 
 
1.4.5 VapBC Toxin-Antitoxin Systems 
VapBC TAs are virulence associated proteins. The first vapBC locus was identified on a 
Salmonella Dublin virulence plasmid (Pullinger & Lax 1992), where inactivation of vapB caused 
the loss of plasmid-associated virulence as well as growth inhibition on selected media. Many 
examples have since followed from both virulence plasmids, where the locus functions by 
killing plasmid-free cells and therefore maintaining plasmid survival (such as mvpAT in Shigella 
fleneri (Sayeed et al. 2000), and chromosomal vapBC loci which will be discussed in greater 
detail in the following sections. 
 
1.4.5.1 PIN-Domain Proteins  
VapC toxins belong to the PIN-domain family of proteins. PIN-domain proteins were originally 
named based on their sequence similarity to the N-terminal domain of a PilT (PilT N-terminus) 
protein, and are small ribonuclease proteins (approximately 130 amino acids) containing four 
conserved acidic residues within an RNase-H-like fold (Arcus et al. 2004;  Mattison et al. 2006;  
Miallau et al. 2009;  Arcus et al. 2011). These conserved amino acids form a negatively 
charged pocket or active site which co-ordinates the binding of a Mg2+ or Mn2+ ion and 
facilitates metal dependent nuclease activity, as shown by structural characterisation of FitB 
from Neisseria gonorrhoeae (Mattison et al. 2006), VapC from Pyrobaculum aerophilum 
(Bunker et al. 2008) and VapC5 from M. tuberculosis (Miallau et al. 2009). Figure 1.6 shows 
the α/β/α stack with a central twisted parallel β sheet of five short strands, typical of PIN-
domain protein structures (Arcus et al. 2011), and the four conserved acidic residues within. 
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Figure 1.6: The structure of the PIN-domains. A cartoon representation of the α/β/α stack containing a 
central 5-stranded parallel β sheet typical of PIN-domain protein structures, and the four conserved acidic 
residues within. The N-terminus to the C-terminus is coloured blue to red and the active site metal 2+ ion 
is shown in black. Figure from Arcus et al. (2011). 
 
1.4.6 Toxin-Antitoxin Systems in M. tuberculosis 
M. tuberculosis belongs to the Mycobacterium tuberculosis complex (MTBC) which includes all 
Mycobacterium species that can cause tuberculosis in humans or other organisms. The 
number of TA systems in M. tuberculosis is greatly expanded with 88 putative candidates, the 
majority of which are conserved only in the MTBC and absent from other, even closely-related 
mycobacterial species (Ramage et al. 2009). This expansion of TA systems in the MTBC (of 
which 37 % are located in regions identified as regions of horizontal gene transfer (HGT)) is 
proposed to have occurred during (or after) the time of divergence from the last common 
ancestor (Stinear et al. 2008;  Ramage et al. 2009). This sudden expansion of TA systems is 
consistent with the theories that TA systems in the MTBC were acquired by HGT, and DNA 
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acquired by HGT played a crucial role MTBC speciation (Becq et al. 2007), strengthening the 
importance of TA systems in the evolution of M. tuberculosis.  
 
Ramage et al. (2009) tested expression of 78 (of the 88) putative M. tuberculosis TA systems 
in M. smegmatis, and found 30 of them to be functional (i.e., expression of the toxin resulted in 
toxicity to the cells and subsequent expression of the cognate antitoxin neutralised the 
toxicity). Of the 30 functional TA systems they identified, 20 were VapBC, four MazEF, two 
RelBE, one HigBA and three were novel TA family systems. These functionality results are 
inconsistent with those obtained previously for 38 of the same candidates in E.coli, where 
seven of the TA systems deemed functional in M. smegmatis were found to not be functional in 
E.coli (Zhu et al. 2006;  Gupta 2009), highlighting the importance of testing the functionality of 
TA systems in a closely related host. While functional TA systems have been identified on M. 
tuberculosis chromosomes, not much is known about what their physiological role is in M. 
tuberculosis itself, as most of what we know about their functionality has been gathered from 
studies of the TA systems in other bacterial species.  
 
1.4.6.1 The RelBE Toxin-Antitoxin System 
To date, only three Rel TA modules have been identified in M. tuberculosis (relBE, relFG and 
relJK), all of which are functional in M. smegmatis and whose antitoxins (by themselves) can 
act on transcription: RelJ as a repressor, and RelB and RelF as activators (Korch et al. 2009). 
All three Rel TA complexes also act to repress expression when combined, consistent with 
other TA systems. Korch et al. (2009) also showed for the first time that M. tuberculosis 
expresses TA modules both in broth culture (all six rel genes) and during infection of human 
macrophages (relE, relF, and relK). This involvement suggests they may be required for 
survival within macrophages and function in bacteriostasis as opposed to cell death, and 
therefore are linked to M. tuberculosis  persistence (Korch et al. 2009;  Min et al. 2012). Initial 
studies in E.coli found RelE associated with the ribosomal A site to initiate endogenous 
ribonuclease activity of the ribosome which preferentially cleaves mRNA between the second 
and third bases of the stop codon (with a higher specificity for the stop codon UAG), leading to 
inhibition of translation elongation and protein synthesis (Christensen & Gerdes 2003;  
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Pedersen et al. 2003;  Hurley & Woychik 2009). However a recent contradictory study reported 
no codon-dependent cleavage by RelE in vivo, but preferential cleavage at the beginning of 
the  5′ end of the coding region (Hurley et al. 2011). The activity of other members of the 
RelBE TA family (such as HigB, YoeB, YafQ and YafO) is dependent on their association with 
the 50S ribosomal subunit, and all have differing cleavage specificities (Hurley & Woychik 
2009). 
 
1.4.6.2 The MazEF Toxin-Antitoxin System 
Nine MazEF TA systems have been identified in M. tuberculosis, four of which have been 
confirmed as functional in M. smegmatis (Pandey & Gerdes 2005;  Ramage et al. 2009). MazF 
cleaves the phosphodiester bond of mRNA at the 5’-end, yielding a free 5’-OH group on the 3’ 
cleavage product and a 2’3’-cyclic phosphate on the 5’ product (Zhang et al. 2005). MazF does 
not cleave RNA/DNA or RNA/RNA duplex sequences, nor ssDNA (Zhu et al. 2009). Activity of 
MazF does not require Mg2+ (like RNase A), which is unlike the other TA endoribonucleases 
(Zhang et al. 2005). MazF toxins recognise different sequences in different organisms ranging 
from three bases in length for E. coli (*ACA) (* indicates cleavage site) (Zhang et al. 2005), to a 
pentad sequence for Staphylococcus aureus and Bacillus subtilis (U*ACAU) (Zhu et al. 2009;  
Park et al. 2011) and Myxococcus xanthus (GU*UGC (although the first G can be replaced 
with an A)) (Nariya & Inouye 2008). The M. tuberculosis MazF homologues each have different 
cleavage site specificities, for example MazF-mt1 = CU*ACC (and to a lesser extent UU*ACA 
sequences), MazF-mt3 = UU*CCU or CU*CCU, MazF-mt7 = U*CGCU and the consensus 
cleavage sites for MazF-mt6 are (U/C)U*(A/U)C(U/C) (Zhu et al. 2006;  Zhu et al. 2008). 
Different cleavage site specificities for each toxin within the same species may allow 
differential mRNA degradation as a way to adapt to the various environmental conditions M. 
tuberculosis encounters. 
 
1.4.6.3 The VapBC Toxin-Antitoxin System 
VapBC TA systems are over-represented in the M. tuberculosis genome, accounting for 47 of 
the 88 systems present (Ramage et al. 2009;  Ahidjo et al. 2011) highlighting the need to 
determine their biological role. No cross talk between non-cognate M. tuberculosis VapB 
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antitoxins and VapC toxins has been observed for the Rv0300/0301, Rv1561/1560, 
Rv2829c/2830c and Rv3408/3407 VapBC TA systems (Ramage et al. 2009). Toxins from 
these four VapBC systems inhibit translation (inhibiting growth) and Rv0301 and Rv1561 
degrade MS2 RNA (though Rv0301 to a lesser extent). These effects were all reversed by co-
expression with a cognate antitoxin supporting the theory that VapC toxins affect translation 
directly via their ribonuclease RNase activity (Ramage et al. 2009). Mg2+ dependent 
ribonuclease activity of another VapC, VapC-5, has also been demonstrated, although a 
portion of the protein was in complex with its antitoxin so the observed activity was weak 
compared to other VapC toxins (Miallau et al. 2009). 
 
A survey of the toxicity of 10 M. tuberculosis VapC proteins showed only Rv0549c, Rv0595c, 
Rv2549c and Rv2829c were toxic when expressed from a tetracycline-regulated promoter 
in M. smegmatis as well as when conditionally expressed in M. tuberculosis, while Rv0627, 
Rv1953, Rv2010, Rv2546, Rv2548 and Rv3320c had no effect on the growth of M. 
tuberculosis in liquid culture (Ahidjo et al. 2011). Toxicity of Rv3320c was observed but only 
when it was constitutively expressed, while toxicity of Rv2549c only occurred once the level of 
protein exceeded a certain threshold. The observations that toxicity of Rv2549c correlated with 
the level of protein expressed, while Rv2456 showed no toxicity and was induced at markedly 
lower levels than Rv2549c, suggested VapC proteins termed ‘non-toxic’ may just have been 
expressed in levels insufficient to exert an effect. This is supported by discrepancies from other 
studies on the effects of VapC toxin expression on the growth of E. coli, M. smegmatis and/or 
M. tuberculosis hosts (Gupta 2009;  Ramage et al. 2009). For example Ahido et al. (2011) 
found Rv0627 was non-toxic in M. smegmatis and M. tuberculosis while Miallau et al. (2009) 
determined it to be toxic in both organisms. These discrepancies are possibly due to 
differences in the expression vectors, growth conditions or strains used, or translation initiation 
signals causing insufficient levels of VapC expression (Gupta 2009;  Ramage et al. 2009;  
Ahidjo et al. 2011). Therefore, it is likely that the current number of VapC proteins described as 
‘toxic’ is under-represented. 
 
Expression of all 30 of the functional M. tuberculosis TA systems has been monitored via 
qPCR under hypoxic conditions, both in culture and during infection of bone marrow-derived 
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macrophages, to test if subsets of TA systems respond to different cellular stressors. Rv2009-
Rv2010 and Rv1955-Rv1956 (a HigBA homologue) were induced during hypoxia while two 
different VapBC systems, Rv0549-Rv0550 and Rv1560-1561, were induced during 
macrophage infection suggesting TA systems may indeed be regulated independently, and in 
response to different environmental stressors (Ramage et al. 2009). 
 
Much of the pioneering investigation into mycobacterial VapBC systems was performed in M. 
smegmatis as it has just three TA systems, only one of which is a VapBC 
(MSMEG_1283/1284). The M. smegmatis VapC toxin, VapCMS1284, is the homologue of 
Rv0624 in M. tuberculosis and its function has been investigated by Jo McKenzie in our lab 
and our collaborators at the University of Otago during the course of this PhD. Robson et al. 
determined that the M. smegmatis VapBC complex binds to an inverted repeat in the promoter 
DNA to regulate its transcription, and vapB and VapC are transcribed as a single leaderless 
mRNA (Robson et al. 2009). While expression of the VapBC complex had no effect on growth, 
expression of VapC inhibited growth in the ΔvapBC background, and to a lesser extent in the 
wild type strain where endogenous VapB was present to counteract some of its activity. 
Growth was restored when conditional expression of VapC ceased, suggesting a 
bacteriostatic, not bacteriocidal effect of VapC (Robson et al. 2009). VapCMS1284 was confirmed 
as an endoribonuclease, specifically cleaving and binding AUA(U/A) ssRNA sequences to 
inhibit translation in vitro and in vivo (McKenzie 2011;  McKenzie et al. 2012b). These 
AUA(U/A) sequences were found to be abundant in transcripts (and their upstream regions) 
which had been down regulated in response to overexpression of VapCMS1284 in microarray 
experiments. A large proportion of the down regulated genes had annotated roles in carbon 
transport and metabolism, suggesting a role for VapC as a regulator of carbon utilisation in 
response to the demands of the cell, in order to balance the rate of anabolism and catabolism 
post-transcriptionally (McKenzie et al. 2012b). 
 
The biological role of M. tuberculosis VapBC systems is largely unknown. The expanded 
number of VapBC systems encoded in the genome together with evidence for various TA 
systems involvement in pathogenesis, persistence, cell death and response to stress 
suggested M. tuberculosis VapBC systems may play a role in slowing or regulating metabolism 
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and cell growth for survival and in tuberculosis persistence. As such, determining the role of 
VapBC systems in M. tuberculosis is crucial to improving our understanding of these systems 
and how this pathogenic organism can adapt to the diverse array of environmental conditions it 
encounters.  
 
1.5 Objectives 
The observations above defined the main objectives to my doctoral research, as outlined 
below: 
 
Objective One - Identify conditions in which M. smegmatis vapB or vapC expression varied to 
help identify the mechanisms involved in the regulation of VapC, and develop an optimised 
RNA isolation and RT-qPCR method suitable for the quantification of these target genes. 
 
Objective Two - Clone the 47 VapBC proteins from M. tuberculosis into M. smegmatis and 
assess their soluble expression and purification. 
 
Objective Three - Determine the specificity and activity of a number of purified M. tuberculosis 
VapC proteins. 
 
Objective Four - Investigate the structure of a M. tuberculosis VapBC complex using X-ray 
crystallography. 
 
Objective Five - Classify the endemic Rangipo strain of M. tuberculosis, and develop a fast 
and efficient Rangipo specific diagnostic assay. 
 
Chapter three details the development of the Rangipo strain-specific diagnostic assay, while 
chapters four and five investigate the regulation and function of mycobacterial VapC. 
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2 Chapter Two: 
Methods 
2.1 Methods relating to Chapter Three: Rangipo 
Diagnostic 
2.1.1 Clinical Isolates and M. tuberculosis genomic DNA (gDNA)  
Crude M. tuberculosis gDNA used for typing PCRs (Section 2.1.3.1) and lineage classification 
(Sections 2.1.3.2 - 2.1.3.5) was extracted in-house from sonicated and heat-killed clinical 
specimens obtained from the Waikato Hospital Laboratory as for Section 2.1.1.1. 
M. tuberculosis gDNA used for developing the Rangipo diagnostic (Section 2.1.3.6) was 
obtained either from clinical isolates from Waikato Hospital Laboratory (Hamilton, NZ) 
extracted by Roberto Colangeli (University of Medicine and Dentistry of New Jersey, USA), or 
crude clinical isolate extracts from labPLUS (Auckland, NZ). 
 
2.1.1.1 M. tuberculosis Genomic DNA Extraction for Typing PCRs  
Isolates ‘A-F’ and ‘J-S’ were extracted using a hexadecyltrimethylammonium bromide (CTAB) 
extraction protocol as described below. 0.5 ml sterilised cells were resuspended in 50 µl Tris-
EDTA-SDS lysis solution and added to 50 µl 10 % SDS before incubating for 30 min at 70 C, 
700 rpm.100 µl 5 M NaCl and 80 µl CTAB/NaCl solution were added, samples mixed, then 
incubated for 2 min at 80 C followed by 10 min at 65 C, 700 rpm. 700 µl chloroform was 
added and samples were shaken vigorously for 1 min before rotating for 15 min at room 
temperature to deproteinise. The samples were spun (13,000 rpm, 10 min, room temperature), 
aqueous top layer transferred to a new tube and an equal amount of isopropanol added. 
Samples were incubated for 50 min at -20 C then spun (13,000 rpm, 15 min, room 
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temperature) before the supernatant was removed. Samples were washed with 1 ml 70 % 
ethanol, spun (13,000 rpm, 5 min, room temperature), supernatant removed then the pellet air 
dried. Pellets were resuspended in 500 µl 5 M GITC, pH 7 by rotating for 15 min at room 
temperature. 250 µl of 7.5 M ammonium acetate and an equal volume of chloroform (750 µl) 
were added before the samples were shaken well and rotated for 15 min at room temperature. 
Samples were spun (13,000 rpm, 10 min, room temperature), the top layer transferred to a 
new tube, and an equal amount of isopropanol added before precipitating for 50 min at -20 C. 
Samples were spun (13,000 rpm, 15 min, room temperature), supernatant removed and the 
pellets air dried before resuspending in 25 µl TE. 
 
Isolate ‘T’ was extracted using a GITC based extracted protocol as follows. 0.5ml heat killed 
and sonicated cells were resuspended in 0.5 ml 5 M GITC, pH7 and transferred to a sterile 
tube containing 0.3 g of 0.1 mm and 2.5 mm zirconia beads. The homogenate was beaten four 
times for 20, 25, 30 and 35 s respectively in a FastPrep cell disrupter (FP120) (Thermo Savant, 
USA) at setting 6 with 1 min rests in between. 250 µl of 7.5 M ammonium acetate and an 
equal volume of phenol/chloroform, pH 8 (750 µl) were added before the samples were 
shaken and rotated for 15 min at room temperature to deproteinise. The samples were spun 
(13,000 rpm, 15 min, room temperature), top layer transferred to a new tube and an equal 
amount of isopropanol added. Samples were precipitated overnight at -20 C then spun 
(13,000 rpm, 15 min, room temperature) before the supernatant was removed. Samples were 
washed with 1 ml 70 % ethanol, spun (13,000 rpm, 5 min, room temperature) and the 
supernatant removed. Samples were washed again with 1 ml 100 % ethanol, spun (13,000 
rpm, 5 min, room temperature), supernatant removed  and the pellets air dried before 
resuspending in 20 µl TE. 
 
2.1.2 Whole Genome Sequencing (WGS) 
WGS was performed by Roberto Colangeli and David Alland at the Department of Medicine, 
University of Medicine and Dentistry of New Jersey (USA) (Colangeli et al. 2014). 10 Rangipo 
clinical isolates from a time range spanning 19 years (A, C, E, F, N, O, R, S, T and U) were 
sent from New Zealand, and DNA was isolated using a CTAB extraction protocol as described 
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in (van Embden et al. 1993). Genome sequencing, processing and SNP detection was 
performed as described in Colangeli et al. (2014). Briefly, gDNA was sheared and barcoded 
libraries prepared then processed on the 5500xl SOLiD™ System (Applied Biosystems, USA) 
as per manufacturer’s recommendation. The overall fold coverage for each strain ranged from 
392 to 40.  Sequence reads were trimmed to remove short and low quality reads and mapped 
to the M. tuberculosis H37Rv genome (NCBI Reference Sequence: NC_000962.3). Analysis 
was performed using CLC Genomics Workbench (CLCbio, Denmark). Single nucleotide 
polymorphisms (SNPs) in the subject sequences were identified by comparing to the reference 
strain genome, H37Rv, and those SNPs with <80 of the reads showing the polymorphism were 
discarded. Mutations found to be common to all 10 of the study isolates (compared to the 
reference strain) were deemed as probable Rangipo specific SNPs. 
 
2.1.3 Polymerase Chain Reaction 
Primers for all PCRs were obtained from IDT (USA). 
 
2.1.3.1 PCR-Based Genotyping of M. tuberculosis targeting GC-rich 
repeats and IS6110 Inverted Repeats 
Two different approaches based on Kotlowski et al. (2004) and Otal et al. (1997) were used for 
preliminary typing of the 15 Rangipo clinical isolates obtained from Waikato Hospital 
Laboratory to see if there were any differences between them. 
 
The first approach used primers which target frequently repeated 16-bp GC rich sequences 
(Mtb1 or Mtb2) in combination with specific primers sited within the inverted repeats flanking 
IS6110 (IS1 and IS2) (Kotłowski et al. 2004). PCR reactions were carried out with Green Taq 
DNA Polymerase (GenScript, USA) in 25 μl volumes using the following concentrations: 1 x 
PCR buffer, 0.25 mM deoxynucleotide mix (dATP, dCTP, dTTP & dGTP), 2.5 mM MgCl2, 
0.625 U Green Taq DNA Polymerase, 0.2 μM each primer (IS1, IS2 and Mtb1 or IS1, IS2 and 
Mtb2) and 200 ng crude template DNA. The following cycling conditions were used for 
amplification: 
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95 °C  3:00   (min:sec)  
95 °C  0:20  
62 C  0:20  x 39 
72 °C   2:00  
72 °C   5:00  
 
PCR reactions were visualised as in Section 2.2.7.5, except on 1.5 % agarose gels. 
 
The second approach used the same primer above targeting the frequently repeated 16-bp GC 
rich sequence (Mtb1) in combination with a primer containing three degenerate inosine bases 
sited within the IS6110 repeat (CAR2) (Otal et al. 1997). PCR reactions and conditions were 
set up as above. 
 
2.1.3.2 Lineage-specific Large Sequence Polymorphism (LSP) based 
PCR for M. tuberculosis Lineage Classification 
PCRs based on LSPs identified by Gagneux et al. (2006) were conducted to classify which of 
the six main M. tuberculosis lineages the Rangipo strain belonged to. Primers used were the 
same as those used by Reed et al. (2009) based on regions of difference (RD) with respect to 
H37Rv. PCR reactions were carried out with Taq DNA polymerase (Invitrogen, USA) in 25 μl 
volumes using the following concentrations: 1 x PCR buffer, 0.2 mM deoxynucleotide mix 
(dATP, dCTP, dTTP & dGTP), 1.5 mM MgCl2, 1 U Taq DNA Polymerase, 0.3 μM each primer 
and 7 - 25 ng template DNA. The following cycling conditions were used for amplification: 
 
95 °C  3:00   (min:sec)  
95 °C  0:45  
58 C  0:30  x 34 
72 °C   0:40  
72 °C   10:00  
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PCR reactions for RD9, RD105, RD239 and RD750 were visualised as in Section 2.2.7.5. 
Those for RD1-15 were visualised as for Section 2.3.1.4 with SYBR SafeTM DNA gel stain 
(Invitrogen, USA) for recovery, then the DNA was extracted from the gel as in Section 2.3.1.5 
prior to sequencing. 
 
2.1.3.3 Euro-American Lineage Classification Based on the katG463 SNP 
Using the ‘on/off Switch Assay’ 
MTBC strains with the katG 463 codon ‘ctg’ rather than ‘cgg’ are considered as belonging to 
the Euro-American lineage (Sreevatsan et al. 1997;  Nahid et al. 2010). This SNP was used in 
an on/off switch assay, in an attempt to speed up and reduce the costs associated with the 
Euro-American strain classification process used above (Section 2.1.3.2) requiring a RD1-15 
PCR, purification and sequencing step. The on/off switch assay (Zhang & Li 2003) uses 
phosphorothioate-modified primers and Pfu polymerase (a high-fidelity DNA polymerase with 
3′ exonuclease activity) to distinguish between matched and mismatched primers. The forward 
primer katG-F is common to both Euro-American and non Euro-American genotypes. The 
reverse primers harbour a 3′ end phosphorothioate-modified nucleotide and are specific to 
Euro-American (katG-R1) or non-Euro-American (katG-R2/3) strains with the katG 463 codon 
‘ctg’ or ‘cgg’ respectively. Primers and reactions were as described in (Alix et al. 2006). 
Primers were obtained from IDT (USA) both with and without HPLC purification. PCR reactions 
were visualised as in Section 2.2.7.5.  
 
2.1.3.4 Euro-American Sub-lineage Classification 
PCRs were carried out for each of the 10 Euro-American sub-lineages as defined by Gagneux 
et al. (2006) and covered regions of difference (RD) 115, 122, 174, 182, 183, 193, 219, 724, 
726 and 761. Here, deletions in each region of difference are specific for a certain Euro-
American sub-lineage, so if the deletion is detected the sample is deemed to belong to that 
sub-lineage and if no deletion is detected it is not. Additional PCR reactions with internal 
flanking primers (de Jong et al. 2009) were required for successful amplification of RD 174, 
182 and 219 due to the size of the original amplicon and fragmented nature of template DNA 
used. 
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PCR reactions with Taq DNA polymerase (Invitrogen, USA) were carried out in 25 μl volumes 
using the following concentrations: 1 x PCR buffer, 0.2 mM deoxynucleotide mix (dATP, dCTP, 
dTTP & dGTP), 1.5 mM MgCl2, 2.5 U Taq DNA Polymerase, 0.3 μM each primer and 25 ng 
template DNA. PCR reactions with HOT FIREPol® DNA Polymerase (Solis BioDyne, Estonia) 
were carried out as for those with Taq, but only 1.25 U HFP polymerase was used. The 
following cycling conditions were used for amplification: 
 
Reactions with Taq    Reactions with HFP 
95 °C  3:00   (min:sec)  95 °C  15:00 
95 °C  0:30     95 °C  0:20 
varied   0:30  x 39   varied   0:30 x 35 
72 °C   varied     72 °C   varied  
72 °C   7:00     72 °C   7:00  
 
Table 2.1: PCR set up for region of difference amplifications 
 
PCR Polymerase Extension Time (min:sec) 
Amplicon size (bp) 
H37Rv Deleted 
RD115* HFP 4:00 3,442 835 
RD122* Taq 1:30 1,456 285 
RD174* not successful 4,524 874 
RD182* not successful 7,292 812 
RD183* HFP 4:30 3,965 1,048 
RD193* Taq 1:30 1,308 807 
RD219* not successful 3,609 717 
RD724^ Taq 1:30 1,288 1,650 
RD726# HFP 2:05 2,062 313 
RD761# HFP 2:05 1,389 295 
All reactions were carried out at 64 C.  
* Primers from (Tsolaki et al. 2004) 
^ Primers from (Mostowy et al. 2004) 
# Primers from Gagneux et al. (2006) 
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Table 2.2: PCR set up for internal flanking region of difference amplifications 
 
PCR Polymerase Extension Time (min:sec) 
Amplicon size (bp) 
H37Rv Deleted 
RD174-Int* Taq 0:40 533 0 
RD182-Int* Taq 0:40 593 0 
RD219-Int* Taq 0:40 395 0 
All reactions were carried out at 60 C. 
* Primers used as described in de Jong et al. (2009). 
 
PCR reactions were visualised as in Section 2.2.7.5.  
 
2.1.3.5 Latin American Mediterranean (LAM) Strain Classification 
The Latin American Mediterranean (LAM) strains belong to a sub-lineage of the Euro-American 
superlineage. Members of the LAM family are identified via screening for the LAM specific SNP 
at codon 103 of the gene encoding Ag85C (Rv0129c) by restriction fragment length 
polymorphism (RFLP) analysis or by LAM-specific IS6110 PCR (Marais et al. 2006;  Gibson et 
al. 2008). PCR reactions were carried out with HOT FIREPol® DNA Polymerase (Solis 
BioDyne, Estonia) in 20 μl volumes using the following concentrations: 1 x PCR buffer, 0.2 mM 
deoxynucleotide mix (dATP, dCTP, dTTP & dGTP), 3.5 mM MgCl2, 1.5 U HOT FIREPol® DNA 
Polymerase, 1.25 μM each primer (reactions for the LAM-restricted IS6110 locus used LAMF, 
LAMR and XhoI, reactions for Ag85C103 PCR-RFLP used Ag85C103F and Ag85C103R), 1 x 
Solution S and 10 ng template DNA. The following cycling conditions were used for 
amplification: 
 
95 °C  15:00   (min:sec)  
95 °C  0:30  
62 C  1:00  x 34 
68 °C   1:00  
72 °C   7:00  
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PCR reactions for the LAM-restricted IS6110 locus were visualised as in Section 2.2.7.5. 
Those for Ag85C103 PCR-RFLP had 8 µl of the reaction visualised as for Section 2.2.7.5 and 
the remaining 12 µl digested with 6 U Mn1I (New England Biolabs, USA) in 1 x NEB buffer 4 
and 1 x BSA for 4 hr at 37 C, 900 rpm, then visualised as for Section 2.2.7.5 but on a 4 % gel. 
 
2.1.3.6  Rangipo Diagnostic PCRs 
2.1.3.6.1 Amplification Across SNPs 
Gene sequences spanning probable Rangipo-specific SNP sites were amplified and 
sequenced to confirm the presence of the SNP in Rangipo strains. PCR reactions were carried 
out with Taq DNA polymerase (Invitrogen, USA) in 20 μl volumes using the following 
concentrations: 1 x PCR buffer, 0.2 mM deoxynucleotide mix (dATP, dCTP, dTTP & dGTP), 
1.5 mM MgCl2, 2 U Taq DNA Polymerase, 0.3 μM each primer and 10 ng template DNA. The 
following cycling conditions were used for amplification: 
 
95 °C  3:30   (min:sec)  
95 °C  0:30  
58 C  0:30  x 34 
72 °C   0:35  
72 °C   7:00  
 
10 µl of PCR reactions for Rv0405, Rv1192, Rv1821, Rv2546, Rv3119, Rv3769 and Rv3881c 
were run on a gel as in Section 2.2.7.5 to check there was just a single product, and then the 
remainder was ExoISAP treated in preparation for sequencing as in Section 2.1.4. Where 
multiple products were amplified (Rv0071, Rv2224c and Rv3616c) a two-step PCR was 
performed as below prior to confirmation of single products and ExoISAP treatment (as above) 
before sequencing. 
 
Two-step PCR reactions were set up as above but cycled as follows:  
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95 °C  3:30   (min:sec)  
95 °C  0:20  
65 C  0:40   
   68 C  7:00 
 
2.1.3.6.2 Uniplex Rangipo-Specific SNP RFLP Assays 
Rangipo-specific SNPs were PCR amplified then digested in a RFLP assay to determine if the 
RFLP assay could detect the SNP in Rangipo or non-Rangipo strains and therefore distinguish 
between the two strains. PCR reactions were set up as for Section 2.1.3.6.1 using the two-step 
cycling protocol with an extension time of 30 s. 10 µl of PCR reactions were run on a gel as in 
Section 2.2.7.5 to check products had amplified, then the remainder was digested overnight 
with 1 µl of the respective restriction enzyme and incubation temperature (see Table 2.3 
below) prior to analysing on a 3 % agarose gel as for Section 2.2.7.5. Digests were initially 
performed in their respective buffers, then all those which produced satisfactory results were 
tested in just the PCR reaction mixture, without the addition of restriction enzyme buffers or 
additives. 
 
x 34 
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Table 2.3: Uniplex Rangipo-specific SNP RFLP assays 
 
SNP 
Restriction 
Enzyme 
NEB 
buffer 
Temperature 
(C) 
Product sizes (bp) 
Undigested Digested 
Rangipo Non-Rangipo 
Rv0071 ApaI1 - 25 221 221 26, 195 
Rv0405 HinfI2 - 37 222 
11, 93, 
118 
11, 22, 71, 
118 
Rv0719 RsaI2 - 37 119 119 40,79 
Rv1821 Sau3AI3 4+BSA 37 493 493 149, 344 
Rv1854c BclI1 - 37 401 401 130, 271 
Rv2224c AvaI4 - 37 146 146 23, 123 
Rv2504c DraIII5 - 37 241 241 48, 193 
Rv2546 EcoR15 3 37 225 225 24, 201 
Rv2716 DraIII5 - 37 208 208 27, 208 
Rv3119 HaeII5 - 37 403 80, 323 403 
Rv3513c HaeIII2 - 37 366 
12, 49, 
150, 155 
12, 150, 204 
Rv3616c TaqI1 - 65 292 23, 269 292 
Rv3769 DraIII5* 3+BSA 37 153 153 27, 126 
Rv3867 MluI1 - 37 144 25, 119 144 
Rv3881c MvaI1 - 37 434 
48, 130, 
256 
178, 256 
Restriction enzymes were from the following manufacturers at the following concentrations: 1 Boehringer 
Mannheim (10 U/µl), 2 Roche (10 U/µl), 3 Stratagene (10 U/µl), 4 Boehringer Mannheim (5 U/µl), 5, NEB (20 
U/µl).* Initial overnight digests of the Rv3769 SNP were performed with DraIII, but later digests performed for 
triplex diagnostic assays used DraIII-HF for only 2 hr. 
 
2.1.3.6.3 Multiplex Rangipo-Specific SNP RFLP Assays 
Multiplex Rangipo-specific SNP RFLP PCR assays were performed using two or three SNPs in 
one reaction to strengthen the ability of the assay to detect and distinguish between Rangipo 
and non-Rangipo strains. PCR reactions and RFLP assays were initially carried out using the 
conditions and parameters used for uniplex assays above (Section 2.1.3.6.2), but then with the 
optimised PCR condition identified using the modified Taguchi methods (below), and with 
digests performed for a total of 2 hr only with 0.4 µl of each RE. The optimised triplex PCR 
condition chosen for the Rangipo SNP-RFLP diagnostic assay were; 1 x PCR buffer, 0.1 mM 
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dNTPs, 2.4 mM MgCl2, 3 U Taq DNA Polymerase, 0.1 μM Rv3119 and Rv1821 primers and 
0.2 μM Rv2504c primers, and 10 ng template DNA annealed at 68 C. 
 
2.1.3.6.4 Taguchi Based Optimisation of Multiplex PCRs   
Di and triplex PCRs were optimised using modified Taguchi methods based on (Cobb & 
Ciarkson 1994;  Anilkumar et al. 2012). Here, the conditions varied were annealing 
temperature, and the concentrations of Taq DNA polymerase, magnesium, primers and 
dNTPs. Apart from the conditions being optimised, PCR reaction conditions were the same as 
those used in Section 2.1.3.6.2, but in a 25 µl total volume. Tables showing the orthogonal 
array conditions for each are shown in Appendix A.1. 
 
2.1.4   ExoISAP (Exonuclease I - Shrimp Alkaline Phosphatase) 
Clean Up of PCR Products 
Single PCR products were cleaned up with ExoISAP treatment prior to sequencing. The 
Exonuclease I removes residual single-stranded primers and DNA while the Shrimp Alkaline 
Phosphatase (SAP) removes remaining dNTPs from the PCR that would otherwise interfere 
with the labelling step of the sequencing process. 0.5 U SAP (Roche Applied Science, 
Switzerland) and 10 U Exonuclease I (Fermentas, Lithuania) were added to 10 µl PCR product 
and incubated for 30 min at 37 °C before the two enzymes were inactivated by incubating for 
15 min at 80 °C. 
 
2.1.5 Identification of Rangipo-Specific SNPs 
After probable Rangipo-specific SNPs were identified through WGS by Roberto Colangeli and 
David Alland at the Department of Medicine, University of Medicine and Dentistry of New 
Jersey (USA) (Section 2.1.2), a shortlist of definite Rangipo-specific SNPs was established. 
SNP positions had been identified relative to the H37Rv genome, so the H37Rv genome was 
used as the reference strain to align and screen all other TB strains in the TB Database 
(Reddy et al. 2009). This initial screen was to check for the presence of annotated SNPs in 
other TB strains at the putative Rangipo-specific SNP position, and the level of genetic 
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variation/number of SNPs present within each putative SNP containing gene. Any putative 
Rangipo-specific SNPs which were found within other strains in the TB Database, or within 
genes containing a high number of annotated SNPs (>20) were ruled out for use as a Rangipo-
specific marker. 
 
Candidate Rangipo-specific SNPs were further ranked according to their surrounding genes 
function to trim the list down to the top 10 Rangipo-specific SNP candidates. Genes of interest 
included vapB or vapC genes, or genes involved with virulence, persistence or pathogenesis. 
Regions of approximately 450 bp spanning the SNP were PCR amplified in Rangipo strains as 
in Section 2.1.3.6.1 then sequenced to confirm the presence of the SNP. 
 
2.1.6 Development of SNP Specific PCR-RFLP Assays  
Rangipo-specific SNPs were initially tested singly in PCR-RFLP assays before testing in 
combination in order to develop the best assay for detecting M. tuberculosis Rangipo isolates. 
 
2.1.6.1 Uniplex Assays 
SNPs can be detected by RFLP analysis if only one of the two variant bases creates a 
cleavage site for a restriction enzyme. WatCut 
(http://watcut.uwaterloo.ca/watcut/watcut/template.php), an on-line SNP-RFLP analysis 
program, was used to deduce all possible restriction enzymes that would selectively recognise 
and cut only one of the two base variants at each SNP site. The choice of restriction enzyme 
used was based on availability and cost, and preference was given to those enymes which 
required no or few base changes in the primers used for the assay (with any modifications at 
least 3bp away from the SNP to anchor it), and enzymes which had few additional recognition 
sequences in the region being amplified surrounding the SNP. Regions surrounding single 
SNPs were PCR amplified, then digested with the appropriate restriction enzyme as for 
Section 2.1.3.6.2. 
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2.1.6.2 Multiplex Assays 
Combinations of two or three PCR-RFLP assays were analysed for assays which produced 
different size bands in Rangipo and non-Rangipo isolates to easily and robustly distinguish 
between the two. A combination containing at least one Rangipo and one non-Rangipo SNP 
variant recognition site as a built in control, and restriction enzymes which worked together at 
the same temperature, for the same time and in PCR buffer alone was chosen for the final 
Rangipo diagnostic. Assays were performed as for Section 2.1.3.6.3. 
 
2.1.7 Testing the Rangipo-Specific PCR-RFLP Diagnostic on 
Clinical Isolates 
The Rangipo-specific PCR-RFLP diagnostic was initially tested on H37Rv and Rangipo clinical 
isolate gDNA before testing both known and blind samples from LabPLUS. Blind samples were 
sent labelled with an identification number only, they were analysed blind with the Rangipo-
specific PCR-RFLP diagnostic and the results sent to LabPLUS who then confirmed whether 
the samples were Rangipo or not according to their MIRU typing results. 
 
2.2 Methods relating to Chapter Four: RT-qPCR 
2.2.1 Bacterial Strains and Growth Conditions 
Mycobacterial glycerol stocks were streaked onto blood agar, Luria-Bertani (LB), or LB 
supplemented with 0.05 % Tween 80 (LBT) plates and incubated at 37 °C until single colonies 
had formed. Single colonies of M. smegmatis: mc26 (wild-type strain); mc2155 (laboratory 
strain) and derived strains (4517 (overexpression strain); and JR121 (deletion strain)) were 
grown in 10 mL of either LB, LBT, brain heart infusion (BHI) or Sauton’s medium. The cultures 
were incubated at 37 °C and either grown planktonically on a shaker at 200 rpm, or as a 
biofilm under stationary conditions in 50 ml CellStar tissue culture flasks (Greiner Bio-One Inc, 
Germany). Cultures used for antibiotic stress experiments were grown as above but with the 
addition of antibiotics at specific concentrations. 
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M. smegmatis mc24517 overexpression strains harbouring pYUBMS1283 (VapB) and 
pYUBMS1283/4 (VapBC) constructs were obtained from Jo McKenzie (The University of 
Waikato) according to the methods outlined in McKenzie, J. L. (2011) (See Appendix A.2 for a 
table of bacterial strains and plasmids). 
 
2.2.2 Total Cellular Protein Determination 
Total protein was extracted and estimated from mycobacterial cultures by the Lewin method 
(Meyers et al. 1998) as follows: 1 ml samples were centrifuged (10 min, 13,000 g, 4 °C) then 
the pellets were washed with 1 ml of phosphate-buffered saline (PBS), pH 7.0 without 
resuspending the cells, and centrifuged again. At this point the pellets were frozen at -20°C for 
later analysis, or resuspended in 0.1 ml of 1 M sodium hydroxide (NaOH) and incubated at 99 
°C for 10 min. The samples were neutralised by adding 0.02 ml of 5 M HCl, and the volumes 
adjusted to 1 ml by adding 0.88 ml of PBS, pH 7.0. Samples were centrifuged (30 min, 13,000 
g, 4 °C) to pellet the debris, and the supernatant was removed for protein determination using 
the Quant-iT Protein Assay Kit and Qubit fluorometer (Invitrogen, USA). A Qubit working 
solution was made by diluting the Qubit protein reagent 1:200 in Qubit protein buffer. An 
aliquot of 190 μl of working solution was added to 10 μl of standard or protein sample in clear 
0.5 ml thin wall Axygen® tubes (Corning, USA), vortexed briefly and incubated at room 
temperature for 15 min before reading. Before reading samples, the fluorometer was calibrated 
using three protein standards. Successful calibration of the instrument resulted in a greater 
than 30 fold difference between the first and second standard values, and a greater than 1.4 
fold difference between the second and third standard values. 
 
2.2.3 RNA Isolation 
A number of different standard laboratory RNA extraction methods were tested including Tri 
Reagent (MRC, USA), Trizol (Invitrogen, USA), RNeasy (Qiagen, Netherlands), and Acidic 
Guanidinium Isothyocynate/Phenol/Chloroform isolation. In order to optimize RNA isolation, 
modifications of the methods were also tested including: multiple culture volumes; various 
bead quantities; combinations of TRI Reageant and GITC methods; RNA precipitation with 
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shorter centrifugation times, and RNA washes without 100 % ethanol. In order to compare the 
different extraction methods, they were performed in duplicate using aliquots of the same 
culture sample. All samples were bead beaten using a FastPrep cell disrupter (FP120) 
(Thermo Savant, USA) on setting 6. Isolated RNA was used immediately or stored at −80 °C 
until use. 
 
2.2.3.1  TRI Reagent and Trizol 
Total RNA was isolated using TRI Reagent or Trizol following the manufacturer’s instructions, 
with the additional step of disrupting the cells by bead beating. Briefly, 1.5 ml of culture 
(approximately between 106 and 107 cells) was pelleted then homogenised in 1 ml of TRI 
Reagent or Trizol. The homogenate was beaten with 0.3 g of 0.1 mm and 2.5 mm zirconia 
beads four times for 20, 25, 30 and 35 s respectively with 1 min rests in between. Either 0.2 ml 
chloroform or 0.1 ml of 1-bromo-3-chloropropane (BCP) was added and shaken vigorously for 
1 min, then left for 5 min at room temperature. After centrifugation (13,000 rpm, 15 min, 4 °C) 
the upper aqueous phase was carefully transferred into a sterile tube. The RNA was 
precipitated with 0.5 ml of isopropanol and incubated at room temperature for 10 min, then 
pelleted by centrifugation (13,000 rpm, 15 min, 4 °C). The precipitated RNA was washed in 1 
ml 70 % ethanol and centrifuged (13,000 rpm, 5 min, 4 °C), briefly air-dried, and then 
solubilised in 35 µl 10 mM Tris pH 7.4, 0.5 mM MnCl2. 
 
2.2.3.2  Acidic Guanidinium Isothiocyanate/Phenol/BCP Method 
Total RNA was isolated based on the Acidic Guanidinium Isothyocynate/Phenol/Chloroform 
(AP-GITC) procedure (Chomczynski & Sacchi 1987) with a few modifications, namely, BCP 
was used instead of chloroform and two successive phenol-BCP extractions were performed 
instead of one. A culture sample (1.5 ml) (approximately between 106 and 107 cells) was 
added to 6 ml of 5 M GITC, pH7, mixed by inverting and pelleted by centrifugation (3,000 g, 10 
min, 4 °C). The pellet was resuspended in 0.5 ml of fresh 5 M GITC, pH7,  transferred to a 
sterile tube containing 0.3 g of 0.1 mm and 2.5 mm zirconia beads and stored at −80 °C until 
use. Cells were disrupted by bead beating as described above (Section 2.2.3.1) and briefly 
centrifuged to remove the resulting foam. NaOAc (50 μl of 2 M, pH 4) and 0.5 ml water 
 44 
 
saturated phenol were added, vortexed for 15 s then rotated for 10 min at room temperature. 
After addition of 100 µl BCP, the sample was shaken vigorously for 1 min, incubated for 5 min 
on ice and centrifuged (13,000 rpm, 15 min, 4 °C). The aqueous phase was re-extracted by 
repeating the two previous steps in a new tube, scaling up the volumes accordingly to account 
for any increase in aqueous phase volume. The RNA contained in the aqueous phase was 
transferred to a new tube and precipitated with an equal volume of isopropanol before being 
incubated on ice for 1 hr. The RNA was pelleted by centrifugation (13,000 rpm, 30 min, 4 °C), 
washed in 1 ml 70 % ethanol and centrifuged again (13,000 rpm, 10 min, 4 °C). Finally, the 
RNA was washed in 1 ml 100 % ethanol, centrifuged (13,000 rpm, 10 min, 4 °C), briefly air-
dried and then solubilised in 35 µl 10 mM Tris pH 7.4, 0.5 mM MnCl2. 
 
2.2.3.3 RNeasy 
RNA was extracted using the RNeasy Mini Kit (Qiagen, Netherlands) according to the 
manufacturer's instructions with the exception that the cells were homogenised via the bead 
beating disruption method, and the RNA was eluted in 10 mM Tris pH 7.4, 0.5 mM MnCl2. 
A culture sample (1.5 ml) (approximately between 106 and 107 cells) was pelleted (13,000 rpm, 
5 min, 4 °C) then resuspended in 600 µl Buffer RLT. The cells were disrupted by beating with 
0.3 g of 0.1 mm and 2.5 mm zirconia beads as described above (Section 2.2.3.1). RNA was 
precipitated with 600 µl 70 % ethanol and then 700 µl was transferred to an RNeasy spin 
column (placed in a 2 ml collection tube) and centrifuged (13,000 rpm, 15 s, 4 °C). Successive 
700 µl aliquots were centrifuged in the same column. The column was washed with 700 μl 
Buffer RW1 and centrifuged (13,000 rpm, 15 s, 4 °C), then 500 μl of Buffer RPE and 
centrifuged. The column was washed one additional time and centrifuged for longer to ensure 
complete removal of ethanol (13,000 rpm, 2 min, 4 °C). The column was transferred to a new 2 
ml collection tube and centrifuged to remove residual buffer (13,000 rpm, 1 min, 4 °C). Finally, 
RNA was eluted by transferring the column to a new 1.5 ml tube, adding 35 µl 10 mM Tris pH 
7.4, 0.5 mM MnCl2 and centrifuged (13,000 rpm, 1 min, 4 °C). A further column wash was 
performed using the eluate, to ensure as much concentrated RNA was retrieved from the 
column as possible. 
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2.2.4 RNA Purity & Quantification 
Total RNA purity and concentration were estimated for all extraction methods by measuring 
A260/A230 and A260/A280 ratios with the NanoDrop®ND-1000 Spectrophotometer (NanoDrop 
Technologies, USA), and by running 800 ng on a 1.5 % agarose gel containing 0.5 µg/ml 
ethidium bromide (EtBr), to check for intact bands representing the 23S and 16S fragments. 
 
2.2.5 DNase Treatment 
RNA was treated with DNase to eliminate free DNA. One unit of RQ1 RNase-free DNase 
(Promega, USA) was added to 1 μg of RNA in 10 μl 10 mM Tris-0.5 mM MnCl2, pH 7.4 and 
incubated at 37 °C for 30 min in a Thermomixer (Eppendorf, Germany) at 900 rpm. The DNase 
was inactivated by the addition of 1 μl RQ1 DNase Stop Solution (Promega, USA) and 
incubating at 65 °C for 10 min, 900 rpm. 
 
2.2.6 Reverse Transcription 
Total RNA was reverse-transcribed using SuperScript III Reverse Transcriptase (RT) 
(Invitrogen, USA) with random primers in a 20 µl total volume using Invitrogen reagents unless 
specified. DNase treated RNA (1 μg) was incubated with 100 ng random primers at 65 °C for 5 
min, cooled on ice for 1 min followed by the addition of 1 X RT buffer, 5 mM DTT, 0.5 mM 
dNTP mix (Fermentas, Lithuania) and 140 U SuperScript III RT. The reactions were incubated 
at 25 °C for 10 min then 50 °C for 1 hr, before they were terminated at 85°C for 5 min and 
chilled on ice. For each sample, a negative RT (no addition of reverse transcriptase) reaction 
was performed and used as a negative control in subsequent reverse transcription quantitative 
real-time PCR (RT-qPCR). 
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2.2.7 Reverse Transcription Quantitative Real-Time PCR (RT-
qPCR) 
2.2.7.1 Primer Design  
Primers for each gene were designed based on the published M. smegmatis mc2155 sequence 
(GenBank accession number NC_008596) with the aid of Primer 3 (Koressaar & Remm 2007) 
and Vector NTI (Life Technologies, USA) software. Where possible, primers were designed to 
have similar properties so that PCRs for different genes could be performed in the same run. 
Secondary template structure was avoided where possible and primers were obtained from 
Sigma Aldrich (USA) or IDT (USA). 
 
2.2.7.2 Reaction Set Up 
All RT-qPCR reactions were carried out in triplicate 20 μl volumes using either SYBR Green I 
or SYTO 82 (Invitrogen, USA). A master mix was prepared consisting of 1 X Thermo-Start 
PCR Buffer (ABgene, UK), 5 mM MgCl2 (ABgene, UK) and 200 μM each dNTP (Fermentas, 
Lithuania), then DNase treated with 10 U/ml of RQ1 RNase-Free DNase (Roche Applied 
Science, Switzerland) at 37 °C for 1 hr at 900 rpm, inactivated at 80 °C for 30 min, and stored 
at -20 °C until use. A PCR master mix was prepared containing the above master mix, a 
fluorescent nucleic acid dye (0.5 X SYBR Green I or 2 μM SYTO 82) and 36 U/ml Thermo-
Start Taq DNA Polymerase (ABgene, UK). For each primer set, a qPCR master mix was 
prepared containing PCR master mix, 125 nM primers and 10 μl of diluted cDNA. cDNA was 
diluted in qPCR master mix at a ratio of 0.075 μl per 1 μl of qPCR master mix, except for the 
16S reference samples where the diluted cDNA was further diluted to give 0.0001125 μl cDNA 
per 1 μl of qPCR master mix. Each sample contained 19 μl of the qPCR master mix, 0.25 μl of 
primer (10 μM) and 0.75 μl of cDNA, and each 16S reference sample contained 19.75 μl of the 
qPCR master mix, 0.25 μl of primer and 0.00125 μl of cDNA. 
 
2.2.7.3 qPCR Run 
Real-time PCR was performed on the Rotor-Gene 6000 (Corbett Research, Australia). The 
reaction conditions were; 1 cycle of 95 °C for 15 min, followed by 35 cycles of 95 °C for 20 s, 
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55 °C for 20 s, 68 °C for 30 s, and 80 °C for 10 s with data acquired on the 80 °C step in the 
green channel (470 - 510 nm) for SYBR Green, and yellow channel (530 - 555 nm) for SYTO 
82. Immediately following amplification, a melt curve was performed consisting of 90 s at 72 °C 
followed by 5 s steps with 0.5 °C increase in temperature per step rising to 99 °C. The identity 
of the PCR products was verified by the melt curve profile and electrophoresis on a 1 % 
agarose gel (Section 2.2.7.5). Each RT-qPCR run included a no template control (NTC) per 
amplicon and a no RT control per sample.  
 
2.2.7.4 Analysis 
Initially, the Wilkening & Bader (2004) equation (below) was used to calculate the initial copy 
number (ICN) for the housekeeping gene and GOI, using quantification cycle (Cq) and 
efficiency values generated from the Rotor-Gene 6000 software.  
 
 N0 = 1.12 × 1010/E^CN  , where 
 N0 = initial copy number or starting concentration 
 E = PCR amplification efficiency 
^ = denotes 'to the power' 
CN = the cycle number at the Cq 
 
The ICNs for the GOI were then normalised by dividing by the ICN of the houseeping gene to 
determine the relative level of expression. 
 
Later, RT-qPCR assays were analysed using the more accurate equation used in LinRegPCR. 
Here, the PCR efficiency for each individual sample was estimated using LinRegPCR (version 
11.1) software based on the slope of the log-transformed fluorescent data of the exponential 
phase (Ramakers et al. 2003). Data were normalised to a reference gene and the resulting 
mRNA expression level ratios were determined using the efficiency corrected calculation 
below. 
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 R = AVERAGE (N0 GOI) 
  AVERAGE (N0 HK)  , where 
R = expression ratio of the gene of interest, normalised to the HK 
N0 = Nq / (E(MEAN)^Cq)  , where 
N0 = starting concentration (expressed in arbitrary fluorescence units) 
Nq = fluorescence threshold set to determine Cq 
E(MEAN) = mean amplicon PCR efficiency  
^ = denotes 'to the power' 
Cq = number of cycles needed to reach Nq (previously referred to as Ct) 
 
First, the starting concentration (N0) values of technical replicates were averaged (per 
biological sample) for the GOI samples and the HK samples, and then the ratio of these two 
averages was calculated to determine the relative expression value. 
 
2.2.7.5 Agarose Gel Electrophoresis 
DNA fragments were separated via agarose gel electrophoresis. Samples were mixed with 6 x 
DNA loading dye prior to loading, and run on a 1 % TAE gel containing 0.3 μg/ml EtBr. Gels 
were visualised by UV light, and images captured. Band sizes were determined by visual 
comparison against a 100 bp DNA ladder (Invitrogen, USA, or GenScript, USA). 
 
2.3 Methods relating to Chapter Five: M. tuberculosis 
VapBC Characterisation 
2.3.1 General Methods/DNA manipulations 
2.3.1.1 Antibiotic stocks 
Hygromycin and kanamycin stocks were prepared at 50 mg/ml in MQ water then filter 
sterilised, and used at a final concentration of 50 μg/ml. 
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2.3.1.2 M. tuberculosis gDNA 
M. tuberculosis H37Ra genomic DNA was obtained from the School of Biological Sciences, 
University of Auckland. 
 
2.3.1.3 Polymerase Chain Reaction (PCR) 
M. tuberculosis vapBC operons were amplified from H37Ra genomic DNA then cloned into the 
vector pYUB28b. The vector was transformed into E. coli prior to transformation and protein 
expression in M. smegmatis. All H37Ra vapBC sequences were compared with those from 
H37Rv to ensure the amplified product would be 100 % identical to that from H37Rv. Primer 
sequences can be found in Appendix A.1. 
2.3.1.3.1 Primer Design 
All primers for cloning were designed using Geneious Pro (Version 5.02) (BioMatters Ltd, NZ) 
to include 5’ and 3’ restriction sites necessary for ligation into pYUB28b including a C-terminus 
His tag. An extra 3 – 6 bases were included to allow for efficient cleavage (dependent on the 
restriction enzymes used). An NcoI site was included at the 5’ end and where the NcoI 
sequence was present within the gene, the gene was ordered from GeneArt® (Life 
Technologies, USA) with the nucleic acid sequence altered to produce the same amino acid 
sequence but without the internal NcoI site. HindIII was used primarily as the 3’ restriction site, 
but where HindIII was present within the gene NdeI or BamHI were used. Where BamHI was 
used, an extra two bases were added in front of the BamHI recognition sequence to put the 
His tag back in-frame. The choice of restriction sites were based on including a C-terminus His 
tag and removing the N-terminus His tag, limiting the linker distance between the restriction 
enzyme and T7 sites, and using sites which occurred only once in the vector and no where in 
the gene. All putative sequences were virtually translated within the pYUB28b vector to ensure 
both the VapB and VapC protein sequences were correct, and the C-terminal His tag was in-
frame. 
 
Primers for amplification of the plasmid by itself contained no flanking restriction sites. All 
primers were supplied by IDT (USA) and resuspended in 1 x TE. 
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2.3.1.3.2 Polymerase Chain Reaction Amplification of vapBC Operons for 
Ligation into pYUB28b 
All PCR reactions amplifying inserts for ligation were carried out with the proofreading enzyme 
Platinum Pfx® DNA polymerase (Invitrogen, USA). The annealing temperature was optimised 
for each primer set by initially performing a gradient PCR spanning 5 °C above and below the 
calculated Tm of the primers. PCR reactions were carried out in 25 μl volumes using the 
following concentrations: 1 x Pfx amplification buffer, 0.3 mM deoxynucleotide mix (dATP, 
dCTP, dTTP & dGTP), 1 mM MgSO4, 1 U Platinum Pfx® DNA polymerase, 1 μM each primer 
and 100 ng template DNA. The following cycling conditions were used for amplification: 
 
94 °C  2:00   (min:sec)  
94 °C  0:30  
56 – 66 C* 0:30  x 29 
68 °C   1:00  
68 °C   7:00  
 
*Annealing temperature determined by gradient PCR  
 
For primer sets where no temperature within the gradient produced clean product, the 
magnesium concentration was further optimised using a selection of MgSO4 concentrations 
between 0.75 mM and 3 mM. PCR reactions were visualised as in Section 2.3.1.4 below. 
 
2.3.1.3.3 PCR Screening of pYUB28b Transformants  
All pYUB28b plasmids purified from E. coli (Section 2.3.1.11) were checked for the presence of 
insert prior to sequencing by performing PCR with T7 primers. PCR reactions were carried out 
with Taq DNA polymerase (Invitrogen) in 25 μl volumes using the following concentrations: 1 x 
PCR buffer, 0.2 mM deoxynucleotide mix (dATP, dCTP, dTTP & dGTP), 1.5 mM MgCl2, 2.5 U 
Taq DNA Polymerase, 1 μM each primer and 30 - 60 ng template DNA. The following cycling 
conditions were used for amplification: 
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94 °C  2:00   (min:sec)  
94 °C  0:30  
55 C  0:30  x 29 
72 °C   0:45  
72 °C   5:00  
 
PCR reactions were visualised as in Section 2.3.1.4 below. 
 
2.3.1.4 Agarose Gel Electrophoresis 
DNA fragments were separated via agarose gel electrophoresis. Samples were mixed with 10 
x DNA loading dye prior to loading, and run on a 1 % TAE gel. Agarose gels were post-stained 
for 20 min with either 0.5 μg/ml EtBr, or 1 x SYBR SafeTM DNA gel stain (Invitrogen, USA) if 
products were going to be recovered. Gels were visualised by UV light (EtBr) or on a blue light 
box (SYBR SafeTM) if products were going to be recovered, and images captured. Band sizes 
were determined by visual comparison against a 1kb-Plus DNA ladder (Invitrogen, USA). 
 
2.3.1.5 DNA Purification and Quantification 
DNA from agarose gels were separated and visualised with SYBR SafeTM DNA dye as 
described in Section 2.3.1.4. The desired bands were extracted using a sterile scalpel blade 
and DNA purified using the QIAquick Gel Extraction Kit (Qiagen, Netherlands) according to the 
manufacturer’s instructions. DNA was eluted in 30 μl of elution buffer. 
 
PCR products in solution from two 50 μl PCR reactions were pooled and purified using a 
Qiaquick PCR Product Purification Kit (Qiagen, Netherlands) according to manufacturer’s 
instructions. 
 
DNA purity and concentration was estimated by measuring A260/A230 nm and A260/A280 nm 
ratios using a NanoDrop®ND-1000 Spectrophotometer (NanoDrop Technologies, USA). 
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2.3.1.6 Restriction Enzyme Digestion 
Restriction enzymes were purchased from Invitrogen (USA), and digests were performed on 
gel purified PCR products (Section 2.3.1.5) or plasmid DNA (Section 2.3.1.11) singly due to 
buffer incompatibilities. Less restriction enzyme was used compared to the manufacturer’s 
recommendation in order to reduce costs. NcoI (1 µl) was added to 28 µl of DNA along with 
the appropriate amount of buffer, BSA and water for a 100 µl reaction according to the 
manufacturer’s instructions. Digests were incubated at 37 °C with shaking at 600 rpm for 3 hrs 
or overnight, and then purified from solution according to Section 2.3.1.5. The second digest 
was performed on the purified product with either 2 µl HindIII, BamHI or NdeI, and treated as 
for the first restriction enzyme digest. 
 
2.3.1.7 pYUB28b Vector Dephosphorylation 
Digested pYUB28b vector (30 µl) was dephosphorylated with 5 U Shrimp Alkaline 
Phosphatase (SAP) and 1 x SAP dephosphorylation buffer (Roche Applied Science, 
Switzerland) at 37 °C with shaking at 600 rpm for 30 min. The reaction was inactivated by 
incubating at 65 °C with shaking at 600 rpm for 15 min. 
 
2.3.1.8 DNA Ligation 
DNA ligations were set up using 1 U of T4 DNA Ligase (Invitrogen, USA), and a vector to insert 
ratio of 30 fmol : 90 fmol in a total volume of 10 µl. Ligations were incubated for 6 hrs at room 
temperature, overnight at 14 C or over the weekend at 4 C. 
 
2.3.1.9 Preparation of Electrocompetent E. coli TOP10 Cells 
A glycerol stock of E. coli TOP10 cells was streaked onto a low salt LB agar plate and 
incubated at 37 °C overnight. An aliquot of low salt LB (10 ml) was inoculated with a single 
colony and grown overnight at 37 C, 200 rpm. The overnight culture was used to inoculate 1 L 
of low salt LB, which was grown at 37 C, 200 rpm until it reached an OD600 of 0.5 - 0.7. All 
subsequent steps were performed with ice-cold 10 % glycerol, in pre-chilled, sterile containers. 
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The cells were chilled on ice for at least 20 min, centrifuged (4,000 g, 15 min, 4 C), the 
supernatant removed and the pellet resuspended in 500 ml 10 % glycerol. The spin and wash 
step was repeated two further times, resuspending in 250 ml then 20 ml respectively. The cells 
were transferred to a 50 ml falcon tube and centrifuged (4,000 g, 15 min, 4 C) one final time 
before resuspending in 2 ml 10 % glycerol, flash freezing 50 µl aliquots in liquid nitrogen and 
storing at -80 C. 
 
2.3.1.10 Electroporation of E. coli 
Plasmid DNA (1 μl) or ligation reaction was added to 50 μl freshly thawed (on ice) 
electrocompetent E. coli TOP10 cells. The mixture was placed in a 2 mm electroporation 
cuvette (BioRad Laboratories, USA), tapped to remove air bubbles and electroporated with a 
Bio-Rad Gene PulserTM (Bio-Rad Laboratories, USA) at 2.5 kV, 25 μF capacitance and 200 Ω 
resistance. Transformed cells were recovered immediately in 1 ml of SOC media and 
incubated at 37 °C shaking at 200 rpm for 30 min. Aliquots of the cells (50 μl and 100 μl) were 
plated onto low salt LB agar plates containing hygromycin for selection and incubated at 37 °C 
overnight. Single colonies from these agar plates were used to inoculate 5 ml low salt LB 
cultures containing hygromycin. These cultures were incubated at 37 °C shaking at 200 rpm 
overnight and used to isolate plasmid DNA according to the method in Section 2.3.1.11. 
 
2.3.1.11 E. coli Plasmid DNA Extraction 
E. coli plasmid DNA was extracted from 5 ml overnight cultures using the QIAprep Spin 
Miniprep Kit (Qiagen, Netherlands) according to manufacturer’s instructions, and eluted in 50 
μl elution buffer. 
 
2.3.1.12 Sequencing of DNA 
DNA was sequenced by the Waikato DNA Sequencing Facility on an Applied Biosystems 
3130xl Genetic Analyzer at The University of Waikato. 
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2.3.1.13 Preparation of Electrocompetent M. smegmatis 
A glycerol stock of M. smegmatis 4517 cells was streaked onto a low salt LBT + kanamycin 
agar plate and incubated in a humidity chamber at 37 °C for three days. Cultures of 5 ml low 
salt LBT + kanamycin were inoculated with a single colony and grown for 48 hrs at 37 C at 
200 rpm. The 5 ml culture was used to inoculate 500 ml of 7H9 + ADC + Tween 80 + 
kanamycin, which was grown at 37 C at 200 rpm until it reached an OD600 of 0.6 - 0.7. 
All subsequent steps were performed with ice-cold 10 % glycerol, in multiple pre-chilled, sterile 
50 ml falcon tubes rather than large centrifuge bottles (in order to achieve a firmer pellet). The 
cells were chilled on ice for 1.5 hrs, centrifuged (4,000 g, 20 min, 4 C), the supernatant 
removed and then the pellet resuspended in 50 ml 10 % glycerol. The spin and wash step was 
repeated two further times, resuspending in 50 ml then 5 ml respectively. The cells were 
pooled and transferred to a single 50 ml falcon tube then centrifuged (4,000 g, 20 min, 4 C) 
one final time before resuspending in 500 µl 10 % glycerol, flash freezing 40 µl aliquots in 
liquid nitrogen and storing at -80 C. 
 
2.3.1.14  Electroporation of M. smegmatis 
Plasmid DNA (1 μl) was added to 40 μl freshly thawed (on ice) electrocompetent M. smegmatis 
4517 cells. The mixture was placed in a 2 mm electroporation cuvette (BioRad Laboratories, 
USA), tapped to remove air bubbles and electroporated with a Bio-Rad Gene PulserTM (Bio-
Rad Laboratories, USA) at 2.5 kV, 25 μF capacitance and 1000 Ω resistance. Transformed 
cells were recovered immediately in 1 ml of 7H9 media and incubated at 37 °C shaking at 200 
rpm for 3 hrs. Aliquots of the cells (50 μl and 100 μl) were plated onto 7H10 agar plates 
containing hygromycin and kanamycin for selection and incubated at 37 °C for 3 days in a 
humidity chamber.  
 
2.3.1.15 Glycerol Stocks 
Glycerol stocks for long term storage of transformed bacteria at -80 °C were made by adding 
0.5 ml of sterile 50%  glycerol to 0.5 ml of overnight culture (LB + hygromycin for E. coli or LBT 
+ hygromycin and kanamycin for M. smegmatis + pYUB28b plasmid). 
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2.3.2 Protein Expression and Purification 
2.3.2.1 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) Protein 
Analysis 
SDS-PAGE gels were cast in a Hoefer mini gel casting system. SDS-PAGE gels consisted 
of a 5 % acrylamide stacking gel overlaid on a 15 or 16.5 % acrylamide resolving gel 
(depending on the protein size). All SDS-PAGE gels were made up with 30 % acrylamide with 
an acrylamide:bisacrylamide ratio of 37.5:1 (Bio-Rad Laboratories, USA), included 0.1 % 
filtered SDS, and were polymerised by the addition of 0.05 % ammonium persulphate (APS) 
and TEMED. 
 
Protein samples were mixed in a 3:1 ratio with 4 x SDS loading buffer and denatured for 5 min 
at 95 °C prior to loading onto the gel. Gels were run with 1 x SDS-PAGE running buffer at 
constant 70 V until the samples entered the resolving gel, then at 150 V until the dye front 
reached the end of the gel. For protein MW estimation, 10 µl of Precision Plus Protein TM 
Unstained Standard (Bio-Rad Laboratories, USA) was run alongside each gel. 
 
2.3.2.2 Native Polyacrylamide Gel Electrophoresis (Native-PAGE) 
Protein Analysis 
Native-PAGE gels of varying concentrations (depending on the size of the proteins being 
separated) were cast and run as for SDS-PAGE gels (Section 2.3.2.1), except with no SDS in 
the gel, running buffer or loading dye. 
 
2.3.2.3 Isoelectric focusing (IEF) SDS-PAGE 
The two-dimensional electrophoresis was carried out with immobilized pH gradient-IEF in the 
first, and SDS-PAGE in the second dimensions. 
 
IEF was performed using the Bio-Rad PROTEAN II IEF Cell and 7 cm linear, pH 3-10 
ReadyStrip ™ IPG strips (Bio-Rad Laboratories, USA). Rehydration was carried out at room 
temperature overnight with either 2 µg or 5 µg of purified protein, plus 45 µl IEF sample buffer 
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and 80 µl re-hydration buffer per strip. Isoelectrofocusing was performed at 200 V for 10 min, 
1500 V for 1.5 hr and 3500 V for 1 hr and 15 min. Following IEF, the strips were reduced then 
alkylated by soaking and gently rocking for 20 min in 2 ml Equilibration Buffer A, then 2 ml 
Equilibration Buffer B. 
 
To separate the proteins in the second dimension by SDS-PAGE, the IPG strips were sealed 
on top of a 1 mm thick 14 % polyacrylamide gel with 0.5 % agarose in 1 x stacking buffer + 
bromophenol blue. Vertical electrophoresis was carried out at 75 V until the samples had 
entered the resolving layer, then 25 V for approximately 1 hr. Gels were fixed in 50 % 
methanol + 2 % phosphoric acid for three 30 min incubations, then stained overnight in 
Coomassie Brilliant Blue G-250 before de-staining in 10 % methanol. The image was captured 
using a GS-800 calibrated densitometer (Bio-Rad), and spots detected with the PDQuest v6.0 
software package (Bio-Rad). 
 
2.3.2.4 Coomassie Blue Stain for Protein Gel Electrophoresis 
Gels were stained by colloidal Coomassie staining using the quick stain method (Wong et al. 
2000) with Fairbanks staining solutions A-D. Gels were microwaved for 30 s in 50 ml Fairbanks 
staining solution A, cooled to room temperature while shaking gently, the stain removed then 
repeated as above with stains B, C and lastly D (de-stain). 
 
2.3.2.5 Quantification of Protein Concentration 
The NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, USA) was used to 
measure absorbance at 280 nm and the Beer-Lambert equation (A=.c.l) applied to correlate 
absorbance with concentration. Here A= absorbance at 280 nm, = the theoretical extinction 
coefficient of the protein, c= concentration, and l=pathlength. Molecular weights of the proteins 
are listed in Table 5.2. Theoretical extinction coefficients were calculated based on the amino 
acid composition using Geneious Pro (Version 5.02 Biomatters Ltd, NZ) or the ExPASy 
ProtParam tool (Gasteiger et al. 2005). 
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2.3.2.6 Concentration of Protein Samples 
Vivaspin concentrators (10 kDa molecular weight cut-off) (Sartorius AG, Germany) were used 
to concentrate protein samples. Protein samples were added to the upper reservoir of 20 ml or 
500 µl concentrators and spun at 3,900 g at 4 °C until the desired volume or concentration 
was reached.   
2.3.2.7 Dialysis of Protein Samples 
Protein samples were dialysed into target buffer using 6 - 8 kDa molecular weight cut off 
Spectra Por® dialysis tubing (Spectrum Laboratories, USA). Samples were loaded into pre-wet 
tubing and the ends sealed using dialysis clips before dialysing into 1 L of gently stirring target 
buffer at 4 C. The buffer was replaced after 2 hrs and protein left to completely dialyse 
overnight. 
 
2.3.2.8 Buffer Exchange 
A 5 ml HiTrap Desalting column (GE Healthcare, UK) was used to desalt protein samples into 
a buffer containing less salt. The column was equilibrated with 25 ml target buffer at 5 ml/min 
before 1.5 ml of protein sample was added. The column was flushed with 5 ml of buffer and 
the eluent (containing the desalted protein) collected. A final wash step with 25 ml of water was 
performed before re-equilibrating the column with 25 ml 20 % ethanol and storing at 4 C. 
 
2.3.2.9 MALDI-TOF Mass Spectrometry (MS) of Whole Protein 
2.3.2.9.1 Sample Preparation 
2,5-dihydrozybenzoic acid and 2-hydroxy-5-methoxybenzoic acid (Super-DHB) matrix (5 mg), 
was mixed with 20 µl acetonitrile and 10 µl 0.1 % T trifluoroacetic acid (TFA) and fully 
resuspended by 10 min sonication in a sonicating water-bath (Elma, Germany). The matrix 
was spun (13,000 rpm for 10min) and mixed with sample or calibrant at a 1:1 ratio (0.5 µl:0.5 
µl) before spotting onto the AnchorChipTM MALDI-TOF target plate (Bruker Daltonics, USA) 
then air dried prior to MALDI-TOF MS analysis.  
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2.3.2.9.2 MALDI-TOF Set Up 
MALDI-TOF analysis was performed with the AutoflexTM II MALDI-TOF mass spectrometer 
(Bruker Daltonics, USA). Analysis were obtained in the reflectron positive ion linear mode with 
a 450 ns pulse, range of 5 - 20 kDa, accelerated voltage in the ion source set at 20 kV and 
laser power at around 60%. Spectra for the Protein Standard I (Bruker Daltonics, USA) were 
collected first, and the spectrometer calibrated to this with an automatic polynomial correction.  
  
Spectra were exported to DataAnalysisTM or FlexAnalysisTM software (Bruker Daltonics, USA), 
and peaks identified and labelled.  
 
2.3.2.10 Cloning of TB VapBCs into pYUB28b 
pYUB28b is an E. coli – mycobacterial shuttle vector with hygromycin resistance. The TB 
vapBC operon open reading frames (ORFs) were amplified from the attenuated M. 
tuberculosis strain, H37Ra after confirming there was 100% sequence homology with the 
H37Rv strain (Section 2.3.1.3). The primers used for amplification were designed to contain an 
NcoI restriction site in the forward primer and either a BamHI, NdeI or HindIII restriction site in 
the reverse primer. The amplified products were digested with the appropriate restriction 
enzymes (Invitrogen, USA) (Section 2.3.1.6), purified using spin columns (Roche Applied 
Science, Switzerland) (Section 2.3.1.5) and ligated into the pYUB28b shuttle vector between 
the NcoI and BamHI/NdeI/HindIII restriction sites enabling expression with a C-terminal His-tag 
(Section 2.3.1.8). Vectors containing the vapBC operons were transformed into E. coli TOP10 
cells (Section 2.3.1.10) and plated onto low salt LB agar plates containing hygromycin for 
selection. The plasmid constructs were purified then sequenced to confirm correct insertion 
before being transformed into M. smegmatis mc24517 electrocompetent cells (Section 
2.3.1.14) and plated onto 7H10 agar plates containing hygromycin and kanamycin for 
selection. 
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2.3.2.11 Small Scale Protein Expression and Purification from M. 
smegmatis 
Expression of M. tuberculosis VapBCs in M. smegmatis were initially confirmed with small 
scale His-tag binding tests using Ni Sepharose beads. A single transformed colony either from 
the freshly transformed plate or a glycerol stock streaked plate was used to inoculate a 5 ml 
PA-0.5G + 0.05 % Tween 80 seeder culture. This culture was grown for 48 hr at 37 C, 200 
rpm then 100 µl was used to seed a 10 ml ZYP-5052 + 0.05 % Tween 80 expression culture 
which was grown for 90 hr at 37 C, 200 rpm. Cultures were spun (4,600 rpm, 20 min, 4 °C) 
and cell pellets resuspended in 1 ml lysis buffer (50 mM phosphate buffer pH 7.4, 200 mM 
NaCl, 20 mM imidazole) before 3 µl was removed and added to 12 µl lysis buffer and 5 µl 4 x 
SDS loading dye (named whole-cell sample). The remainder of the cells were sonicated on ice 
using a fine tip probe for 12 s bursts at setting 3.5 with a Misonix Sonicator (USA) until cells 
were lysed. The lysate was spun (13,000 rpm, 20 min, 4 °C), the insoluble fraction was 
resuspended in 200 µl lysis buffer, then 3 µl of soluble and insoluble fractions were added to 
12 µl lysis buffer and 5 µl 4 x SDS loading buffer (named L and I respectively).  
50 µl of Ni Sepharose (GE Healthcare, UK) was transferred to a 1.5 ml eppendorf tube and 
washed with 1 ml of lysis buffer, then centrifuged (3,000 rpm for 1 min) to settle the beads. The 
wash supernatant was discarded and 200 µl of the sample’s soluble fraction (L) was added 
and then incubated at room temperature for 15 min at 1,000 rpm. The beads were spun again 
(3,000 rpm for 1 min) and supernatant removed before a 15 µl aliquot of the supernatant was 
added to 5 µl 4 x SDS loading buffer (named FT). The beads were washed with 1 ml of lysis 
buffer then spun (3,000 rpm for 1 min) and supernatant removed (named W1), before 
repeating the wash step another two times. An aliquot of W1 (15 µl) was added to 5 µl 4 x 
SDS loading buffer. 50 µl 4 x SDS loading buffer was added to the beads then 20 µl from all 
six samples were analysed by SDS-PAGE. 
 
2.3.2.12 Large Scale VapBC Protein Expression and Purification from 
M. smegmatis 
Large scale VapBC protein expression cultures were grown as for small scale protein 
expression cultures in Section 2.3.2.11, except this time 10 ml seeder cultures were used to 
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inoculate 1 L expression cultures (again, in a 1:100 ratio). Cultures were spun (4,600 rpm, 20 
min, 4 °C) and cell pellets either frozen at -80 C for later use, or resuspended in 25 ml lysis 
buffer (50 mM phosphate buffer pH 7.4, 200 mM NaCl, 20 mM imidazole) with the addition of 
an EDTA free protease inhibitor tablet (Roche Applied Science, Switzerland). The cells were 
sonicated on ice using a large probe for 30 s bursts at setting 7 – 8.5 with 1 min rests in 
between, on a Misonix Sonicator (USA) until cells were lysed (5 – 8 min). The lysate was spun 
(13,000 rpm, 20 min, 4 °C) and the insoluble fraction resuspended in 20 ml lysis buffer, then 3 
µl of soluble and insoluble fractions were added to 12 µl lysis buffer and 5 µl 4 x SDS loading 
buffer for later SDS-PAGE analysis. The remainder of the soluble fraction (containing the His-
tagged protein) was run through a HisTrap HP column (GE Healthcare, UK) or Ni-NTA Column 
(MACHEREY-NAGEL, Germany) and purified via Immobilised Metal Affinity Chromatography 
(IMAC) on an ÄKTA FPLC system as in Section 2.3.2.13. Fractions containing the protein of 
interest were purified further by size exclusion chromatography (SEC) using a Superdex 
column (GE Healthcare, UK) as in Section 2.3.2.14. Aliquots of fractions (15 µl) containing the 
protein of interest from both IMAC and SEC were added to 5 µl of 4 x SDS loading buffer for 
analysis with SDS-PAGE. 
 
2.3.2.13 Purification of His-Tagged Proteins via Immobilised Metal 
Affinity Chromatography (IMAC) 
A 5 ml HiTrapTM Chelating HP column (GE Healthcare, UK) or 1 ml Protino® Ni-NTA Column 
(MACHEREY-NAGEL, Germany) was pre-equilibrated with lysis buffer (50 mM phosphate 
buffer pH 7.4, 200 mM NaCl, 20 mM imidazole) at a flow rate of 1 ml/min. The supernatant 
from lysed large scale expression cultures was filtered through 1.2 and 0.45 μm Minisart filters 
(Sartorius AG, Germany) then loaded onto the IMAC column which was then attached to an 
ÄKTA PrimeTM, ÄKTA BasicTM or ÄKTA PurifierTM FPLC system. Unbound proteins were 
removed by washing the column with 15 - 25 ml of lysis buffer at a flow rate of 1 ml/min, before 
bound proteins were removed using a gradient of 0 – 50 % elution buffer (lysis buffer + 1 M 
imidazole) over 50 ml or 19 ml (for 5 ml or 1 ml columns respectively) at a flow rate of 1 ml/min. 
Aliquots of fractions (15 µl) were then analysed by SDS-PAGE (Section 2.3.2.1). The IMAC 
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column was stripped of Ni2+ ions using 10 ml 100 mM EDTA pH 8.0, washed with 20 ml water 
and re-primed with 5 ml 100 mM NiCl2 between purifications of different proteins. 
 
2.3.2.14 Size Exclusion Chromatography (SEC) 
Proteins were purified further by size exclusion chromatography (SEC) using either a 
preparative HiLoadTM 16/60 SuperdexTM 200 pg (S200 16/60) or analytical SuperdexTM 200 
10/300 (S200 10/300) column (GE Healthcare, UK) which have a separation range of 10 - 600 
kDa. Proteins were concentrated to 5 ml or 500 µl respectively, and filtered with a Nanosep® 
MF 0.2 µm filter (Pall, USA) before loading and running on a pre-equilibrated (50 mM 
phosphate buffer pH 7.4, 200 mM NaCl) column. Aliquots of fractions (15 µl) were then 
analysed by SDS-PAGE (Section 2.3.2.1) and if necessary, agarose gel electrophoresis 
(Section 2.3.1.4) to identify fractions containing protein which was purified along with DNA. 
 
Further SEC of proteins bound to DNA were performed using the S200 10/300 column as 
above but in a high salt (2 M NaCl) buffer to dissociate the co-purified DNA. 
 
Calibration of the S200 16/60 and 10/300 analytical size exclusion columns were carried out by 
Jo McKenzie (Proteins & Microbes Laboratory, University of Waikato) using the high & low 
molecular weight gel filtration calibration kits (GE Healthcare, UK) according to manufacturer’s 
instructions. A calibration curve was prepared for each column by plotting the Kav value 
(elution volume function) of the protein standards against their log molecular weight, to 
generate the following equation for determining Kav values for the VapBC proteins:  
 
Kav = (Ve - Vo) / (Vc – Vo)  
 
Where   Ve = elution volume  
Vo = column void volume  
Vc = geometric column volume  
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The Kav values for VapBC proteins were substituted into equations (determined previously in 
the laboratory using formula from calibration curves) in Table 2.4 to calculate the molecular 
weights of the VapBC complexes.  
 
Table 2.4: SEC calibration curve molecular weight equations. 
  
SEC Column Equation Vo (ml) Vc (ml) 
S200 10/300 MW = e ((Kav – 1.6833)/ -0.115) 8.11 24.0 
S200 16/60 MW = e ((Kav – 2.1739)/ -0.159) 46.26 124.0 
 
2.3.2.15 Tryptic Digest of the VapBC Complex  
The purified VapBC complex was subjected to a limited tryptic digest to preferentially digest 
away the labile VapB protein, leaving the VapC behind. Trypsin from bovine pancreas (0.1 mg) 
(Sigma Aldrich, USA) was added to 0.7 mg VapBC and incubated for 1 hr at room temperature 
with gentle agitation on a rocking platform. Trypsin digest reactions were stopped by the 
addition of an equal amount of trypsin inhibitor from Glycine max (soybean) (Sigma Aldrich, 
USA), and incubating for 15 min at room temperature with gentle agitation prior to purification 
via ion exchange chromatography. 
 
2.3.2.15.1 Crude Tryptic Digest without Ion Exchange Chromatography 
Where ion exchange was not performed on samples after tryptic digestion to produce pure 
VapC, a crude tryptic digest was performed resulting in a mixture of VapC, digested VapB, 
trypsin and trypsin inhibitor. The digest was performed as above, but the concentration of 
resulting VapC was estimated for an impure protein mixture sample where the rough 
concentration of VapC (mg/ml) = absorbance 280 nM / spectrometer path length (1 cm) 
2.3.2.16 Purification of VapC by Anion Exchange Chromatography 
Tryptic digests of purified VapBC complex inhibited with trypsin inhibitor (Section 2.3.2.15) 
were either concentrated until they reached 1 mg/ml then diluted 1:50 into anion exchange 
buffer, or dialysed against anion exchange buffer overnight prior to separating the trypsin + 
inhibitor from VapC via anion exchange chromatography. 
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The predominantly used anion exchange start buffer was 50 mM phosphate buffer pH 7.4, 
100 mM NaCl, although variations on the pH and salt concentration were used for VapC 
proteins which didn’t initially bind with 100 mM salt, or who’s net charge (as judged by their 
predicted pI) was too weak for effective binding at pH 7.4.  
 
A 5 ml HiTrap Q XL Anion Exchange column (GE Healthcare, UK) was pre-equilibrated with 40 
ml of start buffer. The digest was filtered through a 0.2 µm Minisart filters (Sartorius AG, 
Germany) then loaded onto the anion exchange column at a flow rate of 1 - 2 ml/min, which 
was then attached to an ÄKTA PrimeTM, ÄKTA BasicTM or ÄKTA PurifierTM FPLC system. 
Unbound protein and trypsin were removed by washing the column with 25 ml of start buffer at 
a flow rate of 1 ml/min, before bound proteins were removed using a gradient of 0 – 100 % 
elution buffer (start buffer + 1 M NaCl) over 50 ml at a flow rate of 1 ml/min. Aliquots of 
fractions (15 µl) were then analysed by SDS-PAGE (Section 2.3.2.1). The anion exchange 
column was regenerated by washing with 30 ml water followed by 30 ml of 20 % ethanol. 
 
2.3.2.16.1 Anion bead pH screen 
Q SepharoseTM Fast Flow beads (GE Healthcare, UK) were used in a buffer pH screen to find 
the optimal pH for binding to an anion column for proteins with problematic or unknown pI’s. 
40 µl of beads were transferred to a 1.5 ml eppendorf tube and washed with 1 ml of buffer 
(Table 2.5) then centrifuged (3,000 rpm for 4 min) to settle the beads. The wash supernatant 
was discarded and 20 µl of buffer + 2.5 µl protein was added to the beads before incubating at 
room temperature for 15 min at 1,000 rpm. The beads were spun again (3,000 rpm for 4 min) 
and supernatant removed. 15 µl of the supernatant was added to 5 µl 4 x SDS loading buffer. 
The beads were washed with 200 µl of buffer then spun (3,000 rpm for 4 min) and supernatant 
discarded. 4 x SDS loading buffer (10 µl) was added to the beads then both bound (bead) and 
unbound (supernatant) samples were analysed by SDS-PAGE. 
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Table 2.5: Buffers used in anion exchange chromatography pH screen 
 
Substance Concentration (mM) pH 
Piperazine 20 4.8 
Piperazine 20 5.8 
L-Histidine 20 5.5 
L-Histidine 20 6.5 
Bis-Tris 20 6.0 
Bis-Tris 20 7.0 
Tris 20 7.4 
Phosphate 20 8.0 
Tris 20 8.5 
Bis-Tris propane 20 8.6 
Bis-Tris propane 20 9.6 
Ethanolamine 20 9.0 
Diethanolamine 50 9.4 
Piperazine 20 10.0 
 
2.3.2.17 Purification of VapC by Cation Exchange Chromatography 
Tryptic digests of purified VapBC complex were purified by cation exchange chromatography 
as for Section 2.3.2.16, but using cation exchange buffers (Table 2.6) and a 5 ml HiTrap SP XL 
Cation Exchange column (GE Healthcare, UK). The cation exchange column was stored in 20 
% ethanol containing 0.2 M sodium acetate. 
 
2.3.2.17.1 Cation bead pH screen 
SP SepharoseTM Fast Flow beads (GE Healthcare, UK) were used in a buffer pH screen to find 
the optimal pH for binding to a cation column for proteins with problematic or unknown pI’s. 
Bead aliquots (40 µl) were transferred to a 1.5 ml eppendorf tube and washed with 1 ml of 
buffer then centrifuged (3,000 rpm for 4 min) to settle the beads. The wash supernatant was 
discarded and 20 µl of buffer + 2.5 µl protein was added to the beads before incubating at 
room temperature for 15 min at 1,000 rpm. The beads were spun again (3,000 rpm for 4 min) 
and supernatant removed. 15 µl of the supernatant was added to 5 µl 4 x SDS loading buffer. 
The beads were washed with 200 µl of buffer then spun (3,000 rpm for 4 min) and supernatant 
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discarded. 4 x SDS loading buffer (5 µl) was added to the beads then both bound (bead) and 
unbound (supernatant) samples were analysed by SDS-PAGE. 
 
Table 2.6: Buffers used in cation exchange chromatography pH screen 
 
Substance Concentration (mM) pH 
Citric acid 50 3.5 
Citric acid 50 4.5 
Acetic acid 50 4.4 
Acetic acid 50 5.4 
MES 50 5.6 
MES 50 6.6 
Phosphate 50 7.0 
Phosphate 50 8.0 
BICINE 50 8.8 
 
2.3.2.18 Size Exclusion Chromatography of VapC 
SEC using an analytical SuperdexTM 75 10/300 GL column (GE Healthcare, UK) (3 – 70 kDa 
separation range) was performed (Section 2.3.2.14) on VapC resulting from a trypsin digest of 
VapBC in an attempt to purify away the trypsin from VapC. 
 
2.3.2.19 Small Scale (20 μl) Buffer Screen 
A small selection of buffers more suited to using in crystallography experiments than 
phosphate buffer were chosen for a buffer screen with purified VapC. A protein aliquot (20 µl) 
was dialysed in 20 µl dialysis buttons against 50 mM Tris, HEPES or MOPS at pH 7.4 + 200 
mM NaCl at 4 °C overnight. Buttons were examined under the microscope and scored for 
precipitate. 
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2.3.3 Crystallography  
2.3.3.1 Initial Crystallisation Trials 
Initial crystallisation trials for proteins were set up using the high throughput mosquito® Crystal 
robotic system (TTP Labtech Ltd, UK), using PEGRx HT, Crystal Screen HT, Index HT and 
SaltRx HT crystallisation screens (Hampton Research, USA). Aliquots of each screen condition 
(100 µl) were manually pipetted into either a 96 well Intelli-plate (Hampton Research, USA) or 
triple drop 96-well plate (TTP Labtech Ltd, UK) before 100 nl of protein and reservoir solutions 
were robotically added into the crystallisation well. All plates were sealed with ClearSealTM Film 
(Hampton Research, USA) and stored in a temperature controlled crystallisation room at 18 
C. 
 
2.3.3.2 Optimisation of Crystallisation Conditions (Fine Screening) 
Once promising crystallisation conditions had been identified, a variety of second optimisation 
steps were employed to produce crystals of the highest possible quality suitable for X-ray 
analysis. All conditions tested included a negative buffer only control to rule out the possibility 
of crystals forming due to the purification buffer crystallising with the reagents rather than the 
protein itself. 
 
2.3.3.2.1 Hanging Drops 
VDX 24-well plates (Hampton Research, USA) were pre-greased with Glisseal N then 0.5 ml of 
fine screen ‘mother liquor’ (ML) was transferred into the well. In general, the fine screen ML 
trialled contained a variation on the original concentration of the macromolecule, precipitant, or 
pH. The appropriate volume of protein (usually 1 µl) and ML was pipetted onto either a 22 mm 
square siliconised or unsiliconised coverslip (Hampton Research, USA) which was then 
inverted on top of the greased well.  
 
2.3.3.2.2 Microseeding 
Streak seeding 
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A parent crystal of inadequate quality was stroked with a cat’s whisker (which had previously 
been cleaned with ethanol and dried) to pick up invisible seeds. Those seeds were then 
introduced into a fresh source drop of ML by streaking the whisker straight through it. A 
variation of this streak seeding was also performed which involved streaking the seeds through 
three drops serially. 
 
Dilution seeding 
A 2 µl hanging drop containing a parent crystal of inadequate quality was resuspended in 55 
µl fresh ML and then serially diluted 1/10, 1/100 or 1/1,000 into the new ML condition. 0.5 ml of 
this seeding mixture was used as the ML for laying down hanging drops as for Section 
2.3.3.2.1. 
 
Pulverized seeding 
As for dilution seeding above, but resuspending the drop in only 10 µl of fresh ML, and using 
the much more vigorous resuspension method of vortexing. 
 
2.3.3.2.3 Additive Screens 
Crystals were grown in ML containing a set concentration of an additive as for Section 
2.3.3.2.1. Additives and concentrations chosen for testing were based on those included in the 
Hampton Research Additive Screen HT (see Appendix A.8 for conditions tested). 
 
2.3.3.2.4 Tryptic and DNase Digests 
Trypsin digest screens 
Trypsin (from bovine pancreas) (Sigma Aldrich, U.S.A) was diluted in varying volumes of SEC 
buffer so that 1 µl could be added to the same volume of protein to give 1:125, 1:250, 1:500, 
1:1,000, 1:5,000 and 1:50,000 molar ratios of Trypsin to protein. The various trypsin/protein 
dilutions were made up one at a time then used to lay down crystals immediately (as for 
Section 2.3.3.2.1) so as to limit the activity of the trypsin on the protein prior to beginning the 
crystallisation process. 
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DNase digest screens 
DNase I (from bovine pancreas) (Sigma Aldrich, U.S.A) was diluted in varying volumes of 
nuclease free water so that 1 µl could be added to the same volume of protein to give 1:500, 
1:1,000, 1:2,000 and 1:5,000 ratios of DNase to protein. The various DNase/protein dilutions 
were made up one at a time then used to lay down crystals immediately (as for Section 
2.3.3.2.1) so as to limit the activity of the DNase on the protein prior to beginning the 
crystallisation process, or after 10 min incubation at room temperature. 
 
Duplicates were set up and 10 mM MnCl2 was added to the ML for one of each of the 
duplicates to promote DNase activity. Additional controls were used to rule out the possibility of 
crystals forming due to the DNase or MnCl2 crystallising in the ML. 
 
DNase control: 1 µl of DNase was used in place of the 1 µl of protein 
DNase + MnCl2 control: 1 µl of DNase was used in place of the 1 µl of protein, and the 
ML contained 10 mM MnCl2 
 
2.3.3.2.5 Protein Concentration, Age and Drop Size Trials 
A variety of protein concentrations were trialled, along with drop sizes and protein to ML drop 
ratios. Each protein purification yielded differing amounts of protein, so crystal trials were 
tested with protein ranging from 4 mg/ml to 19 mg/ml. Drop sizes of (protein + ML) 0.6 µl + 0.6 
µl, 1 µl + 1 µl, 2 µl + 2 µl and 1.5 µl + 1 µl, and drop ratios of 1:1, 2:1 and 2:3 were all trialled, 
as was pre-equilibrating the protein with an equal volume of water before adding to the ML 
drop. 
 
2.3.3.2.6 Liquid Bridge 
As for a hanging drop (Section 2.3.3.2.1), but the protein and ML drops were pipetted onto the 
coverslip with a gap in between, then a cat’s whisker was used to ‘join’ the two drops so that 
free diffusion could occur between them and induce crystallisation. 
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2.3.3.3 Heavy Metal Soaks 
Prior to testing crystals at the synchrotron, a mercury soak was performed to incorporate the 
heavy metal into the crystal at the single cysteine position. ML (250 µl) containing 2 mM 
mercury(II) acetate was transferred into a pre-greased well. 2 µl of ML/mercury(II) acetate was 
spotted onto a coverslip, five crystals were transferred into the drop then sealed above the well 
for 3 hrs before freezing down ready for testing. 
 
2.3.3.4 Testing of Crystals by X-Ray Diffraction 
Protein crystals were tested at The Australian Synchrotron on the high-throughput 
Macromolecular Crystallography Beamline, MX1. Here, single crystals were robotically loaded 
then detected with an ADSC Quantum 210r Detector (Area Detector Systems Corporation, 
USA), and analysed using multiple wavelength anomalous dispersion (MAD). 
 
2.3.4 VapC Ribonuclease Activity 
An assay testing for ribonuclease activity of VapC protein was originally developed by Jo 
McKenzie (Proteins & Microbes Laboratory, University of Waikato) for testing VapCMS1284 from 
M. smegmatis and VapCPAE0151 and VapCPAE2754 from Pyrobaculum aerophilum (McKenzie et 
al. 2012a). 
 
2.3.4.1 Urea Denaturing Polyacrylamide Gel Electrophoresis (Urea 
Denaturing-PAGE) 
Urea denaturing-PAGE gels were cast in a Hoefer mini gel casting system and consisted of a 
10 or 20 % acrylamide resolving gel (depending on the RNAs size). Gels were made with 30 % 
acrylamide with an acrylamide:bisacrylamide ratio of 37.5:1 (Bio-Rad Laboratories, USA), 
included 6 M urea, and were polymerised by the addition of 0.05 % ammonium persulphate 
(APS) and TEMED. 
 
RNA samples were mixed in a 1:1 ratio with 2 x formamide loading dye and denatured for 5 
min at 70 °C prior to loading onto the gel. Gels were pre-run in 1 x TBE buffer at 70 V for 30 
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min and wells flushed to remove any leached urea before samples were loaded. Gels were run 
at constant 150 V until the xylene cyanol dye front reached the end of the gel. 
 
For RNA band size estimation, 10 µl of prepared Low Range ssRNA ladder (New England 
Biolabs, USA) was run alongside each gel. Gels were stained for 40 min with SYBR® Green II 
RNA Stain (Invitrogen, U.S.A) and visualised under UV light. 
 
2.3.4.2 Isolation of Total RNA from M. smegmatis 
Total RNA was isolated from M. smegmatis as for Section 2.2.3.2. 
 
2.3.4.3 The Pentaprobe System 
The pentaprobe system is made as six overlapping dsDNA plasmid molecules and covers 
every combination of five bases (Kwan et al. 2003). Each single strand of pentaprobe was 
cloned under a T7 promoter in pcDNA3 in Joel McKay’s laboratory, School of Molecular 
Bioscience, University of Sydney. 
The plasmids containing pentaprobe strands in the forward direction are termed A922, A923, 
A924, A925, A926 and A927 and in the reverse direction A928, A929, A930, A931, A932 and 
A933. A922 is complementary to A928, A923 to A929 etc. All inserts were cloned into pcDNA3 
using KpnI and XbaI restriction sites except A926 and A932 which, due to cloning difficulties 
were cloned into pcDNA3 using blunt-end cloning and the EcoRV restriction site. This resulted 
in a larger gap or “linker” before the start of pentaprobe sequence compared with the inserts 
cloned using KpnI and XbaI restriction sites. RNA fragments covering every combination of five 
bases, are transcribed from this set of 12 plasmids (sequences in Appendix B.3). 
 
The set of 12 pentaprobe inserts were produced by Jo McKenzie (Proteins & Microbes 
Laboratory, University of Waikato) from plasmids obtained from Joel McKay, School of 
Molecular Bioscience, University of Sydney. Briefly, pentaprobe plasmids were electroporated 
into E. coli DH5α electrocompetent cells, linearised with ApaI then filled with Klenow Enzyme 
(Roche Applied Science, Switzerland) and purified. Pentaprobe inserts were then amplified 
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using the Pfx® DNA polymerase system (Invitrogen, USA) with the forward primer flanking the 
T7 promoter in pcDNA3 and reverse flanking the end of the pentaprobe insert, and gel purified. 
 
2.3.4.3.1 In Vitro Transcription of Pentaprobe Inserts 
RNA was transcribed from Jo McKenzie’s pentaprobe PCR product using the T7 MEGAscript® 
kit (Ambion, USA). Reactions of 1 μg DNA template, 2 μl each rNTP (75 mM stock), 2 μl T7 
polymerase enzyme mix, 2 μl 10 x reaction buffer and nuclease free water in a total volume of 
20 μl were incubated at 37 °C for 4 hr (time determined by time course transcription reaction) 
then DNase treated with 1 μl TURBOTM DNase for 15 min at 37 °C, 600 rpm. 
 
Transcribed RNA was purified by sodium acetate and ethanol precipitation as for Section 
2.3.4.5.1. Secondary structure of RNA molecules were predicted using mfold (Zuker 2003). 
 
2.3.4.3.2 Design of 932 Pentaprobe Oligonucleotides 
932 Pentaprobe RNA oligonucleotides were designed by Jo McKenzie. Nine 30 – 36 base 
oligonucleotides were designed to cover bases 54 - 242 of pentaprobe 932 RNA so that their 
secondary structure mimicked the corresponding region on the whole 932 pentaprobe RNA 
molecule. 
 
2.3.4.4 VapC Ribonuclease Activity Assay 
Ribonuclease activity of VapC is monitored across four time points, as well as over three 
different negative controls: RNA only to ensure there is no RNase contamination of the assay 
buffer; with EDTA included in the buffer to rule out the possibility of metal independant RNases 
also being purified during the purification process; and with the VapBC complex to show lack 
of VapC ribonuclease activity when in complex with VapB. Total RNA from M. smegmatis is 
used initially as the target substrate to test for ribonuclease activity, and once activity is 
confirmed, specific RNA’s are used for determining the cut sites of the VapC proteins. 
 
Assay Reactions (Time Course) 
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Four 10 µl reactions containing 1 μg purified VapC protein, 1 μg purified RNA, 6 μl assay 
buffer (20 mM phosphate buffer pH 7.4, 20 mM NaCl, 10 mM MgCl2*), and nuclease free water 
were incubated at 37 °C for the appropriate time (time course). 
 
* NB. Oligonucleotide assays analysed by MALDI-TOF MS were carried out in 20 mM 
ammonium phosphate buffer pH 7.4, 20 mM NaCl, 10 mM MgCl2. 
 
Negative Controls 
RNA Only Negative Control (0 hr and 1 hr) 
Assay reactions were set up as above but no VapC was added to the reaction. Two reactions 
were set up, 0 hr (which was stopped immediately) and 1 hr which was incubated at 37 °C for 
1 hr (or the assay duration). 
 
EDTA Negative Control (1 hr) 
One assay reaction was set up for 1 hr (or the assay duration) as above but using assay buffer 
containing 20 mM EDTA.  
 
VapBC Negative Control (1 hr) 
One assay reaction was set up as above but purified VapBC complex was added to the 
reaction and incubated at 37 °C for 1 hr (or the assay duration) instead of purified VapC 
 
Assay reactions were stopped by the addition of 10 μl 2 x formamide loading dye, or for 
analysis by mass spectrometry; assays were heat inactivated at 70 °C for 10 min. 
 
2.3.4.5 MALDI-TOF Mass Spectrometry of RNA Oligonucleotides 
2.3.4.5.1 Sample Purification 
932 RNA oligonucleotides were ordered HPLC purified from either Sigma Aldrich (USA) or IDT 
(USA). 
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RNA from ribonuclease assays (Section 2.3.4.4) was precipitated to remove contaminants and 
de-salted via ammonium acetate and ethanol precipitation ready for MALDI-TOF MS analysis. 
Each 10 µl reaction was precipitated either on ice for 1 hr or at -20 C overnight, with 8 µl 5 M 
ammonium actetate and three times the volume (54 µl) of 100 % ethanol. Samples were spun 
(13,000 rpm, 20 min, 4 C) and all the supernatant carefully removed without disturbing the 
pellet. The pellet was washed with 50 µl 70 % ethanol and spun as above. After carefully 
removing all of the supernatant, the pellet was air dried briefly then resuspended in 5 µl 
nuclease free water and stored at -80 C. 
 
2.3.4.5.2 Sample Preparation 
Matrix for MALDI-TOF MS of RNA oligonucleotides was made by vortexing 5 mg of 3-
hydroxypicolinic acid (3-HPA), 10 μl 2.5 M diammonium citrate, 125 μl of acetonitrile (ACN) 
and 365 μl of nuclease free water until dissolved, then centrifuging for 5 min at 13,000 rpm. 
Matrix (1 μl) was spotted onto an AnchorchipTM target plate (Bruker Daltonics, USA) and left to 
air dry. An aliquot of sample or oligonucleotide calibration standard (1 μl) (Bruker Daltonics, 
USA, or made in the lab) was spotted on top of the dried matrix and left to air dry. 
 
2.3.4.5.3 Construction of Oligonucleotide Calibration Standard 
For oligonucleotide calibration standard mixture made in the lab, the three oligonucleotides 
specified in the Oligonucleotide Calibration Standard (#206200) (Bruker Daltonics, USA) were 
purchased HPLC purified from IDT (USA) (oligo sequences can be found in Appendix A.1). 
The oligos were made up in UltraPure water then mixed together to give a calibration mixture 
containing the prescribed amount of each oligo as specified by Bruker, or at a customised ratio 
which was empirically determined. 
 
Bruker mix: oligo1 = 0.25 pmol/µl; oligo2 = 1.25 pmol/µl; oligo3 = 5 pmol/µl 
Custom mix: oligo1 = 0.83 pmol/µl; oligo2 = 1.66 pmol/µl; oligo3 = 5 pmol/µl 
 
Aliquots of oligonucleotide calibration standard mix (5 µl) were stored at -80 C until needed. 
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2.3.4.5.4 MALDI-TOF target cleaning 
The MALDI-TOF target plate was cleaned when full to remove all traces of previously analysed 
samples. Deionised water and lint-free Kimwipes were used in all steps. Old matrix was 
removed from the plate by wiping with water before wiping with 50 % methanol then ACN. The 
plate was sonicated upside down in a container with 50 % methanol for 10 min in a sonicating 
water-bath (Elma, Germany) then rinsed with water. Acetone was poured over the plate to 
remove the water then left to air dry. 
 
2.3.4.5.5 MALDI-TOF Set Up 
MALDI-TOF analysis was performed with the AutoflexTM II MALDI-TOF mass spectrometer 
(Bruker Daltonics, USA). Analysis were obtained in the positive ion linear mode with a 150 ns 
pulse, range of 2 - 12 kDa, accelerated voltage in the ion source set at 20 kV and laser power 
at around 50%. Spectra for the oligonucleotide calibration standard (Bruker Daltonics, USA) 
were collected first, and the spectrometer calibrated to this with an automatic polynomial 
correction.  
 
Spectra were exported to DataAnalysisTM or FlexAnalysisTM software (Bruker Daltonics, USA), 
and peaks identified and labelled. 
 
2.3.4.6 Determination of VapC Cut Sites 
The mass list and corresponding intensities were exported from the MALDI-TOF analysis 
software into a comma separated excel file then processed using in-house software developed 
by Tony Smith and Vic Arcus (The University of Waikato) to determine possible cut sites. The 
software identifies all one and two point cuts in the oligonucleotide and calculates the putative 
mass for each resulting fragment, factoring in a 5′ phosphate on the 3′ cleavage product. 
Comparisons are made to the actual peak masses from the MALDI-TOF data, and those 
fragments resulting from single cuts which match the actual peak masses most closely are 
considered as a putative VapC target cut sites. The intensity cut off was set to greater than 
800, so all peaks above an intensity of 800 were picked for analysis. 
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3 Chapter Three: 
Rangipo Diagnostic 
3.1 Introduction 
3.1.1 M. tuberculosis in a New Zealand Context 
Unless otherwise indicated, the following statistics were obtained from (Lim & Heffernan 2013). 
3.1.1.1 Notifications of Disease  
Tuberculosis notification rates in New Zealand have remained relatively stable over the last 
five years, with the 2012 figure totalling 6.6 per 100,000 population. Although this figure is 
much lower than the global average of 122 incident cases per 100,000, rates in New Zealand 
are still higher than those in other developed countries such as Australia, Canada and America 
(5.7, 4.0 and 3.2 per 100,000 respectively) (WHO 2013). The overall rates were higher in 
males than in females and in Asian and Middle Eastern/Latin American/African (MELAA) ethnic 
groups, with the dominant risk factors being born outside New Zealand or residence with a 
person born outside of New Zealand, and living in socio-economically deprived areas. 
 
The highest notification rates in 2012 were from the Asian (41.4 per 100,000 population) and 
Middle Eastern/Latin American/African (MELAA) (31.8 per 100,000) ethnic groups, followed by 
the Pacific 12.4 per 100,000), Maori (5.4 per 100,000) and European or Other (0.9 per 
100,000) ethnic groups. While the percentage of cases born in the Pacific Islands and Africa 
and the Middle East regions has decreased significantly (26 - 30 %) over the past five years, 
there has been an increasing trend in notification rates for the Asian ethnic group, where cases 
born in the Southern and Central Asia region (predominantly from India) had the highest 
notification rate, followed by the South-East Asia region (most commonly from the Philippines). 
Notably, the majority of New Zealand born cases were from the Maori ethnic group (50 %), 
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while just 29 % accounted for the European or Other ethnic groups. Consistant with previous 
observations that TB incidence is associated with household crowding (Baker et al. 2008), a 
disproportionate number of TB cases reside in the most socioeconomically deprived areas of 
New Zealand (over 60 %), an observation which was even more apparent in New Zealand 
born cases.  
 
The clinical characteristics of TB from foreign born and New Zealand born cases was strikingly 
different in the period between 2008 and 2012. While foreign born cases tended to present 
with pulmonary or extra-pulmonary TB in approximately equal numbers, 80 % of cases born in 
New Zealand were pulmonary. The common sites of infection for the extra-pulmonary cases of 
TB were the lymph nodes (excluding abdominal), followed by pleural and intra-abdominal 
(excluding renal), and there were approximately equal numbers of tuberculous meningitis and 
miliary TB reported during this timeframe.  
 
3.1.1.2 Treatment 
The vast majority of new TB cases were reported to have received treatment (98.7 %) in 2012, 
with the median time to the start of treatment from the onset of symptoms being two months for 
the 52 % of cases for which the interval could be calculated for. This interval between onset of 
symptoms and treatment was approximately the same for pulmonary cases, where the delay 
poses a risk to public health due to transmission of the disease from person to person. 
 
The majority of cases in 2012 (85.4 %) were fully susceptible to all five antimicrobials routinely 
tested for (isoniazid, rifampicin, ethambutol, pyrazinamide and streptomycin), and just four 
cases were multi drug resistant (MDR) (resistant to at least isoniazid and rifampicin). In the last 
five years, the average number of MDR culture-positive TB cases was 1.2 %, the majority of 
which (94 %) were from foreign born individuals (predominantly from the Asian ethnic group) 
assumed to have acquired their MDR-TB overseas. Only one case of extensively drug 
resistant TB (XDR-TB) which is MDR-TB plus resistance to any fluoroquinolone and at least 
one of the following second-line drugs: amikacin, capreomycin or kanamycin, has been 
identified in New Zealand thus far, occurring in 2010. TB cases which had previously been 
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treated were less likely to be fully susceptible to the antimicrobials tested, significantly more 
resistant to rifampicin and streptomycin and more likely to be MDR-TB compared with new 
cases of TB.   
 
Of the 279 new cases of TB in 2012, the fatality rate remained low with just four cases (all of 
which were over 60 years of age), as did the HIV co-infection rate (three cases of co-infection). 
The number of TB reactivation cases also remained low in 2012 with 15 reactivation 
notifications. 
 
3.1.1.3 Confirmation and Classification of TB Cases 
Laboratory confirmation of new TB cases is by: positive culture for MTBC, positive microscopic 
examination for acid-fast bacilli when a culture has not been or cannot be obtained, 
demonstration of MTBC nucleic acid directly from specimens, or histology strongly suggestive 
of tuberculosis when there is a strong clinical probability (Jacobs 2012). Figures for 2012 
indicate that approximately 85 % of new TB cases were laboratory-confirmed, the majority of 
which were by culture of MTBC (97.7 % were M. tuberculosis, 1.8 % M. bovis, and 0.45 % 
MTBC) from a clinical specimen. Approximately 70 % of all new TB cases in New Zealand are 
diagnosed by presentation to a health practitioner, while immigrant or refugee screening and 
contact tracing detect 11.2 % and 7.2 % of cases respectively.  
 
Presently, all molecular typing of human TB cases in New Zealand is carried out by LabPLUS 
consisting of primary (12 loci) and secondary (a further 12 loci) Mycobacterial Interspersed 
Repetitive Units (MIRU) analysis alone. Prior to this, primary typing was by MIRU 12 and 
secondary typing was by IS6100 Restriction Fragment Length Polymorphism (RFLP) at 
LabPLUS, and before this, mycobacteriology reference laboratories throughout the country 
performed RFLP typing alone to type TB isolates. Of the typing results available for new TB 
cases in 2012, approximately two thirds had a unique strain type while the remainder had non-
unique molecular types, assigned to 44 separate molecular clusters (five of which were new). 
Over the past five years, the median cluster size was two, with most clusters ( 90 %) 
containing less than five cases. Interestingly, non-unique molecular types were much more 
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prevalent than unique strain types among Maori (29.3 % vs. 5.1 % for unique) and Pacific 
(28.5 % vs. 7.5 %) ethnic groups, and for cases born in New Zealand (40.8 % vs. 11.6 %). The 
opposite trend was observed for the Asian/MELAA ethnic group where the proportion of cases 
was lower amonst those with non-unique molecular types. 
 
In 2012, there were three outbreaks and 22 associated cases of M. tuberculosis. The 
outbreaks comprised of two, six and 14 cases, and involved exposure to an index case in a 
private home,  during church gatherings and in private homes, and in a work environment and 
in private homes respectively. Large outbreaks are responsible for spikes in the rates of TB in 
New Zealand, such as in 1999 where two outbreaks (one of which was the Rangipo strain) 
contributed to the highest incidence recorded  over a 25 year period of 12.6 cases per 100,000 
(De Zoysa 2001). 
 
3.1.2 Rangipo 
The Rangipo strain of M. tuberculosis is the main endemic strain in New Zealand as well as the 
largest single M. tuberculosis strain cluster (Sexton et al. 2008;  Bower 2013). It predominantly 
circulates in the Waikato and Bay Of Plenty regions, and has been responsible for a number of 
outbreaks over previous decades. The Rangipo strain is highly transmissible, and previous 
analysis of Rangipo outbreaks found the majority of cases were of Maori or Pacific Islands 
ethnicity under 30 years of age, and tended to have gang affiliations or contact with persons 
who had been incarcerated in prison (De Zoysa 2001;  Health 2012;  Karalus 2013). The 
Rangipo strain was thought to originate from an index case incarcerated at Rangipo prison, 
and was thus called ‘Rangipo’, but isolates from cases preceding this have since been 
identified. 
 
The number of cases within a Rangipo cluster is generally much larger than clusters from other 
M. tuberculosis strains (Sexton et al. 2008;  Lim & Heffernan 2013) demonstrating its high 
transmissibility. As well as this, index cases in Rangipo outbreaks are highly infectious 
(McElnay et al. 2004) and while no virulence testing has been undertaken in the Rangipo 
strain, it is regarded as being a virulent M. tuberculosis strain (Karalus 2013). It has been 
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suggested the apparent high transmissibility of the endemic Rangipo strain may be instead 
due to lifestyle and environmental factors within this population, causing them to be more 
susceptible to transmission, such as high density housing and social or work gatherings, 
alcohol and drug abuse and socioeconomic deprivation. This proposal is unlikely however, 
given the general theory that one person infected with tuberculosis must infect 20 people in 
order to cause one active case of disease (Sutherland 1976), as the number of Rangipo 
infected individuals in outbreaks developing active disease is much higher (Karalus 2013). In a 
recent investigation of a Rangipo outbreak in Hawkes Bay, there were 94 infected cases 
identified and 14 cases of active disease, approximately three times more active cases than 
would be expected from a ‘normal’ tuberculosis infection (McElnay et al. 2004;  Calder 2013). 
Other M. tuberculosis strains such as those belonging to the Beijing lineage, have also been 
noted as having an increased ability to transmit within particular populations, and generate 
active disease (Reed et al. 2009). 
 
3.1.3 M. tuberculosis Typing Methods 
Molecular typing of M. tuberculosis strains is essential for identifying and linking source cases 
to contacts, as well as identifying specific strains (such as drug resistant isolates) or tracking 
strains as they spread throughout the population. This insight allows researchers to identify 
and stop the spread of clustered cases, observe how particular strains are evolving, and in the 
case of drug resistant isolates, prevent the emergence of more MDR or XDR strains from 
developing by ensuring the optimal treatment is provided and adhered to. 
 
Because mycobacteria exhibit very low DNA sequence diversity, the Multilocus Sequence 
Typing (MLST) method used routinely to subdivide microbes on the basis of neutral sequence 
diversity is not possible as the level of resolution is too low for the subdivision of these and 
other genetically monomorphic bacteria. The investigation of mycobacterial genetic diversity up 
until now has therefore relied on non-sequencing based methods such as Restriction 
Fragment Length Polymorphism (RFLP) typing, and PCR based methods such as Clustered 
Regulatory Short Palindromic Repeats (CRISPR) and Variable Number Tandem Repeats 
(VNTR) genotyping (Figure 3.1). 
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Figure 3.1: Schematic comparison of the three common M. tuberculosis typing methods. a) VNTR typing 
(or MIRU in mycobacteria) uses PCR amplification to ascertain the variable copy number of specific 
tandemly repeated sequences within the genome. There are 41 MIRU loci (shown in blue on the M. 
tuberculosis genome), of which 12, 15 or 24 are selected for genotyping. a) Shows the 12 tandemly 
repeated sequences used in MIRU 12 analysis and the number of tandem repeat copies present within 
each one for the representative strain. The MIRU 12 genotype is represented as 12 characters 
(221642251334), where each character corresponds to the number of repeats within each of the 12 MIRU 
loci. b) IS6110 RFLP typing. M. tuberculosis genomes vary in the number and position of IS6110 copies 
(black boxes) which they possess. Restriction enzymes cleave DNA at specific sites (green arrowheads 
on the M. tuberculosis genome) then the fragments are separated by size by gel electrophoresis and 
those containing IS6110 insertion sequence hybridise to a specific radioactive probe thereby producing a 
characteristic banding pattern or fingerprint for each isolate. c) Spoligotyping patterns differentiate three 
M. tuberculosis strains by comparing the presence (black boxes) or absence (white boxes) of the 43 
spacers located between direct repeats in the DR locus. 
 
IS6110 RFLP typing is a southern blot based assay which detects the mobile IS6110 insertion 
sequence found exclusively within the MTBC (Thierry et al. 1990), where strains are described 
according to the number and position of IS6110 copies which they possess. IS6110 
fingerprinting was the ‘gold standard’ method for discriminating M. tuberculosis isolates for 
over a decade, but is technically demanding, time-consuming (as it requires several weeks for 
culturing the M. tuberculosis isolates), difficult to interpret and reproduce between laboratories, 
and does not always discriminate low-IS6110-copy (</= five copies) (Smittipat et al. 2005) 
isolates. 
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CRISPR based genotyping in MTBC is referred to as spoligotyping (spacer oligonucleotide 
typing). Spoligotyping began in 1997 and is a rapid PCR-based genotyping method targeting 
the well-conserved 36 bp direct repeat (DR) locus of MTBC bacteria. Amplification of ‘spacers’ 
(43 short unique regions) contained between the DRs is followed by hybridisation onto a 
membrane with oligonucleotides complementary to each spacer, and variation in the presence 
of spacer sequences among strains results in a characteristic spot pattern which is then 
translated into a numerical code of 15 digits (Kamerbeek et al. 1997). Spoligotyping is fast (as 
genotyping is performed on DNA directly isolated from clinical samples so bacteria do not need 
to be cultured first), cheap, and the binary data is represented digitally enabling comparisons 
between laboratories. However, spoligotyping does not differentiate well within large strain 
families (eg. Beijing) (Driscoll 2009), nor distinguish between unrelated strains possessing 
identical patterns as a result of independent evolutionary events which caused deletion of the 
same spacer sequences (Flores et al. 2007). While spoligotyping has the lowest discrimination 
power to differentiate strains, it has proven to be a very useful tool to add to the discriminatory 
power of IS6110 RFLP or MIRU-VNTR typing when used in combination, especially for strains 
harbouring low numbers of IS6110 copies (Dale et al. 2003;  Supply et al. 2006). 
 
VNTR based genotyping in MTBC is referred to as Mycobacterial Interspersed Repetitive Units 
(MIRU)-VNTR typing. MIRU-VNTR is a PCR based assay used to detect and compare the 
strain-specific numbers of regions within M. tuberculosis DNA (called MIRU loci) which are 
prone to possessing short tandemly repeated sequences. There are a total of 41 MIRU loci, of 
which 24 have been selected for use in genotyping. MIRU results are represented as either 12, 
15 or 24 digit numbers (depending on the depth of coverage required), where each digit 
corresponds to the number of repeats present at each one of the 12, 15 or 24 MIRU loci, listed 
in a standard order. Unlike IS6110 RFLP or spoligotyping, MIRU-VNTR can be used by itself to 
differentiate between M. tuberculosis isolates that have low copy numbers of or are without 
IS6110 elements (Supply et al. 2000). Initially, assays using just 12 MIRU loci were used, but 
this was less discriminatory than IS6110 RFLP even in combination with spoligotyping, so 
more recently a set of 24 MIRU-VNTR loci with a significantly higher discriminatory power than 
the original 12 locus system, and close to that of IS6110 fingerprinting, was developed (Supply 
et al. 2006). Interestingly, studies in some populations have suggested a lower discriminatory 
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power of the 24 loci MIRU-VNTR typing method than IS6110 RFLP for strains belonging to 
particular phylogenetic lineages, especially the Beijing strain (Roetzer et al. 2011). A pared 
down discriminatory subset of 15 loci has since been defined, and was proposed as the new 
gold standard (in combination with spoligotyping) for fast, simple, routine epidemiological 
discrimination of M. tuberculosis isolates (Supply et al. 2006;  Oelemann et al. 2007), and is 
the typing method used currently in the majority of laboratories around the world. 
 
Recently, a fully automated cartridge-based diagnostic was developed for the detection of 
MTBC DNA, and mutations within the rifampin resistance-determining region of the rpoB gene 
(as a proxy for MDR-TB). This Xpert MTB/RIF test is based on the Cepheid GeneXpert 
system, and uses six molecular beacons multiplexed within the same qPCR reaction, 
producing results in less than two hours directly from sputum (Helb et al. 2010). The ability of 
the Xpert MTB/RIF test to quickly detect smear-negative cases is especially useful for the 
detection of rifampicin resistant TB in people displaying low numbers of bacilli, and has similar 
accuracy as culture for detecting TB (Boehme et al. 2010). This rapid, automated diagnostic 
minimises handling and safety risks, and requires little technical training to operate, increasing 
the likelihood of timely treatment for rifampicin resistant cases (although standard drug-
susceptibility testing is still required to determine the complete drug-resistance profile). 
 
Rangipo isolates from 2002 onwards used in this research were typed as identical by IS6100 
RFLP typing at Waikato Hospital (Table 3.1), and isolates A, C, F, N, O, and S were also also 
sent to LabPLUS for MIRU 12 and 24 typing to determine if any differences could be detected 
between them. All six isolates were typed as identical: 233325153324 by MIRU 12 typing, and 
341444223362 by MIRU 24* (Table 3.2). 
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Table 3.1: Rangipo isolates used in this study. 
 
Year RFLP type Specimen type Isolate Code 
1991 N/A Sputum A 
1992 N/A Sputum B 
1992 N/A Sputum C* 
1992 N/A Gastric Aspirate D 
1992 N/A CSF E 
1996 N/A CSF F 
2002 13/008RP Sputum J 
2004 13/008RP Pleural Biopsy K 
2006 13/008RP Sputum L 
2006 13/008RP Sputum M 
2007 13/008RP Sputum N 
2008 13/008RP Sputum O 
2008 13/008RP Sputum P 
2009 13/008RP Sputum R* 
2010 13/008RP Sputum S 
* Isolates are from the same patient, separated by 17 years. N/A = Not Available 
 
Table 3.2: MIRU 12 and MIRU 24 Loci for Rangipo isolates A, C, F, N, O, and S. 
 
MIRU 12 Loci 
Loci 
name 
2 4 10 16 20 23 24 26 27 31 39 40 
Rangipo 2 3 3 3 2 5 1 5 3 3 2 4 
MIRU 24 Loci 
Loci 
name 
Mtub04 ETRC Mtub21 QUB11b ETRA Mtub29 Mtub30 ETRB Mtub34 Mtub39 QUB26 QUB4156 
Rangipo 3 4 1 4 4 4 2 2 3 3 6 2 
 
3.1.3.1 Molecular Typing and Phylogenetics  
While spoligotyping and MIRU-VNTR are used routinely for local molecular epidemiological 
applications, tracing tuberculosis transmission and distinguishing new cases from those which 
are relapsed, some studies have proposed its use as a tool for global phylogenetic and 
population genetic analyses of the MTBC (Brudey et al. 2006;  Wirth et al. 2008). The use of 
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spoligotyping and MIRU-VNTR in evolutionary studies is questionable however, as a later 
study comparing a robust MTBC phylogeny obtained from multilocus sequence analysis 
(MLSA) of 108 MTBC strains with that inferred from spoligotyping or MIRU-VNTR found while 
the phylogenetic accuracy of MIRU-VNTR was better than spoligotyping, both methods were 
unable to detect all strain lineages (Comas et al. 2009). It was determined that the limited 
number of loci and markers used in spoligotyping and MIRU-VNTR evolved rapidly, tending to 
converge, and it was this level of homoplasy in the markers which deemed these typing 
methods inappropriate for defining deep phylogenetic relationships (Filliol et al. 2006;  Comas 
et al. 2009). Comas et al. (2009) also found that the MLSA derived MTBC phylogeny 
corresponded with one which had been determined previously based on LSPs (Gagneux et al. 
2006), just as Ford et al. (2012) found the reconstructed phylogeny from 55 whole genomes 
resolved the same main lineages as those derived from the 45 SNP position phylogeny (Filliol 
et al. 2006). Comas et al. (2009) thereby proposed strain assignment to the main MTBC 
lineages should be based on phylogenetically robust markers like SNPs or LSPs, while MIRU-
VNTR loci be used for epidemiological discrimination purposes, as currently there is not a sole 
method which fulfils the requirements for both local (molecular epidemiology such as strain 
typing/transmission) and global (phylogeography/large scale evolutionary analyses) strain 
classification which is affordable for routine application. 
 
3.1.3.2 Molecular Typing and Whole Genome Sequencing (WGS) 
WGS is a relatively new tool used for bacterial genotyping but is currently cost prohibitive to 
use routinely for typing bacterial strains. WGS has been used to investigate the spread of M. 
tuberculosis and how it is evolving, both long and short term, as well as it’s geographic 
distribution and evolutionary response to antimicrobial therapies (Filliol et al. 2006;  Ioerger et 
al. 2010;  Ford et al. 2011;  Gardy et al. 2011;  Saunders et al. 2011). 
 
WGS has advantages over other typing methods at a global, local, individual and bacterial 
level. WGS allows the detection of M. tuberculosis global genetic diversity with unparalleled 
resolution, for example, two Beijing isolates with the same genotype according to both IS6110 
RFLP and MIRU-VNTR patterns were found to differ at 131 individual sites by WGS (one of 
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which was a large deletion), highlighting the limited ability of the current typing methods to 
distinguish between closely related strains (Niemann et al. 2009;  Ford et al. 2012).  
At a local level, WGS has improved investigations into: the acquisition and spread of drug 
resistant strains, identifying that MDR and XDR strains from the same region are not just 
emerging once and undergoing clonal expansion and transmission, but evolving independently 
from each other (Ioerger et al. 2010;  Ford et al. 2012); as well as outbreak and contact 
tracing. A TB outbreak in Canada was defined by MIRU-VNTR analysis as a single clonal 
outbreak, with identical MIRU-VNTR patterns for all isolates and no identifiable source case 
(even after contact tracing). WGS was used and revealed there were in fact two distinct 
transmission chains. This WGS based phylogenetic analysis in combination with a social 
network analysis allowed the researchers to identify the route through which the infection had 
spread, where the high resolution 24 loci MIRU-VNTR method could not (Gardy et al. 2011).  
WGS has been useful for identifying diversity at the individual level too. While Mtb infection is 
generally considered to be clonal, the emergence of variants leading to a greater than 
expected level of heterogeneity within the infecting bacterial population challenges this dogma 
(García de Viedma et al. 2004;  Martin et al. 2007). Heterogeneity within the bacterial 
population could arise from simultaneous infection by multiple strains, reinfection by a new 
strain, or within host evolution of an individual strain such as the development of drug 
resistance (Ford et al. 2012). The fine resolution that WGS offers has allowed investigation of 
genetic heterogeneity in greater detail, revealing that exposure to antibiotics creates a strong 
bottleneck during the development of drug resistance (Saunders et al. 2011), and the mutation 
rate during latent and active disease is approximately equal quelling the assumption that Mtb 
does not aquire mutations during latency (Ford et al. 2011;  Colangeli et al. 2014). WGS has 
also provided valuable information regarding diversity at the bacterial level, allowing the 
identification of nonsynonymous to synonymous genetic change ratios (dN/dS) which indicate 
that the Mtb genome is under purifying selection (Hershberg et al. 2008;  Comas et al. 2010). 
 
The ability of WGS to fulfil the requirement for both molecular epidemiology fine typing and 
large scale evolutionary analyses means as the cost reduces, it is likely to become the next 
gold standard in routine molecular typing, and will be of particular benefit for M. tuberculosis 
and other monomorphic pathogens where limited sequence diversity has prevented strain 
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differentiation via other readily available sequence based typing methods. However limitations 
such as the more challenging detection of repetitive regions, genomic duplications and 
genomic rearrangements do exist with WGS (Ford et al. 2012), so these challenges must be 
kept in mind when using WGS to mine the wealth of information within bacterial strain 
sequences. Once WGS becomes readily affordible, researchers will be able to trace the 
transmission and evolution of strains of interest in real time (in particular those which are more 
virulent or resistant to antimicrobials) which will result in better control, treatment and 
understanding of this pathogenic organism. 
 
3.1.3.3 Molecular Typing and Large Sequence Polymorphism (LSP) or 
Single Nucleotide Polymorphism (SNP) analysis 
Detection of LSPs or regions of difference (RDs) representing well-characterised unique-event 
deletions are effective, simple and robust methods for assigning strains to the main Mtb 
lineages (Gagneux et al. 2006;  Alland et al. 2007;  Gagneux & Small 2007;  Reed et al. 2009). 
Each of the six major Mtb lineages is defined by just one LSP present in all isolates within that 
particular lineage (Reed et al. 2009). Because Mtb exhibits very low sequence diversity, there 
are few SNPs within the genome and therefore only a very remote chance of the same SNP 
existing in independent lineages. This means SNPs, like LSPs, can also be used for population 
analysis, however using LSPs to genotype isolates is simplier and more efficient (Reed et al. 
2009).  
 
3.1.4 M. tuberculosis Lineage Classification 
It is proposed that M. tuberculosis originated in East Africa and spread throughout the world, 
diversifying as it went, resulting in M. tuberculosis lineages possibly adapted to different 
human host populations (Gagneux et al. 2006). 
Early phylogenetic studies classified Mtb strains using several different nomenclatures, but the 
strain classification system proposed by Gagneux et al. (2006) which defines the global 
population structure of M. tuberculosis into six main lineages, and 15 sublineages is now used. 
It was initially thought each of the six main lineages was restricted to patients from a particular 
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geographical area, so as such, the main lineages were named: (1) Indo-Oceanic, (2) East 
Asian (or W/Beijing), (3) East African/Indian, (4) Euro-American, (5) West African 1 and (6) 
West African 2. Lineages corresponding to earlier reported strain groupings include: Indo-
Oceanic, containing strains previously referred to as ‘ancestral’ because they contain the TbD1 
region which is deleted in ‘modern’ Mtb strains (Brosch et al. 2002); West-African 1 and 2, 
previously referred to as Mycobacterium africanum (Mostowy et al. 2004); and Euro-American 
strains which were previously referred to as principal genetic groups 2 and 3 (Sreevatsan et al. 
1997).  
 
Lineage specific LSP PCRs are used to classify isolates into the six main M. tuberculosis 
lineages (Figure 3.2). Here, PCR is used to detect either the presence or absence of the 
lineage specific LSP markers, where RD239, RD105, and RD750 deletions are used to 
specifically classify isolates belonging to the Indo-Oceanic (1), East Asian (2) and East 
African/Indian (3) strain lineages respectively (Gagneux et al. 2006), and deletion of RD711 
and RD702 characterises the West African 1 (5) and West African 2 (6) lineages respectively. 
Deletion of RD9 confirms the presence of all atypical MTBC infections, as RD9 is absent from 
all members of the MTBC other than M. tuberculosis and M. canetti (Brosch et al. 2002;  Reed 
et al. 2009). The Euro-American (4) lineage could not be defined by a LSP so is instead 
defined by a seven base pair deletion in the pks1-15 gene (Gagneux et al. 2006). 
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Figure 3.2: Schematic representation of the global phylogeny of M. tuberculosis as defined by LSPs. 
Coloured boxes indicate the six main lineages, while black boxes represent the lineage-defining LSPs or 
regions of difference which characterise each of the groups 
 
Different M. tuberculosis lineages and sublineages have shown varying abilities to cause 
infection and disease (de Jong et al. 2008;  Reed et al. 2009;  Kato-Maeda et al. 2010;  Kato-
Maeda et al. 2012). For example, a study in The Gambia found while transmission rates were 
similar between strains from different lineages, pathogenicity (or progression to disease) was 
variable with rates ranging from 1 % to 5.6 % for strains from lineage 6 and 2 respectively, and 
from 1.2 % to 3.9 % for strains from three lineage 4 sublineages (de Jong et al. 2008). No 
significant differences between lineages and their correlation with particular clinical phenotypes 
has been observed (Reed et al. 2009).  
 
3.1.4.1 Euro-American Sublineage Classification 
The Euro-American lineage is the most recent ‘modern’ (containing strains with a deleted TbD1 
region) Mtb lineage, as it includes strains belonging to principal genetic groups 2 and 3 
(Sreevatsan et al. 1997). It is also the predominant lineage of M. tuberculosis in many parts of 
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the world, including North and South America, as well as several European countries and New 
Zealand (Gagneux & Small 2007;  Bower 2013). Euro-American strains can be further 
classified into into: 11 distinct sublineages according to deletions of a region of difference 
(RD); RD115, RD122, RD174, RD182, RD183, RD193, RD219, RD724, RD726 and RD761, 
and the remaining strains with no deletion (called H37Rv-like) (Gagneux et al. 2006); or five 
lineages (T, Haarlem, Latin American-Mediterranean (LAM), S and X) and 34 sublineages by 
spoligotyping (Rindi et al. 2012); or 35 sublineages by analysis with multiple-biomarker tensors 
(Ozcaglar et al. 2011). While certain deletions are associated with a particular spoligotype 
lineage (deletion RD115 to T and LAM, RD174 to LAM, RD182 to Haarlem and RD219 to T for 
example), RD-defined sublineages and spoligotype groupings often do not correspond. This 
disagreement between LSP and spoligotype analysis is likely due to the high degree of 
homoplasy in the direct repeat locus resulting in convergent evolution and identical 
spoligotypes, which renders spoligotyping unsuitable for determining the phylogenetic 
relationships within the Euro-American lineage (Rindi et al. 2012). 
 
While diagnostic tools have been recently developed to distinguish the apparently more drug 
resistant and high virulence ‘Beijing’ strains plaguing other parts of the world (Lopez et al. 
2003;  Manca et al. 2004;  Leung et al. 2011;  Zhang et al. 2014), no such work has been 
performed for the virulent Rangipo strain endemic in New Zealand. The high transmissibility 
and virulence of the Rangipo strain of M. tuberculosis together with the extended period it has 
been circulating for in the Waikato and Bay Of Plenty regions, is why this particular strain 
needs to be classified and a rapid diagnostic test for it developed. 
 
3.1.5 Objectives 
Given the high transmissibility and virulence of the M. tuberculosis Rangipo strain within New 
Zealand, we attempted to classify the Rangipo strain and develop a fast and efficient Rangipo 
specific diagnostic assay which could be implemented into the current hospital diagnostic 
setting. 
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3.2 Results and Discussion 
3.2.1 PCR-Based Genotyping of M. tuberculosis targeting GC-rich 
repeats and IS6110 Inverted Repeats 
Primers targeting frequently repeated 16-bp GC rich sequences (Mtb1 or Mtb2) were used in 
combination with either specific primers (IS1 and IS2), or a single degenerate primer (CAR2) 
sited at the inverted repeats (IR) flanking IS6110, to investigate the degree of differentiation 
across 15 suspected clinical M. tuberculosis Rangipo isolates isolated over a 20 year period. 
IS6110 typing only became routine at Waikato hospital in 2002, so only nine out of these 15 
isolates (J – S) were typed and identified as belonging to the Rangipo strain (13/008RP) (see 
Table 3.1). Figure 3.3 is a theoretical illustration of the genotyping method used, and Figure 
3.4 shows the banding pattern obtained for each isolate using either specific or degenerate 
primers to amplify regions between IS6110 copies and the frequently repeated 16-bp GC rich 
sequences. The banding patterns across all 15 Rangipo isolates are similar (supporting the 
previous typing results identifying most of these as belonging to the Rangipo strain), but show 
some subtle differences indicating there is sequence diversity among the isolates. Isolates C 
and R, which were from the same patient isolated 17 years apart, show clear differences in 
banding for the Mtb2 + IS1 & IS2 genotyping. This sequence diversity suggests a robust 
genotyping method needed to be developed to ensure the correct identification of Rangipo 
isolates.   
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Figure 3.3: Theoretical illustration of genotyping by PCR amplification between copies of IS6110 and Mtb1 
(a) or Mtb2 (b). Depiction of agarose gel (c) shows the resulting banding pattern for the above theoretical 
PCR reactions, while the enlargement of the IR region (d) shows the variation within the IR and the 
differences between oligonucleotides. Mtb1 and Mtb2 are oligonucleotides for common, frequently 
repeated 16-bp GC rich sequences found within the M. tuberculosis genome. The IR flanking IS6110 
differs by three nucleotides (indicated in bold). Oligonucleotides specific for each IR sequence (IS1 and 
IS2) were used together, or else a single degenerate oligonucleotide containing inosines (CAR2) was 
used in the amplification reaction. Figure adapted from Kotłowski et al. (2004). 
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Figure 3.4: Genotyping banding patterns of 15 Rangipo clinical isolates based on amplification between 
IS6110 and frequently occurring GC rich sequences. Mtb1 and Mtb2 are oligonucleotides for two 
frequently repeated 16-bp GC rich sequences. PCR amplification was performed with either Mtb1 or Mtb2 
in combination with either two specific oligonucleotides (IS1 and IS2) or a single degenerate 
oligonucleotide (CAR2) for the IS6110 IR. Letters at the top represent the 15 isolates tested. 
 
3.2.2 Rangipo lineage classification 
While the Rangipo strain had already been typed by RFLP and MIRU methods, it was 
unknown which M. tuberculosis lineage it belonged to. A series of PCRs based on LSPs 
identified by Gagneux et al. (2006) were performed to determine which of the six main M. 
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tuberculosis lineages the Rangipo strain belonged to, followed by sublineage classification 
PCRs. 
 
3.2.2.1 Lineage-specific Large Scale Polymorphism (LSP) based PCR 
for M. tuberculosis Strain Classification 
Multiplex PCRs including two reverse primers - one internal to the deleted region and the other 
immediately downstream of the LSP, were used to detect lineage-defining LSPs and provide a 
clear visual assignment of strain lineage based on the size of the PCR products produced. The 
presence of a band at the ‘deleted’ size for each RD PCR confirms the isolate belongs to that 
lineage, while a band of the ‘intact’ size suggests it does not. All nine Rangipo isolates tested 
were found to be intact for the four LSP PCRs which classify strains into five of the six lineages 
(see Table 3.3), suggesting they may belong to the Euro-American lineage (Figure 3.5). Euro-
American lineage classification was determined by amplifying across the pks1-15 gene and 
sequencing to confirm a representation of the isolates (C, F, S, T and U) contained the seven 
bp deletion characteristic of the Euro-American lineage (Gagneux et al. 2006) (Figure 3.6). 
 
Table 3.3: Expected product sizes for LSP PCRs 
 
Lineage LSP 
Product Size (bp) 
Intact Deleted 
Indo-Oceanic RD239 531 344 
East African/Indian RD750 556 371 
East Asian (or West Beijing) RD105 547 330 
West African 1              
West African 2 
RD9 501 368 
Euro-American pks1-15 561* N/A 
* Euro-American lineage classification is defined by a 7 bp deletion in the pks1-15 gene, determined by DNA 
sequencing of the of pks1-15 PCR fragment. N/A = Not applicable. 
 
Atypical MTBC 
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Figure 3.5: Lineage classification of nine Rangipo isolates using lineage specific LSP based PCRs. 
Letters across the top represent the nine isolates tested and RD numbers refer to the LSP tested. All four 
LSP PCRs show bands at the ‘intact’ size of 531, 556, 501 and 547 bp suggesting isolates do not belong to 
the Indo-Oceanic (RD239), East Africa/Indian (RD750), Atypical MTBC (including West African 1&2) (RD9) 
or East Asian (RD105) lineages respectively. 
 
Some non-specific banding was observed in the RD239 and RD750 PCRs, but it was of lesser 
intensity and larger than that of the correct ‘intact’ product. Personal communication with 
Michael Reed (Reed et al. 2009) confirmed they also saw the same two larger non-specific 
bands in their ‘intact’ PCRs, while any isolates belonging to these lineages produced a very 
clear single band of the deleted size. 
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Figure 3.6: Alignment of Rangipo isolates over the pks1-15 deletion region confirming classification 
within the Euro-American lineage. All Rangipo isolates (C – U) contain the 7 bp pks1-15 deletion 
characteristic of the Euro-American lineage as shown by alignment with M. tuberculosis H37Rv (Euro-
American), and the two control M. bovis BCG and M. canettii (non Euro-American) sequences. 
 
3.2.2.2 Euro-American Lineage Classification Based on the katG463 SNP 
Using the ‘on/off Switch Assay’ 
Another marker used to define Euro-American lineage is the ctg to cgg substitution at codon 
463 of katG, which encodes the catalase-peroxidase enzyme (Sreevatsan et al. 1997). 
Attempts were made at using an on/off switch assay (Section 2.1.3.3) to distinguish between 
Euro-American and non Euro-American genotypes, to reduce the time and costs involved in 
the above Euro-American strain classification method. The assay uses a forward primer 
common to both genotypes, while the two reverse primers are specific for the Euro-American 
(katG-R1) or non-Euro-American (katG-R2/3) strains with the katG 463 codon ‘ctg’ or ‘cgg’ 
respectively. Both reverse primers harbour a 3′ end phosphorothioate-modified nucleotide so 
when PCR is carried out with a proofreading polymerase, a product is only produced when the 
matched primer for the katG 463 codon is present, and not the mismatched primer. 
Unfortunately, a band was produced when either of the reverse primers were used, on both 
isolates tested (S and T) (Figure 3.7). HPLC purified 3′ end phosphorothioate-modified 
nucleotide reverse primers were then used in case the original primers contained a mixed 
population of oligonucleotides both with and without the modification which the polymerase 
could act on and produce a product, but both reverse primers still produced a product. Even 
though HPLC purification results in a purer oligo than a standard desalted purification, purity is 
only guaranteed at  ̴ 85 % so it is possible that there was still a mixed population of 
oligonucleotides present which is why a fragment was produced for both reverse primers. 
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Figure 3.7: katG 463 codon phosphorothioate-modified PCR for Euro-American lineage classification. 
Rangipo isolate S (belonging to the M. tuberculosis Euro-American lineage) containing the katG 463 
codon ‘ctg’, should amplify only with the matched reverse primer (R1) in this katG 463 codon 
phosphorothioate-modified PCR, and not with the mismatched reverse primer (R2/3). A product of the 
expected size (403 bp) was observed for both the matched (R1 +) and mismatched (R2/3 +) reactions 
above (no product for the no template negative controls (-)), indicating the katG 463 codon 
phosphorothioate-modified on/off switch PCR was unsuccessful and therefore is not an appropriate 
method for detecting strains belonging to the Euro-American lineage. 
 
3.2.2.3 Euro-American Sublineage Classification 
Euro-American sublineage classification PCRs were initially performed solely on isolate T, and 
then a representative sample of PCRs were repeated with isolates A, C, F, N, O, R, S and 
H37Rv to confirm the same results were obtained for all Rangipo isolates tested. All 10 region 
of difference (RD) PCRs defining each of the 10 Euro-American sublineages resulted in an 
‘intact’ sized PCR product (see Table 2.1 and Table 2.2 for intact and deleted sizes). This 
suggests the Rangipo strain of M. tuberculosis does not belong to any of the sublineages 
currently defined by region of difference deletions. Figure 3.8a shows the ‘intact’ product 
obtained for RD 115, 122, 183, 193, 724, 726 and 761 PCRs on isolate T. Initial PCRs for the 
three remaining RD PCRs (174, 182 and 219) were unsuccessful due to the large size of the 
original amplicon and fragmented nature of the template DNA used (due to sonication), so 
were successfully repeated with internal flanking primers as seen in Figure 3.8b. Figure 3.8c 
shows the ‘intact’ product obtained for RD 182 and 219 PCRs on Rangipo isolates  A, C, F, N, 
O, R, S as well as H37Rv, confirming the results obtained initially for Rangipo isolate T. 
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Figure 3.8: Region of Difference (RD) Euro-American sublineage classification PCRs. a) RD and b) RD 
internal (RDint) PCRs performed on Rangipo isolate T. Numbers across the top show the RD PCR 
performed, followed by the no template negative control (-). c) shows RDint219 (top) and RDint182 
(bottom) PCRs performed on Rangipo isolates A, C, F, N, O, R and S as well as H37Rv and a no template 
negative control (-). All PCRs show products of the ‘intact’ RD size (see Table 2.1 and Table 2.2 for sizes) 
(Gagneux et al. 2006;  de Jong et al. 2009) confirming the Rangipo isolates do not belong within any of the 
currently defined Euro-American sublineages. 
 
3.2.2.4 Latin American Mediterranean (LAM) Strain Classification 
Preliminary results from WGS suggested the Rangipo isolates may belong to the Euro-
American LAM sublineage. Strains belonging to the Euro-American LAM lineage are found 
worldwide, and are characterised by an IS6110 insertion at position 932204 of the H37RV 
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genome (Sampson et al. 1999) as well as by the LAM lineage specific SNP at codon 103 of 
Rv0129c which encodes Ag85C (Gibson et al. 2008). 
Rangipo isolates A, E, S and T were subjected to LAM-specific IS6110 PCR (Section 2.1.3.5) 
and produced a 141 bp fragment (Figure 3.9a), not a 205 bp fragment, indicating no LAM-
specific IS6110  element is present and they therefore do not belong to the LAM lineage 
(Marais et al. 2006). A second LAM-specific screen was also performed on isolates A, C, F, N, 
O, R and S as well as H37Rv to confirm the Rangipo strain did not belong to the LAM lineage. 
RFLP analysis using the LAM-specific SNP at codon 103 of the gene encoding Ag85C 
(Rv0129c) showed an absence of the SNP due to the 519 bp PCR product being cut into three 
fragments (365, 96 and 58 bp) instead of two (461 and 58 bp) (Figure 3.9b), as is seen in LAM 
strains containing the SNP (Gibson et al. 2008). 
 
Figure 3.9: LAM-specific IS6110 PCR (a) and Ag85C RFLP analysis (b) of Rangipo isolates. a) Rangipo 
isolates A, E, T and S were amplified with LAMF, LAMR and XhoI primers resulting in an approximately 
141bp product indicating the absence of the LAM specific IS6110 insertion element. b) Rangipo isolates 
A, C, F, N, O, R and S as well as H37Rv were amplified with Ag85C103F and Ag85C103R primers in a LAM 
specific Ag85C103 SNP RFLP. The resulting 519 bp products (top gel) were digested with MnlI then run on 
a 4 % agarose gel (bottom gel). The presence of the 3 bands at 365, 96 and 58 bp indicates a lack of the 
AG85C103 SNP and confirms Rangipo is not a LAM strain. 
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The Rangipo strain was successfully determined as belonging to the Euro-American lineage of 
M. tuberculosis (Figure 3.6), but did not match to any of the classified Euro-American 
sublineages, suggesting it belongs to an as-yet unclassified Euro-American sublineage. 
 
3.2.3 Rangipo-Specific SNPs  
3.2.3.1 Whole Genome Sequencing SNP Results 
WGS of 10 Rangipo isolates was employed to identify SNPs common to all of the Rangipo 
isolates sequenced, in order to design a robust Rangipo specific diagnostic. WGS was carried 
out by our collaborators at the Department of Medicine, University of Medicine and Dentistry of 
New Jersey (USA) as per (Colangeli et al. 2014), and identified 247 putative Rangipo-specific 
SNPs. 
 
3.2.3.2 Identification of Rangipo-Specific SNPs 
All 247 SNPs were cross checked against all mycobacterial strains available in the TB 
Database (TBDB) (http://www.tbdb.org) and Broad Institute database 
(http://www.broadinstitute.org/scientific-community/data) to check for the presence of 
annotated SNPs in other strains at the putative Rangipo-specific SNP position: nine were 
found not to be SNPs relative to the H37Rv genome reference strain, 80 were present in at 
least one other strain, 59 were located in the same position as a different SNP in at least one 
other strain and 99 were not currently annotated in any other strain in the databases (see 
Table 3.4). A list of mycobacterial strains (and their lineage classification) used for the SNP 
analysis is included in Appendix A.2. Any putative Rangipo-specific SNPs which were found 
within other strains, or within genes containing a high number of annotated SNPs (and 
therefore in a region of high genetic variation) were ruled out for use as a Rangipo-specific 
marker before a shortlist of Rangipo-specific SNPs was established. The shortlist of Rangipo 
SNPs included those in genes containing no (or few) annotated SNPs in other mycobacterial 
strains, or those which fell within genes with interesting functions such as virulence, 
persistence/dormancy, pathogenesis or within vapC genes. There were five SNPs which fell 
within genes containing no annoted SNPs (Rv0071, Rv2546, Rv3119, Rv3573c and Rv3769), 
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and two which were within vapC toxin genes (Rv1953 and Rv2546). The full list of SNPs 
identified by WGS and annotations is incuded on the compact disk - Appendix D. 
 
Table 3.4: Classification of 247 putative Rangipo-specific SNPs  
 
Classification # of SNPs 
Present in H37Rv and  not a SNP 9 
Present in at least one other strain 80 
Located in same position as a different SNP 59 
Not in any other strains and  Rangipo-specific 99 
Total SNPs identified by WGS 247 
 
3.2.3.3 Amplification and Sequencing to Confirm SNPs 
A representative sample (10) of the 99 Rangipo-specific SNPs identified above were PCR 
amplified from Rangipo isolate S, ExoISAP treated then sequenced as for Section 2.1.3.6.1 to 
confirm presence of the SNP. The presence of each SNP (relative to H37Rv) was confirmed by 
aligning the sequence with that from the H37Rv genome (see Appendix C.3). 
 
3.2.4 Development of a Rangipo RFLP Diagnostic Assay  
SNPs can be detected by RFLP analysis if only one of the two variant bases creates a 
cleavage site for a restriction enzyme. Rangipo-specific SNPs were screened in WatCut to 
identify REs which would selectively recognise only one of the two base variants at each SNP 
site as for Section 2.1.6.1. A number of the preferentially ranked SNPs were ruled out from 
being used in the diagnostic at this stage because no suitable RE could be identified to 
distinguish between the variants for those SNPs. The suitability of REs was based on: 
availability; cost; the number of base changes required for the recognition sequence; and the 
number of RE recognition sites within the amplification region in addition to that at the SNP 
position, to allow for clearly distinguishable cleavage fragments. An example of the WatCut 
SNP-RFLP analysis is shown in Figure 3.10, where HaeII has been chosen as the RE to 
differentially cleave samples with the SNP variant ‘G’ for the Rv3119 SNP. HaeII was chosen 
because it requires no changes to be made in the primer sequence in order for the RE to 
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recognise the sequence. This allows for flexibility in primer design when amplifying the region 
surrounding the SNP, as one of the primers does not need to be positioned in this region like it 
would be if HincII was used for example, where a T must be changed to a G. HaeII was 
chosen over the other seven REs which also require no base changes for recognition due to its 
availability already in the lab.  
 
Figure 3.10: WatCut SNP-RFLP analysis of the Rangipo-specific SNP in Rv3119. The sequence 
surrounding the 2 SNP variants A/G (indicated by the square brackets) for Rv3119 was analysed in 
WatCut, which returns a list of REs able to selectively recognise only one of the two base variants. The 
SNP variant recognised by each RE is shown in blue text while any changes required for the RE 
recognition sequence are shown in red. The RE HaeII (highlighted in green) was chosen as the Rv3119 
RFLP RE because it requires no changes to be made to the recognition sequence unlike others such as 
HincII (higlighted in purple), and because it was already available in the lab. 
 
3.2.4.1 Uniplex Rangipo-Specific SNP RFLP Assays 
Initially, SNP-RFLP assays were conducted singularly to check products amplified for both 
Rangipo and non-Rangipo samples, and REs selectively cut the products as expected in PCR 
buffer at 37 C. Table 3.5 shows details of the theoretically suitable SNP-RFLP assays, and 
summarises the success of each applied uniplex assay. Figure 3.11 shows SNP containing 
PCR products both before and after RE digestion, for H37Rv as the non-Rangipo control and 
isolate S as the Rangipo control. 
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Table 3.5: Summary of SNP-RFLP designs and applied outcomes. 
SNP 
Substitution 
(S/NS) 
# annotated 
SNPs in gene 
gene function RE 
# base 
changes 
required 
SNP base 
variant 
recognised 
strain 
differentially 
cut 
outcome of 
physical 
uniplex assay 
Rv0071 NS 0 
Deleted in Beijing isolates (RD105). 
Orthologs = RNA-directed DNA polymerase. 
ApaI 2 G/T NR x 
Rv0405 NS 39 pks6, pathogenesis, virulence1 HinfI 2 C/T NR  
Rv0719 NS 3 50S ribosomal unit protein RsaI 0 T/C NR  
Rv1821 S 6 
secA2, pathogenesis, blocks apoptosis of 
infected macrophages, encodes a component of 
a virulence related secretion system2 
Sau3AI 0 G/A NR  
Rv1854c NS 3 ndh BclI 0 T/G NR  
Rv2224c NS 2 
caeA, pathogenesis, post-translational protein 
modification, response to host immune response, 
required for survival and virulence in mice3 
AvaI 1 C/A NR x 
Rv2504c NS 1 scoA DraIII 0 G/T NR  
Rv2546 NS 0 vapC18 EcoR1 2 G/A NR x 
Rv2716 NS 3 conserved hypothetical protein DraIII 2 G/C NR  
Rv3119 NS 0 moaE1 HaeII 0 A/G R  
Rv3513c NS 0 fadD18 HaeIII 0 T/G R x 
Rv3616c NS 7 espA, pathogenesis, interacts with ESX-1 genes TaqI 1 C/A R x 
Rv3769 NS 0 hypothetical protein DraIII 2 C/T NR  
Rv3867 NS 1 conserved hypothetical protein MluI 1 G/C R x 
Rv3881c NS 8 
espB, pathogenesis, inhibits phagosome 
maturation4 
MvaI 0 A/C R x 
Bold type indicates which of the two SNP base variants is recognised, NR = non-Rangipo, R = Rangipo, x = SNP-RFLP assay not successful,  =  SNP-RFLP assay moderately 
successful,  = SNP-RFLP assay successful. Notes on gene functions were primarily gathered from the TBDB’ Functional Annotations’ or from other sources as indicated 
1 (Hisert et al. 2004), 2 (Baena & Porcelli 2009), 3 (Lun & Bishai 2007), 4 (Xu et al. 2007) 
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Figure 3.11: SNP-RFLP uniplex assays. SNP-RFLP assays showing resulting fragments for Rangipo (isolate S (S)) and non-Rangipo (H37Rv (H)) samples, both before 
and after (cut) RE digestion. Differentially digested products were obtained from SNP-RFLP assays for Rv1821, Rv3119, Rv3769, Rv2504c, Rv0719 and Rv1854c while 
the rest were either not cut (indicated in red text), had both SNP variants cut (orange), or the digest patterns for each variant were not clearly distinguishable from 
each other (blue).  
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SNPs which were not cut as expected were Rv0071, Rv2224c, Rv2546, Rv3513c, Rv3867 and 
Rv3881c. Rv0071, Rv3616c and Rv3867 were not cut for either variant, Rv0071 and Rv3616c 
require digestion with ApaI at 25 C and TaqI at 65 C respectively, instead of 37 C so are 
not ideal SNPs to include in the multiplex diagnostic, and the MluI used to digest Rv3867 was 
expired, which may be why it did not digest the product. Both SNP variants were cut for 
Rv2224c and Rv2546 (Rv2546 only partially so both ‘cut’ and ‘un-cut’ products were observed) 
indicating some degeneracy in the RE recognition sequences. REs cut non-SNP specific RE 
recognition sites for the Rv3513c and Rv3881c products, but not for the Rangipo SNP specific 
RE recognition site in Rangipo isolate S. These SNP-RFLP assays required no base changes 
in order for the RE to recognise the SNP, so theoretically if the SNP is present (as it should be 
in isolate S) cleavage should occur here as well as at the other recognition sequences within 
the amplification product. The absence of cleavage at the SNP specific RE recognition 
sequence initially suggested the absence of these SNPs in isolate S, but while the Rv3513c 
SNP had not been confirmed by PCR and sequencing, the Rv3881c SNP had, (Section 
3.2.3.3) which ruled this possibility out. Another analysis program was used to theoretically 
digest the Rv3881c product in case there was an error in the SNP-RFLP design but the same 
size fragments and cut sites were observed as those obtained from using the Geneious 
software. MvaI cuts CC/WGG sequences (where W stands for A or T, and / designates the 
cleavage site), of which there are two in the Rv3881c product for isolate S; CC/AGG for the 
SNP specific recognition site and CC/TGG for the non-SNP specific site. No evidence for 
preferential cleavage of T over A sites could be found in the literature for MvaI in non-
methylated DNA so the reason for MvaI not cleaving at both the Rv3513c and Rv3881c SNP 
specific recognition sites remains unknown. The above six SNPs which were not cut as 
expected in the SNP-RFLP assays were not carried through to the following stage of 
diagnostic development. 
 
SNPs which were cut as expected but produced fragments hard to visually distinguish were 
those in Rv0405 and Rv2716. The Rv0405 SNP produced cut fragments of 118, 93 and 11 bp 
for Rangipo and 118, 71, 22 and 11 bp for non-Rangipo samples which were too close to 
easily distinguish from each other, while the Rv2716 SNP did not amplify cleanly under the 
standard diagnostic conditions (probably due to the higher Tm of the primers; 68 C compared 
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to  60 C). Both Rv0405 and Rv2716 SNPs were not carried through to the following stage of 
diagnostic development as they produced fragments which were not easily distinguishable and 
therefore not suitable for the diagnostic. 
 
SNPs which were cut producing clearly distinguishable fragments of the expected sizes were 
Rv3119 (which cuts Rangipo the strain) and Rv0719, Rv1821, Rv1854c, Rv2504c and Rv3769 
which cut non-Rangipo strains. 
 
3.2.4.2 Multiplex Rangipo-Specific SNP RFLP Assays 
Duplex and triplex SNP-RFLP assays were theoretically digested to ascertain which 
combinations would produce fragments that easily distinguished between Rangipo and non-
Rangipo strains. Figure 3.12 shows theoretical digest results for the Rv1821, Rv2504c and 
Rv3119 triplex SNP-RFLP assay. Promising combinations (see Table 3.6) were then 
performed experimentally to confirm that the specific REs cut the duplex or triplex products as 
expected (Figure 3.13).  
 
 106 
 
 
Figure 3.12: Theoretical Rv1821, Rv2504c and Rv3119 triplex SNP-RFLP assay. a) Schematic showing 
positions of RE recognition sequences (arrows) and the resulting fragment sizes (in bp) once each of the 
three amplicons is digested. Single arrows targeting only one of the two strains (N = non-Rangipo, R = 
Rangipo) represent the RE recognition sequence for the SNP within that gene, where blue = Sau3AI, green 
= HaeII and red = DraIII. b) Theoretical banding patterns of fragments resulting from the triplex SNP-RFLP 
assay. L = ladder, NR = non-Rangipo and R = Rangipo.  
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Table 3.6: Promising SNP-RFLP combinations and fragment sizes. 
 
SNP combination identifier un-cut size (bp) cut size - R (bp) cut size - NR (bp) 
Rv0719, Rv3119 1 119, 403 80, 119, 323 40, 79, 403 
Rv2504c, Rv3119 2 241, 403 80, 241, 323 48, 193, 403 
Rv1821, Rv3119 3 493, 403 
25, 80, 135, 164, 
493 
25, 149, 164, 215, 
344 
Rv0719, Rv1821, 
Rv3119 
4 119, 493, 403 
25, 80, 119, 135, 
164, 204, 289 
25, 40, 55, 79, 149, 
164, 215, 289 
Rv1821, Rv2504c, 
Rv3119 
5 493, 241, 403 
6, 19, 24, 36, 75, 
80, 105, 135, 
164, 493 
6, 19, 24, 29, 36, 46, 
105, 149, 164, 215, 
344 
Identifier refers to the SNP combinations displayed in Figure 3.13 below, cut size refers to the size of predicted 
fragments after RE digestion, R = Rangipo, NR = non-Rangipo. 
 
 
Figure 3.13: SNP-RFLP duplex and triplex assays. SNP-RFLP assays showing resulting fragments for 
Rangipo (isolate S (S)) and non-Rangipo (H37Rv (H)) samples, both before and after (cut) RE digestion. 
Expected fragment sizes are shown in Table 3.6 above for each duplex (assays 1 - 3) and triplex (assays 4 
& 5) reaction. SNP combinations are as follows: 1 = Rv0719/Rv3119; 2 = Rv2504c/Rv3119; 3 = 
Rv1821/Rv3119; 4 = Rv0719/Rv1821/Rv3119 and 5 = Rv1821/Rv2504c/Rv3119. Differentially digested 
products were obtained from SNP-RFLP assays 1, 2, 3 and 5, while fragments produced for assay 4 were 
not clearly distinguishable from each other. 
 
Fragments which are similar in size often appear as one band, while fragments which are small 
(less than 25 bp) are not usually observed on the agarose gels, therefore, the optimal assay 
produces vastly different sized fragments and/or a different number of fragments between the 
two SNP variants which are easily distinguishable by eye. All of the assays in Figure 3.13 
above show distinct fragment banding for the two strains, except for assay 4 where the band 
sizes are too similar to separate them easily by eye on the gel. Assay 5 is therefore the best 
triplex SNP-RFLP assay to use for the Rangipo diagnostic, as the fragment banding is easily 
distinguishable between Rangipo and non-Rangipo strains, contains a RE recognition site 
specific for both Rangipo (Rv3119) and non-Rangipo (Rv2504c and Rv1821) SNP variants as 
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a built in control, and uses REs which function together at the same temperature, for the same 
duration and in PCR buffer alone. 
 
3.2.4.3 Optimisation of RE Digest in the SNP-RFLP Assays 
All previous RE digests for SNP-RFLP assays had been performed overnight at 37 C which 
meant it took at least one day to obtain the results from the diagnostic assay. A RE digest 
timecourse assay was performed to determine the minimum amount of time the products 
needed to be digested for to achieve full digestion, in order to reduce the turnaround time and 
thereby improve the diagnostic assay. The triplex assays were digested for 2 hr, 4 hr or 
overnight, this time using DraIII-HF in place of DraIII as the DraIII had been discontinued. The 
digests appeared smeary and showed non-specific cleavage products even after 2 hr (Figure 
3.14a). While the DraIII-HF supposedly has reduced star activity compared to its DraIII 
predecessor, it appears to be exhibiting a lot of star activity under these triplex conditions 
where PCR buffer is used instead of RE buffer, and where 3 µl of REs are used in a 13 µl total 
volume resulting in a high glycerol concentration (11.5 %). A series of triplex assays were 
digested for 2 hr with reducing concentrations of the REs to eliminate the star activity of the 
DraIII-HF, until suitable fragment banding was observed (Figure 3.14b), like that observed 
previously when DraIII was used instead of DraIII-HF (see Figure 3.13). All future digests were 
performed with 0.4 µl of each RE for 2 hr, which reduced the total time taken for the Rangipo 
SNP-RFLP assay to approximately 4.5 hr. 
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Figure 3.14: SNP-RFLP triplex RE digest timecourse assays using DraIII-HF instead of DraIII a) Initial 
assays were performed with 1 µl of each RE for 2 hr, 4 hr or overnight (O/N) resulting in non-specific 
digestion of both the non-Rangipo (H37Rv (H)) and Rangipo (isolate S (S)) control samples. b) Optimised 
assays on the H37Rv non-Rangipo control were digested for 2 hr only with either 0.25 or 0.4 µl of each RE 
resulting in the correct banding pattern of fragments at 344, 215, 164+149, 105, and 46+36+29+24 bp 
(where numbers on either side of the + appear as one band on the gel). 
 
An attempt was made to reduce the cost of the diagnostic by replacing the RE Sau3AI with 
one of its cheaper isoschizomers, MboI in the triplex digest. When used in combination with 
the other two RE used in the SNP-RFLP assay (HaeII and DraIII-HF), MboI didn’t cut the 
Rangipo and non-Rangipo samples as efficiently, and also appeared to cut the non-Rangipo 
sample incorrectly so Sau3AI continued to be used.  
 
3.2.4.4 Taguchi Based Optimisation of Multiplex PCRs   
A Taguchi based optimisation was performed on the triplex PCR to determine the optimal 
conditions to then be used in the Rangipo SNP-RFLP assay. Optimisations were performed 
with both Rangipo (isolate C) and non-Rangipo (H37Rv) DNA to find the condition which 
produced each of the three products in relatively equal amounts for both strains. Figure 3.15 
shows condition #14 amplified and was digested well for both strains, so this PCR condition 
was used for the Rangipo triplex SNP-RFLP diagnostic assay; 1 x PCR buffer, 0.1 mM dNTPs, 
2.4 mM MgCl2, 3 U Taq DNA Polymerase, 0.1 μM Rv3119 and Rv1821 primers and 0.2 μM 
Rv2504c primers, and 10 ng template DNA annealed at 68 C. 
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Figure 3.15: Taguchi optimisation of SNP-RFLP triplex PCR using a) non-Rangipo DNA and b) Rangipo 
DNA. The banding pattern obtained from the 18 reactions of the orthogonal array. Numbers across the top 
correspond to the 18 reactions in the orthogonal array (see Table A.3 in Appendix A.1). The 3 bands 
represent each of the 3 amplification products for Rv1821 (493 bp), Rv3119 (403 bp) and Rv2504c (241 bp). 
c) shows both Rangipo (isolate C) and non-Rangipo (H37Rv) samples were successfully amplified then 
digested using the #14 conditions from the orthogonal array, - depicts the negative control. 
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3.2.5 Screening Clinical Isolates with the Rangipo Specific 
PCR/RE Diagnostic 
Clinical M. tuberculosis isolates from LabPLUS of known MIRU type were initially screened 
with the Rangipo SNP-RFLP diagnostic to confirm it correctly identifies all Rangipo samples 
without any false positives or negatives. Figure 3.16 shows no non-Rangipo samples were 
identified as Rangipo, and all Rangipo samples were correctly identified while one sample 
(#12) assigned to the Rangipo strain by MIRU typing was found to be unique by the SNP-
RFLP diagnostic. Upon discussion with LabPLUS, it was ascertained that sample #12 was 
from a case which likely contracted TB outside of New Zealand, and the strain was not actually 
Rangipo in the strictest sense, but probably a related strain. This illustrates the limitation of 
MIRU typing for distinguishing closely related strains (even with MIRU 24 typing), and re-
affirms why WGS is becoming the method of choice for pathogen typing. The figure also 
shows that this Rangipo SNP-RFLP diagnostic assay groups samples in identical groups as 
the MIRU typing does, as well as differentiating isolates belonging to the Otara (062) cluster 
(responsible for the third largest cluster endemic to New Zealand).  
 
 
Figure 3.16: Rangipo SNP-RFLP diagnostic screening of clinical isolates of known M. tuberculosis MIRU 
type. Samples 1 - 22 were screened with the Rangipo SNP-RFLP diagnostic assay. The three digit number 
at the top of samples indicates which 12 MIRU loci and therefore strain they belong to (040 = Rangipo, 062 
= Otara, 061 = Southern Cross) according to MIRU typing. Sample 22 = H37Rv and S = the Rangipo isolate 
S positive control. The banding patterns show that no non-Rangipo samples share the same banding as 
samples from the Rangipo strain, and all Rangipo samples were correctly identified as Rangipo by their 
banding pattern, except for sample 12 which was grouped as Rangipo by MIRU typing but showed a 
unique MIRU 24 pattern so is likely to infact be a related strain to and not Rangipo. 
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Batches of ‘blind’ clinical samples (labelled with an identification number only) were then 
screened with the Rangipo SNP-RFLP diagnostic and the results sent to LabPLUS for 
confirmation according to their MIRU typing results. Figure 3.17a shows the banding patterns 
obtained from the diagnostic for all blind samples, which correctly identified all 4 Rangipo and 
the 40 non-Rangipo samples. Rangipo isolates A, C, F, N, O, R and S were also screened with 
the Rangipo SNP-RFLP diagnostic assay confirming the same banding pattern (Figure 3.17b).  
 
 
Figure 3.17: Rangipo SNP-RFLP diagnostic screening of ‘blind’ clinical isolates of unknown M. 
tuberculosis MIRU type, and Rangipo isolates A, C, F, N, O, R and S. a) blind M. tuberculosis samples 23 - 
66 were screened with the Rangipo SNP-RFLP diagnostic assay revealing 4 Rangipo (shown in red text) 
and 40 non-Rangipo samples when compared with the Rangipo (isolates C & S) and non-Rangipo (H37Rv 
(H)) controls. b) Rangipo isolates A, C, F, N, O, R and S were screened along with a H37Rv non-Rangipo 
control (H), and repeats of blind samples 36 and 37 which were not clear in a) (above). All Rangipo 
samples were correctly identified, as confirmed by MIRU typing results from LabPLUS. 
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3.3 Conclusions 
The Rangipo strain of M. tuberculosis is responsible for the largest cluster of tuberculosis 
infections within New Zealand. This strain has been circulating readily in the Waikato and Bay 
of Plenty regions for a quarter of a century, and its control has proved difficult owing to its high 
transmissibility and virulence, as well as a lack of a rapid and reliable test to identify the strain.  
 
During the course of this research, the Rangipo strain was identified through LSP and RD PCR 
analysis, as belonging to an as yet unclassified Euro-American sublineage of M. tuberculosis. 
Robust strain classification is essential for revealing how M. tuberculosis has evolved and may 
continue to do so (Achtman 2008), and how strains can differentially effect the pathology of the 
disease (de Jong et al. 2008;  Thwaites et al. 2008). 
 
10 Rangipo isolates were fully sequenced and MIRU typed by collaborators, and during the 
course of this research Rangipo specific SNPs were identified and used to develop a Rangipo 
strain specific diagnostic assay. This RFLP based diagnostic is able to quickly and sensitively 
distinguish Rangipo isolates from other M. tuberculosis strains (4.25 hr once DNA has been 
obtained), with high specificity and at little cost. While the samples tested here involved DNA 
from fully grown cultures, it is expected that the diagnostic would also work well using DNA 
from partially grown cultures and even directly from sputum (for culture positive samples), 
given the extreme sensitivity of PCR based methods which are already used in TB detection 
tools such as the Xpert MTB/RIF system. The median time to start treatment from the onset of 
symptoms is approximately 2 months in New Zealand (Lim & Heffernan 2013). This delay 
before treatment starting is precariously long in the context of the Rangipo strain due to its high 
transmissiblity and virulent nature, and the majority of Rangipo infections being pulmonary. 
The ability of the Rangipo diagnostic assay to reduce the diagnosis turnaround time will be 
immensely beneficial in disrupting the chain of transmission of this highly transmissible strain, 
which is instrumental in controlling tuberculosis infection (Barnes & Cave 2003). 
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4 Chapter Four: 
Expression of vapB and 
vapC in Mycobacterium 
smegmatis using RT-
qPCR 
4.1 Introduction 
Mycobacterial VapBC systems have been linked to pathogenesis, persistence, cell death and 
response to stress (Gerdes et al. 2005;  Korch et al. 2009;  Ramage et al. 2009;  Min et al. 
2012). Here, reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) 
is used to attempt to identify conditions in which the M. smegmatis vapB or vapC genes are up  
or downregulated, in order to gain a better understanding of the biological roles and 
mechanisms involved in the regulation of the numerous VapBC systems in M. tuberculosis. 
Quantitative real-time polymerase chain reaction (qPCR) is used extensively to quantitate RNA 
and DNA. RT-qPCR is an extremely sensitive and robust method for measuring the expression 
of genes of interest (GOI), validating microarray experiments, and monitoring biomarkers. RT-
qPCR is especially useful for detecting lowly expressed mRNA transcripts, or where there are 
small changes in expression levels (Bustin 2000). As such, it has become known as the gold 
standard in quantification of mRNA and validation of microarray data (Canales et al. 2006), but 
due to the variability in materials and protocols used, and limited understanding of the 
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principals involved in the data analysis, it is not a standard assay. The possibility that VapBC 
systems may play a role in the ability of M. tuberculosis to survive in the varied and hostile 
conditions/environments it encounters, suggests growing M. smegmatis under conditions of 
stress may be an ideal way to elicit a change in the expression of vapB or vapC. Many 
microarray and RT-qPCR studies performed in M. smegmatis have shown a multitude of 
stressors can effect the expression of particular genes, including temperature shock, nutrient 
starvation, oxidative stress, and antibiotic stress (Fernandes et al. 1999;  Smeulders et al. 
1999;  Milano et al. 2001;  Shires & Steyn 2001;  Singh & Singh 2009). The expression of 
these particular genes is regulated by the bacteria, in order for it to adapt to the particular 
stress condition(s) it is experiencing. 
 
4.1.1 The Principles and Pitfalls of Real-Time Reverse-
Transcription PCR (RT-qPCR) 
In conventional PCR, only the end product can be quantified (by running it on an agarose gel) 
which is time consuming and does not reliably reflect differences in the starting quantity of the 
template material. Real-time PCR differs from conventional PCR in that the increase in 
amplification product is measured in real time by using a fluorescent reporter molecule, with 
product quantification after every cycle. The ability to isolate just the exponential phase of 
amplification for analysis where component concentrations are not limiting, allows information 
about the initial quantity of template DNA to be calculated. In the case of RT-qPCR, where 
RNA is first converted into cDNA by the reverse-transcription reaction, the difference in mRNA 
expression levels of particular GOI can be determined. RT-qPCR has traditionally been used to 
detect lowly expressed mRNA transcripts and validate microarray data, but with the recent 
introduction of RNA sequencing (RNA-Seq) for mapping and quantifying entire transcriptomes, 
RT-qPCR will become an even more important tool for validating the differentially expressed 
transcripts identified (Fang & Cui 2011). 
 
There are two main methods for detecting amplicons in RT-qPCR: gene-specific fluorescent 
probes which depend on Förster Resonance Energy Transfer (FRET) technology to produce a 
fluorescence signal via the uncoupling of a fluorogenic dye molecule and its quencher, and 
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non-sequence specific fluorescent intercalating double stranded (ds) DNA binding dyes. The 
most common probe based system is TaqMan which is sequence specific, requires little 
optimization but is expensive. Fluorogenic intercalating dyes are inexpensive and have much a 
higher fluorescence when bound to dsDNA compared to the unbound dye (Vitzthum et al. 
1999), but are not sequence specific so require thorough optimisation to distinguish specific 
from non-specific products. SYBR Green I has been used as the default fluorogenic dye until 
recently, when other dyes such as SYTO 82 were found to have a much better detection limit 
than SYBR Green. This is because unlike SYBR Green I, they don’t inhibit PCR and do not 
preferentially bind to GC rich sequences (Gudnason et al. 2007). This makes SYTO 82 a 
valuable tool in detecting the lowly expressed TA genes in the GC rich (67 % (Schneider et al. 
2006)) M. smegmatis bacterium. 
 
There is no universally accepted method for data normalisation which accounts for all variables 
possible during the course of a RT-qPCR experiment. Therefore, selection of a normalliser is 
dependent upon the studies aims, and levels of acceptable tolerance (Huggett et al. 2005). 
The main strategies are: normalisation to sample size, total RNA quantity, or the common 
practice of normalising to an internal reference or housekeeping (HK) gene. These are not 
mutually exclusive and it is recommended that sample sizes are matched, quality RNA of a 
similar quantity is used for the RT reactions, and an endogenous control (reference gene) is 
also measured (Huggett et al. 2005).  
 
There are two main methods of gene quantification: absolute and relative. Absolute 
quantification uses a standard curve for each reaction run and determines the copy number or 
concentration of the target transcripts based on their quantification (or threshold) cycle (Cq) 
values. While this method can correct for differences in primer efficiencies, there is a large 
reduction in the number of samples that can be analysed per run. Relative quantification 
determines variation in mRNA levels of a target gene relative to a reference/HK gene, and is 
expressed as a relative fold change in target expression values. There are many mathematical 
models available to calculate relative expression, some take into account the amplification 
efficiency of the PCR reaction and correct for this while others do not, instead assuming an 
‘ideal’ efficiency where the PCR product doubles every cycle during the exponential phase. 
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Models which correct for efficiency are highly recommended and result in a more accurate 
estimation of the relative expression ratio, as not all PCRs have an ideal amplification 
efficiency, and small efficiency differences between genes can result in a large over- or under-
estimation of the ‘real’ initial mRNA amount (Pfaffl 2004).  
 
Both of the above quantification strategies require normalisation of target gene expression to a 
reference or housekeeping gene. This is to account for sample to sample variation (such as 
yield and integrity of RNA, RT efficiency, cDNA loading variation and PCR efficiency), which 
should affect the normaliser and the GOI equally, and ensures that all the steps required to 
obtain the final PCR measurement are controlled for within the same sample (Nolan et al. 
2006). The ideal housekeeping gene must be stably expressed under all the experimental 
conditions used, express at a similar level relative to target gene levels (Pfaffl 2004), and not 
have related pseudogenes. Housekeeping gene expression can vary considerably between 
cell type, stage of growth, and experimental conditions (Thellin et al. 1999;  Bustin 2000) so 
the chosen housekeeping gene(s) needs to be experimentally validated. Recent studies 
identifying suitable housekeeping genes suggest that the ideal and universal control gene does 
not exist, so where possible, multiple housekeeping genes should be used for reliable 
normalisation of RT-qPCR data (Pfaffl et al. 2002;  Vandesompele et al. 2002;  Andersen et al. 
2004). 
 
4.1.1.1 Minimising Technical Variation 
The difference in mRNA expression levels between samples is not just due to biological 
variation, it is also a result of experimentally induced or technical variation. In order to 
determine an accurate account of the changes occurring at the biological level, technical 
variation must be kept to a minimum. Technical variation may be introduced at multiple stages 
along the RT-qPCR process, and includes factors such as differences in the quality and 
amount of starting material, overall transcriptional activity, and enzymatic efficiencies in the RT 
and RT-qPCR processes (Vandesompele et al. 2002;  Pfaffl 2004). To minimise technical 
variation, the materials and protocols employed to isolate, quantitate and reverse transcribe 
the RNA must be kept consistent, and also be able to produce material of sufficient quantity 
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and quality for the downstream qPCR application. Any remaining differences in the amount 
and quality of starting material can then be normalised for by using a suitably selected 
housekeeping gene, to more competently assess the true biological variation. 
 
4.1.1.2 Analysis and Quantitation of Results 
A typical RT-qPCR amplification consists of an exponential phase (where the amount of 
amplification product approximately doubles per cycle), followed by a plateau phase once 
reagents begin to deplete. Initially (in the exponential phase), fluorescence remains at 
background levels with no detectable increase in signal from the amplified product. At a 
particular point in the reaction, enough product is accumulated to produce a detectable 
fluorescent signal above the background noise, and the cycle number at which this occurs is 
called the quantification cycle (Cq) (also referred to as the threshold cycle (Ct), crossing point 
(Cp), and take-off point (TOP)). The linear phase is reached when reaction components 
become limited and the reaction no longer progresses exponentially (mainly due to product 
renaturation competing with primer binding (Dharmaraj), and the point at which this begins 
varies greatly. Because the Cq is obtained in the exponential phase where reaction 
components are not limited and amplification is extremely reproducible, this methodology can 
be employed to calculate the starting quantity of template. In a typical reaction, a higher 
starting template concentration will result in an earlier or lower Cq, as relatively fewer 
amplification cycles are needed for the amplification product to rise above the background 
fluorescence signal. 
 
The two main strategies commonly used to quantify results obtained by real-time RT-qPCR are 
the standard curve method (for both absolute and relative quantitation), and the comparative 
Ct method (for relative quantitation only). The standard curve method uses a curve constructed 
from RNA of known concentration, as a reference to extrapolate the titre of template mRNA in 
samples. While this method is relatively simple and robust (Cikos et al. 2007), it requires 
dilution curves to be run for both the standard and reference genes which takes up valuable 
space during each run. An alternative model was proposed which utilised the observed 
correlation between PCR efficiency and Cq to estimate the initial copy number of template 
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molecules without having a standard of known concentration (Wilkening & Bader 2004). Here, 
the average number of copies of PCR product at the Cq for 16 PCRs using a known amount of 
starting material, was found to be 1.12 × 1010 ± 3.66 × 109. This value was then substituted 
into the equation in order to calculate the approximate initial copy number of unknown samples 
where the PCR efficiency is known (see Equation 1). 
 
Equation 1 
  
N0 = 1.12 × 1010/E^CN  , where 
 N0 = initial copy number or starting concentration 
 E = PCR amplification efficiency 
^ = denotes 'to the power' 
CN = the cycle number at the Cq 
 
For relative quantitation, the comparative Ct method (also called the Ct method) (Livak & 
Schmittgen 2001) also removes the need for a standard curve, by comparing the Cq values 
(referred to as Ct values when the equation was created) of the samples of interest with a 
control (such as a non-treated sample or RNA from a wt cell) after they have been normalised 
to a HK gene. The original comparative Ct method however, assumes that the amplification 
efficiencies of both the HK gene and the target GOI are approximately equal and are at 
maximum (ie.100 %) (see Equation 2), which is often not the case. A modified method from the 
original calculation was developed by Pfaffl (2001) which factors in the efficiency of each of the 
amplification reactions (see Equation 3), and gives a more accurate estimation of the initial 
mRNA concentration (Pfaffl 2001;  Pfaffl 2004). 
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Equation 2 
 
 ΔΔCt = ΔCt (sample) − ΔCt (control) , where 
ΔCt = Ct (GOI) − Ct (HK)  , therefore 
ΔΔCt = (Ct (HK sample) − Ct (GOI sample)) − (Ct (HK control) − Ct (GOI control)), 
where 
Ct (GOI) = Ct value of gene of interest in the sample or control 
Ct (HK) = Ct value of housekeeping gene in the sample or control 
 
The ratio of the GOI in the sample relative to in the control is calculated as follows:  
R = 2ΔΔCT. 
 
Equation 3 
 
 R =  (E GOI)^Ct GOI (MEAN control - MEAN sample) 
(E HK)^Ct HK (MEAN control - MEAN sample)    , where 
ΔCt = MEAN Ct (control) - MEAN Ct (sample)  , where 
R = expression ratio of the gene of interest relative to the control, normalised to the HK 
E = PCR amplification efficiencies of gene of interest or HK gene 
^ = denotes 'to the power' 
Ct control = Ct value for ‘control’ gene of interest or HK gene 
Ct sample = Ct value for ‘sample’ gene of interest or HK gene 
 
There are many programs for analysing RT-qPCR data, both off the shelf and instrument 
specific, each using different methodologies to interpret the resulting data. The plethora of 
instruments and methods for analysing the resulting RT-qPCR data makes interpreting and 
comparing results from the literature difficult. One of the earlier analysis programs published 
(2003) is LinRegPCR, which has been used extensively since, with improvements made along 
the way (Ramakers et al. 2003;  Ruijter et al. 2009). The LinRegPCR program performs a 
baseline correction and determines a window-of-linearity for the data, then uses linear 
regression analysis to calculate the PCR efficiency for each sample from the slope of the 
resulting regression line. The starting concentration (expressed in arbitrary fluorescence units) 
for each sample is then calculated (based on Pfaffl’s equation) using PCR efficiency and Cq 
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values, which can then be used to determine the normalised, relative change in expression 
levels (see Equation 4). This calculation is very similar to Equation 1 derived from the 
computation model, except it is not based on a set value obtained from the averaging the 
number of copies of PCR product at the Cq from a random group of 16 genes, but instead 
more accurately utilises the Nq values for the actual amplicons in question.  
 
Equation 4 
 
: R = AVERAGE (N0 GOI) 
  AVERAGE (N0 HK) , where 
R = expression ratio of the gene of interest, normalised to the HK 
N0 = Nq / (E(MEAN)^Cq) , where 
N0 = starting concentration (expressed in arbitrary fluorescence units) 
Nq = fluorescence threshold set to determine Cq 
E(MEAN) = mean amplicon PCR efficiency  
^ = denotes 'to the power' 
Cq = number of cycles needed to reach Nq (previously referred to as Ct) 
 
Statistical software has been developed to help the user identify the most appropriate 
housekeeping genes for normalisation of their experimental data set. GeNorm uses the 
average pairwise variation of an individual gene to other genes to determine their expression 
stability, and progressively eliminates the least stabily expressed ones (Vandesompele et al. 
2002). NormFinder also assigns expression stability values to single candidate reference 
genes, but uses a model-based approach, and factors in the possible variations within and 
between sample groups (Andersen et al. 2004). The BestKeeper algorithm combines all 
reference genes into an index, and calculates the correlation between it and each of the 
reference genes (based on their raw Cq values) utilising the coefficient of variance, standard 
deviation and coefficient of correlation variables (Pfaffl et al. 2004). While there is no 
consensus on which software is the best, GeNorm is the most widely used, and often, multiple 
algorithms are compared in order to identify which genes are consistently ranked as the most 
stable.  
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Where experimental design and treatment(s) effect housekeeping gene expression, multiple 
endogenous housekeeping genes, or an introduced RNA standard may be required for 
normalisation. Whilst spiking in a synthetic RNA (usually with the ends identical to the target 
gene so as the same primer sequence can be used for both the synthetic standard and target) 
can be useful in normalising reaction efficiencies, they are costly and easily degraded, making 
them a less satisfactory option than using multiple housekeeping genes. GeNorm and 
BestKeeper are two algorithms which take into account the the geometic mean of multiple 
housekeeping genes, to reduce the effect of treatment(s) on these housekeeping genes, and 
thereby strengthen the validity of the resultant data (Vandesompele et al. 2002;  Pfaffl et al. 
2004). 
 
The vast array of sample preparation methods, reagents, platforms, normalisation and analysis 
strategies which are available to users, combined often with a limited understanding of the 
principals involved in RT-qPCR analysis, makes interpretation of the data difficult and results 
sometimes impossible to reproduce. A unified approach to RT-qPCR is therefore required for it 
to become a standard assay.  
 
4.1.2 Isolation of Mycobacterial RNA 
Intact mycobacterial mRNA is difficult to extract due to the physical strength and mycolic acid 
content of the cell wall, the short half-life of RNA (Lewin 1990), and the low content of RNA per 
unit of DNA (Verma et al. 1999). The functional half-life of the bulk of E. coli mRNA is only 2.4 
minutes (Regnier & Arraiano 2000). Degradation (by both endo and exonucleases) of the 
transcribed mRNA is thought to begin within one minute of the start of transcription (Lewin 
1990), so in order to extract high yields of intact mycobacterial RNA the cells must be rapidly 
disrupted, releasing their RNA directly into chaotropic buffers (such as guanidinium 
isothiocyanate to inhibit any endogenous RNases (Chomczynski & Sacchi 1987)) and 
preserved (Dietrich et al. 2000). 
 
RNA is somewhat unstable and easily degraded by inadequate sample handling or storage 
once extracted (Schoor et al. 2003;  Bustin et al. 2005;  Perez-Novo et al. 2005), and RNA 
 124 
 
quality and yield can be vastly different between two extraction methods, even if just the 
method of homogenisation changes (Fleige et al. 2006). This is also true for the purity of RNA, 
it has been shown that levels of DNA carried over during the RNA extraction process varies 
greatly between extraction methods (Schagat et al. 2008). Starting with RNA of poor purity or 
integrity may affect the results of downstream applications such as gene expression evaluation 
which can be labour-intensive, time-consuming and highly expensive (Raeymaekers 1993;  
Imbeaud et al. 2005). Traditionally, determination of RNA purity was assessed via analysis of 
the A260/A280 ratio and its integrity analysed via rRNA bands on an agarose gel. The recent 
introduction of micro-fluidic capillary electrophoresis instruments such as the Agilent 
Bioanalyzer (Agilent Technologies) have allowed RNA quality, quantity and integrity to be 
measured much faster and using only picogram amounts of RNA.  
 
The first mycobacterial RNA extraction method (Katoch & Cox 1986) resulted in poor yields of 
RNA prone to degradation. There have been many different methods employed since utilising 
rapid lysis techniques such as sonication (Patel et al. 1991), the French press (Kinger et al. 
1993) and bead beating (Hurley et al. 1987;  Mangan et al. 1997), but the problem of obtaining 
intact RNA free of contaminating DNA still remains. A variety of factors such as yield 
variations, processing requirements, and sample availability of cells or tissues must be taken 
into account when choosing an extraction method as they can all influence the ability to obtain 
intact, high-quality RNA that is free of  RNases, inhibitors, proteins and genomic DNA (Bustin & 
Nolan 2004). 
 
Each isolation method extracts the total pool of RNA, of which only ~ 1 - 5 % is mRNA in 
bacteria (McGrath et al. 2008). An isolation method’s efficiency or preference for extracting 
non-messenger RNAs (i.e., transfer RNA and ribosomal RNA which make up ~ 15 % and 80 % 
of the total RNA in bacteria respectively (Gonzalez-y-Merchand et al. 1998;  Clark & Pazdernik 
2013)) may lead to a difference in the amount of mRNA isolated in relation to the amount of 
total RNA present in a cell.  
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4.1.3 Objectives 
The aims of this study were to identify conditions in which M. smegmatis vapB or vapC 
expression varied in order to help identify the mechanisms involved in the regulation of VapC, 
and to develop an optimised RNA isolation and RT-qPCR method suitable for the 
quantification of these target genes. 
 
The biochemical function of VapC from M. smegmatis and activity of VapC proteins from M. 
tuberculosis was unknown at the beginning of my research. 
 
4.2 Results and Discussion 
4.2.1 Comparison of Protein Concentration and Optical Density 
Tween 80 acts as a carbon source for mycobacteria (Saito et al. 1983;  Wayne 1994) and 
inhibits the growth of some microorganisms, thereby reducing the possibility of contamination 
(Singh & Reyrat 2009). Detergents such as Tween 80 are also used to reduce clumping in 
bacterial cultures, which are most probably caused by exposed lipids of the cell surface 
establishing hydrophobic interactions (Singh & Reyrat 2009). Tween 80 was initially used here 
to reduce clumping in the wild type (wt) mc26 cultures (as mc2155 is a non-clumping daughter 
strain), but during the course of later environmental stress experiments, possible differences in 
gene expression between cultures grown in media with and without Tween 80 were observed. 
This difference in expression may be due to the ability of detergents such as Tween 80 to 
promote aerobic growth by improving the transfer of oxygen (Tang et al. 2009). To limit 
extrinsic variation, cultures were grown in media without Tween 80, and cell growth was 
estimated in relation to the OD 600 values of cultures grown in media with Tween 80 using the 
total cellular protein method. 
 
The total cellular protein method (Meyers et al. 1998) was used to successfully estimate cell 
growth along with optical density measurements in M. smegmatis cultures grown both with and 
without Tween 80. M. smegmatis cultures were grown in LB or LBT and sampled over a time 
course to measure absorbance at OD 600 and total cellular protein concentration. Figure 4.1 
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shows a comparison of the protein and OD methods for monitoring the growth of M. 
smegmatis. 
 
 
Figure 4.1: Growth curves of M. smegmatis cultures in LBT. Curves were plotted from total protein yield 
(pink and black), and OD 600 (blue and grey) data for both wt and mc2155 cultures. Each data point 
represents the average of two measurements. Error bars show the standard deviations of the means. 
 
4.2.2 Optimisation of Total RNA Isolation 
Several total RNA isolation procedures were compared in combination with DNA removal 
methods to determine an optimal protocol for isolating sufficient quantities of sound quality, 
pure RNA from M. smegmatis. Here we show how the different isolation methods produce total 
RNA varying in integrity, concentration, and residual DNA levels.  
 
4.2.2.1 Comparison of RNA Isolation Methods 
Methods investigated included variations of Trizol, TRI Reagent, and RNeasy supplier 
protocols, and modifications of the Acidic Guanididium Isothiocynate/Phenol/Chlorofom (AP-
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GITC) procedure (Chomczynski & Sacchi 1987) including the use of BCP instead of 
chloroform, and performing two successive phenol-BCP extractions instead of one. Due to the 
recalcitrant nature of mycobacterial cell walls, all extraction methods involved initial bead 
beating to rapidly disrupt the cells. The quality of the extracted RNA was assessed by 
spectrophotometry using the NanoDrop, and by analysis of the 23S to 16S ribosomal RNA 
band ratio on a 1 % non-denaturing agarose gel. The absorbance ratios (A260/A280 and 
A260/A230) for pure RNA at 230, 260 and 280 nm should be close to 2.0. Any deviation from this 
value indicates the presence of contaminants that absorb strongly at or near these 
wavelengths. Sharp 23S and 16S rRNA bands which display a ratio of close to 2:1, without the 
presence of degraded RNA (visable as smears or small fragments) indicates the RNA is intact 
and of sound quality (Sambrook et al. 1989).  
 
Absorbance readings showed that the modified AP-GITC and RNeasy methods produced the 
most pure RNA (Table 4.1), as well as intact RNA when assessed on an agarose gel (Figure 
4.2) for both the concentrated and dilute cell culture samples. The concentration of the total 
RNA extracted with the modified AP-GITC method was slightly lower than that for RNeasy 
(Table 4.1). This minor loss of RNA probably results from the multiple phase separation steps 
during the extraction method. Total RNA produced using the RNeasy method showed little 5S 
or other small or degraded RNAs. This is because RNAs less than 200 nucleotides (accounting 
for approximately 15 - 20 % of total RNA) do not bind the RNeasy column quantitatively and 
are selectively excluded, thereby enriching mRNA recovery (RNeasy® Mini Handbook 2012). 
 
The TRI Reagent method extracted less total RNA compared to the modified AP-GITC and 
RNeasy methods (Table 4.1), as well as produced RNA of an inferior quality as demonstrated 
by the lower absorbance ratios (Table 4.1) and degraded 23S product (Figure 4.2). The low 
A260/A230 ratio is likely due to the carry over of phenol from the TRI Reagent, which absorbs in 
the UV both at 230 nm and approximately 270 nm (260/280 and 260/230 Ratios 2008), and the 
production of degraded RNA is most likely due to the speed with which the cells are initially 
lysed and preserved. The modified AP-GITC method lyses cells immediately when the culture 
is added directly into GITC, whereas the TRI reagent method requires the cells to be pelleted 
(in order to remove media) prior to the addition of lysis solution. The RNeasy method also 
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requires the cells to be pelleted prior to adding the lysis solution, but the lack of degradation 
observed with this method may be due to the RNeasy lysis solution possibly acting faster than 
the TRI reagent, or the TRI reagent possibly preferentially isolating smaller RNA fragments. 
 
Table 4.1: Comparison of RNA concentration and absorbance values extracted by three different methods 
 
Method 
Culture     
(OD 600) 
Absorbance Concentration 
(ng/µl) 
Average concentration 
(ng/µl) A260/A280 A260/A230 
RNeasy 
0.5 
1.93 1.97 311 
252 
2.13 1.97 193 
1.0 
1.06 1.96 520 
642 
2.24 1.96 765 
TRI Reagent 
0.5 
0.94 1.89 160 
185 
1.09 1.93 210 
1.0 
0.77 1.86 426 
482 
1.37 1.94 537 
Modified AP-
GITC 
0.5 
1.98 1.95 311 
290 
1.73 1.95 268 
1.0 
1.98 1.94 506 
556 
2.07 1.97 606 
Total RNA extractions were performed at two different OD’s (OD 600 = 0.5 and 1.0), on two biological replicates 
 
 
Figure 4.2: Non-denaturing agarose gel electrophoresis of M. smegmatis total RNA comparing RNA 
extraction methods. 800 ng of total RNA extracted by AP-GITC, TRI Reagant and RNeasy methods was 
separated on a 1% SB agarose gel to show the difference in integrity of resulting 23S and 16S products. 
Each extraction method was tested on cultures at two different OD’s (OD 600 = 1.0 and 0.5 respectively). 
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4.2.2.2 Effect of DNase Treatment 
While the modified AP-GITC and RNeasy total RNA extraction methods produced RNA of 
sound quality, the RNeasy extracted RNA co-purified with a large amount of genomic DNA. 
Figure 4.2 shows the co-purified DNA as a large molecular weight smear, and RT experiments 
confirm the presence of DNA by the visualisation of products in the noRT controls after RT-
qPCR (Figure 4.3, lanes 2 and 4). Residual DNA in the RNeasy isolated RNA was also present 
after attempting on-column DNase digestion (data not shown). 
 
Figure 4.3: RT-qPCR of Reverse Transcription (RT) controls from the three RNA extraction methods. RNA 
(both with and without DNase treatment) was reverse transcribed and the resulting cDNA PCR amplified 
(with VapC toxin primers), and run on a 1 % SB agarose gel (stained with 0.5 μg/ml EtBr). Lanes: 1-4 = 
RNeasy, 5-8 = TRI Reagent, 9-12 = modified AP-GITC, and 13 = negative control. Lanes: 1,5,9 = +DNase, 
+RT; 2,6,10 = +DNase, -RT; 3,7,11 = -DNase, +RT; and 4,8,12 = -DNase, -RT. Amplification of the PIN toxin 
product (231 bp) was observed for all RNA extraction methods when RT was included in the cDNA 
preparations. Amplification of carry over DNA was observed for all -RT control reactions where the RNA 
was not DNase treated (lanes 4,8,12). The circled amplification product in lane 2 shows RNeasy was the 
only extraction method containing residual DNA after DNase treatment. 
 
RNA extracted using the modified AP-GITC method contained far less contaminating DNA 
compared to the RNeasy extracted RNA (as visualised by the intensity of bands in the -DNase 
and -RT controls in Figure 4.3 (lanes 4 and 12)), which was able to be removed by DNase 
treatment prior to cDNA synthesis (Figure 4.3 lane 10). RNA extracted using the TRI Reagent 
method also contained less contaminating DNA than RNeasy extracted RNA, as a product of 
medium intensity was observed in the -DNase and -RT control (Figure 4.3 lane 8), which was 
also able to be removed by DNase treatment (Figure 4.3 lane 6). 
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BCP was used in place of chloroform in the modified AP-GITC method as it is less toxic and 
less volatile than chloroform (Chomczynski & Mackey 1995), and possibly resulted in the 
removal of slightly more chromosomal DNA from the RNA (observations from our laboratory 
and Chomczynski and Mackey (1995)). This is likely due to the ability of BCP to produce a 
more compact interphase than chloroform, so therefore less residual DNA from the interphase 
is carried over during the phase separation step. 
 
During the course of this research I observed better performance from the RQ1 RNase-free 
DNase when the reactions were shaken during incubations rather than kept still. 
 
4.2.3 Optimisation of RT-qPCR 
RT-qPCR experiments were optimised on M. smegmatis cDNA using either SYBR Green I or 
SYTO 82 as the dsDNA binding dye. While both dyes produced satisfactory amplification plots 
and melt curves, and no obvious differences were observed in primer dimer formation across 
the genes being studied, the range of amplification efficiencies for genes of interest (GOI) and 
reference genes varied slightly more with the SYBR Green I chemistry. The greater range 
observed in efficiencies between our reference genes and GOI, as well as the documented 
inhibition of PCR and preferential binding of SYBR Green I to GC rich sequences, is the 
reason Syto 82 was deemed a more appropriate dye for the quantification of gene expression 
levels in this study even though the amplification efficiencies were slightly lower. A ‘homemade’ 
dye master mix was used over a ready made product to reduce the costs involved with the 
assays, and keep the reaction set up flexible so reagent concentrations could be varied if 
needed. Interestingly, it was noticed that the SYTO 82 colour reduces over time (even when 
stored at -20 °C), and possibly caused a reduction in the levels of fluorescence detected. It 
was for this reason that batches of master mix were stored at -20 °C without the dye, and the 
dye was added immediately prior to use. 
 
RT-qPCR products were between 150 and 250bp, with melting temperatures ranging from 89.7 
to 93 C using SYTO 82 chemistry (see Appendix B.1). SYBR Green I reactions produced 
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products with melting temperatures approximately 0.7 °C higher than those using SYTO 82 
dye. 
 
Optimal template and primer concentrations yielding the lowest Cq, highest amplification 
efficiency and least amount of nonspecific amplification were established for amplicons by 
performing RT-qPCR trials. A template concentration trial was performed for the amplicon with 
the lowest efficiency (vapB), using 0.65, 0.75 and 0.85 µl cDNA per 20 µl reaction, which 
determined using 0.75 µl of template resulted in the greatest amplification efficiency with no 
formation of primer dimers. Variations of forward or reverse primer concentrations at 125, 250 
and 500 nM were tested, resulting in fairly consistent amplification efficiencies and Cq’s, 
although the 125 nM concentrations produced samples with little primer dimer, and the least 
baseline errors compared to the higher concentrations when analysed in LinRegPCR.  
 
Amplification of primer dimers during RT-qPCR may mask the actual results when using a 
dsDNA binding dye. Melt curves for RT-qPCRs were analysed to check for contamination from 
primer dimers or other non-specific amplification products in the samples. The formation of 
primer dimers were avoided where possible with good primer design, but were apparent in the 
melt curves and gel electrophoresis for some of the primer sets used, especially in the no-
template controls and reactions with limited/low abundance target. Accurate quantification of 
the target dsDNA product was ensured by eliminating fluorescence induced by primer dimers 
or unspecific minor products. This was achieved by acquiring the fluorescence data at 80 °C 
instead of during the 68 °C extension phase, as most primer dimers have completely 
denatured at this elevated temperature while the target products are still intact (Klein et al. 
2000;  Pfaffl 2004;  Mehndiratta et al. 2008). 
 
The amplification efficiencies of the GOI were low (approximately 1.6 and 1.7 for vapB and 
vapC respectively), as is often the case when detecting low abundance mRNA targets in a GC-
rich organism such as M. tuberculosis (Grassi et al. 2006), and varied. Because M. 
tuberculosis is GC-rich, strong RNA secondary structures are often created which can prevent 
full-length RT-PCR products due to the RT enzyme stopping or falling off the template when it 
hits loop structures (Mathews et al. 1999). The high GC content (66.6 % and 60.79 % for 
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MSMEG_1283 (vapB) and MSMEG_1284 (vapC) respectively) and low free energy (G) 
values predicted for the GOI RNA (-50.49 kcal/mol and -78.32 kcal/mol for MSMEG_1283 and 
MSMEG_1284 respectively, calculated in mfold (Zuker 2003) at 55 C, the same temperature 
experienced in the RT-PCR denaturation/annealing step), suggests RNA secondary structure 
may be limiting the RT-PCR transcription of these already lowly expressed GOI transcripts. 
Due to the variation in efficiencies between amplicons, the efficiency corrected analysis 
computations (Equation 1 or Equation 2 in Section 4.1.1.2) were used to more accurately 
calculate the relative levels of expression. New primers were designed in an attempt to 
improve the resulting PCR efficiencies, but the difference in efficiencies was negligable. Of the 
methods reported to improve PCR efficiency and specificity (using additives such as DMSO, 
formamide and ammonium sulphate among others (Kovarova & Draber 2000;  Grassi et al. 
2006)), formamide was trialled and found to be somewhat successful in improving the 
efficiency of the vapB amplicon. Whilst a slight improvement was made for the vapB amplicon, 
the use of formamide was discontinued because the resulting change in efficiencies was not 
universal, which skewed the change in expression value relative to the vapC amplicon, making 
it even more difficult to detect a ‘real’ change in expression. Increasing the concentration of 
DNA polymerase in the reactions to 50 U/ml from 36 U/ml was also unsuccessful in improving 
the efficiencies of the amplicons. 
 
4.2.4 Selection of a Suitable Housekeeping Gene for Relative 
Quantification 
Because intersample variation affects data analysis, expression results needed to be 
normalised to an endogenous housekeeping gene whose expression remained unchanged 
under the experimental conditions tested. Candidate housekeeping genes were selected and 
tested for stability of expression under some or all of the following experimental conditions: 
antibiotic (rifampicin, streptomycin, tetracycline), oxidative (H2O2), temperature, or 
age/nutritional stress; other stressors (methylglyoxal, 2,4-Dinitrophenol (DNP), clotrimazole, 
UV); and growth conditions (planktonic v biofilm) or between strains (deletion and 
overexpression strains). The selection of housekeeping genes was initially based on those 
most commonly used in the literature such as 16S rRNA which is ubiquitously expressed in 
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cells and tissues, and whose transcription is generally resistant to experimental conditions 
(Thellin et al. 1999;  Bustin 2000;  Suzuki et al. 2000), and then on those which had been 
recorded in the literature as suitable internal controls (ftsZ (Delogu et al. 2006), rpoB (Gutierrez 
et al. 2005), sigA (Geiman et al. 2006), were identified from microarray studies as being 
similarly expressed in the conditions tested (oxcA (Ojha & Hatfull 2007)), or were trialled based 
on work done previously in the lab (unpublished) (guanylate kinase, Rv0930, rpsB, sigH and 
metC). 
 
16S was the most stably expressed transcript under all of the experimental conditions tested, 
however because M. smegmatis posseses two 16S gene copies, it amplified much earlier than 
the lowly expressed GOI (approximately 15 - 20 cycles earlier). The remainder of HK genes 
tested were either poorly expressed (and therefore amplified after the GOI), or showed variable 
levels of expression under the spectrum of experimental conditions tested (see Appendix B.2). 
In RT-qPCR, it is important to have the reference gene amplifying within the same range as the 
GOI, so that both genes are experiencing the same conditions and RT-qPCR kinetics during 
amplification (Pfaffl 2004). To achieve this, 16S cDNA was diluted 1:99 to enable amplification 
within a similar range as the GOI. A five-fold dilution series of cDNA was run for each amplicon 
as a control, to check for inhibition in the RT-qPCR and ensure amplification was in the linear 
range. Dilutions of cDNA produced fluorescent curves with equally distant quantification cycles 
(Cq’s) with the same slope (Figure 4.4), and approximately equal amplification efficiencies. 
This indicates that the reactions were not being inhibited, and therefore that diluting the 16S 
cDNA (or not diluting the GOI cDNA) would not distort the amplification efficiencies and gene 
expression values.  
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Figure 4.4: Representative real-time PCR plots following amplification of an M. smegmatis cDNA dilution 
series. Each sample was subjected to five-fold serial dilution (from red down to yellow) and then analyzed 
by real-time PCR in triplicate. Graph shows fluorescence intensity as a function of the number of 
amplification cycles. Primers were specific for the vapC gene. 
 
As with many of the so called housekeeping genes used in the literature (Vandesompele et al. 
2002;  Liu & Slininger 2007), the majority of candidate housekeeping genes tested here were 
inconsistently expressed under the environmental stimuli, and were therefore deemed 
unsuitable as internal controls. The recommendation that a panel of housekeeping genes 
belonging to different functional and abundance classes should be used for accurate 
normalisation (Vandesompele et al. 2002) is valid, but under the conditions tested here, only 
the expression of one housekeeping gene (16S) remained constant, so using a panel of 
suitable genes was not possible. While the use of multiple housekeeping genes is likely to 
provide statistically more significant results in RT-qPCR (especially for lowly expressed 
transcripts) (Vandesompele et al. 2002), the use of a single gene for normalisation in RT-qPCR 
is an acceptable approach, so long as it has been validated (Bustin 2000;  Suzuki et al. 2000;  
Erickson et al. 2007). 16S ribosomal ribonucleic acid (rRNA) genes (rrs genes) have frequently 
been rejected as normalisers by some researchers due to their high transcript levels compared 
to the GOI (sometimes 100 fold higher than the GOI), even when their transcription remained 
constant (Frost & Nilsen 2003;  Robinson et al. 2007;  Ritz et al. 2009). This difference in the 
kinetic interactions during qPCR between the highly expressed rrs genes and (often) lowly 
expressed GOI can be avoided however, by diluting the cDNA used for the 16S sample to 
enable its amplification within the same range as the GOI, as was performed here. Because 
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just a single normalising housekeeping gene was used here, any small resulting changes in 
GOI expression levels (fold changes close to the often cited two-fold cut-off for differential 
expression (Yang et al. 2002)) would need to be treated with caution to account for any 
unperceivable differences in expression that may be occurring for the single housekeeping 
gene.  
 
4.2.5 VapBC Gene Expression Levels in M. smegmatis 
Initial experiments used the M. smegmatis mc24517 overexpression strain containing VapB 
(pYUBMS1283) or VapBC (pYUBMS1283/4) constructs, to confirm the RT-qPCR assay could 
detect the vapB and vapC transcripts, as well as the change in expression levels resulting from 
their overexpression. These experiments were performed before the RT-qPCR assay was fully 
optimised so whilst the exact normalised expression levels of vapB and vapC can not be read 
from the data, the overall picture of expression can be obtained from the cycle numbers where 
fluorescence levels are detected above background (represented as Cq values). In a typical 
reaction, a higher starting template concentration will result in an earlier or lower Cq, as 
relatively fewer amplification cycles are needed for the amplification product to rise above the 
background fluorescence signal. Table 4.2 shows how equal amounts of the vapB amplicon 
are detected for both the VapB and VapBC overexpression strains, while the expected 
increase in vapC for the VapBC overexpression strain is represented by the lower Cq value of 
16.16, compared to 29.52 for the VapB only overexpression strain.  
 
Table 4.2: Cq values of vapB and vapC amplicons in the VapB and VapBC overexpression strains.    
 
Overexpression strain Cq vapB Cq vapC 
VapB (pYUBMS1283) 14.37 29.52 
VapBC (pYUBMS1283/4) 14.46 16.16 
 
 
As well as the difficulties identifying a reliable housekeeping gene for robust data analysis, 
interpretation of results was also complicated by the use of different analysis methods and 
LinRegPCR versions. Initially, analysis was performed using LinRegPCR version 7.4 and 
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relative expression levels calculated using Equation 1 (Section 4.1.1.2), but later experiments 
used the improved LinRegPCR version 11.1 which included the following features: estimation 
of baseline fluorescence, different approaches for determining the window-of-linearity and 
fluorescence threshold, definition of sample groups per amplicon, calculation of the mean PCR 
efficiency per amplicon group, calculation of starting concentrations based on mean efficiency 
and individual Ct values, and reports on data quality for each sample, and Equation 4 (Section 
4.1.1.2) to determine relative levels of expression. The biggest improvement with the later 
versions of LinRegPCR was the change to using the mean PCR efficiency (per amplicon 
group) in determining initial fluorescence, as using the efficiency per sample is too variable to 
provide robust, reproducible results (Cikos et al. 2007;  Karlen et al. 2007). 
 
Given the very low levels of expression, the low amplification efficiencies, and the use of a 
single housekeeping gene (all of which may result in inaccurate normalisation, masking any 
subtle variations in expression levels), any small resulting differences in expression would 
need to be carefully examined to ensure they were real, and not as a result of compensation 
during analysis or statistical variation. Many of the ‘stress’ conditions which were tested for 
effects on expression of vapB or vapC, occurred as a result of searching for the vapC 
phenotype which was unknown at the time. As it was, no significant and consistent changes in 
the expression of vapB or vapC were observed under any of the conditions tested which 
included: antibiotic (rifampicin, streptomycin, tetracycline), oxidative (H2O2), temperature, or 
age/nutritional stress; other stressors (methylglyoxal, 2,4-Dinitrophenol (DNP), clotrimazole, 
UV); and growth conditions (planktonic v biofilm) or between strains (deletion and 
overexpression strains) (see Table 4.3). This is demonstrated by the stress experiment using 
wt M. smegmatis shaken in LB, where 1 mM DNP is added for the final 15 minutes incubation 
period (Figure 4.5). Here, the levels of vapB are greater than those of vapC both with and 
without DNP present in the media (approximately five and three-fold respectively), but in a 
replicate experiment, vapB and vapC levels were determined to be equal, and the increase in 
expression observed here with DNP (approximately 2.8 fold for vapB and 1.6 fold for vapC) 
was reversed (data not shown). This is representative of the other stress experiments in 
general, where: approximately equal levels of vapB and vapC were expressed, and any 
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changes in vapB or vapC expression observed due to conditions of stress were inconsistent, 
and unable to be reliably repeated in replicate experiments.  
 
Table 4.3: Conditions tested in vapB and vapC RT-qPCR experiments.    
 
Type Treatment Concentration Duration 
Growth 7H9 v bhi - 24 hr, 3 d, 5 d 
Sautons +/- RPMI 1640 Medium (GIBCO) 25 % 24 hr, 5 d, 6 d 
+/- Tween 80 0.05 % 1 hr, 18 hr 
biofilm v planktonic - 7 d 
Temperature 0 C or 42 C - 30 min 
48 C - 15 min, 90 min 
Antibiotic +/- Tween 80, +/- streptomycin 0.05%, 2 µg/µl 6 hr, 24 hr 
streptomycin 2 µg/µl 30 min, 1 hr 
streptomycin for 6 hr, followed by rifampicin for 
30 min 
10 µg/ml, 10 µg/ml 6 hr, 30 min 
streptomycin in planktonic v biofilm 5 µg/ml 1 hr 
rifampicin 1.25 µg/ml 40 hr 
rifampicin 8 µg/ml 30 min 
Other substitution of supernatant from 4, 5 or 6 d 
cultures with ‘aged’ supernatant (from 1 month 
old cultures left at RT) 
- 10 min 
+/- substitution of supernatant from 3 d culture 
with ‘aged’ supernatant (from 1 month old 
cultures left at RT), +/- streptomycin 
-, 8 µg/ml 30 min 
EtOH, tetracycline 50 %, 25 µg/ml 35 min 
H2O2 17.64 µM 30 min, 1 hr 
DNP 1 mM 15 min, 6 hr 
Clotrimazole 24 µg/ml 15 min 
DNP, clotrimazole 1 mM, 24 µg/ml 15 min 
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Figure 4.5: Relative M. smegmatis wt vapB and vapC expression levels in response to 15 min DNP stress. 
RNA isolated from wt M. smegmatis cultures inubated +/- 1 mM DNP for 15 minutes was subjected to RT-
qPCR to determine the expression levels of vapB and vapC transcripts. Expression of vapB is greater 
than that of vapC, and expression of both appear to increase marginally after DNP treatment by 
approximately 2.8 and 1.65 fold respectively. Expression levels (normalised to 16S) were determined 
using LinRegPCR version 11.1, and are expressed in arbitrary fluorescence units. 
 
The fact that no reproducible large increase in vapC expression was detected under any of the 
stress conditions tested here intimates the importance of tightly regulating this toxic protein, 
and suggests that regulation of toxic VapC may be occurring at the proteomic level, and not at 
a transcriptional level. Strengthening the proposed requisite for tight regulation of this toxin, 
were the unfruitful attempts by others in the lab to express VapC protein by itself (without its 
associated antitoxin to neutralise the toxicity), repeatedly resulting in the occurance of a stop 
codon (McKenzie 2011), and the absence of VapC protein despite the presence of mRNA 
transcript in the vapB deletion strain (Robson et al. 2009). The lack of correlation between 
proteomic and transcriptomic analyses has been observed elsewhere, where it was postulated 
to occur as a result of differring protein turnover and/or RNA stability (Scherl et al. 2005;  Ritz 
et al. 2009).  
 
The negative RT-qPCR result observed here was the impetus for looking at modelling changes 
in protein levels compared with RNA levels to explain how the production of VapC could be 
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being regulated (discussed in Chapter Six), and why we now hypothesise it is the rate of 
translation which is important in regulating the level of VapC toxin, not the difference in levels 
of vapB and vapC transcription themselves.  
 
4.3 Conclusions 
This research presents an optimised RNA isolation and RT-qPCR method suitable for the 
quantification of the vapB and vapC target genes, and determined there was no differential 
expression of vapC under the conditions tested.  
 
As pointed out in the above sections, there were many issues identified with the RT-qPCR 
process as it was in 2008 when this data was collected. I am aware these (and other) issues 
have been highlighted by others since, and vast developments have been made within the field 
of RT-qPCR. I support the changes proposed in the Minimum Information for Publication of 
Quantitative Real-Time PCR Experiments (MIQE) guidelines (Bustin et al. 2009), which 
addresses these issues and will result in more reliable RT-qPCR results, presented in a 
standard and easily interpreted format. As with the vast array of subsequent reports which 
found many HK genes were unacceptable and often produced unreliable results, this research 
also found the majority of HK genes tested here were not suitable (so the results were 
rejected), and any expression change ratios obtained with the single 16S HK gene were 
treated with caution. Even if we were to go back and implement the recommended MIQE 
controls (specifically, using a panel of HK genes for normalisation), we are confident this 
wouldn’t change our finding that no consistent change in the mRNA expression levels of vapB 
and vapC occurs, especially given since this observation was made there have been no 
entries in the TB Database showing any confirmed significant changes. This negative result is 
very important, as together with the modelling data it supports our current hypothesis that it is 
not the transcriptional differences between vapB and vapC which are important in the 
regulation of VapC, but the overall rate of VapBC translation itself. 
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5 Chapter Five: 
Mycobacterium 
tuberculosis VapBC 
Characterisation 
5.1 Introduction 
This chapter focuses on characterisation of the VapBC proteins from M. tuberculosis, in 
particular, the specificity and ribonuclease activity of the VapC proteins. The biological role of 
VapBC proteins in M. tuberculosis is poorly understood, but their link to regulating cell growth 
in response to environmental stress is an inviting intimation that they may play an important 
part in the pathogenesis of its disease. 
  
5.1.1 M. tuberculosis VapC Ribonuclease Activity 
Recently, the structures have been determined for two M. tuberculosis VapBC complexes, 
VapBC-5 (Rv0626/0627) (Miallau et al. 2009) and Rv0301/0300 (Min et al. 2012). The toxins 
from these structures are consistent with other PIN-domain proteins, forming an α/β/α 
sandwich consisting of five parallel beta strands flanked by alpha helices, and containing four 
conserved acidic residues (Asp26, Glu57, Asp115 and Asp135 for VapC-5, and Asp9, Glu43, 
Asp99, and Asp117 for Rv0301). This conformation forces the conserved acidic residues 
together which coordinate an Mg2+ ion and form the putative RNase active site (Miallau et al. 
2009;  Arcus et al. 2011;  Min et al. 2012). Both of these M. tuberculosis VapBC complexes 
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show overall structural similarity to VapBC complexes from other organisms such as FitAB 
from N. gonorrhoeae (Figure 5.1), Shigella flexneri VapBC, and Rickettsia felis VapBC2 (Min et 
al. 2012), illustrating tight binding between VapB and VapC as a tetramer of VapBC 
heterodimers. While the M. tuberculosis toxin proteins show limited conformational differences 
to their closest structural homologue FitB, their antitoxin partners have notably different 
conformations (Miallau et al. 2009;  Min et al. 2012).  
 
 
Figure 5.1. Tetramer of FitAB heterodimers from N. gonorrhoeae bound to IR from its promoter DNA. Pink 
and mauve, and dark and light blue chains denote two FitA dimers each binding to one half of the DNA 
inverted repeat. Surface diagrams depict FitB dimers. Each FitA monomer is bound to a FitB monomer, 
forming heterodimers. Figure from Arcus et al. (2011). 
 
Ribonuclease activity has been demonstrated for toxins from many of the other TA systems, 
few VapC proteins have been fully characterised. Those which have been characterised also 
demonstrate ribonuclease activity (Daines et al. 2007;  Hurley & Woychik 2009;  Ramage et al. 
2009;  McKenzie et al. 2012b). Of the two M. tuberculosis VapC proteins characterised thus 
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far, Mg2+ dependent ribonuclease activity has been demonstrated for VapC-5 (but its catalytic 
mechanism or sequence specificity was not determined) (Miallau et al. 2009), while only 
suggested for Rv0301 from its structural characterisation (Min et al. 2012). During the course 
of my PhD, a possible biochemical function of VapC from M. smegmatis was determined, as 
was confirmation of ribonuclease activity for two further M. tuberculosis VapC proteins, Rv0065 
and Rv0617, which were cloned in this thesis and published in Ahidjo et al. (2011). Rv0065 
and Rv0617 are Mg2+ dependent, sequence-selective ribonucleases which target ssRNA 
rather than dsRNA, ssDNA or dsDNA (and unlike VapC from M. smegmatis, they do not show 
ss or dsRNA binding), whose activity is selectively inhibited by their cognate antitoxins 
(Rv0064 and Rv0616 respectively) (Ahidjo et al. 2011;  McKenzie et al. 2012a). Both M. 
tuberculosis VapC proteins were found to have the same sequence specificity targeting GC-
rich 4mers (i.e., GGCG, GCCG and GGGC) but with a certain level of redundancy, suggesting 
that the biologically relevant target may combine RNA sequence and secondary structure 
(McKenzie et al. 2012a) and raising the possibility that both VapC toxins could target different 
secondary structural motifs. VapC from enteric bacteria have recently been shown to 
specifically cleave initiator tRNAfMet between the anticodon stem and loop (Winther & Gerdes 
2011). However experiments with mycobacterial VapCs (VapCMS1284, VapCRv0065 or 
VapCRv0617) in our lab have not displayed any such activity, despite the VapCMS1284 cut site 
being present in tRNAfMet, strengthening the idea that the optimal substrate combines both 
sequence and RNA secondary structure (McKenzie et al. 2012a;  McKenzie et al. 2012b). 
 
5.1.2 Protein Cloning, Expression, Purification & Crystallisation 
5.1.2.1 Protein Expression in M. smegmatis  
Previous work in our lab showed expressing mycobacterial proteins in a mycobacterial host 
could overcome the problem of insoluble protein expression which occurred when expressed in 
E. coli (McKenzie 2011). Expression of the M. smegmatis VapBC proteins in M. smegmatis 
also ensured recognition of the one base pair overlap between vapB and vapC genes in the 
operon enabling expression of VapC in complex with VapB. This overlap was not recognised 
when expressed in E. coli, instead resulting in insoluble VapB protein only (McKenzie 2011). 
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The non-pathogenic mycobacterial species M. smegmatis has a relatively fast doubling time of 
approximately three hours (Snapper et al. 1990), as well as mycobacterial chaperones to aid 
protein folding, making it an ideal host for expression of mycobacterial proteins. The M. 
smegmatis overexpression strain mc24517 with mycobacterial expression vector pYUB28b 
(allowing a C–terminal His–tag) can be cultured in autoinduction media using methods 
established for E. coli, which reduces the cost of culturing by removing the need for albumin 
dextrose catalase supplement (ADC) enrichment and optical density monitoring/induction 
traditionally used for mycobacterial cultures (Bashiri et al. 2007). Autoinduction media was also 
chosen over growing in standard media and inducing expression with IPTG, because M. 
smegmatis cultures grew well under these conditions but did not produce VapBC protein 
whereas they did when autoinduction media was used (McKenzie 2011). Autoinduction media 
functions due to the bacteria being able to utilise a variety of carbon sources (including latose), 
but initially glucose. While glucose is in the seeder media, it is limited in the autoinduction 
media so once glucose from the seeder media is exhausted, the bacteria switches to using 
lactose. Lactose enters the cell and induces expression of T7 polymerase, and therefore the 
production of VapBC protein. 
 
Soluble expression of VapC proteins is difficult due to their toxicity (Mattison et al. 2006;  
Miallau et al. 2009;  Ramage et al. 2009). Previous attempts in the lab to express M. 
smegmatis VapB and VapBC in M. smegmatis were fruitful, however expression of the toxic 
VapC protein by itself (without its associated antitoxin to neutralise the toxicity) repeatedly 
resulted in a two base pair insertion causing a stop codon downstream, and no protein 
expression (McKenzie 2011). This insertion is likely due to basal expression of VapC from the 
leaky T7 promoter prior to induction, causing the bacteria to mutate the plasmid before 
expression is induced. While expression systems are available in E.coli which supress basal 
expression from leaky promoters therefore enabling expression of toxic proteins (Saida et al. 
2006), no such system exists for expression in mycobacteria. 
  
Expression of VapC as a maltose binding protein (MBP) fusion in E. coli has been shown to 
increase the solubility of VapC, and expression of M. tuberculosis VapC proteins as MBP 
fusions has been successful in other labs (Ramage et al. 2009), however expression of the M. 
 145 
 
smegmatis MBP-VapC fusion was not successful in our lab as it formed a soluble aggregate 
which could not be refolded (McKenzie 2011). 
 
Soluble M. smegmatis VapC can be expressed in M. smegmatis when in complex with VapB 
and various strategies have been employed previously to disrupt the interaction between the 
two proteins and produce functional VapC. Disruption with 8 M urea, 2 M NaCl and buffers 
ranging in pH from 3.5 to 7 were all unsuccessful, and while 6 M guanidium and 0.1 % and 0.5 
% SDS did disrupt the VapBC complex, they presumably denatured the VapC which could not 
be successfully refolded (McKenzie 2011). It was proposed that the strong interaction between 
VapB and VapC in the VapBC complex from M. smegmatis is the same as that for FitAB from 
Neisseria gonorrhoeae where the hydrophobic surfaces of FitA and FitB proteins associate 
tightly (Wilbur et al. 2005;  Mattison et al. 2006). The strong interaction in the M. smegmatis 
VapBC complex was disrupted by taking advantage of the antitoxin being more susceptible to 
proteolytic degradation than the toxin, a common feature of TA systems (Buts et al. 2005;  
Gerdes et al. 2005). The protease trypsin was used to digest away VapB, leaving behind 
functional VapC, and trypsin was removed by anion exchange chromatography (McKenzie 
2011). Dynamic light scattering determined the molecular weight of the purified M. smegmatis 
VapBC complex to be 152 kDa, suggestive of a tetramer of VapBC heterodimers bound to 
DNA (McKenzie 2011). This is consistent with the FitAB complex which has a molecular weight 
of 121 kDa and forms a tetramer of FitAB heterodimers when bound to an inverted repeat in 
the fitAB promoter (Mattison et al. 2006). 
 
5.1.3 Objectives 
Given the different systems and contradictions presented in the literature, I attempted to 
identify all of the unannotated M. tuberculosis VapB proteins, then clone, express and purify all 
47 VapBC proteins from M. tuberculosis into M. smegmatis. Due to the ribonuclease activity 
described previously for VapC proteins from other organisms, I then set out to determine the 
specificity and activity of a number of the purified M. tuberculosis VapC proteins.  
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The biochemical function of VapC from M. smegmatis and activity of VapC proteins from M. 
tuberculosis was unknown at the beginning of my research. 
 
5.2 Results and Discussion 
5.2.1 Cloning of M. tuberculosis VapBC’s into M. smegmatis 
The first step in characterising the 47 M. tuberculosis VapBC proteins was to locate the many 
unannotated antitoxins. Here, BLAST was used with the upstream region of VapC to identify 
VapB (a hypothetical antitoxin approximately 250 bp in size) and the VapBC overlap (see 
Figure 5.2). Once the antitoxins were identified, each M. tuberculosis VapBC operon was 
successfully cloned into the E. coli - mycobacteria shuttle vector pYUB28b between the NcoI 
and HindIII, BamHI or NdeI restriction sites enabling expression of protein with a C-terminal 
His tag. The modified pYUB1049 vector pYUB28b was used rather than the traditional E. coli - 
mycobacteria shuttle vector pYUB1049, as it allows in-frame C-terminal His tag expression 
without having to add additional bases to the forward primer, and does not require digestion 
and gel purification to remove a large (approximately 1,000 bp) multiple cloning site segment 
before inserting the gene of interest (Bashiri et al. 2010). A C-terminal tagged VapC protein 
was required so as both the VapB and VapC could be expressed in an operon (as VapCs are 
generally toxic and unable to be expressed by themselves), and the VapC could be recovered 
once VapB had been removed. A summary of the restriction sites used for each operon are 
shown in Table 5.1 below, and full gene sequences and cloning information can be found on 
the compact disk - Appendix D. 
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Figure 5.2: Identification of unannotated antitoxins. Top: TBDB image of the genomic region surrounding Rv0960, a VapC toxin, showing the absence of an annotated 
cognate antitoxin. Bottom: Nucleotide and amino acid sequences for Rv0960 and its upstream region, showing the overlapping unannotated assumed cognate 
antitoxin Rv0959A identified through BLAST analysis, which is translated in a different frame.  
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Table 5.1: Summary of restriction sites used to clone each M. tuberculosis VapBC operon into pYUB28b. 
    
VapBC Operon 
Position in H37Rv genome, 
strand direction, and size (bp) 
Restriction sites included in 
primers (Fwd/Rev) for ligation 
into pYUB28b 
Rv0064/0065 
71589 - 71828 (+) (240 bp) /  
71821 - 72222 (+) (402 bp) 
NcoI/HindIII 
Rv0229c 274306 - 274986 (-) (681 bp) GeneArt* 
Rv0239/0240 
289104 - 289337 (+) (234 bp) / 
289345 - 289782 (+) (438 bp) 
NcoI/HindIII 
Rv0277a/0277c 
333160 - 333417 (-) (258 bp) / 
332708 - 333136 (-) (429 bp) 
NcoI/HindIII 
Rv0300/0301 
363826 - 364047 (+) (222 bp) / 
364044 - 364469 (+) (426 bp) 
NcoI/HindIII 
Rv0549/0550 
640228 - 640641 (-) (414 bp) / 
640638 - 640904 (-) (267 bp) 
GeneArt* 
Rv0582/0581 
677922 - 678329 (+) (408 bp) / 
677710 - 677925 (+) (216 bp) 
NcoI/HindIII 
Rv0595/0596c 
694839 - 695231 (-) (393 bp) / 
695228 - 695485 (-) (258 bp) 
NcoI/HindIII 
Rv0598c/0599 
697154 - 697567 (-) (414 bp) / 
697564 - 697800 (-) (237 bp) 
NcoI/HindIII 
Rv0609/0608 
703486 - 703887 (+) (402 bp) / 
703244 - 703489 (+) (246 bp) 
NcoI/HindIII 
Rv0617/0616 
711006 - 711407 (+) (402 bp) / 
710782 - 711009 (+) (228 bp) 
NcoI/HindIII 
Rv0627/0626 
718282 - 718689 (+) (408 bp) / 
718025 - 718285 (+) (261 bp) 
NcoI/HindIII 
Rv0656/0657 
752984 - 753367 (-) (384 bp) / 
753462 - 753617 (-) (156 bp) 
NcoI/HindIII 
Rv0661c/0662c 
755335 - 755772 (-) (438 bp) / 
755769 - 756137 (-) (369 bp) 
NcoI/HindIII 
Rv0665/0664 
758801 - 759139 (+) (339 bp) / 
758532 - 758804 (+) (273 bp) 
NcoI/HindIII 
Rv0749/0748 
841228 - 841656 (+) (429 bp) / 
840947 - 841204 (+) (258 bp) 
NcoI/HindIII 
Rv0960/0959a 
1073545 - 1073928 (+) (384 bp) / 
1073327 - 1073548 (+) (222 bp) 
NcoI/HindIII 
Rv1114/1113 
1239610 - 1239984 (+) (375 bp) / 
1239416 - 1239613 (+) (198 bp) 
NcoI/HindIII 
Rv1242/1241 
1384535 - 1384966 (+) (432 bp) / 
1384278 - 1384538 (+) (261 bp) 
NcoI/HindIII 
Rv1397c/1398c 
1574112 - 1574513 (-) (402 bp) / 
1574510 - 1574767 (-) (258 bp) 
NcoI/HindIII 
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Rv1561/1560 
1764979 - 1765383 (+) (405 bp) / 
1764755 - 1764973 (+) (219 bp) 
NcoI/HindIII 
Rv1720/1721c 
1947030 - 1947419 (-) (390 bp) / 
1947416 - 1947643 (-) (228 bp) 
GeneArt* 
Rv1741/1740 
1967917 - 1968165 (+) (249 bp) / 
1967705 - 1967917 (+) (213 bp) 
NcoI/HindIII 
Rv1838c/1839c 
2087257 - 2087652 (-) (396 bp) / 
2087649 - 2087912 (-) (264 bp) 
NcoI/HindIII 
Rv1953/1952 
2200938 - 2201249 (+) (312 bp) / 
2200726 - 2200941 (+) (216 bp) 
NcoI/HindIII 
Rv1962c/1962a 
2204866 - 2205273 (-) (408 bp) / 
2205277 - 2205549 (-) (273 bp) 
GeneArt* 
Rv1982c/1982a 
2225413 - 2225832 (-) (420 bp) / 
2225841 - 2226101 (-) (261bp) 
NcoI/BamHI 
Rv2010/2009 
2258273 - 2258671 (+) (399 bp) / 
2258030 - 2258272 (+) (243 bp) 
NcoI/HindIII 
Rv2103c/2104c 
2364086 - 2364520 (-) (435 bp) / 
2364527 - 2364781 (-) (255 bp) 
NcoI/BamHI 
Rv2494/2493 
2808310 - 2808735 (+) (426 bp) / 
2808083 - 2808304 (+) (222 bp) 
NcoI/HindIII 
Rv2527/2526 
2851315 - 2851716 (+) (402 bp) / 
2851091 - 2851318 (+) (228 bp) 
NcoI/HindIII 
Rv2530c/2530a 
2854267 - 2854686 (-) (420 bp) / 
2854683 - 2854907 (-) (225 bp) 
NcoI/HindIII 
Rv2546/2545 
2868154 - 2868567 (+) (414 bp) / 
2867783 - 2868061 (+) (279 bp) 
GeneArt* 
Rv2548/2547 
2868860 - 2869237 (+) (378 bp) / 
2868606 - 2868863 (+) (258 bp) 
NcoI/NdeI 
Rv2549c/2550c 
2869727 - 2870122 (-) (396 bp) / 
2870119 - 2870364 (-) (246 bp) 
GeneArt* 
Rv2596/2595 
2925734 - 2926138 (+) (405 bp) / 
2925492 - 2925737 (+) (246 bp) 
NcoI/HindIII 
Rv2602/2601 
2930344 - 2930784 (+) (441 bp) / 
2930070 - 2930357 (+) (288 bp) 
NcoI/HindIII 
Rv2757/2758c 
3070170 - 3070586 (-) (417 bp) / 
3070583 - 3070849 (-) (267 bp) 
GeneArt** + BamHI 
Rv2759c/2760c 
3070875 - 3071270 (-) (396 bp) / 
3071267 - 3071536 (-) (270 bp) 
NcoI/HindIII 
Rv2829c/2830c 
3136620 - 3137012 (-) (393 bp) / 
3137009 - 3137224 (-) (216 bp) 
NcoI/HindIII 
Rv2863/2862a 
3174992 - 3175372 (+) (381 bp) / 
3174801 - 3174995 (+) (195 bp) 
NcoI/HindIII 
Rv2872/2871 
3183382 - 3183825 (+) (444 bp) / 
3183138 - 3183395 (+) (258 bp) 
NcoI/HindIII 
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Rv3320c/3321 
3707642 - 3708070 (-) (429 bp) / 
3708074 - 3708316 (-) (243 bp) 
NcoI/BamHI 
Rv3384c/3385c 
3799243 - 3799635 (-) (393 bp) / 
3799635 - 3799943 (-) (309 bp) 
NcoI/HindIII 
Rv3408/3407 
3826548 - 3826958 (+) (411 bp) / 
3826252 - 3826551 (+) (300 bp) 
NcoI/HindIII 
Rv3697c/3697a 
4139805 - 4140242 (-) (438 bp) / 
4140239 - 4140463 (-) (225 bp) 
NcoI/HindIII 
Positions in H37Rv genome relative to those published in TBDB. * Operons containing the NcoI sequence were 
ordered from GeneArt (with the internal NcoI site removed), and ligated into pYUB28b using NcoI and HindIII. ** 
Rv2757/2758 contained both NcoI and HindIII sequences so was ordered from GeneArt with the NcoI site 
removed, then amplified with a 3’ primer containing BamHI to put the BamHI site in frame.  
 
Purification of plasmids from mycobacteria is difficult due to the waxy nature of the 
mycobacterial cell wall which makes it hard to lyse cells whilst still retaining plasmid integrity. 
Therefore, ligation reactions were initially transformed into electrocompetent E. coli cells to 
facilitate plasmid purification and screening via sequencing, prior to transforming into M. 
smegmatis mc24517 cells. TOP10 cells were used rather than other E. coli strains due to their 
high transformation efficiency and the ability to select transformants using hygromycin B. 
 
Successful insertion of the vapBC genes was confirmed by extracting the plasmid from positive 
E. coli transformants (identified through colony PCR screening) and sequencing with primers 
flanking the pYUB28b multiple cloning site (T7 forward and reverse). 
 
5.2.2 Expression and Purification of M. tuberculosis VapBC’s 
5.2.2.1 Small Scale Expression Trials of M. tuberculosis VapBC’s 
Once all 47 of the M. tuberculosis VapBC operons were successfully cloned into M. 
smegmatis, small scale protein expression tests were performed in duplicate and used to 
evaluate VapBC expression and his-tag binding affinity (Figure 5.3). Protein expression of M. 
tuberculosis VapBC’s in M. smegmatis using the standard expression protocol (Section 
2.3.2.11) was moderately successful, as summarised in Table 5.2. 
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Figure 5.3: Small scale expression screens of M. tuberculosis VapBC (pYUB28b constructs) in M. 
smegmatis. Expected band sizes of His-tag bound and expressed VapC (black box), VapB (green box), 
fused VapBC (red box) and unknown protein (yellow box) are displayed. Labels: whole cell fraction (WC), 
soluble fraction loaded onto Ni2+ resin (L), insoluble fraction (I),flow through (FT), wash one (W1), Ni2+ 
resin with protein bound after wash steps (R). pYUB28b sample shows the empty vector control. 
 
 155 
 
Table 5.2: Summary of small scale expression tests and his-tag binding affinity. 
 
Operon VapB VapC 
  
expected 
size 
(kDa) 
expressed 
insolubly 
expressed 
solubly 
 
expected 
size 
(kDa) 
expressed 
insolubly 
expressed 
solubly 
Rv0064/0065 Rv0064 8.7   Rv0065 15.8 x  
Rv0229c* - - - - Rv0229c 26.8 x x 
Rv0239/0240 Rv0239 11.5 x  Rv0240 17.9 x  
Rv0277a/0277c Rv0277a 6.0 x x Rv0277c 17.4 x x 
Rv0300/0301 Rv0300 8.1   Rv0301 17.2 x  
Rv0549/0550 Rv0550 9.5  x Rv0549c 17.7  x 
Rv0582/0581 Rv0581 7.6 x x Rv0582 15.9 x x 
Rv0595/0596c Rv0596c 9.7 x x Rv0595c 15.6 x x 
Rv0598c/0599 Rv0599 8.2 x  Rv0598c 17.2 x  
Rv0609/0608 Rv0608 8.8 x x Rv0609 16 x x 
Rv0617/0616 Rv0616 8.2   Rv0617 15.5 x  
Rv0623/0624** Rv0623 9.1 x x Rv0624 17.3 x x 
Rv0627/0626 Rv0626 9.5 x x Rv0627 15.9 x x 
Rv0656/0657 Rv0657 11.1  x Rv0656c 16.9 x x 
Rv0661c/0662c Rv6062c 14 x x Rv0661 16.8 x x 
Rv0665/0664 Rv0064 9.2 x x Rv0665 13.1 x  
Rv0749/0748 Rv0748 9 x x Rv0749 17.4 x x 
Rv0960/0959a Rv0959a 7.9 x x Rv0960 15.4 x x 
Rv1114/1113 Rv1113 6.9   Rv1114 15   
Rv1242/1241 Rv1241 9.8 x x Rv1242 17.4 x x 
Rv1397c/1398c Rv1398c 9.4 x x Rv1397c 16.5 x  
Rv1561/1560 Rv1560 8.3  x Rv1561 16.2 x x 
Rv1720/1721c Rv1721c 7.9 x x Rv1720 15.4 x x 
Rv1741/1740 Rv1740 7.6 x x Rv1741 10.4  x 
Rv1838c/1839c Rv1839c 10.4 x  Rv1838c 16.2 x x 
Rv1953/1952 Rv1952 7.8 x x Rv1953 13.1 x x 
Rv1962c/1962a Rv1962a 9.9   Rv1962c 16 x  
Rv1982c/1982a Rv1982a 9.6  x Rv1982c 17.1  x 
Rv2010/2009 Rv2009 9.0   Rv2010 16.3  x 
Rv2103c/2104c Rv2104c 9.3  x Rv2103c 18.1 x  
Rv2494/2493 Rv2493 8.0  x Rv2494 16.9 x  
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Rv2527/2526 Rv2526 8.2   Rv2527 16.7   
Rv2530c/2530a Rv2530a 7.9 x x Rv2530 16.3   
Rv2546/2545 Rv2545 10.3  x Rv2546 16.6 x x 
Rv2548/2547 Rv2547 9.9   Rv2548 17.4   
Rv2549c/2550c Rv2550c 9.1 x x Rv2549c 16.1  x 
Rv2596/2595 Rv2595 9.2 x x Rv2596 15.9 x  
Rv2602/2601 Rv2601 10.4 x x Rv2602 17.6 x x 
Rv2757/2758c Rv2758c 9.4 x x Rv2757 18.2 x x 
Rv2759c/2760c Rv2760c 10.1 x x Rv2759c 15.9 x x 
Rv2829c/2830c Rv2830c 7.5 x x Rv2829c 16.1 x x 
Rv2863/2862a Rv2862a 7.4 x x Rv2863 15.8 x x 
Rv2872/2871 Rv2871 9.1 x x Rv2872 18.1 x x 
Rv3320c/3321 Rv3321 8.8 x x Rv3320c 18.2 x x 
Rv3384c/3385c Rv3385c 11.0 x  Rv3384c 15.8 x  
Rv3408/3407 Rv3407 10.9   Rv3408 16.2   
Rv3697c/3697a Rv3697a 8.4 x x Rv3697c 17.8 x x 
VapBC operons in red bold type indicate those which expressed soluble VapC protein. * indicates VapB fused to 
VapC, ** indicates operon cloned previously in the laboratory. 
 
No VapB or VapC expression, either soluble or insoluble, was observed for the following 
operons; Rv0229c, Rv0277a/0277c, Rv0582/0581, Rv0595/0596c, Rv0609/0608, 
Rv0627/0626, Rv0661c/0662c, Rv0749/0748, Rv0960/0959a, Rv1242/1241, Rv1720/1721c, 
Rv1953/1952, Rv2602/2601, Rv2757/2758c, Rv2759c/2760c, Rv2829c/2830c, Rv2863/2862a, 
Rv2872/2871, Rv3320c/3321 or Rv3697c/3697a. 
 
Insoluble expression of VapB and VapC was observed for Rv0549/0550, Rv1982c/1982a and 
Rv2010/2009. Insoluble expression of VapB only was observed for Rv0656/0657, 
Rv1561/1560 and Rv2546/2545. Insoluble expression of VapC only was observed for 
Rv1741/1740 and Rv2549c/2550c. 
 
Soluble expression of VapB and VapC was observed for; Rv0064/0065, Rv0239/0240, 
Rv0300/0301, Rv0598c/0599, Rv0617/0616, Rv1114/1113, Rv1962c/1962a, Rv2527/2526, 
Rv2548/2547, Rv3384c/3385c and Rv3408/3407. Soluble expression of VapB only was 
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observed for Rv1838c/1839c. Soluble expression of VapC only was observed for 
Rv0665/0664, Rv1397c/1398c, Rv2103c/2104c, Rv2494/2493, Rv2530c/2530a and 
Rv2596/2595. 
 
The 20 VapBC operons which displayed no expression of either VapB or VapC under standard 
conditions could be screened for protein expression under reduced incubation temperatures 
and/or lysis buffer screens to attempt expression of these proteins in the future. 
 
Rv2010/2009 showed a small amount of insolubly expressed VapB and VapC, as well as a 
large amount of soluble VapB (as seen by the intense band in the Flow Through sample). Due 
to the insoluble expression of VapC, no His tag was present in the soluble fraction for the 
soluble VapB protein to be able to bind to the resin. This was also the case for Rv1838c/1839c 
where a small amount of Rv1839c was solubly expressed, but with no soluble expression of 
Rv1838c, therefore there was no His-tag for the VapB to bind the resin.  
 
Rv1962c/1962a and Rv3384c/3385c both showed soluble expression of VapB and VapC but 
no binding of VapB to the resin (as seen by VapB bands in the Flow Through but not Resin 
samples). This suggests that these VapBC complexes may be bound less tightly than the other 
VapBC complexes, and the VapB portion is dissociating from VapC more readily.  
 
Out of the 47 M. tuberculosis VapBC’s, 17 were picked for large scale expression studies 
based on their soluble expression of VapC in the small scale protein expression tests. Only 10 
of those 17 M. tuberculosis VapBC’s were purified during the course of this research, three 
were purified by others in the lab (Rv0064/0065, Rv0300/0301 and Rv0617/0616) and the 
remaining four (Rv0665/0664, Rv1114/1113, Rv1397c/1398c and Rv2596/2595) are awaiting 
purification. 
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5.2.2.2 Large Scale Expression and Purification of Soluble M. 
tuberculosis VapBC’s 
Having established that 17 of the 47 M. tuberculosis VapCs could be expressed solubly, 10 of 
these small scale expression screens yielding soluble VapC were then scaled up and the 
resulting proteins successfully purified by IMAC as in Section 2.3.2.13. The following 
chromatograms and SDS-PAGE gels are representative of the resulting peaks and fractions 
observed from IMAC purifications, and show proteins bound to the column non-specifically 
eluted early in the gradient, whereas VapBC eluted later at ~250 - 300 mM imidazole, SDS-
PAGE gels show the column load, flow through and insoluble purification fractions, followed by 
the resulting IMAC fractions. Fractions identified by IMAC as containing just the VapBC protein 
complex, were further purified by SEC (Section 2.3.2.14) and typically eluted as a double peak. 
Purified VapBC samples were also run on an agarose or native PAGE gel when the resulting 
chromatogram peaks indicated they may have co-purified with DNA. Molecular weights for 
each SEC purified VapBC complex were calculated as described in Section 2.3.2.14 and are 
summarised in Table 5.3. 
 
Rv0239/0240 
Rv0239/0240 VapBC was successfully purified using both IMAC (Figure 5.4a) and SEC 
(Figure 5.4b and c). SDS-PAGE and agarose gels of SEC fractions showed DNA was purified 
along with VapBC for both chromatogram peaks, although the first peak contained the majority 
of the DNA (Figure 5.4b). A further SEC purification using 2 M NaCl successfully purified the 
VapBC protein away from the DNA, as seen by the absence of protein in peak A (present only 
in peak B) on the SDS-PAGE gel, and the absence of DNA in peak B (present only in peak A) 
on the agarose gel in Figure 5.4c. Native (non-denaturing) PAGE gels also confirm both the 
presence of DNA (as seen by the difference in size of the VapBC protein bands for A and B 
fractions in Figure 5.4b), and its removal after SEC with 2 M NaCl (as seen by the absence of 
protein for peak A fractions, and presence in peak B fractions only in Figure 5.4c). The 
calculated MWs of the purified VapBC based on elution volume (for SEC peaks B) are 94.89 or 
121.74 kDa (after further purification in 2 M NaCl), which equates to approximately a trimer (or 
3.23 x the MW of VapBC) or tetramer (or 4.14 x the MW of VapBC) of Rv0239/0240 VapBC 
complexes respectively. 
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Figure 5.4: Purification of Rv0239/0249 via a) IMAC, b) SEC and c) 2 M NaCl SEC. Chromatograms depict 
the UV absorbance (blue) and for IMAC, the elution profile of the protein complex as the concentration of 
elution buffer increases (green). The corresponding SDS-PAGE gel depicts a) the column load, flow 
through and insoluble purification fractions followed by the resulting IMAC fractions, or b) and c), the 
SEC fractions alone. Fractions and their elution position are shown by the black bar. Right hand side, 
middle (a), b) and c)) = agarose gels showing the presence of DNA in purified fractions, right hand side, 
bottom (b) and c)) = native PAGE gels confirming the separation of VapBC from co-purified DNA in 
chromatogram peaks A and B.  
 
Rv0598c/0599 
Rv0598c/0599 VapBC was successfully purified using both IMAC and SEC (Figure 5.5). The 
calculated MW of the purified VapBC based on elution volume (for SEC peak B) is 64.82 kDa 
which equates to approximately a trimer (or 2.55 x the MW of VapBC) of Rv0598c/0599 
VapBC complexes. 
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Figure 5.5: Purification of Rv0598c/0599 via a) IMAC and b) SEC. Chromatograms depict the UV 
absorbance (blue) and for IMAC, the elution profile of the protein complex as the concentration of elution 
buffer increases (green). The corresponding SDS-PAGE gel depicts a) the column load, flow through and 
insoluble purification fractions followed by the resulting IMAC fractions, or b), the SEC fractions alone. 
Fractions and their elution position are shown by the black bar.  
 
Rv1962c/1962a 
Rv1962c/1962a VapBC was successfully purified using both IMAC and SEC (Figure 5.6). The 
calculated MW of the purified VapBC based on elution volume is 92.98 kDa which equates to 
approximately a tetramer (or 3.59 x the MW of VapBC) of Rv1962c/1962a VapBC complexes. 
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Figure 5.6: Purification of Rv1962c/1962a via a) IMAC and b) SEC. Chromatograms depict the UV 
absorbance (blue) and for IMAC, the elution profile of the protein complex as the concentration of elution 
buffer increases (green). The corresponding SDS-PAGE gel depicts a) the column load, flow through and 
insoluble purification fractions followed by the resulting IMAC fractions, or b), the SEC fractions alone. 
Fractions and their elution position are shown by the black bar. 
 
Rv2103c/2104c 
Rv2103c/2104c VapBC was successfully purified via IMAC (Figure 5.7). SEC was not 
performed as the resulting protein from IMAC appeared clean, containing only one other faint 
band at approximately 27.4 kDa which is the size of the Rv2103c/2104c complex. 
 
 
Figure 5.7: Purification of Rv2103c/2104c via IMAC. Chromatogram depicts the UV absorbance (blue) and 
elution profile of the protein complex as the concentration of elution buffer increases (green). The 
corresponding SDS-PAGE gel depicts the column load, flow through and insoluble purification fractions 
followed by the resulting IMAC fractions. Fractions and their elution position are shown by the black bar.  
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Rv2494/2493 
Only a small amount of Rv2494/2493 VapBC was purified using IMAC and SEC (Figure 5.8). 
The calculated MW of this purified VapBC based on elution volume is 149.27 kDa, equating to 
approximately a hexamer (or 6 x the MW of VapBC) of Rv2494/2493 VapBC complexes. 
However, this MW may be incorrect as it was calculated using the elution volume from the 
SEC trace below, which is imperfect due to there being so little protein purified. Further 
purification, possibly under different expression conditions, should be undertaken in the future 
to purify a greater amount of protein (which elutes with a sharp SEC peak) suitable for 
calculating an accurate MW value for the protein complex. 
 
 
Figure 5.8: Purification of Rv2494/2493 via a) IMAC and b) SEC. Chromatograms depict the UV 
absorbance (blue) and for IMAC, the elution profile of the protein complex as the concentration of elution 
buffer increases (green). The corresponding SDS-PAGE gel depicts a) the column load, flow through and 
insoluble purification fractions followed by the resulting IMAC fractions, or b), the SEC fractions alone. 
Fractions and their elution position are shown by the black bar.  
 
Rv2527/2526 
Rv2527/2526 VapBC was successfully purified using both IMAC and SEC (Figure 5.9). The 
calculated MW of the purified VapBC based on elution volume is 86.67 kDa which equates to 
approximately a tetramer (or 3.48 x the MW of VapBC) of Rv2527/2526 VapBC complexes. 
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Figure 5.9: Purification of Rv2527/2526 via a) IMAC and b) SEC. Chromatograms depict the UV 
absorbance (blue) and for IMAC, the elution profile of the protein complex as the concentration of elution 
buffer increases (green). The corresponding SDS-PAGE gel depicts a) the column load, flow through and 
insoluble purification fractions followed by the resulting IMAC fractions, or b), the SEC fractions alone. 
Fractions and their elution position are shown by the black bar.  
 
Rv2530c/2530a  
Rv2530c/2530a VapBC was successfully purified using both IMAC and SEC (Figure 5.10). 
VapB was not observed on the 16.5 % SDS-PAGE gels in Figure 5.10a and b, nor on a 20 % 
SDS-PAGE gel (data not shown), but its presence was confirmed by MALDI-TOF MS (Section 
2.3.2.9) of the VapBC protein complex (data not shown) and when SEC fractions were run on 
a native PAGE gel (Figure 5.10b). The fact that the VapB protein could be visualised on a 
native PAGE gel and that Rv2530a VapB has the lowest pI of all the VapB (and VapC) 
proteins (3.9), suggests there is something about the protein in its denatured state which 
prohibits it from migrating through an SDS-PAGE gel in the standard manner. The calculated 
molecular weights of the purified VapBC based on elution volume for peaks A and B are 
663.54 and 119.25 kDa, which equate to approximately 27.42 or 4.93 x the MW of 
Rv2530c/2530a VapBC complexes respectively. The MW of peak A is unusually large, 
suggestive of the presence of DNA, but SEC fractions run on an agarose gel showed little 
DNA, of which there was an equivalent amount in fractions from both A and B peaks (data not 
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shown). The large MW for peak A may be due to an oligomer with a larger hydrodynamic 
volume, or a larger oligomeric species. 
 
Figure 5.10: Purification of Rv2530c/2530a via a) IMAC and b) SEC. Chromatograms depict the UV 
absorbance (blue) and for IMAC, the elution profile of the protein complex as the concentration of elution 
buffer increases (green). The corresponding SDS-PAGE gel depicts a) the column load, flow through and 
insoluble purification fractions followed by the resulting IMAC fractions, or b), the SEC fractions alone. 
Fractions and their elution position are shown by the black bar. Right hand side, bottom, b) = native 
PAGE gel confirming the presence of VapB in the most concentrated fractions.  
 
Rv2548/2547 
Rv2548/2547 VapBC was successfully purified using both IMAC and SEC (Figure 5.11). SDS-
PAGE and agarose gels of SEC fractions showed DNA (and a small amount of protein) was 
present in peak A, whilst the majority of protein was in peak B (Figure 5.11b). The calculated 
MW of the purified VapBC from peak B (based on elution volume) is 98.73 kDa which equates 
to approximately a tetramer (or 3.61 x the MW of VapBC) of Rv2548/2547 VapBC complexes. 
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Figure 5.11: Purification of Rv2548/2547 via a) IMAC and b) SEC. Chromatograms depict the UV 
absorbance (blue) and for IMAC, the elution profile of the protein complex as the concentration of elution 
buffer increases (green). The corresponding SDS-PAGE gel depicts a) the column load, flow through and 
insoluble purification fractions followed by the resulting IMAC fractions, or b), the SEC fractions alone. 
Fractions and their elution position are shown by the black bar. Right hand side, bottom b) = agarose gel 
showing the presence of DNA in purified peak A fractions.  
 
Rv3384c/3385c  
Rv3384c/3385c VapBC was successfully purified via IMAC (peak C, Figure 5.12). SEC was 
not performed as the resulting protein from IMAC peak C appeared clean, containing only one 
other faint band at approximately 26.84 kDa which is the size of the Rv3384c/3385c complex. 
VapBC protein was observed in earlier IMAC chromatogram peaks (A and B) but these also 
contained DNA as seen in the agarose gel, Figure 5.12. 
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Figure 5.12: Purification of Rv3384c/3385c via IMAC. Chromatogram depicts the UV absorbance (blue) and 
elution profile of the protein complex as the concentration of elution buffer increases (green). The 
corresponding SDS-PAGE gel depicts the column load, flow through and insoluble purification fractions 
followed by the resulting IMAC fractions. Fractions and their elution position are shown by the black bar. 
Right hand side, bottom = agarose gel showing the presence of DNA in purified peak fractions.  
 
Rv3408/3407 
Only a small amount of Rv3408/3407 VapBC was purified via IMAC and SEC (Figure 5.13). 
The calculated MW of the purified VapBC from peak A (based on elution volume) `is 152.69 
kDa, equating to approximately a hexamer (or 5.63 x the MW of VapBC) of Rv3408/3407 
VapBC complexes. Protein is also present along the broad shoulder (labelled B) coming off 
peak A, with molecular weights ranging from 152.69 down to 26.22 kDa. The true MW of this 
VapBC complex is likely to be in the middle of this range, and would be more accurately 
determined if a larger amount of protein were purified. 
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Figure 5.13: Purification of Rv3408/3407 via a) IMAC and b) SEC. Chromatograms depict the UV 
absorbance (blue) and for IMAC, the elution profile of the protein complex as the concentration of elution 
buffer increases (green). The corresponding SDS-PAGE gel depicts a) the column load, flow through and 
insoluble purification fractions followed by the resulting IMAC fractions, or b), the SEC fractions alone. 
Fractions and their elution position are shown by the black bar.  
 
Table 5.3 denotes the elution volume of each purified VapBC protein and its corresponding MW as 
calculated using the equation MW = e ((Kav – 2.1739)/ -0.159) from Section 2.3.2.14. 
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Table 5.3: Calculated MW of purified VapBC proteins after SEC. 
 
Protein 
Elution 
volume (ml) 
Kav MW (kDa) 
Predicted 
VapBC MW 
MW / 
Predicted MW 
Rv0239/0240 
Rv0239/0240* 
47.09 / 73.6 
13.50* 
0.01 / 0.35 
0.34* 
810 / 95 
122* 
29.40 
 
27.56 / 3.23 
4.14* 
Rv0598c/0599 78.31 / 88 0.41 / 0.54 65 / 30 25.38 2.55 / 1.17 
Rv1962c/1962a 74.35 0.36 93 25.90 3.59 
Rv2103c/2104c N/A 
Rv2494/2493 68.00 0.28 149 24.89 6.00 
Rv2527/2526 74.72 0.37 87 24.89 3.48 
Rv2530c/2530a 49.56 / 70.78 0.04 / 0.32 664 / 119 24.20 27.42 / 4.93 
Rv2548/2547 73.61 0.35 99 27.33 3.61 
Rv3384c/3385c N/A 
Rv3408/3407 68.22 0.28 153 27.13 5.63 
Predicted MWs were calculated using ProtParam (http://web.expasy.org/cgi-bin/protparam/protparam). * indicates 
Rv0239/0240 protein purified after 2 M NaCl SEC purification on the S200 10/300 column. SEC was not 
performed for Rv2103c/2104c or Rv3384c/3385c.  
 
The calculated molecular weights suggest these M. tuberculosis VapBCs are large protein 
complexes, the majority of which may be trimeric or tetrameric. These results are in accordance 
with the VapBC structures from M. smegmatis and M. tuberculosis (Rv0300/0301 and VapBC-5 
(Rv0626/0627)), which are tetramers of heterodimers (Miallau et al. 2009;  McKenzie 2011;  Min et 
al. 2012) in an arrangement similar to the N. gonorrhoeae FitAB structure (Mattison et al. 2006). 
 
Of the 10 purified VapBC complexes above, only eight were carried through to the following 
stage (VapC purification, Section 5.2.3), as not enough VapBC protein was produced during 
the purification process for Rv2494/2493 and Rv2527/2526 (which precipitated readily at both 
4 and 18 C during concentration and dialysis). 
 
The order with which proteins were purified/focussed on was based on VapC toxicity results 
and the requirement of VapBCs during various stages of growth which were published during 
the course of this research (Beste et al. 2009;  Gupta 2009;  Ramage et al. 2009;  Ahidjo et al. 
2011). Toxicity studies were performed in M. smegmatis, M. tuberculosis or E.coli, while the 
TraSH analysis was performed on BCG and identified the genes required or selected for 
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(either positively or negatively) at slow, fast or the switch from slow to fast growth rates and 
vice-versa (see Table 5.4). Results published during the course of this research identified 
VapC proteins of potential interest for the following reasons: Rv2527 and Rv2530c were 
prioritised due to their classification in the group of genes most potent in disrupting the 
bacteriums latency and dormancy program. These genes were identified through predicted 
gene regulatory networks and computational gene deletion experiments, from microarray gene 
expression profiles of bacilli adaptation and survival in latency, simulated by hypoxia 
(Magombedze & Mulder 2013). Rv0595c, Rv0598c, Rv0627, Rv1838c, Rv2103c, Rv2494, 
Rv2530c, Rv2548, Rv2602, Rv2829c and Rv3320c proteins were found to be increased in 
nutrient starved cultures using proteomic profiling, implicating a metabolic role for the M. 
tuberculosis toxin proteins in the switch to dormancy (Albrethsen et al. 2013).  
 
The M. tuberculosis VapBC proteins Rv0064/0065, Rv0300/0301 and Rv0617/0616 were all 
purified by others in the laboratory; Rv0665/0664, Rv1114/1113, Rv1397c/1398c and 
Rv2596/2595 were not purified during the course of this research and are earmarked for future 
work. 
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Table 5.4: Basis for preferential purification of VapBC proteins. 
 
Protein 
VapC Toxicity studies 
Genetic Requirements for Fast and Slow 
Growth -  TraSH analysis (BCG) 
Ahidjo 
et al. 
(M.tb & 
M.sm) 
Gupta et 
al. 
(E.coli) 
Ramage 
et al. 
(M.sm) 
VapB VapC 
Rv0064/0065 NT - -   
Rv0229c NT NT NT  Pos selected at fast GR 
Rv0239/0240 NT NT -   
Rv0277a/0277c NT NT +   
Rv0300/0301 NT slight +   
Rv0549/0550 + slight +  Pos selected at fast GR 
Rv0582/0581 NT NT +   
Rv0595/0596c + + - Neg selected at fast GR  
Rv0598c/0599 NT NT - Req slow-fast GR switch  
Rv0609/0608 NT NT +   
Rv0617/0616 NT NT -   
Rv0627/0626 - slight -   
Rv0656/0657 NT - - Req slow-fast GR switch  
Rv0661c/0662c NT - -   
Rv0665/0664 NT slight -  Pos selected slow-fast 
Rv0749/0748 NT NT +   
Rv0960/0959a NT - -   
Rv1114/1113 NT NT +   
Rv1242/1241 NT NT +  Pos selected slow-fast 
Rv1397c/1398c NT slight -   
Rv1561/1560 NT + +   
Rv1720/1721c NT - -   
Rv1741/1740 NT NT -  Req slow-fast GR switch 
Rv1838c/1839c NT - -   
Rv1953/1952 
-‘ve 
control 
slight - Pos selected at slow GR Neg selected at slow GR 
Rv1962c/1962a NT NT +  
Neg selected at fast GR  
+ pos selected slow-fast 
Rv1982c/1982a NT NT -   
Rv2010/2009 - - +   
Rv2103c/2104c NT NT + ^  
Neg selected at slow GR 
+ pos selected slow-fast 
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Rv2494/2493 NT NT - Pos selected slow-fast Neg selected at slow GR 
Rv2527/2526 NT slight -   
Rv2530c/2530a NT NT +   
Rv2546/2545 - - - Pos selected slow-fast  
Rv2548/2547 - - +   
Rv2549c/2550c + + -   
Rv2596/2595 NT NT -   
Rv2602/2601 NT NT +   
Rv2757/2758c NT slight + Req slow-fast GR switch  
Rv2759c/2760c NT NT -  Req slow-fast GR switch 
Rv2829c/2830c + - +   
Rv2863/2862a NT slight -  Pos selected fast-slow 
Rv2872/2871 NT NT +   
Rv3320c/3321 +* NT - 
Pos selected at slow GR 
+ pos selected slow-fast 
Pos selected slow-fast 
Rv3384c/3385c NT NT +  Req slow-fast GR switch 
Rv3408/3407 NT NT +  Req slow-fast GR switch 
Rv3697c/3697a NT NT NT  Pos selected at slow GR 
VapC toxicity studies show VapC proteins which were toxic for cell growth in the organism stated, NT = not 
tested, + = toxic, +* = toxic but only when constitutively expressed, - = not toxic (Gupta 2009;  Ramage et al. 
2009;  Ahidjo et al. 2011). Toxicity could be rescued with each cognate VapB protein but rescue of Rv2103c 
toxicity with Rv2104c VapB was not tested (^). TraSH analysis identified genes required for (Req) or positively 
(Pos) or negatively (Neg) selected for, for fast, slow or the switch to/from fast to slow growth rates (GR) (Beste et 
al. 2009). 
 
5.2.3 Purification of M. tuberculosis VapCs 
The next stage in obtaining VapC proteins for functional analysis was separating and purifying 
the VapCs from the purified VapBC complexes. Previous work (McKenzie 2011) showed that 
functional VapC could be recovered from the M. smegmatis VapBC complex by performing a 
tryptic digest on the protein complex. This method takes advantage of the differences in 
stability of the VapB and VapC proteins, and the greater susceptibility of VapB to proteolytic 
degradation which is a trait common to TA systems (Gerdes et al. 2005;  Miallau et al. 2009). 
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5.2.3.1 Purification of VapC Following Trypsin Digestion of the VapBC 
Complex 
VapB proteins were digested from the VapBC complexes by treating the complex with 0.1 mg 
trypsin per 0.7 mg protein for 1 hr then stopping the reaction by the addition of an equal 
amount of trypsin inhibitor for 15 min. Pure VapC was required for RNase activity analysis, so 
anion exchange chromatography was employed to purify VapC away from trypsin, inhibitor and 
any remaining VapB degradation products.  
 
For VapCs with isoelectric points unsuitable for anion exchange, attempts were made using 
size exclusion chromatography, Immobilised Metal Affinity Chromatography or cation 
exchange chromatography to purify the VapC protein. 
 
5.2.3.1.1 Successful anion exchange 
Rv2530c 
VapC (pI 7.2) was successfully purified by anion exchange chromatography in 50 mM 
phosphate buffer pH 8, 100 mM NaCl. VapC elutes from the column at 200 - 300 mM NaCl 
(Figure 5.14). Higher molecular weight bands are also present with the VapC samples on the 
SDS-PAGE gel, and as with the SEC results for this protein (Figure 5.10), the fractions appear 
to consist of two different populations. Fractions from peak B include a faint band at 
approximately 30 kDa which is possibly a dimer of VapC proteins (corresponding to a 
molecular weight of ~32 kDa), whilst those from A include faint bands at approximately 18 and 
24 kDa. 
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Figure 5.14: Purification of Rv2530c via anion exchange. Chromatograms depict the UV absorbance (blue) 
and elution profile of the protein complex as the concentration of elution buffer increases (green). The 
corresponding SDS-PAGE gel depicts the column load, flow through (FT) and resulting anion exchange 
fractions (elution positions are shown by the black bar) containing VapC at approximately 16.3 kDa.  
 
Rv2548 
VapC (pI 5.7) was successfully purified by anion exchange chromatography in 50 mM 
phosphate buffer pH 7.4, 100 mM NaCl. VapC elutes from the column at 200 - 300 mM NaCl 
(Figure 5.15). Two smaller molecular weight bands are present with the VapC samples on the 
SDS-PAGE gel, as well as a large low molecular weight smear. The two bands appear to be 
truncated VapC products which have been degraded by trypsin, and the smear degraded 
VapB and VapC. MALDI-TOF MS (data not shown) revealed VapC at 17.4 kDa which 
correlates to VapC including the C-terminal His-tag, and multiple smaller species of VapC 
ranging from 14.4 to 16 kDa. These smaller species account for VapC minus the C-terminal 
His-tag as well as portions of the linker region which would have molecular weights of 16.6 and 
13.7 kDa respectively (Protparam), and other VapC degradation products. The low molecular 
weight smear seen on the SDS-PAGE gels is represented by multiple peaks ranging from 7.4 
to 10.8 kDa. None of these peaks are at 9.9 (the calculated molecular weight of VapB) 
indicating that VapB has been degraded during the tryptic digest leaving behind only VapC and 
various degradation products. 
 
A further tryptic digest was performed with less trypsin (a trypsin to protein ratio of 0.1 mg : 1 
mg repectively) in an attempt to stop the cleavage of VapC. This still produced the three VapC 
bands observed in Figure 5.15 and also failed to completely digest VapB, leaving behind 
enough intact VapB to hinder RNase activity of the VapC (data not shown), suggesting the 
conformation of this VapC makes it more susceptible to degradation by trypsin. All subsequent 
digests were performed with the standard trypsin to protein ratio. 
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Figure 5.15: Purification of Rv2548 via anion exchange. Chromatograms depict the UV absorbance (blue) 
and elution profile of the protein complex as the concentration of elution buffer increases (green). The 
corresponding SDS-PAGE gel depicts the column load, flow through (FT) and resulting anion exchange 
fractions (elution positions are shown by the black bar) containing VapC at approximately 17.4 kDa and 
degraded VapC products at lower molecular masses.  
 
5.2.3.1.2 Unsuccessful anion exchange 
Rv0240 
VapC (pI 6.8) did not bind the anion exchange column in 50 mM phosphate buffer pH 7.4, 100 
mM NaCl, or when NaCl was dropped to 50 mM and buffer at pH 8.2, instead it remained in 
the flow through (data not shown). The lack of binding suggests the actual pI of the protein in 
its native state is higher than 6.8, probably due to an abundance of basic amino acid residues 
concentrated on the outside of the protein structure.  
 
A cation bead screen to determine ion exchange conditions where the protein would bind 
showed Rv0240 successfully bound the cation beads at approximately pH 4.5 and below 
(Figure 5.16a). An anion bead screen was unsuccesfull as the protein did not bind the beads 
properly, although a small amount of binding to the beads and a corresponding decrease in the 
amount of protein in the supernatant samples was observed above pH 8.5 (Figure 5.16b). This 
lack of good binding to the anion beads is probably due to the conditions never reaching a high 
enough pH to deprotonate the outer residues and allow binding to the positively charged 
beads. The pI of the protein in its native state is possibly higher than its predicted pI due to an 
abundance of basic amino acids such as arginine concentrated on the outside of the protein 
structure. Arginine (of which Rv0240 has 16 of its 145 aa) has a high pka value (12) so 
requires a higher pH for deprotonation to occur and create an overall negative net charge on 
the protein so it can therefore bind to a positively charged anion column. From these results 
we can assume the actual pI of Rv0240 in its native state is between approximately 5.4 and 
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8.6, and would require pH conditions of greater than 10 for anion exchange purification which 
would be fruitless as the protein is likely to denature in this pH range. 
 
 
Figure 5.16: Rv0240 ion exchange affinity tests on a) cation beads, and b) anion beads. The SDS-PAGE 
gels depict varying ion exchange pH conditions across the gel, and the resulting protein bound to the 
bead (bottom gels) and corresponding supernatant fractions (top gels). Numbers at the top of gels refer 
to the pH of the buffers trialled (note, ion exchange buffer conditions can be found in Sections 2.3.2.16 
and 2.3.2.17), BC refers to VapBC protein run to confirm no VapB was present in the VapC samples. 
 
A full cation exchange purification was performed in 20 mM citric acid pH 3.5, 50 mM NaCl, 
Figure 5.17 shows Rv0240 of approximately 17.9 kDa eluting at approximately 700 mM NaCl 
(peak C), after what appears to be trypsin (which has a molecular weight of 23.3 kDa) in peak 
B. Whilst purification of Rv0240 away from trypsin appeared to be successful via cation 
exchange in citric acid pH 3.5, the protein quickly degraded in this buffer at low pH and was 
unusable. Cation exchange on a fresh preparation of trypsin treated Rv0240 in 20 mM acetic 
acid pH 4.4, 50 mM NaCl was trialled, but was unable to cleanly separate trypsin (with a pI of 
10.1 – 10.5) from the VapC protein (data not shown). Future cation exchange purifications may 
be successful in citric acid pH 3.5 if the fractions are collected immediately into an equal 
volume of neutralising buffer. 
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Figure 5.17: Purification of Rv0240 via cation exchange in 20 mM citric acid pH 3.5, 50 mM NaCl. 
Chromatogram depicts the UV absorbance (blue) and elution profile of the protein complex as the 
concentration of elution buffer increases (green). The corresponding SDS-PAGE gel depicts the column 
load (L), flow through (FT) and resulting cation exchange fractions (elution positions are shown by the 
black bar). VapC is eluted in peak C (approximately 17.9 kDa), separate from trypsin which elutes in peak 
B (approximately 23.3 kDa).  
 
Rv0598c 
VapC (pI 8.5) did not bind the anion exchange column in 50 mM phosphate buffer pH 9.4, 100 
mM NaCl, instead it remained in the flow through (data not shown). It was unlikely that the 
phosphate buffer was buffering properly at this pH as it is too far away from any of its three 
pKa’s of 2.15, 7.2 or 12.32. It was also unlikely that the protein would remain stable or 
biologically active at a pH closer to the highest pKa value where anion exchange would be 
possible, so VapB was digested with a limited tryptic digest (Section 2.3.2.15.1) without 
purifying the VapC afterwards.  
 
Rv1962c 
VapC (pI 6.1) did not bind the anion exchange column 50 mM phosphate buffer pH 7.4, 100 
mM NaCl, instead it remained in the flow through (data not shown), and so would be a good 
candidate for an anion bead screen in future experiments. 
 
Rv2103c 
VapC (pI 7.2) did not bind the anion exchange column in 50 mM phosphate buffer pH 8.2, 100 
mM NaCl, or when NaCl was dropped to 50 mM, instead it remained in the flow through (data 
not shown).  
 
Cation exchange was performed at a pH below the predicted pI for VapC (7.2) in case 
Rv2013c wasn’t binding the anion column because its actual pI in solution was higher than the 
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predicted pI. SEC of Rv2130c in 50 mM MES pH 5.6, 200 mM NaCl was performed prior to 
cation exchange where it eluted from the column at the correct size of approximately 18.1 kDa 
(Figure 5.18a), however no binding of 2103c was observed during cation exchange in 50 mM 
MES pH 5.6, 100 mM NaCl (data not shown). IEF was performed as in Section 2.3.2.3 to 
determine the actual pI of the Rv2103c VapC protein. The specific pI of a protein is the pH at 
which the protein has no net charge and therefore stops migrating through a pH gradient in an 
electric field. Figure 5.18b shows VapC at pH 7.3 and trypsin inhibitor at pH 4.7. Both of these 
proteins have migrated through the IEF gel close to their predicted pI’s of 7.2 and 4.5 
respectively. This result suggests the VapC protein should have bound the cation column at 
pH 5.6, and possibly could have bound the anion column at pH 8.2. However, during IEF the 
protein is in its denatured state, so during ion exchange when it’s in its native state, it may 
harbour a vastly different overall net charge and therefore pI. This may explain why the VapC 
protein didn’t bind the ion exchange columns at the pH range tested, so future experimentation 
could be conducted using a wider pH range in an attempt to obtain binding. 
 
 
Figure 5.18: Rv2103c a) SEC in MES and b) IEF gel. a) SEC chromatogram depicts the UV absorbance of 
the VapC protein. The corresponding SDS-PAGE gel depicts the SEC fractions with their elution position 
shown by the black bar. b) Numbers at the top of the IEF gel represent the pH gradient across the gel 
while coloured boxes indicate the pH at which proteins have been immobilised. The red box indicates 
Rv2103c is immobilised at pH 7.3, and blue box indicates trypsin inhibitor at pH 4.7.  
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Rv3384c 
The pI of VapC (10.6) was too close to that of trypsin (10.1 - 10.5) to purify the protein using 
anion exchange chromatography. A small scale limited tryptic digest and His-tag affinity 
binding test using Ni Sepharose beads was performed to see if the VapC protein still contained 
its His-tag after the digest and could therefore be purified by this process. Figure 5.19a shows 
binding of VapC to the nickel resin after a limited tryptic digest (Resin sample), although some 
has been lost (when compared to the VapBC control sample). This suggests the standard 
limited tryptic digest partially removes the His-tag from VapC as well as degrades the VapB 
protein. A full scale limited tryptic digest and purification via IMAC using a HisTrap HP column 
was then performed but with limited success. Figure 5.19b shows only a small amount of VapC 
(15.8 kDa) in peak B with very little present in the Load or Flow Through samples when 
compared to the trypsin band at approximately 23.3 kDa, suggesting the remainder of VapC 
has been degraded by the trypsin. This is supported by the presence of two very faint smaller 
bands at approximately 14 and 13 kDa which are likely to be VapC minus the C-terminal His-
tag and linker region (which would have a predicted molecular weight of 14.3 kDa (Gasteiger et 
al. 2005), and further cleaved VapC products. Another full scale limited tryptic digest and IMAC 
purification was performed with digestion for only 45 minutes (compared to one hour 
previously), to limit the cleavage of VapC and its His-tag and increase the amount of purified 
VapC recovered after the process. More VapC was recovered in the fractions this time (data 
not shown), although once these fractions were concentrated to approximately 1 mg/ml, a 
small amount of VapB could still be seen at 11 kDa when run on an SDS-PAGE gel (Figure 
5.19b, BC lane), and no RNase activity was observed when the sample was tested on total 
RNA (data not shown).  
 
The molecular weights of VapC and trypsin are close (15.8 and 23.3 kDa respectively), but 
size exclusion chromatography was performed on VapC resulting from a standard limited 
trypsin digest of VapBC in a final attempt to purify the VapC protein away from trypsin. The 
sample was analysed on an analytical S75 10/300 gel filtration column with a separation range 
of 3 – 70 kDa as in Section 2.3.2.18, but no separation of trypsin and VapC bands were 
observed (data not shown). 
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Figure 5.19: Rv3384c IMAC purification from a) small scale affinity test, and b) full scale HisTrap HP 
column. a) SDS-PAGE gel depicts the untreated VapBC control (BC), flow through (FT), wash (W), and Ni 
resin with Rv3384c bound after wash steps (R). b) Chromatogram depicts the UV absorbance (blue) and 
elution profile of the protein complex as the concentration of elution buffer increases (green). The 
corresponding SDS-PAGE gel depicts the column load (L), flow through (FT) and resulting IMAC fractions 
(elution positions are shown by black bar). The gel slice on the right shows VapC protein (concentrated to 
1 mg/ml) resulting from the 45 min tryptic digest and IMAC purification also contains VapB. 
 
Rv3408 
VapC (pI 6.7) did not bind the anion exchange column in 50 mM phosphate buffer pH 8, 100 
mM NaCl, nor did it appear in the flow through or load fractions (data not shown) It is likely that 
both the VapB and VapC proteins have been degraded during the standard limited tryptic 
digest protocol, which suggests the Rv3408/3407 complex is less stable than other VapBCs. 
Limited tryptic digests were performed with a lesser trypsin to protein ratio and for a shorter 
duration by others in the laboratory resulting in digested VapB and intact active VapC which 
could be separated by anion exchange using the standard protocol (Chelsea Vickers, 
unpublished data). 
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5.2.4 Identification of RNase Contamination during Limited Tryptic 
Digests 
5.2.4.1 Identification of Contaminating RNase in Trypsin Stocks 
The possibility of RNase contamination arising during the limited tryptic digest process was 
noticed during RNase activity testing of Rv0598c. This VapC was unable to be purified away 
from trypsin in Section 5.2.3.1.2, so crude VapC without anion exchange was tested for RNase 
activity and demonstrated unusually fast RNase activity. During the total RNA RNase activity 
assay, a trypsin control consisting of RNA + trypsin and trypsin inhibitor in assay buffer and 
water completely degraded the RNA, indicating a contaminating RNase was present. As a 
consequence of these results, various RNase activity assay controls were carried out to 
ascertain which reagent or labware the RNase contamination was coming from, as such high 
levels of RNase activity hadn’t been noticed previously in any of the other M. tuberculosis 
VapC assays. Total RNA RNase activity assays were set up without any VapC protein added, 
instead testing equal volumes of water, buffer and trypsin + trypsin inhibitor aliquots, as well as 
various tubes and spatulas used to make up the reagents. There was no contamination 
observed in the water, buffer aliquots or tubes used (Figure 5.20a) whilst samples including 
trypsin + trypsin inhibitor still exhibited RNase activity. New trypsin + trypsin inhibitor reagents 
were made up using existing laboratory spatulas or gamma irradiated loops and tested in 
standard RNase activity buffer as well as buffer including EDTA. The fresh aliquots of trypsin + 
trypsin inhibitor exhibited RNase activity regardless of how they were prepared, and whether 
they were in buffer containing EDTA or not which indicated the contaminating RNase activity 
was not metal dependent. To confirm if the contaminant was in the trypsin or trypsin inhibitor, 
each reagent was added individually to assays samples and tested. Figure 5.20b shows all 
samples containing trypsin were affected whilst those containing trypsin inhibitor were not. An 
un-opened vial of TPCK trypsin was also tested in Figure 5.20b and found to be contaminated 
indicating the contamination was inherent in, and not introduced into, the trypsin stocks. 
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Figure 5.20: Total RNA RNase assays identifying RNase contamination of trypsin stocks. RNase assays 
were set up minus VapC protein and included the addition of 0.7 µl of each of the following reagents: a) 
nuclease free water, trypsin + trypsin inhibitor prepared in baked tubes (T + TI 1), assay buffer stock 1 (B 
1), assay buffer stock 2 (B 2) and trypsin + trypsin inhibitor prepared in non-baked tubes (T + TI 2); or b) 
nuclease free water, trypsin (T 1), trypsin inhibitor (TI) and TPCK treated trypsin from an unopened vial (T 
2). Figure a) shows only samples containing trypsin + trypsin inhibitor show RNase activity, and figure b) 
that RNase activity occurs in the trypsin not trypsin inhibitor samples. 
 
5.2.4.2 Removal of Contaminating RNase via Anion Exchange 
Chromatography 
Attempts to source RNase-free trypsin or another protease harbouring a pI dissimilar to that of 
the VapC proteins to enable purification via ion exchange chromatography were unsuccessful.  
Therefore, due to a contaminating RNase being introduced into the VapC samples during the 
limited tryptic digest stage, further analysis was required to elucidate if the contaminant could 
be removed during the ion exchange process. A M. tuberculosis VapC which had been 
successfully purified by anion exchange previously, Rv2548, was purified as for Sections 
2.3.2.13 - 2.3.2.15 and split into two aliquots. Only one of the aliquots was further purified via 
anion exchange chromatography before their RNase activities were tested. An identical anion 
exchange was also performed on a mock trypsin + trypsin inhibitor control (the same as that 
for Rv2548 but without any VapC protein) to clarify which anion exchange fraction contained 
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the contaminating RNase. Fractions from both of the anion exchange purifications were split 
into five groups: FT (flow through), A, B (fractions containing VapC), C and D as illustrated in 
Figure 5.21a. The B samples were concentrated to 1 mg/ml from 12 ml down to 1.2 ml, and 
this concentration factor of 10 was used as a guide for concentrating the other four samples to 
volumes reflecting a similar concentration relative to VapC, because there is no actual protein 
concentration to be physically measured for these samples. 
 
RNase activity assays were set up on total RNA as for Section 2.3.4.4 using fractions from the 
two anion exchange purifications at their relative 1mg/ml concentrations, and the crude 
Rv2548 without anion exchange purification. Figure 5.21b demonstrates fast RNase activity of 
crude Rv2548 compared to anion exchange purified Rv2548, indicating the contaminating 
RNase from trypsin has been removed from the VapC sample by anion exchange purification. 
The figure also shows the contaminating RNase appears to not bind the anion exchange 
column, instead ending up in the flow through sample as demonstrated by RNase activity of 
the anion exchange purified Rv2548 and mock trypsin FT samples. The RNase activity is much 
more intense in the Rv2548 FT sample compared to that from mock trypsin, most probably due 
to the combined effect of the contaminant and VapC. 
 
These results confirm a contaminating RNase is introduced to the VapC samples during the 
limited tryptic digest process, which is subsequently removed during anion exchange 
purification. This indicates crude VapC samples resulting from tryptic digests will be 
contaminated and unfit for testing in RNase activity assays unless further purified by anion 
exchange, and trypsin digested protein purification by other means such as cation exchange, 
SEC or IMAC would need to be verified first to ensure the contaminant is also removed during 
these procedures.  
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Figure 5.21: Purification of VapC via anion exchange removes the RNase contamination acquired from 
trypsin. a) Purification of Rv2548 and a control trypsin + trypsin inhibitor sample via anion exchange. 
Chromatograms depict the UV absorbance (blue) and elution profile of the protein complex as the 
concentration of elution buffer increases (green). The corresponding SDS-PAGE gel depicts the flow 
through (FT) and resulting anion exchange fractions (elution positions are shown by the black bar) 
containing VapC at approximately 17.4 kDa for the Rv2548 anion samples, and nothing for the trypsin 
control anion samples. b) Total RNA RNase assays on samples with and without anion exchange 
purification. RNase assays were set up using M. smegmatis total RNA as a substrate. Negative controls 
are shown by R 0hr and 1hr (RNA only) and VapBC, while time points represent the assay time course (60 
min if not specified). Rv2548 in black = protein purified via anion exchange or red = crude (without anion 
exchange purification), Trypsin = mock trypsin + trypsin inhibitor control purified via anion exchange. The 
contaminating RNase is removed via anion exchange purification as observed by activity in the Rv2548 
FT sample, and the reduction in activity of the purified Rv2548 samples compared to crude assay time 
point samples. 
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5.2.5 VapC Ribonuclease Activity 
Once the M. tuberculosis Rv2548 and Rv2530c VapC proteins had been successfully purified, 
the next step was to test them for general ribonuclease activity. Multiple VapC toxin proteins 
have been shown to cleave ribosomal RNA in vitro (Daines et al. 2007;  Hurley & Woychik 
2009;  Ramage et al. 2009;  McKenzie et al. 2012b), and recently in vivo activity has also been 
demonstrated with E. coli MazF targeting 16S rRNA within the 30S ribosomal subunit (Vesper 
et al. 2011). Total RNA screens for general ribonuclease activity of M. tuberculosis VapC 
toxins in vitro were followed with determination of the VapC ribonuclease sequence-specificity, 
using screens developed previously in our laboratory for M. smegmatis (VapCMS1284) and 
Pyrobaculum aerophilum (VapCPAE2754 and VapCPAE0151) (McKenzie 2011). Here, pentaprobe 
RNA was used as a substrate for VapC, and MALDI-TOF MS employed to analyze the 
resulting cleavage products and thus determine the RNA cleavage sites (Kwan et al. 2003).   
 
Previous work on M. smegmatis and P. aerophilum VapCs demonstrated these 
endoribonucleases only cleaved ssRNA and did not degrade alternative substrates such as 
dsDNA, ssDNA or dsRNA (McKenzie 2011). 
 
5.2.5.1 General RNase Activity Screening with M. smegmatis Total RNA 
Rv2548 and Rv2530c both displayed general ribonuclease activity against M. smegmatis total 
RNA, degrading 23S rRNA and 16S rRNA to smaller products during the time course assay 
(Figure 5.22a and b). Both M. tuberculosis VapCs also demonstrated Mg2+ dependent activity 
as when EDTA was included in the assay buffer, ribonuclease activity was abolished. Inclusion 
of multiple control samples indicated no ribonuclease contamination of buffers or protein 
preparations was present as no RNA degradation was observed in these samples. RNA 0 hr 
and 1 hr samples indicate reagents were free of contaminants, the VapBC control sample 
implies the purification process up until the VapBC stage didn’t introduce any RNase 
contaminants as well as shows that VapB inhibits the ribonuclease activity of VapC, and the 
EDTA sample shows no non metal-dependent RNases such as ribonuclease A were present.  
Ribonuclease activity of Rv2548/7 VapC and VapBC proteins was determined after storage at -
80 C to test for retention of RNase activity. Figure 5.22c and d shows that freezing the protein 
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does not appear to affect the VapC’s RNase activity, nor the ability of the VapBC complex to 
inhibit RNase activity, on both total M. smegmatis RNA and pentaprobe 932 RNA. 
 
 
Figure 5.22: Time course assays showing ribonuclease activity of M. tuberculosis a) VapCRv2548 and b) 
VapCRv2530c using M. smegmatis total RNA as a substrate, and frozen VapCRv2548 on c) M. smegmatis total 
RNA and d) pentaprobe 932 RNA as substrates. Negative controls are shown by R 0hr and 1hr (RNA only), 
E (EDTA) and BC (VapBC), time points represent the assay time course, black indicates non-frozen 
protein and blue indicates freeze/thawed protein. 
 
5.2.5.2 VapC RNase Activity Assays on Pentaprobe RNA  
After the VapC proteins had displayed general ribonuclease activity on the total RNA 
substrate, they were tested against pentaprobe RNA’s (Kwan et al. 2003) to try and determine 
their specificity. Pentaprobe RNA’s (containing every combination of five bases) were used as 
substrates in VapC ribonuclease activity assays, allowing screening of up to pentad 
recognition sequences. All six pentaprobe RNA’s (from the forward direction) as well as 932 
(the reverse complement of 926) were tested as substrates for VapC RNase activity. 932 was 
also included because previous assays had found VapCMS1284 cleaved pentaprobe RNA 926 
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and 932 the most efficiently out of the pentaprobe RNAs (McKenzie 2011). Figure 5.23 and 
Figure 5.24 show VapCRv2548 and VapCRv2530c display Mg2+-dependent ribonuclease activity 
against a variety of pentaprobe RNA molecules. Sequence specificity is shown by the different 
banding patterns produced by the cleaved RNA fragments for each of the pentaprobe 
substrates. Both VapCRv2548 and VapCRv2530c show similar cutting efficiencies to each other 
against all of the pentaprobe substrates. The lack of one pentaprobe substrate being cut 
preferentially over the others suggests that none of these are the ‘ideal’ substrate for either of 
the VapC proteins, possibly due to unsuitable RNA sequence and/or secondary structure. The 
larger size of RNA substrates 926 and 932 compared to the others is due to the different 
restriction enzymes used in the cloning process.  
 
 
Figure 5.23: Ribonuclease Activity of VapCRv2548 against pentaprobe RNA substrates. Numbers at bottom 
left corner of gels denote the pentaprobe insert (932 is the reverse complement of 926). 0 hr and 1 hr = 
RNA only negative controls, numbers = the time at which the sample was taken in the assay (minutes), E 
= EDTA negative control, BC = VapBC. Numbers down the side of the 10 % urea-denaturing gels denote 
the low range ssRNA ladder base sizes. The multiple bands observed for 926, 927 and 932 RNA are due to 
the larger amount of secondary structure in these RNA molecules compared with the others. 
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Figure 5.24: Ribonuclease Activity of VapCRv2530c against pentaprobe RNA substrates. Numbers at bottom 
left corner of gels denote the pentaprobe insert (932 is the reverse complement of 926). 0 hr and 1 hr = 
RNA only negative controls, numbers = the time at which the sample was taken in the assay (minutes), E 
= EDTA negative control, BC = VapBC. Numbers down the side of the 10 % urea-denaturing gels denote 
the low range ssRNA ladder base sizes. The multiple bands observed for 926, 927 and 932 RNA are due to 
the larger amount of secondary structure in these RNA molecules compared with the others. 
 
Based on the gels in Figure 5.23 and Figure 5.24, the recognition sequences of VapCRv2548 
and VapCRv2530c are likely to be the same, as the fragment patterns of the cut RNA for each 
protein look similar. The same banding pattern was also observed for two other M. tuberculosis 
VapCs (VapCRv0065 and VapCRv0617) previously (McKenzie et al. 2012a), suggesting the 
possibility that M. tuberculosis VapCs target the same recognition sequence. Previous work 
found VapCPAE0151 and VapCPAE2754 were also sequence-specific and targeted the same 
sequence as each other for the 924 pentaprobe substrate, but this sequence was different to 
that which the M. tuberculosis VapCs targeted on the same 924 substrate (McKenzie et al. 
2012a). The sequence-specificity of VapCPAE0151, VapCPAE2754, VapCRv0065, VapCRv0617, 
VapCRv2548 and VapCRv2530c also differ from that of VapCMSMEG_1284, which does not cut the 924 
Pentaprobe RNA (McKenzie et al. 2012a). 
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Interestingly, as with P. aerophilum VapCs, no binding to the RNA was seen with the M. 
tuberculosis VapCs, contrary to that observed with VapC from M. smegmatis. VapCMS1284 
appeared to bind the RNA which it cleaved (evidenced by smearing on the gels), but not to 
RNA it did not cleave, nor when EDTA was present, or when VapB was in complex with VapC 
(McKenzie 2011;  McKenzie et al. 2012b). Therefore, while binding and cleavage may be 
separable properties of VapC in M. smegmatis, this is not the case with VapC proteins from M. 
tuberculosis or P. aerophilum. 
 
5.2.5.3 Determination of Rv2530c VapC Cut Sites 
VapCRv2548 and VapCRv2530c appeared to cleave all pentaprobe RNA substrates with equal 
efficiency, so overlapping 932 RNA oligonucleotides (with similar secondary structure to the 
original 932 RNA molecule) were chosen as substrates for determining sequence specificity of 
VapCRv2530c, as these had been used previously in determining the sequence specificity for 
VapCMS1284, VapCPAE2754 and VapCPAE0151. 932 RNA oligonucleotide design and sequences can 
be found in Appendices B.3 and B.4. VapC ribonuclease activity assays on 932 RNA oligos 
were performed, purified and analysed with MALDI-TOF MS to identify the cleaved fragments, 
then target recognition sites were determined using in-house software which identifies all one 
and two point cuts in the oligonucleotide as in Sections 2.3.4.4 - 2.3.4.6.  
 
5.2.5.3.1 MALDI-TOF Mass Spectrometry of 932 RNA Oligonucleotide 
Ribonuclease Assays with VapCRv2530c 
Raw data can be found on the compact disc - Appendix D. 
 
Mass spectra display the mass to charge (m/z) values of the ions plotted against their intensity 
to portray the number of components in the sample, their size, and their relative abundance in 
the gas phase (this is not usually representative of abundance in solution). In MALDI-TOF, 
ions are nearly always singly charged species (so the m/z measurement is equal to the mass 
of the ionized molecule), although they can be accompanied by salt adducts, doubly charged 
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ions (at approximately half the m/z value), or traces of dimeric species at approximately twice 
the m/z value.  
 
All 932 RNA oligonucleotides were cut by VapCRv2530c over the assay time course, some better 
than others. Spectra show no degradation of oligos in the RNA only negative controls (0 hr and 
1 hr) but the EDTA samples were not useful as negative controls as these showed some 
degree of activity. Oligonucleotide fragments four bases or less could not be detected due to 
the suppression of matrix peaks in this range (matrix suppression was 1000 Da). Multiple 
‘noise’ peaks in the lower m/z range were observed for oligo 2, 3 and 8 controls indicating 
these oligos contain multiple species formed during the manufacturing process, even though 
they were HPLC purified. These ‘noise’ peaks can mask the true cleavage peaks formed 
during RNase assays unless they are of sufficient intensity to rise above the noise, so are not 
ideal substrates for determining sequence specificity of VapCRv2530c. Figure 5.25 - Figure 5.32 
display the mass spectra results for VapCRv2530c ribonuclease activity on 932 RNA 
oligonucleotides 1 - 8. 
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Oligo 1 was not cut well. Only one small peak was observed in the spectra (m/z 7631.8) after 
15 minutes which, without an additional ‘partnered’ peak (adding up to the total mass of the 
oligo), suggests it was not produced as a result of just a single cleavage event, so may not be 
a primary/major cut site. Two additional peaks of low intensity (m/z 5752.7 and 8263.7) were 
not produced until 60 minutes, again suggesting these were not primary target cut sites due to 
the time taken for these to be formed.  
 
 
Figure 5.25: 932 RNA Oligo 1 VapCRv2530c MALDI-MS results. R 0 hr and 1 hr negative refer to assay 
reactions with no VapC protein; EDTA, inclusion of 20 mM EDTA in the reaction buffer, and time course 
(15 to 60 minute) assay samples with VapCRv2530c. Data analysed by Bruker Data Analysis. 
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As mentioned above, the data for oligo 2 were noisy so peaks resulting from cleavage of the 
oligonucleotide were hard to distinguish from the background. As with the peaks produced for 
the oligo 1 assays, the only peaks produced for oligo 2 at 30 and 60 minutes (with intensities 
which were above the background (m/z 4512 and 5146)) were un-partnered so unlikely to be 
products from a single cleavage event, and therefore not from a primary target cut site.  
 
 
Figure 5.26: 932 RNA Oligo 2 VapCRv2530c MALDI-MS results. R 0 hr and 1 hr negative refer to assay 
reactions with no VapC protein; EDTA, inclusion of 20 mM EDTA in the reaction buffer, and time course 
(15 to 60 minute) assay samples with VapCRv2530c. Data analysed by Bruker Data Analysis. 
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Oligo 3 was also noisy so peaks resulting from cleavage of the oligonucleotide were hard to 
distinguish from the background. Peaks with intensities above background were visible at 15 
minutes (m/z 2669, 3304, 4268 and 6530), although only peaks of m/z 4268 and 6530 were 
partnered totalling the whole oligo mass and therefore likely to be products from a single 
cleavage event.  
 
 
Figure 5.27: 932 RNA Oligo 3 VapCRv2530c MALDI-MS results. R 0 hr and 1 hr negative refer to assay 
reactions with no VapC protein; EDTA, inclusion of 20 mM EDTA in the reaction buffer, and time course 
(15 to 60 minute) assay samples with VapCRv2530c. Data analysed by Bruker Data Analysis. 
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The majority of oligo 4 was degraded by 60 minutes, although the resulting major peaks 
formed (m/z 2299, 3914 and 5065) were all of lower masses which couldn’t be formed from the 
11531 MW oligo with just a single cut. Therefore, these were likely to be products formed from 
multiple subordinate cut sites.  
 
 
Figure 5.28: 932 RNA Oligo 4 VapCRv2530c MALDI-MS results. R 0 hr and 1 hr negative refer to assay 
reactions with no VapC protein; EDTA, inclusion of 20 mM EDTA in the reaction buffer, and time course 
(15 to 60 minute) assay samples with VapCRv2530c. Data analysed by Bruker Data Analysis. 
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Oligo 5 was the best substrate tested for VapCRv2530c as it was cut the fastest (cleavage 
fragments were visible after five minutes) at what appeared to be two separate major single cut 
sites, each producing two ‘partnered’ fragments (m/z 6774.6 + 3181.9 and m/z 3473 + 6483.7) 
which added up to the mass of the whole RNA oligo (m/z 9957). Two additional peaks were 
also visible (m/z 8364.6 + 1593.2) but these were not as abundant. Cleavage products of 932 
RNA oligo 5 observed in the 5 minute assay sample were also present at 15, 30 and 60 
minutes, but no additional cleavage fragments were observed at these time points. By 60 
minutes, the majority of the RNA oligo was degraded. 
 
 
Figure 5.29: 932 RNA Oligo 5 VapCRv2530c MALDI-MS results. R 0 hr and 1 hr negative refer to assay 
reactions with no VapC protein; EDTA, inclusion of 20 mM EDTA in the reaction buffer, and time course 
(15 to 60 minute) assay samples with VapCRv2530c. Data analysed by Bruker Data Analysis. 
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Oligo 6 was cut by Rv2530c but the peaks were hard to distinguish from background until 60 
minutes due to the noise, by which time products from initial cleavage events may have been 
cut further masking the major cleavage event fragments. 
 
 
Figure 5.30: 932 RNA Oligo 6 VapCRv2530c MALDI-MS results. R 0 hr and 1 hr negative refer to assay 
reactions with no VapC protein; EDTA, inclusion of 20 mM EDTA in the reaction buffer, and time course 
(15 to 60 minute) assay samples with VapCRv2530c. Data analysed by Bruker Data Analysis. 
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Oligo 7 was cut marginally by 15 minutes at two separate single cut sites, each producing 
partnered fragments (m/z 4110.6 + 5758.3 and 4747 + 5121.7). These peaks were low in 
intensity, and given the whole oligo was still largely intact were unlikely to be products from a 
major optimal cut site.  
 
 
Figure 5.31: 932 RNA Oligo 7 VapCRv2530c MALDI-MS results. R 0 hr and 1 hr negative refer to assay 
reactions with no VapC protein; EDTA, inclusion of 20 mM EDTA in the reaction buffer, and time course 
(15 to 60 minute) assay samples with VapCRv2530c. Data analysed by Bruker Data Analysis. 
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Oligo 8 was also cut but peaks were hard to distinguish from background until 60 minutes due 
to the noise. A large majority of the oligo was degraded by 60 minutes, although the resulting 
major peaks formed (m/z 2550.8 and 2917.9) were all of lower masses which couldn’t be 
formed from the whole oligo with just a single cut. These were likely to be products formed 
from multiple subordinate cut sites. 
 
 
Figure 5.32: 932 RNA Oligo 8 VapCRv2530c MALDI-MS results. R 0 hr and 1 hr negative refer to assay 
reactions with no VapC protein; EDTA, inclusion of 20 mM EDTA in the reaction buffer, and time course 
(15 to 60 minute) assay samples with VapCRv2530c. Data analysed by Bruker Data Analysis. 
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Resulting peaks in the mass spectra from VapCRv2530c ribonuclease activity on 932 
oligonucleotide substrates (above) and from those performed previously for VapCRv0065 and 
VapCRv0617 were almost identical. Therefore, the three M. tuberculosis VapC proteins appear to 
be targeting the same sequence. Spectra peaks for identical 932 oligonucleotide substrates 
from M. tuberculosis VapC proteins (VapCRv2530c, VapCRv0065 and VapCRv0617) are different to 
those obtained for P. aerophilum (VapCPAE0151, VapCPAE2754) indicating that these species 
target different sequences. 
 
5.2.5.3.2 Analysis of 932 RNA Oligonucleotide Ribonuclease Assays and 
VapCRv2530c Cut Site Determination 
Mongo Oligonucleotide Calculator V2.06 (Rozenski 1999) (which allows the addition of 5’ and 
3’ modifications to RNA oligonucleotides) was used to determine theoretical masses of RNA 
oligonucleotide fragments to compare to masses from the MS spectra. It was determined that 
VapCRv2530c cleaved RNA in the same manner as VapCPAE2754, VapCPAE0151, VapCRv0065, and 
VapCRv0617 which all cleave the 3′ phosphodiester bond of RNA to produce 3′ hydroxyl and 5′ 
phosphate cleavage products, consistent with other metal-dependent ribonuclease enzymes 
(Tadokoro & Kanaya 2009;  McKenzie et al. 2012a). This is in contrast to the reported 
mechanism of the MazF toxin, as well as that for VapCpMYSH6000 from S. flexneri and 
VapCLT2 from Salmonella enterica which cleave the phosphodiester bond yielding a free 5′ OH 
group on the 3′ cleavage product, and 2′-3′ cyclic phosphate on the 3′ end of the 5′ cleavage 
product, similar to RNase H (Muñoz-Gómez et al. 2005;  Zhang et al. 2005;  Winther & Gerdes 
2011). 
 
The mass list and corresponding intensities from the spectra were exported into a comma 
separated excel file then processed using in-house software to determine possible cut sites. 
The software determines the difference between the predicted mass of the oligonucleotide and 
the actual peak mass (as measured by MALDI-TOF MS) for all one and two point cuts, 
including a 5’ phosphate on the 3’ cleavage product. Different parameters can be selected by 
setting a threshold cut-off for intensity values (so only peaks above a certain intensity level will 
be included for analysis), and by selecting fragments with the closest matching predicted and 
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actual masses. Any products containing less than four bases do not fly well resulting in 
nonsense MW values, therefore their size is disregarded during analysis. 
 
Logic dictates that if the optimal cut site is present in a substrate, it would be cut preferentially 
over other subordinate cut sites almost immediately, and produce just two fragments. If no 
‘optimal’ cut site were present, then it is likely that multiple fragments could be produced from 
many subordinate cut sites over the duration of the ribonuclease assays. Initially, results for all 
one point cuts were analysed to check they accounted for the major peaks in the MALDI-TOF 
MS spectra and labelled as probable major cut sites, and if no major peaks could be matched 
to single cut sites then all two point cuts were analysed and labelled as probable minor cut 
sites. Any spectra peaks unable to be matched were deemed to be products from more than 
two cuts and therefore not from optimal cut sites. 
 
Once all major single and two point cut possibilities were identified, the orientation of the 
fragments and therefore the sequence of the cut site was determined. Results from most major 
cuts produced candidates with only one possible fragment orientation combination (eg, all 
candidates having fragment x on the left and y on the right), but where two different fragment 
orientation combinations were present (x/y and y/x), the orientation with the greatest number of 
candidates was picked, and if there was an equal number of candidates for each combination 
then both cut sites were proposed as putative sites (cut sites summarised in Table 5.5). 
 
The intensity threshold was set low to 800 (or higher if back ground noise was present), so as 
to include peaks from the spectra which may be being produced from a major cut site and 
simultaneously cleaved at a subordinate site which would be keeping their relative intensity 
low. 
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Table 5.5: Summary of major cut sites for VapCRv2530c on 932 RNA oligonucleotides 1 – 8. 
 
Oligo Major cut site target sequence Time cut site detected 
Oligo 1 None N/A 
Oligo 2 Complex activity on this substrate N/A 
Oligo 3 AU*AU or GC*CG 15 minutes 
Oligo 4 None N/A 
Oligo 5 UA*GG and UA*GG 5 minutes 
Oligo 6 Complex activity on this substrate N/A 
Oligo 7 UC*UA 15 minutes 
Oligo 8 Complex activity on this substrate N/A 
* denotes cleavage site. 
 
For oligo 5, all four major peaks could be matched to two single cuts for the 5 minute assay 
(m/z 6774.6 + 3181.9 and m/z 3473 + 6483.7). Both of these single cuts occur at the same 
sequence, UA*GG (* denotes cleavage site). This major cut site sequence occurs only twice in 
all of the oligo substrates, both of which are present in oligo 5. This appears to be the most 
optimal substrate tested for VapCRv2530c as it is cut the fastest producing the most conclusive 
cut site. Two minor peaks were also able to be matched to a single cut in the 15 minute assay 
(m/z 8367.7 + 1592.7), AU*CA. 
 
For oligos 3 and 7, only two of the major peaks could be matched to a single cut for each of 
the 15 minute assays (m/z 4268 + 6530, and m/z 4747 + 5121.7 respectively), and the 
orientation of fragments could not be conclusively determined for oligo 3 so both candidates 
are postulated as major cut sites (see Table 5.5). No major peaks from oligos 1 and 4 could be 
matched to cut sites from a single cut, but one major peak (m/z 7631.8) from oligo 1 was found 
in a two point cut for the 15 minute assay with the minor cut site sequence of UC*AC. No major 
peaks from spectra for oligos 2, 6 or 8 could be matched to cut sites from single or two point 
cuts for oligos 2, 6 and 8 once the intensity threshold was raised above the background noise. 
It was assumed oligos 2, 6 and 8 did not contain any major cut sites for VapCRv2530c. 
 
As oligo 5 appeared to contain the most optimal cut site for VapCRv2530c (UA*GG), the MALDI-
TOF MS data analysis method focussing on only single cuts described above, was applied to 
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oligo 5 spectra data obtained previously for VapCRv0065 and VapCRv0617 to see if these M. 
tuberculosis VapC proteins may in fact target this same sequence, and not GC-rich 4mers as 
previously thought (McKenzie 2011;  McKenzie et al. 2012a). MS data for these assays had 
been obtained during a period of poor laser performance from the MALDI-TOF MS, and 
produced spectra not ideal to work from. Spectra showed substantial noise with broad peaks, 
but some major peaks could be matched to single cuts for the 30 minute assays. Of the four 
ambiguous single cut sites, UA*GG appeared twice which is the same as that obtained for 
VapCRv2530c. This suggests that UA*GG is the preferred cut site for the three M. tuberculosis 
VapC proteins tested thus far. Repeat oligo 5 RNase assays should be performed again on 
VapCRv0065 and VapCRv0617 once the laser is fully functional, to confirm UA*GG is the preferred 
cut site for these two VapC RNases as well as for VapCRv2530c. The reason different cut sites 
were obtained for the two VapCs from the same data is likely due to the analysis technique 
applied. Here, only one point cuts were considered (two point cuts were only included if no one 
point cuts were identified), and only the predominant orientation was included, rather than 
taking all one and two point cuts and every combination of their orientation, as was done in the 
previous analysis (McKenzie 2011). This analysis technique seems a more robust and logical 
method for determining the major or preferred cut site, as if the optimal cut site was present in 
a substrate, it should be cut preferentially over other suboptimal sites and produce just two 
fragments. 
 
The M. tuberculosis VapC RNases appear to have a different recognition sequence to VapCs 
from both P. aerophilum (targeting G rich sequences) and M. smegmatis (targeting AU 
sequences) (McKenzie et al. 2012a;  McKenzie et al. 2012b). Confirming exactly which target 
sequence residues are crucial for the RNase activity of the M. tuberculosis VapCs, will be 
instrumental in determining their optimal target sequence, and therefore the pathways and 
roles they may perform. One way of achieving this could be performing a microarray to identify 
genes which are downregulated in response to expression of a particular M. tuberculosis VapC 
in its VapBC knockout, as was the case with VapC from M. smegmatis (McKenzie et al. 
2012b). 
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5.2.5.3.3 Bioinformatic Analysis of the VapCRv2530c Target Sequence 
The M. tuberculosis H37Rv genome was analysed to determine the frequency of the 
VapCRv2530c target sequence, TAGG (UAGG). This analysis included a 100 bp region upstream 
of all genes, because cleavage of the stable stem loop structure of 5’ untranslated regions 
(UTR) could leave the mRNA more susceptible to general nuclease degradation, as well as 
destabilise mRNA secondary structure, and possibly improving the translation efficiency of 
these genes (Rocha et al. 1999;  Gu et al. 2010). TAGG is present in 2,435 of the 4,111 
protein coding genes (or their upstream region) (see Table 5.6) and is the 40th rarest quartet 
(out of 256 possible quartets) in the H37Rv genome, appearing a total of 5,171 times (the least 
common quartet is TTAA which appears 1,271 times, and the most common is GCCG which 
occurs 79,400 times).  
 
Table 5.6: Prevalence of VapCRv2530c target sequence in genes and their upstream regions in the M. 
tuberculosis H37Rv genome. 
 
Region 
Number of genes or upstream 
sequences with TAGG 
Number of times TAGG 
occurs 
Upstream (U) 709 781 
Gene (G) 2067 4260 
U + G 2435 5041 
Genes and upstream sequences refer to the number of genes or upstream regions the VapC target sequence is 
present in. Times TAGG occurs refers to the total number of times the VapC target sequence is present in the 
genes or upstream region. Total number of H37Rv protein coding genes analysed was 4,111, including a 100bp 
region upstream of each. 
 
Bioinformatic analysis of the M. tuberculosis H37Rv genome revealed an abundance of 
hypothetical proteins and genes involved in metabolic processes containing the TAGG 
VapCRv2530c target sequence. This was observed when the number of target sequences 
contained in either the gene and/or upstream region was ranked from greatest to fewest, and 
occurred in ever higher frequency when ranked according to the number of target sequences 
relative to size of the gene (Table 5.7), so genes with an equal number of TAGG sequences 
will appear earlier in the rankings if they are smaller. The majority of genes with a greater 
relative number of target sequences were annotated as hypothetical proteins, but also included 
those annotated as transposases, TA genes and other genes associated with horizontal gene 
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transfer (Table 5.8). An intriguing explanation for why VapCRv2530c is targeting genes involved 
in HGT could be that it is also functioning as a selfish element – targeting and eliminating the 
other selfish elements in order to survive the genome war within. The number of TA genes 
appearing in the top 40 results once the data has been ranked according to relative size is also 
very interesting (four out of 40), especially since only 88 putative TA genes have been 
identified in the M. tuberculosis H37Rv genome. A possible explanation for why one toxin may 
target another toxin or antitoxin is to initiate a transcriptional regulation cascade when a rapid 
change in the proteomic response and metabolic state of the cell is required during conditions 
of stress. Identifying which genes are being targeted by VapCRv2530c in vivo (possibly by 
microarray analysis comparing genes up or down regulated in response to its expression, or 
RNA-seq), would greatly help in the understanding of the biochemical function and target 
sequence of VapCRv2530c. 
 
Table 5.7: Prevalence of M. tuberculosis H37Rv annotated genes containing the VapCRv2530c target 
sequence in the top 40 rankings. 
 
Annotation Upstream (U) Gene (G) U + G Relative size 
Hypothetical 15/40 10/40 9/40 23/40 
Transposase 0/40 6/40 6/40 6/40 
Toxin/Antitoxin 0/40 0/40 0/40 4/40 
Numbers reflect the top 40 results for the greatest prevalence of TAGG according to their ranking (U, G, U+G or 
relative size). Genes (G) and upstream (U) sequences refer to the number of genes and/or upstream regions the 
VapC target sequence is present in; relative size refers to genes ranked (in ascending order) according to the 
number of target sequences relative to the size of the gene (smaller genes with the same number of target 
sequences as a larger gene will appear earlier in the ranking). 
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Table 5.8: Top 20 M. tuberculosis H37Rv genes according to number of VapCRv2530c target sequences 
present in the gene and upstream region, relative to gene size. 
 
rank annotation position size (bp) size/count U G U+G 
1 hypothetical protein 3081028 105 53 2 0 2 
2 hypothetical protein (Rv1950c) 2200005 192 64 0 3 3 
3 hypothetical protein 3585673 273 68 2 2 4 
4 hypothetical protein 1784305 216 72 0 3 3 
5 hypothetical protein 986677 150 75 2 0 2 
6 hypothetical protein 545191 231 77 0 3 3 
7 glutaredoxin-like protein NrdH 3414730 240 80 0 3 3 
8 antitoxin (Rv0456B - MazE1) 547347 174 87 1 1 2 
9 hypothetical protein 3841894 363 91 1 3 4 
10 phosphoribosyl-ATP pyrophosphatase 2380671 282 94 3 0 3 
11 transcriptional regulator (Rv1473A) 1662387 192 96 2 0 2 
12 hypothetical protein 3019824 390 98 0 4 4 
13 immunogenic protein MPT64 2223351 687 98 1 6 7 
14 hypothetical protein (rv2401A) 2698052 204 102 1 1 2 
15 hypothetical protein 3594190 102 102 1 0 1 
16 phiRv1 phage protein (Rv1579c) 1783316 315 105 1 2 3 
17 toxin (Rv2142c - ParE2) 2402201 318 106 0 3 3 
18 hypothetical protein 530299 429 107 2 2 4 
19 hypothetical protein 1301253 108 108 1 0 1 
20 hypothetical protein 2055688 432 108 0 4 4 
The top 20 genes are ranked (in ascending order) according to the number of TAGG target sequences present in 
the combined gene (G) and upstream (U) regions (G+U) relative to gene size (size/count). ‘Position’ refers to the 
position of the TAGG sequence in the H37Rv genome and ‘size’, the number of bp for each gene. Gene names in 
red show annotated toxin or antitoxin genes, their gene number, and which TA family they belong to. 
 
5.2.6 Crystallisation of Rv2530a/c 
The three-dimensional structure of a protein can reveal details about its molecular organisation 
and interactions with other proteins, as well as its function. Purified Rv2530a/c and Rv2530c 
proteins were subjected to crystallisation trials in an attempt to gain further insight into their 
molecular functions. Initial crystallisation trials with purified VapBC proteins was challenging 
due to the low yield and buffer requirements of these proteins. Many of the crystals obtained 
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from initial robot crystallisation screens were phosphate salt crystals due to the low solubility of 
particular compounds in the protein purification buffer (50 mM sodium phosphate pH 8, 200 
mM NaCl). In an attempt to reduce crystals forming from the purification buffer, VapBC was 
dialysed overnight into 50 mM HEPES, MOPS or Tris at pH 7.4 + 200 mM NaCl and observed 
for precipitation. Heavy precipitation of the VapBC complex was observed upon dialysis into 
HEPES and MOPS buffers, and a little precipitation was observed in Tris buffer, which 
indicated the protein was not as stable in these buffers. The crystallisation screens below 
continued to be performed in the initial sodium phosphate protein purification buffer. 
 
5.2.6.1 Initial Crystallisation Trials 
Rv2530a/c VapC and VapBC was purified by IMAC and SEC in 50 mM sodium phosphate 
buffer pH 7.4, 200 mM NaCl then subjected to robot crystallisation screens (Section 2.3.3.1) at 
concentrations ranging from 7 to 14.5 mg/ml. VapBC SEC fractions were pooled covering 
either the whole protein containing population, or split into two populations covering fractions 8 
- 14, and 17 – 23 which appeared to have different banding patterns to each other on an SDS-
PAGE gel (as seen in Figure 5.10). A number of promising conditions producing either crystals 
or needles were identified for each of the protein samples although more were obtained for the 
VapBC complex than VapC by itself (Appendix C.2). Once conditions containing reagents 
unavailable in the lab, or those containing lithium, calcium, magnesium or high concentrations 
of ammonium were removed due to the likelihood that the crystals formed would be phosphate 
salt crystals formed in the presence of the purification buffer, only two candidate conditions 
remained. Crystals from the candidate conditions 0.2 M ammonium acetate, 0.1 M Bis-tris pH 
5.5, 45 % (+/-) -2-Methyl-2,4-pentanediol (MPD) and 0.5 M ammonium sulfate, 0.1 M HEPES 
pH 7.5, 30 % (+/-) MPD were tested for X-ray diffraction on the Home-Source at the University 
of Auckland which confirmed that they were protein crystals, then followed up with fine screen 
testing. No cryoprotectant was required for testing these crystals as the MPD in the 
crystallisation condition fulfilled this role adequately. 
 
 207 
 
5.2.6.2 Optimisation of Crystallisation Conditions (Fine Screening) 
There are various strategies available for optimising crystal formation, the most common being 
fine-tuning precipitant and protein concentrations, adjusting the pH, and screening additives. 
All of these fine screening procedures were attempted, as well as many other less common 
crystal optimisation techniques in order to produce crystals of as higher as possible quality that 
are suitable for X-ray analysis. 
 
5.2.6.2.1 0.2 M ammonium acetate, 0.1 M BIS-TRIS pH 5.5, 45 % (+/-) MPD 
An initial fine screen for Rv2530a/c SEC 8 – 14 (8.13 mg/ml) of 0.1 - 0.5 M ammonium acetate 
spanning a Bis-tris pH range of 5.3 – 6 produced crystals by day 23 in all 0.2 M ammonium 
acetate drops. Variation in Bis-tris pH made no difference to whether crystals formed or not, 
most likely due to the pH being dominated by that of the 0.2 M ammonium acetate (Figure 
5.33a). 
 
A finer ammonium acetate screen was performed along with varying MPD (25, 35 or 45 %) and 
Bis-tris (0.05, 0.1 or 0.15 M) concentrations on both Rv2530a/c SEC 8 – 14 and 17 – 23 five 
day old protein samples at 6.8 and 14.5 mg/ml respectively. Crystals of small, very thin plates 
were observed by day 14 for the SEC 17 – 23 protein for all Bis-tris and ammonium acetate 
concentrations when 45 % MPD was included (Figure 5.33b). No crystals were observed for 
the SEC 8 – 14 protein under any condition, even by day 38. The inability to reproduce crystals 
for the SEC 8-14 sample in this fine screen could be due to the lower concentration for this 
protein purification (6.8 mg/ml compared to 8.13 mg/ml used in the initial fine screen above), 
as crystals for this condition had been observed previously for RV2530a/c (whole) at 7.03 
mg/ml by day 45, Rv2530c at 8.73 mg/ml by day eight, and Rv2530a/c SEC 8 – 14 at 8.13 by 
day 14. A range of crystals from SEC 17-22 (Figure 5.33b) were tested for X-ray diffraction at 
the Australian Synchrotron but diffracted to a poor resolution (approximately 8 Å). Identical 
screens were repeated for the Rv2530a/c SEC 17 – 23 protein when it was five weeks old but 
no crystals had appeared by day 33 suggesting the protein may have succumbed to proteolytic 
degradation after five weeks of storage at 4 C. 
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Figure 5.33: Crystals from fine screens in a) 0.2 M ammonium acetate, 0.1 M Bis-tris pH 5.3, 45 % (+/-) 
MPD from Rv2530a/c SEC fractions 8 – 14 (8.13 mg/ml) and b) 0.2 M ammonium acetate, 0.1 M Bis-tris pH 
5.5, 45 % (+/-) MPD from Rv2530a/c SEC fractions 17 – 23 (14.5 mg/ml). 
 
Crystals formed in 0.2 M ammonium acetate, 0.1 M Bis-tris pH 5.5, 45 % (+/-) MPD had been 
obtained for the whole Rv2530a/c protein, Rv2530a/c SEC fractions 8 – 14 and 17 – 23, and 
Rv2530c by itself so, for consistency, whole Rv2530a/c (containing pooled SEC fractions 8 – 
23) was used for all further fine screen trials. 
 
5.2.6.2.2 0.2 M ammonium acetate/sulphate, 0.1 M Bis-tris pH 5.5, 45 % (+/-) 
MPD and 0.5 M ammonium sulphate, 0.1 M HEPES pH 7.5, 30 % 
(+/-) MPD 
A robot crystallisation screen (Section 2.3.3.1) was performed with eight day old Rv2530a/c 
protein (12.92 mg/ml) dialysed into anion exchange buffer (50 mM sodium phosphate pH 8, 
100 mM NaCl). By day eight, delicate crystals were observed in 0.5 M ammonium sulphate, 
0.1 M HEPES pH 7.5, 30 % (+/-) MPD (Figure 5.34a), and promising needles had formed in 
the original 0.2 M ammonium acetate, 0.1 M Bis-tris pH 5.5, 45 % (+/-) MPD condition. A fine 
screen was laid down around 0.5 M ammonium sulphate, 0.1 M HEPES pH 7.5, 30 % (+/-) 
MPD when the protein was 15 days old but no crystals had appeared by day 13, suggesting 
the protein may have begun to aggregate, or suffered from proteolysis when laid down at 15 
days.  
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In an attempt to resurrect the ageing protein, at 27 days, proteolytic digest screens in 0.2 M 
ammonium acetate, 0.1 M Bis-tris pH 5.5, 45 % (+/-) MPD were performed with trypsin added 
to the protein immediately prior to laying down at 1:125 - 1:50,000 ratios of trypsin to protein. 
Identical screens were also performed but with ammonium sulphate used instead of the 
ammonium acetate seeing as crystals had formed in the robot screen previously in similar 
conditions with ammonium sulphate. Crystals were observed by day five in both ammonium 
sulphate (1:1,000) and ammonium acetate (1:500 and 1:1,000) conditions, although the rods 
were larger in drops with ammonium sulphate as seen in Figure 5.34b and c. No crystals had 
formed previously once the protein was over eight days old in the fine screens above without 
trypsin, suggesting trypsin is required to make the conformational changes necessary for 
crystallisation of the protein once it ages and begins to degrade.  
 
Because the addition of trypsin to aged protein successfully produced crystals above, a 
proteolytic digest screen was also performed around the other successful crystallisation 
condition (0.5 M ammonium sulphate, 0.1 M HEPES pH 7.5, 30 % (+/-) MPD) but only needles 
developed (for the 45 % MPD drops with trypsin at 1:5,000 and 1:50,000). The 0.2 M 
ammonium acetate/sulphate, 0.1 M Bis-tris pH 5.5, 45 % (+/-) MPD condition was used for all 
further fine screen trials.  
 
 
Figure 5.34: Robot and fine screen crystals from 12.92 mg/ml Rv2530a/c protein  at a) 8 days old in 0.5 M 
ammonium sulphate, 0.1 M HEPES pH 7.5, 30 % (+/-) MPD , and at 27 days old with trypsin added at  b) 
1:1,000 in 0.2 M ammonium acetate, 0.1 M Bis-tris pH 5.5, 45 % (+/-) MPD and c) 1:1,000 in 0.2 M 
ammonium sulphate, 0.1 M Bis-tris pH 5.5, 45 % (+/-) MPD.  
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5.2.6.2.3 Additive Screens and Drop Ratios 
An additive screen with 36 day old protein was laid down to see if any additives would stabilise 
or improve crystal conformity in an aged protein, as well as trialling varying ratios of protein to 
ML (1:1, 2:1 and 2:3). Crystals had grown by day six for many of the additive conditions, with 
L-Proline, butanol, glycerol and urea looking the most promising (Figure 5.35), while only a 
protein to ML ratio of 1:1 produced crystals. In an attempt to reduce the number of 
microcrystals forming, microseeding and liquid bridge diffusion was performed (Section 
2.3.3.2) but crystals were only formed with a liquid bridge diffusion drop, and these were small 
and no improvement on those from the standard drop set up. 
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Figure 5.35: Additive screen crystals at day six in 0.2 M ammonium sulphate, 0.1 M Bis-tris pH 5.5, 45 % 
(+/-) MPD with 36 day old 12.92 mg/ml Rv2530a/c protein. Additives used at [10 mM] unless specified. 
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Positive improvements made to crystal formation from the above fine screens were applied to 
screens using freshly purified Rv2530a/c protein at 11.05 mg/ml. Day old protein was 
subjected to 0.2 M ammonium acetate/sulphate, 0.1 M Bis-tris pH 5.3, 45 % (+/-) MPD screens 
with the additives L-Proline, butanol, glycerol or urea, and varying the drop sizes. By day three, 
rods formed in all ammonium sulphate conditions while smaller rods were only observed in the 
control and L-Proline drops for ammonium acetate. By day seven, the crystals in ammonium 
sulphate drops had begun to decline and ‘feather’ around the edges, and X-ray diffraction at 
the Australian Synchrotron determined the best crystal (from the control drop) only diffracted to 
approximately 6 Å. Further fine screens around the most promising condition (0.2 M 
ammonium sulphate, 0.1 M Bis-tris pH 5.3, 45 % (+/-) MPD +/- glycerol) comparing drop sizes 
and pre-equilibration of protein with water before the addion of ML did not significantly improve 
the diffraction. 
 
5.2.6.2.4 Crystal Dehydration and DNase Treatment 
No great improvement in diffraction had been made in fine screens thus far varying ionic 
strength, slowing growth rate (drop dilutions/varied drop ratios) or adding co-factors to assist 
the protein in assuming a more rigid conformation, so screens aimed at dehydrating the 
crystals or removing any bound DNA from the protein with DNase were performed to try and 
improve crystal packing and therefore diffraction. Dehydrating crystals in a condition with such 
a high MPD concentration (45 %) is problematic because the highly volatile solvent competes 
with protein for water, so just dehydrating the drop actually results in the crystals becoming 
more hydrated. Instead of dehydrating the whole drop, a 2.5 – 25 % PEG 400 to PEG 10,000 
additive screen was performed in an attempt to dehydrate the crystals themselves using one 
day old Rv2530a/c protein at 17, 13 and 11 mg/ml, but the needles and tiny crystal rods 
formed were inferior to those in the control drops. DNase was added to protein immediately 
prior to laying down drops in an attempt to stabilise crystal formation in case there was any 
DNA present causing structural heterogeneity. DNase additive drops (at 1:500, 1:1,000 and 
1:2,000 DNase to protein) were laid down using one day old Rv2530a/c at 16 mg/ml both with 
and without the addition of manganese chloride (as DNase requires calcium, magnesium or 
manganese for activity, and previous crystallisation screens showed that the first two additives 
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form phosphate salt crystals). Phosphate salt crystals were apparent in the manganese 
chloride control drop (where no protein was added) so only drops without the addition of 
manganese chloride were followed up. Crystal rods were observed in drops for all DNase 
ratios by day 14. Interestingly, DNase I is having an effect on crystal formation even though 
DNase I activity has been shown to be almost negligible in buffers containing no divalent 
cations (Guéroult et al. 2010), and has a large reduction in activity in NaCl concentrations over 
30 mM (Latham 2001) as is the case in the crystalisation buffer. 
 
Screens replacing Bis-tris with alternate buffers yielded no crystals when Tris was used, and 
feathered and inferior crystals with Bis-tris propane. As it appeared better crystals formed as 
the protein aged, a screen of three day old Rv2530a/c was laid down with DNase (at 1:2,000 
and 1:5,000) immediately as well as after 10 minutes incubation at room temperature. Protein 
was diluted to 17, 13, 11 and 9 mg/ml for the screen in water as well as in purification buffer 
(50 mM sodium phosphate pH 8, 200 mM NaCl) to compare crystal integrity in each of the 
diluents. Figure 5.36 shows protein diluted in water formed superior crystals to those from 
protein diluted in buffer indicating either the phosphate or salt has a detrimental effect on 
crystal formation in this crystallisation condition. Superior crystals were also produced in drops 
with protein concentrations of 9 – 13 mg/ml compared to 17 mg/ml, and without the 10 minute 
incubation when DNase was added. X-ray diffraction at the Australian Synchrotron indicated 
crystals in the control drops were slightly better than those with DNase treatment as they 
diffracted to a greater resolution (5.5 – 9 Å compared to 8 - 10 Å). Data to 5.5 Å (Figure 5.37) 
were collected for one crystal taken from a control drop laid down at 9 mg/ml (Figure 5.36a). 
The dataset was indexed in iMosflm giving mosaicity of 0.72 and defining the space group as 
I4. Indexed data was then scaled and truncated using Aimless which suggested resolution of 
5.5 Å with an rmerge value of 0.8 in the outer shell. The space group was redefined as I4122 
with mosaicity of 0.67, which together with the MW calculated from SEC is suggestive of 
tetrameric symmetry. Given the resolution of the dataset, it was not feasible to solve the 
structure of Rv2530a/c with this dataset. 
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Figure 5.36: Fine screen crystals with three day old Rv2530a/c at day 12 in 0.2 M ammonium sulphate, 0.1 
M Bis-tris pH 5.3, 45 % (+/-) MPD  a) controls with protein diluted in water, b) protein diluted in buffer and 
c) + DNase at 1:2,000 or 1:5,000 ratio of DNase to protein +/- a 10 min incubation before drops laid down.  
 
 
Figure 5.37: Rv2530a/c crystal and X-ray diffraction to 5.5 Å a) Rv2530a/c crystal from Figure 5.36a used 
to collect dataset, b) X-ray diffraction of one frame obtained during data collection at the Australian 
Synchrotron (plate resolution 2.37 Å).  
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Crystallisation attempts of Rv2530c in the future should focus on reducing the structural 
flexibility and therefore structural heterogeneity of the protein. Removal of the His-tag would 
reduce the structural flexibility, but as it is C-terminal it is difficult to do, especially given there 
are no protease sites between the protein and His-tag. Other approaches for reducing the 
structural heterogeneity of the protein could involve screening ligands (and inhibitors), different 
additives and co-factors which may help the protein assume a more rigid conformation. 
Another strategy which may improve the diffraction quality of the protein crystal is slowing the 
rate of crystal growth (Heras & Martin 2005). While attempting to slow the rate of crystal 
growth, one could investigate the use of MPD as the precipitant in the crystallisation condition. 
MPD is a small polyalcohol which can act as a precipitant via competition for water, and also 
functions as a cryoprotectant. MPD is mildly denaturing and promotes hydration of proteins via 
association with hydrophobic protein surface patches, suggesting it may stabilise the protein 
by filling up cavities on the protein surface and indirectly facilitate proper crystallisation (Anand 
et al. 2002). Once the rate of crystallisation was slowed, possibly by laying crystals down at a 
different temperature (especially given MPDs additional role as a cryoprotectant), packing of 
the voids by MPD may also improve resulting in improved diffraction of the crystal.  
 
5.3 Conclusions 
The role of VapBC systems in M. tuberculosis has been the subject of great interest over 
recent years, due to their expanded number in the genome and links with the regulation of cell 
growth in response to environmental stress. Their ability to regulate or slow growth under 
adverse conditions for presumed survival advantages possibly leading to latency, persistence 
or bacteriostasis, make them ideal candidates for developing new treatments to target these 
persistent or non-replicating bacteria. The finding that the three M. tuberculosis VapC toxins 
tested thus far display ribonuclease activity and may target the same mRNA sequence is 
intriguing. This raises the possibility that all 47 VapCs in M. tuberculosis are RNases and target 
the same sequence, although maintaining such a large surfeit of genes to perform the same 
function would be excessive and seemingly costly to the organism in terms of energy and 
maintenance. Alternatively, perhaps they belong to sub-groups which each target a different 
sequence. If multiple VapCs share the same target, they may still be regulated by, or under the 
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control of different activators, which are triggered in response to different environmental stimuli. 
This would allow the bacteria to respond and adapt to the diverse range of conditions which 
they encounter. The ability of an organism to have groups of VapCs with different targets, 
could allow it to exude both gross and fine control over the cells metabolism. One set of 
RNases could target a ubiquitous cleavage site in response to critical stressors effecting a 
large and fast change in the cells transcriptional profile, while another set may respond to less 
adverse stressors with a more gentle effect, targeting infrequent mRNA sites and therefore 
specific messages. Having this combined approach may explain why M. tuberculosis has 
maintained 47 VapBC loci in its genome, as it must be able to survive and regulate its growth 
in many environments, and under a diverse range of stressors (supported by the observation 
that the majority of TA systems are only found in virulent mycobacteria of the MTBC (Ramage 
et al. 2009)). It is also possible that it is a combination of sequence and secondary structure 
which is being targeted by the various VapCs as, while target sequences were preferentially 
cut, other suboptimal sites were also cut, although to a lesser degree. While multiple VapCs 
may target the same sequence, other factors are likely to be involved in the regulation of this 
efficient RNase. Research being undertaken currently in our lab indicates AmtR (a global 
repressor in the nitrogen regulation system of a closely related organism to M. tuberculosis 
(Jakoby et al. 2000)) may play a role in the regulation of VapBC in M. smegmatis (Chelsea 
Vickers, unpublished data), suggesting VapCs may not only be involved in the regulation of 
glycerol or carbon utilisation, but of other metabolic substrates as well such as nitrogen. 
Another way in which the VapCs may be differentially regulated is via targeted degradation of 
their cognate antitoxin by different proteases. The method by which VapB degradation occurs, 
and the environmental triggers which initiate activation of these proteases to act on the VapB 
protein are poorly understood, so it is possible that particular conditions of stress activate 
specific proteases which only target a certain VapB (or subset of VapBs), leading to targeted 
VapC RNase activity. There is also a possibility that not all 47 of the M. tuberculosis VapCs 
function as an RNase, although this is becoming less likely as each new VapC is characterised 
and shown to display RNase activity. 
 
While the exact biological function of VapBCs in M. tuberculosis has not been elucidated, it is 
clear they play some role in regulating growth in response to changes in the environments the 
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organism encounters. The ability to adapt to these changes allows the bacterium to evade host 
responses and the effects of antibiotics, and persist for long periods. This, together with their 
suggested role in virulence (Arcus et al. 2005;  Magombedze & Mulder 2013), make VapBCs 
ideal candidates to target when investigating the treatment for, and pathogenesis of, M. 
tuberculosis. 
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6 Chapter Six 
Conclusions 
Given that the two major impediments to effective TB eradication are the time to diagnosis and 
duration of treatment, the overarching intention of this research was to develop a rapid strain 
specific M. tuberculosis diagnostic assay, and investigate the role M. tuberculosis toxin-
antitoxins play in the pathogens survival and persistence. To do this, we focussed on the 
VapBC system of toxin-antitoxins, and proposed three objectives: one, to scrutinise the highly 
transmissible and virulent Rangipo strain of M. tuberculosis prevalent within New Zealand, and 
develop a fast and efficient Rangipo specific diagnostic assay which could be implemented into 
the current hospital diagnostic setting; two, to identify conditions where vapB or vapC 
expression was differentially expressed (in M. smegmatis) in order to help identify the 
mechanisms involved in the regulation of VapC, as well as to develop an optimised RNA 
isolation and RT-qPCR method suitable for the quantification of these target genes expression. 
And lastly, to identify all unannotated M. tuberculosis VapBC proteins, then clone, express and 
purify all 47 into M. smegmatis, and to determine the specificity and activity of a number of the 
purified M. tuberculosis VapC proteins.  
 
6.1 Rangipo Diagnostic 
Control of the M. tuberculosis Rangipo strain, which has been circulating in the Waikato and 
Bay of Plenty regions for a quarter of a century and is responsible for the largest cluster of 
tuberculosis infections within New Zealand, has proved difficult owing to its virulence and high 
transmissibility. Whole genome sequencing of 10 Rangipo isolates revealed that two of the 99 
Rangipo specific SNPs identified were within vapC toxin genes, while LSP and RD PCR 
analysis determined the Rangipo strain belongs to an as yet unclassified M. tuberculosis Euro-
American sublineage. Robust discrimination between strains of pathogenic bacteria is 
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essential for controlling infection, as well as gaining insight into the differences in 
transmissibility, virulence and pathology of disease between strains, which will lead to better 
targeted microbial therapies. A pivotal factor in the effective control of tuberculosis is the 
development of rapid and robust methods for M. tuberculosis infection diagnosis. An 
affordable, rapid and reliable diagnostic RFLP assay based on the Rangipo specific SNPs has 
been developed to quickly identify the Rangipo strain. Fast diagnosis of this highly 
transmissible strain will reduce the delay in treatment of its predominantly pulmonary infection, 
in turn limiting its spread, reducing the associated contact tracing and treatment costs, and 
improving patient outcomes.  
 
6.2 Expression of vapB and vapC in M. smegmatis 
using RT-qPCR 
A modified AP-GITC RNA isolation method was successfully developed, and used in RT-qPCR 
to determine that there was no differential expression of vapC under the conditions of stress 
tested. Housekeeping genes belonging to a range of functional and abundance classes were 
trialled for use as RT-qPCR normalisers in the stress experiments, but almost all were deemed 
unsuitable due to inconsistent or poor expression. A single housekeeping gene (16S) was 
found to be consistently expressed, but its expression was much higher than that for the genes 
of interest due to the presence of two copies. 16S was used successfully as a normalising 
housekeeping gene however, by diluting the amount of cDNA used in the housekeeper 
samples during RT-qPCR. Because just a single housekeeping gene was used to normalise 
the data (when multiple housekeeping genes have been shown to produce more reliable 
results), the resultant expression data was treated cautiously. The fact that no consistent 
change in the mRNA expression levels of vapB and vapC occurred, prompted the use of 
modelling to investigate how the levels of toxic VapC are being controlled. This negative 
expression data together with the modelling data, form the basis for our current hypothesis that 
it is not the transcriptional differences which are important in the regulation of VapC, but post-
transcriptional factors. 
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Modelling of changes in protein and mRNA levels suggests transcription of the VapBC operon 
results in a ratio of VapB to VapC of approximately 10 : 1. This is due to the ribosome only 
occasionally slipping back across the VapB/C overlap to transcribe the toxic VapC, instead of 
falling off once it reaches the end of VapB. The equilibrium ‘norm’, is that VapC is always in a 
complex with VapB and is very rarely free, so under ‘normal’ conditions, the majority of the 
toxic VapC is held in a benign complex with its antitoxin, and only a very small amount is free 
to exert its toxic effect. VapB is much more susceptible to proteolytic degradation than VapC, 
so over time the VapB is degraded at a faster rate than VapC which pulls the equilibrium 
backwards, leading to an increase in free VapC. Therefore, under ‘normal’ conditions VapBC 
must be constantly translated so that the equilibrium holds, avoiding the release of free VapC 
into the cell. As translation slows, be it due to encountering external stressors or the growth 
rate reaching stationary phase, the equilibrium is forced backwards resulting in a spike of free 
VapC, which only settles back to low steady state levels once the VapBC translation steadies 
again (see Figure 6.1) (Arcus 2013 (unpublished); (Fasani & Savageau 2013). 
 
The VapC regulation model proposes there is a very slight amount of free VapC present under 
normal conditions. This is strengthened by the subtle increase in growth rate observed for the 
vapBC deletion mutant, vapBC, where no trace amounts of free VapC are present to exert 
their toxicity and slow growth (McKenzie et al. 2012b). Microarray data has shown that genes 
involved in carbon transport and metabolism are downregulated when VapC is overexpressed 
(Robson et al. 2009), and it was observed that glycerol uptake for the vapBC deletion mutant 
was approximately twice that of its wildtype counterpart, while the amount of biomass 
produced (relative to glycerol uptake) was halved (McKenzie et al. 2012b). This suggests 
glycerol uptake in vapBC is inefficient, and results in unregulated growth due to the absence 
of VapBC to control glycerol metabolism. Taken together with the modelling data, this suggests 
that VapC is required for the regulation, or fine tuning of carbon and possibly nitrogen (Arcus 
2013 unpublished) metabolism in response to growth rate. 
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Figure 6.1: Top: The VapBC equilibrium. Translation results in VapB and VapC which form the benign 
VapBC complex, but if VapB is degraded, the equilibrium shifts to the left, resulting in free VapC toxin. 
Bottom: Model depicting the regulation of VapC toxin. Over time, the toxin-antitoxin (TA) complex 
concentration (green) increases to a steady state, prior to the (much lower) free toxin levels (red). If the 
translation rate is changed to a lower rate (at the blue arrow), there is a temporary spike in free toxin 
levels before they return to their lower concentration. Figure from unpublished results from Arcus (2013). 
 
6.3 M. tuberculosis VapBC Characterisation 
The large number of VapBC systems in M. tuberculosis and their links to the regulation of cell 
growth in response to environmental stress, have prompted questions as to the role VapBC 
systems may play in M. tuberculosis, and make them interesting candidates for the 
development of new M. tuberculosis treatments. Small scale protein expression tests identified 
17 of the 47 M. tuberculosis VapBC’s as expressing soluble VapC protein, 13 of which were 
put through large scale expression studies during the course of this research (three of those 
were purified by others in the lab). Because the VapC protein from M. smegmatis (VapCMS1284) 
had previously been shown to exhibit ribonuclease activity (McKenzie 2011), the M. 
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tuberculosis VapC proteins VapCRv2548 and VapCRv2530c purified here, were also tested for 
RNase activity. Both VapCs displayed general Mg2+-dependent RNase activity against M. 
smegmatis total RNA, as well as the same specific activity (with similar cutting efficiencies to 
each other) against all of the pentaprobe substrates. This was also the case for the two other 
M. tuberculosis VapCs (VapCRv0065 and VapCRv0617), determined by others in the lab 
(McKenzie et al. 2012a). This same banding pattern suggests that M. tuberculosis VapCs may 
target the same recognition sequence, which is different to that observed for VapCPAE0151 and 
VapCPAE2754 from P. aerophilum, and VapCMS1284 from M. smegmatis (McKenzie et al. 2012a). 
The lack of one pentaprobe substrate being cut preferentially over the others observed here for 
VapCRv2548 and VapCRv2530c, suggests that none of these are the ‘ideal’ substrate for either of 
the VapC proteins, possibly due to unsuitable RNA sequence and/or secondary structure. 
MALDI-TOF MS using overlapping 932 RNA oligonucleotide substrates was used to determine 
the sequence specificity of VapCRv2530c, in order to gain a better understanding of the targets, 
and therefore the possible pathways and functions the M. tuberculosis VapC proteins are 
involved with. The most optimal cut site for VapCRv2530c as determined by MALDI-TOF MS, was 
UA*GG. When this same analysis method for determining the optimal cut site was applied to 
historical MS data for VapCRv0065 and VapCRv0617, UA*GG was also the most likely preferred cut 
site, suggesting that UA*GG is the preferred cut site for the three M. tuberculosis VapC 
proteins tested thus far. Previously, GC-rich 4mers were thought to be the preferred cut sites 
for VapCRv0065 and VapCRv0617 (McKenzie 2011;  McKenzie et al. 2012a), but the analysis 
method used then appears to be less robust than that which has generated the UA*GG 
sequence. It must be noted however, that both analyses have relied on imperfect MALDI-TOF 
MS spectra obtained from a period of poor laser performance, so repeat assays should be 
performed again on VapCRv0065 and VapCRv0617 to confirm UA*GG is the preferred cut site for 
these two VapC RNases, as well as for VapCRv2530c. The fact that the three M. tuberculosis 
VapC toxins tested thus far display identical ribonuclease activity raises the possibility that all 
47 VapCs are RNases and are targeting the same sequence. The resulting cost to the 
organism of maintaining such an excessive number of genes in order to seemingly perform the 
same function would appear extreme. Alternatively; the 47 VapCs may belong to sub-groups, 
each targeting a different sequence and/or secondary structure allowing M. tuberculosis to 
exude both gross and fine control over the cells metabolism; or they may in fact share the 
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same target, but are regulated by different activators triggered in response to different 
environmental stimuli, in order to respond and adapt to the diverse range of conditions which 
M. tuberculosis encounters. While multiple VapCs may target the same sequence, other 
factors are likely to be involved in the regulation of this efficient RNase, such as AmtR, 
suggesting that as with the VapC in M. smegmatis, M. tuberculosis VapCs may be involved in 
the regulation of a wide range of metabolic substrates. Bioinformatic analysis of the M. 
tuberculosis H37Rv genome revealed an abundance of hypothetical proteins and genes 
involved in metabolic processes containing the TAGG VapCRv2530c target sequence. Once 
ranked relative to gene size, genes containing the highest number of TAGG sequences were 
annotated as hypothetical proteins, transposases, TA genes and other genes associated with 
horizontal gene transfer. VapCRv2530c could be targeting HGT elements because it is also 
functioning as a selfish element - to eliminate the other selfish elements in order to survive the 
genome war within, and targeting TAs in order to initiate a transcriptional regulation cascade 
when a rapid change in the proteomic response and metabolic state of the cell is required, 
such as during conditions of stress. 
 
6.4 Future Research 
The three M. tuberculosis VapC RNases tested thus far, appear to have an identical 
recognition sequence. As well as attempting to purify the four remaining solubly expressed 
VapCs and testing for RNase activity, MALDI-TOF MS of RNA oligos should be performed 
again on VapCRv0065 and VapCRv0617 as well as VapCRv2548 once the laser is fully functional, to 
obtain better data and more conclusively confirm they share the same preferred cut site as 
VapCRv2530c. Because this cut site is different to that for VapCs from both P. aerophilum 
(targeting G rich sequences) and M. smegmatis (targeting AT sequences) (McKenzie et al. 
2012a;  McKenzie et al. 2012b), confirming exactly which target sequence residues are crucial 
for the RNase activity of the M. tuberculosis VapCs, will be instrumental in determining their 
optimal target sequence and therefore their biochemical function. One way of achieving this 
would be performing a microarray or RNA-Seq to identify genes which are downregulated in 
response to expression of a particular M. tuberculosis VapC in its VapBC knockout, as was the 
case with VapC from M. smegmatis (McKenzie et al. 2012b). 
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The exact biological function of M. tuberculosis VapBCs is yet to be elucidated, but their ability 
to regulate or slow growth under adverse conditions for presumed survival advantages 
possibly leading to dormancy, persistence or bacteriostasis, make them ideal candidates for 
developing new treatments to target the persistent or non-replicating M. tuberculosis 
bacterium. 
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8 Appendices 
Appendix A: Reagents 
A.1 Primers Used in This Study 
Table A.1: A list of primers and their sequence, used in Chapters Three, Four and Five. 
Primer Sequence 
Chapter Three: 
Mtb1 CCGGCGGGGCCGGCGG 
Mtb2 CGGCGGCAACGGCGGC 
IS1 CGGACTCACCGGGGCGGTTCA 
IS2 CGGACATGCCGGGGCGGTTCA 
CAR2 GACIIICCGGGGCGGTTCA 
Lineage Classification Primers 
RD9 Fwd GTGACGGTATCGTCGAGCAG 
RD9 RevInt CGCGCCAACTATGTCTACGG 
RD9 RevDel GCTCGAGCTAGACCTGCAC 
RD105 Fwd GGTCATATCACGCGTTCGTG 
RD105 RevInt TGCGGTCAAAGCACGCCTTG 
RD105 RevDel GGTGGCCCAGAAACCACCA 
RD239 Fwd CGTAGACTGCTCGCATGACC 
RD239 RevInt CAGTGAGATCCCAAATGCTGC 
RD239 RevDel CGACGCAATCTGACCGACAG 
RD750 Fwd GTCAACTGCCGATGGCTGAC 
RD750 RevInt CGTCAGCGATGATCACCTCG 
RD750 RevDel GTGAACTAGGTCGAGCATCG 
katG-F GCCTTGGGCTCCAGCACG 
katG-R1 CAGCCTTAAGAGCCAGATCCPST 
katG-R2/3 GCCTTAAGAGCCAGATCCPSG 
Euro-American Sublineage Primers 
RD115 Fwd TTCGGGGGCCAGGTCGTTGAT 
RD115 Rev CCGCGGGAATGCCTGCTGTTAT 
RD122 Fwd GCCGGCACCGCTAATCGCTACTT 
RD122 Rev TTCTCTTGGGCATGATCATCCTTTCGTTA 
RD174 Fwd GGTGCCCTCCCGCAGAACTGTG 
RD174 Rev AGCGCGATCGCAGCGGTGAA 
RD-Int 174 Fwd GCTCGGCGACACAGGGTTGGT 
RD-Int 174 Rev GCCGCCGGTGGTGTCTGTTTC 
RD182 Fwd TGTTATACGCCCTGTCGGCGGTCACCAT 
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RD182 Rev GCGCATCCCGCCGGCGTTGGTT 
RD-Int 182 Fwd GATGACTACCCCACCCGACA 
RD-Int 182 Rev AGCACCACACCGAGCACCT 
RD183 Fwd CCGAACCGCCCGCATCAAG 
RD183 Rev ACGACGGCCGAAACCACAGGAA 
RD193 Fwd CCGACTACGCCTGGCGCTAAACC   
RD193 Rev GTAGGGGCCACCCGGATTGTCAC 
RD219 Fwd GCGTCGGTGCCCAGTTGC 
RD219 Rev GCGACGGCGGTTTTGATGC 
RD-Int 219 Fwd GGATGCGACTCATCGTGGAC 
RD-Int 219 Rev GAGCAGGATCTTGGCGTCCT 
RD724 Fwd CCATGCGATTTGACTTCCGATTGA 
RD724 Rev ATATACCGTGCCGCGACTTGCTCT 
RD726 Fwd GCCCGGGCGGATGCTGTT 
RD726 Rev CGGCGGCGCGTTTGTCA 
RD761 Fwd GCCGGCGTGCTCAATGCTCAG 
RD761 Rev CCTAGGCCGGCGACGAAGTGC 
Ag85C103F CTGGCCGTTGCTCTGCGAGGGCTGATACCA 
Ag85C103R CGATCTCGCGCTGCGGCCACGACATT 
LAMF TAGCCCACCACCACAGCTTC 
LAMR ACCACCCTGCCTAACCAATTC 
XhoI TTCAACCATCGCCGCCTCTAC 
SNP Confirmation Primers 
Rv0071 Fwd ATCACGGTGTCGGTGGACCC 
Rv0071 Rev ATCAGGTCCGCGTGGTCGAT 
Rv0405 Fwd TTCGTCTGATGCACTGCCGC 
Rv0405 Rev GCAGTTCGCCACCGGTTGAT 
Rv1192 Fwd TCGTATCCCGGCTTCCCGAC 
Rv1192 Rev TACCCGAGGCGACGCAAGAT 
Rv1821 Fwd GTGCAGGCCCTGATCAACCG 
Rv1821 Rev CGCCCGGCCATTTGAGTTGA 
Rv2224c Fwd TGGCGTTGGTTCTTGTGGGC 
Rv2224c Rev TCCAGGTCCTTGGCGACGTT 
Rv2546 Fwd TGTACTCGGCGAACTCCGCT 
Rv2546 Rev CTCCGTAGGTTGGCCGGTGA 
Rv3119 Fwd GCCTACCCTTACTGTCGGCTCA 
Rv3119 Rev CCCATTCAGCACCGGTCGAG 
Rv3616c Fwd CGTTTCCGGGTGATGGCTGG 
Rv3616c Rev ACCCCGTGAGCTTGTCCCAA 
Rv3769 Fwd AAGGAGCTTGGAGCACGGGT 
Rv3769 Rev CGAGCTGGCCGACTTTGGTC 
Rv3881c Fwd ATGACGCAGTCGCAGACCGT 
Rv3881c Rev CCTTGGTCGCCCGTTTCGAG 
Rangipo Diagnostic Primers 
Rv0405 RFLP Fwd GGCGGCAGCTGCCGTTTTGTGGAGT 
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Rv0405 RFLP Rev TCTGGCCACTCGAATTACTTCACGG 
Rv0071 Fwd see SNP Confirmation Primers for sequence 
Rv0071 RFLP Rev AACCCGCCCGGTTTGGGGATCTTGCGGGCC 
Rv0719 RFLP Fwd ACCCTGGTGTCCAACCTGGTC 
Rv0719 RFLP Rev TACCCCAGCGCAAACTCCAGA 
Rv1821 RFLP Fwd TGCGGAATGACGGGAACCGC 
Rv1821 RFLP Rev GACCGCGCAGCTGGTTGTCT 
Rv1854c RFLP Fwd CTGCAGCGGTCGGGTTGACTAC 
Rv1854c RFLP Rev GTAGGTGTGACCGAGCAATTCCG 
Rv2224c Fwd see SNP Confirmation Primers for sequence 
Rv2224c RFLP Rev CTTGCCGCATAACGCGCCCCCG 
Rv2504c RFLP Fwd GACCGACTTCGCACTGGTGCAT 
Rv2504c RFLP Rev CACCGTCTCCCTCTCGATCTTCT 
Rv2546 RFLP Fwd TGTTCTGCGTCGACACCAGCG 
Rv2546 RFLP Rev CTTGGCATGCGCGCGTAAAGAATT 
Rv2716 RFLP Fwd CGGACACCCGACCGTGGGAGCCACC 
Rv2716 RFLP Rev CGGAAAGTCGGCGGGGTCGGCGG 
Rv3119 Fwd see SNP Confirmation Primers for sequence 
Rv3119 Rev see SNP Confirmation Primers for sequence 
Rv3513c RFLP Fwd TGGCGGCATCTTTAAGTGAGAAC 
Rv3513c RFLP Rev CCTTCAAAGCGGCCTCGACC 
Rv3616c RFLP Fwd ACCTACATCCCGGTCGTCGGGCTCG 
Rv3616c Rev see SNP Confirmation Primers for sequence 
Rv3769 Fwd see SNP Confirmation Primers for sequence 
Rv3769 RFLP Rev TTTGGTCGTCACGCGGTCCAGTCGCACGG 
Rv3867 RFLP Fwd CTCACCGAACGCGACGAGGAGCC 
Rv3867 RFLP Rev CTGCGCTTCGGACATGCTGGACG 
Rv3881c RFLP Fwd ATGACGCAGTCGCAGACC 
Rv3881c RFLP Rev TGGTCGCCCGTTTCGAGCTT 
Chapter Four: 
16S Fwd CAGCTCGTGTCGTGAGATGT 
16S Rev AGACCGGCTTTGAAAGGATT 
Msmeg_0930 Fwd TCGACACCACACTCAGATCG 
Msmeg_0930 Fwd GCGTTGACCGATTCGTCAT 
ftsZ Fwd ACTACCTCGCGGTCATCAAG 
ftsZ Rev AGCTCCTCGATGTCGTCCT 
guanylate kinase Fwd GGCGTGGACTACACCTTTGT 
guanylate kinase Rev GGTCGACCTCGATCAGTACC 
metC Fwd ACGTGTCGTCGGTGAACTA 
metC Rev ATGTTGGCGACGTGACTGT 
oxcA Fwd GGTTCAGCGGTATGGAACTC 
oxcA Rev CCGAAGGCCTTGATCATGTA 
rpoB Fwd GTCGACGAGTGCAAAGACAA 
rpoB Rev TGGTCTCGTCGAAGTACACG 
rpsB Fwd CAACGGCATCTACATCATCG 
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rpsB Rev ACGGTGGAGAAGTTGGTGAG 
sigA Fwd CCAAGGGCTACAAGTTCTCG 
sigA Rev TGGATCTCCAGCACCTTCTC 
sigH Fwd ACCTCAAGGCGTGGCTCTAC 
sigH Rev TGCCAGTCGGTGATCTCGTC 
vapB Fwd TGGCTCTAAGCATCAAACACC 
vapB Rev TTCCTCACGAAGCGGAAC 
vapC Fwd CTGACGATCCTGTTCGGACT 
vapC Rev AGGAAAAACAGTCGCCGTAA 
Chapter Five: 
Cloning Primers 
Rv0064A Fwd GTTACCATGGCTACCATTCAAGTTCGGGA 
Rv0065 Rev GGCAAGCTTCCGAACGAGTTTGATTTCG 
Rv0229c Fwd TAGTCCATGGTGAGACAGCCGCGCCGG 
Rv0229c Rev TATAAGCTTGTCGATCGTGCCCGCTGGC 
Rv0239 Fwd ATGTCCATGGCTCGAACGCAAGTCCAG 
Rv0240c Rev ATTAAGCTTGCCATCCGACGTTATCGGGT 
Rv0277A Fwd AATGCCATGGCCGAAGACGCCCTTCG 
Rv0277c Rev CAATAAGCTTGATTGGCGGGCGAATATGGCG 
Rv0300 Fwd TAATCCATGGCTGATGTACTGATTCGGGA 
Rv0301 Rev TATAAGCTTAGCGGAAGGCGGGCG 
Rv0550 Fwd- GeneArt ATCTATGCATATGTTGTTGAGCCGGCGCA 
Rv0549 Rev- GeneArt CATAAGCTTCAGCCGATGGCGTGAGC 
Rv0581 Fwd ATTACCATGGACAAGACGACGGTCTACC 
Rv0582 Rev ATTAAGCTTCGGAATGACGGTGAAGCGC 
Rv0596c Fwd CATTCCATGGCTGCTACGATACCCGCTC 
Rv0595 Rev TATAAGCTTGATCGTTATGACCTCGACGTCGG 
Rv0599 Fwd AGAACCATGGCGGCTGTTGTGGATGC 
Rv0598c Rev TATTAAAGCTTCGCGGCGACAACGACGTG 
Rv0608 Fwd ATTACCATGGCGTTGAACATCAAAGAT 
Rv0609 Rev TATAAGCTTCCGCCGATCCAGTGC 
Rv0616 Fwd TAATCCATGGTGCGCACTACCATCGA 
Rv0617 Rev TTAAAGCTTGGTGGTCGTTGGAATGAG 
Rv0626 Fwd TACTCCATGGCTGAGGTGGCCTCG 
Rv0627 Rev AGAAAGCTTGACCCGAATGATCTCCACA 
Rv0657 Fwd ATACCCATGGCGGTGACCCAGATCGA 
Rv0656c Rev ATCAAGCTTGTCGTCGGCGCTGAC 
Rv0662 Fwd CCAACCATGGCCCTCCCTAATACGCGTGC 
Rv0661c Rev TATAAGCTTGCGGTCGCCGAGCAGGCTGA 
Rv0664 Fwd TCATCCATGGAAAAGTCACGGTGCCAC 
Rv0665 Rev TATAAGCTTCACCTTGATCTCCGCGGTTGC 
Rv0748 Fwd AATACCATGGCCACCACGGTGTCAATCT 
Rv0749 Rev  AATAAGCTTGAGCGGCGGGCGAATGTGGCG 
Rv0959A Fwd TCACCATGGCGACGCTGTATCTGCGC 
Rv0960 Rev TCAAAGCTTCCTGGGCACAACGGTAATCGGA 
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Rv1113 Fwd ATCACCATGGCGACGACGGTGACCGTT 
Rv1114 Rev TTAAAGCTTGGACACTTCCTCAGCCAGCGCAA 
Rv1241 Fwd TTCACCATGGCCACCACCTTGACGCT 
Rv1242 Rev TACAAGCTTCGCGCAACGGGTCGGTCC 
Rv1398c Fwd AACTCCATGGCGCGGACCAACATCTAC 
Rv1397c Rev CATAAGCTTTGCCCGCGGTCGGTGCCC 
Rv1560 Fwd CATTCCATGGTGTATCGTTGGTGTATGTCAC 
Rv1561 Rev TTAAAGCTTCCGAAACGATGCGGCCTGC 
Rv1720  GeneArt 
Rv1721  GeneArt 
Rv1740 Fwd CTACCATGGAATTGGCGGCTCGAATGGG 
Rv1741 Rev CATAAGCTTGCCGGCGAGAACCGCGCGAAT 
Rv1839c Fwd AATCCCATGGCTAAGCGCCTGCAGGTTC 
Rv1838 Rev TATAAGCTTGGCCAGACGCTTGATCCCCGGAT 
Rv1952 Fwd TTAACCAATGGTGATCCGCAACCTTCCC 
Rv1953 Rev CCGAAGCTTAAACCAGCTTATACCAGAATATAG 
Rv1962c GeneArt 
Rv1962A GeneArt 
Rv1982A Fwd AATGCCATGGCGCTGAATATCAAAGACC 
Rv1982c Rev TATCGGATCCGCGACGCCTGGCCAGT 
Rv2009 Fwd TTAGCCATGGTGTATAGTGGTGTTGTGT 
Rv2010 Rev TTAAAGCTTGAACAACGGCTCGGTGC 
Rv2104 Fwd ATTGCCATGGCGACGACTGTCACATTGG 
Rv2103 Rev TAATGGATCCGCCAACAGCGCGGG 
Rv2493 Fwd TAAGCCATGGTGCGAACGACACTTGACC 
Rv2494 Rev CATAAGCTTGAGGATGGTCAGCAGCTCC 
Rv2526 Fwd CTTACCATGGCCGTAAAGAGGACCACGA 
Rv2527 Rev  TATAAGCTTGCGCCCGCGAGAGAGTT 
Rv2530A Fwd ATTACCATGGCCACCACGTTGCAGATTGAT 
Rv2530c Rev TATAAGCTTCAACACCTCGACGAGGCC 
Rv2545 Fwd  - GeneArt ATTGCCATGGTGAGCACCACCATCGTTG 
Rv2546 Rev  - GeneArt TATAAGCTTAAGGGTCCCGCGCGGCA 
Rv2547 Fwd ATTGCCATGGCTGGTGATGTCATGCGGA 
Rv2548 Rev ATTGCATATGGTACGGCGGCTGCAGATC 
Rv2549  GeneArt 
Rv2550  GeneArt 
Rv2595 Fwd TATGCCATGGCAACAACCATCGATGTCG 
Rv2596 Rev CATAAGCTTGGTCACCAGCTCAACCTCG 
Rv2601 Fwd ATTACCATGGCGACCACGCTCGACCTGC 
Rv2602 Rev TATAAGCTTCTTGGCCAGGAGCCGCAGC 
Rv2758c Fwd  GeneArt + CTAGCCATGGCTCGCGGATATGCATTAG 
Rv2757 Rev  GeneArt + TATTGGATCCGGCGCTGTCCCTGGG 
Rv2760 Fwd CCAGCCATGGCCCTCAATATCAAGAGCC 
Rv2759 Rev ATAAAGCTTGGTGCACGCGGGCCGGATA 
Rv2830 Fwd TAATCCATGGCCGCTACGGAGGTGAAGG 
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Rv2829c Rev TATAAGCTTCCAGACGGTGACCGGTCGT 
Rv2862A Fwd AATGCCATGGCCCTCAGTAACTGGCTGC 
Rv2863 Rev AATAAGCTTTGATCGGAATGCGCTGGCC 
Rv2871 Fwd TATGCCATGGTGCGCACGACGATCCGTA 
Rv2872 Rev CTCGAAGCTTTAGATGGGTCTGACCGTCCAAC 
Rv3321 Fwd ATTACCATGGCCACCACGTTGTCCATCG 
Rv3320 Rev TATTGGATCCAGCGTTGCCAGGTGCTGT 
Rv3385c Fwd TTATCCATGGCGCCGACCGCTTGTGC 
Rv3384c Rev ATTAAGCTTCGACGGGGCGATCACGGCC 
Rv3407 Fwd TTAGCCATGGCTGCTACCGTTGGGCTTG 
Rv3408 Rev TATAAGCTTCCGGACTGCGCCGGGTGAG 
Rv3697A Fwd ATTGCCATGGCCACTACGATCGACCTCG 
Rv3697c Rev TATAAGCTTGCCGGAGAAGGGGTCGCGA 
T7 Fwd TAATACGACTCACTATAGGG 
T7 Rev TAGTTATTGCTCAGCGGTGG 
MALDI-TOF MS Oligonucleotide Calibration Standard Oligos 
Oligo 1 (12mer)  ACGTACGTACGT 
Oligo 2 (20mer) ACGTACGTACGTACGTACGT 
Oligo 3 (30mer)  ACGTACGTACGTACGTACGTACGTACGTAC 
932 RNA Oligonucleotide Sequences 
Oligo 1  GGAAUUCUGCAGAUCUCCAACCUCACACCA 
Oligo 2  CCUCACACCACAUUACACUGGGGUGAUAUA 
Oligo 3  GGGGUGAUAUAAUAUGAUGCCGGGCGGGGGCCG 
Oligo 4  GGGCCGUAACGUAGCACUACAUGACCCGAUACGCUA 
Oligo 5  CCGAUACGCUAGGUGGGAUUAGGCAUCACAC 
Oligo 6  AGGCAUCACACUGGCGGCCGCUCGAGCAUGC 
Oligo 7 UAGAGGGCCCUAUUCUAUAGUGUCACCUAAA 
Oligo 8  CGAGCAUGCAUCUAGCUAAAUGCUAGAGCUCG 
PS Indicates phosphorothioate modification 
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Table A.2: Orthogonal array used for the optimisation of diplex PCRs 
Reaction T (C) Taq (U) MgCl2 (mM) dNTP (mM) P1 (µM) P2 (µM) 
1 64 2.5 1.5 0.1 0.1 0.1 
2 64 2.5 2 0.15 0.2 0.2 
3 64 2.5 2.5 0.2 0.3 0.3 
4 64 3 1.5 0.1 0.2 0.2 
5 64 3 2 0.15 0.3 0.3 
6 64 3 2.5 0.2 0.1 0.1 
7 66 3.5 1.5 0.15 0.1 0.3 
8 66 3.5 2 0.2 0.2 0.1 
9 66 3.5 2.5 0.1 0.3 0.2 
10 66 2.5 1.5 0.15 0.3 0.2 
11 66 2.5 2 0.2 0.1 0.3 
12 66 2.5 2.5 0.1 0.2 0.1 
13 68 3 1.5 0.1 0.3 0.1 
14 68 3 2 0.2 0.1 0.2 
15 68 3 2.5 0.15 0.2 0.3 
16 68 3.5 1.5 0.1 0.1 0.3 
17 68 3.5 2 0.2 0.3 0.1 
18 68 3.5 2.5 0.15 0.2 0.2 
19 (-‘ve) 66 3 2 0.15 0.2 0.2 
The orthogonal array used for the optimisation of diplex PCRs based on modified Taguchi 
methods. The different shaded cells in each column represent 3 different concentrations 
chosen for each variable and the 19 rows represent 19 different reactions. T = annealing 
temperature; P1 = primer Rv3119; P2 = primer Rv3769. 
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Table A.3: Orthogonal array used for the optimisation of triplex PCRs 
Reaction T (C) Taq (U) MgCl2 (mM) dNTP (mM) P1 (µM) P2 (µM) P3 (µM) 
1 62 2.5 1.5 0.1 0.1 0.1 0.1 
2 62 2.5 2.4 0.15 0.2 0.2 0.2 
3 62 2.5 3.3 0.2 0.3 0.3 0.3 
4 62 3 1.5 0.1 0.2 0.2 0.3 
5 62 3 2.4 0.15 0.3 0.3 0.1 
6 62 3 3.3 0.2 0.1 0.1 0.2 
7 64.4 3.5 1.5 0.15 0.1 0.3 0.2 
8 64.4 3.5 2.4 0.2 0.2 0.1 0.3 
9 64.4 3.5 3.3 0.1 0.3 0.2 0.1 
10 64.4 2.5 1.5 0.2 0.3 0.2 0.2 
11 64.4 2.5 2.4 0.1 0.1 0.3 0.3 
12 64.4 2.5 3.3 0.15 0.2 0.1 0.1 
13 68 3 1.5 0.15 0.3 0.1 0.3 
14 68 3 2.4 0.2 0.1 0.2 0.1 
15 68 3 3.3 0.1 0.2 0.3 0.2 
16 68 3.5 1.5 0.2 0.2 0.3 0.1 
17 68 3.5 2.4 0.1 0.3 0.1 0.2 
18 68 3.5 3.3 0.15 0.1 0.2 0.3 
19 (-‘ve) 64.4 3 2.4 0.15 0.2 0.2 0.2 
The orthogonal array used for the optimisation of triplex PCRs based on modified Taguchi 
methods. The different shaded cells in each column represent 3 different concentrations 
chosen for each variable and the 19 rows represent 19 different reactions. T = annealing 
temperature; P1 = Rv3119 primers; P2 = Rv2504c primers; P3 = Rv1821 primers. 
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A.2 Plasmids & Bacterial Strains Used in This Study 
Table A.4: Plasmids & bacterial strains used in Chapters Three, Four and Five 
Bacterial Strain Description 
Escherichia coli  
DH10B (TOP10) F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80dlacZΔM15 ΔlacX74 
deoR recA1 araD139 Δ(ara leu) 7697 galU galK rpsL 
endA1 nupG λ- 
Mycobacterium smegmatis  
mc26 M. smegmatis wild-type strain 
mc2155 Electrocompetent lab strain of M. smegmatis 
mc24517 M. smegmatis expression strain with T7 RNA polymerase; 
Kmr  
Plasmids  
pYUB1049 E. coli mycobacterium shuttle vector with T7 promoter 
encoding both C- and N-terminal His-tags; Hygr 
pYUB28b E. coli mycobacterium shuttle vector with T7 promoter, 
MCS pET28b, encoding both C- and N-terminal His-tags; 
Hygr 
pMind M. smegmatis tetracycline inducible expression vector; Kmr 
Hygr 
Hygr = hygromycin B resistance, Kmr = kanamycin resistance 
 
Table A.5: Strains screened in the Rangipo-specific SNP identification process and their 
respective MTBC lineage 
First round of screening (TB Database) 
Strain MTBC Lineage 
M. tuberculosis T83 Lineage 1* 
M. tuberculosis CDC1551 Lineage 4* 
M. tuberculosis SG1 Lineage 3* 
M. tuberculosis T67 Lineage 2 
M. tuberculosis T85 Lineage 2 
M. tuberculosis 00_1695 Lineage 2 
M. tuberculosis 98_1833 Lineage 2 
M. tuberculosis M4100A Lineage 2 
M. tuberculosis 91_0079 Lineage 3 
M. tuberculosis K49 Lineage 3 
M. tuberculosis GM_1503 Lineage 4 
M. tuberculosis 4783_04 Lineage 4 
M. tuberculosis K37 Lineage 4 
M. tuberculosis T17 Lineage 1 
M. tuberculosis T92 Lineage 1 
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M. tuberculosis 95_0545 Lineage 1 
M. tuberculosis K21 Lineage 1 
M. tuberculosis K67 Lineage 1 
M. tuberculosis K93 Lineage 1 
M. africanum 11821_03 Lineage 5 
M. africanum 5444_04 Lineage 5 
M. africanum 4141_04 Lineage 6 
M. africanum GM_0981 Lineage 6 
M. canetti K116 Outgroup 
M. tuberculosis H37Rv Lineage 4 
M. tuberculosis F11 Lineage 4 
Additional strains screened in second round of screening (Broad Institute) 
Strain MTBC Lineage 
M. tuberculosis Haarlem Lineage 4 
M. tuberculosis KZN 4207 (DS) Lineage 4** 
M. tuberculosis KZN 1435 (MDR) Lineage 4** 
M. tuberculosis KZN 605 (XDR) Lineage 4** 
M. tuberculosis C Lineage 4 
M. tuberculosis 98-R604 INH-RIF-EM N/A 
M. tuberculosis W-148 Lineage 2 ^ 
M. tuberculosis 02_1987 Lineage 2 
M. tuberculosis EAS054 Lineage 1 
M. tuberculosis 94_M4241A Lineage 2 
M. tuberculosis T46 Lineage 1 
M. africanum CPHL_A Lineage 5 
M. africanum K85 Lineage 6 
* (Hershberg et al. 2008), ** (Feuerriegel et al. 2010), ^ This strain is a variant of the Beijing family which belongs 
to the East-Asian Lineage, therefore, it belongs to MTBC Lineage 2 
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A.3 Buffers, Media and Solutions 
All concentrations in % are percentages in weight per volume (w/v) unless otherwise indicated. 
Table A.6: General buffers and solutions used in this study 
Reagent Description 
CTAB/NaCl solution 10 % CTAB, 0.7 M NaCl 
5 x DNA Loading Dye 
0.05 % bromophenol blue, 0.25 % xylene cyanol, 30 % 
(v/v) glycerol 
Equilibration Buffer A 
50 mM Tris-HCl pH 6.8, 6 M Urea, 30 % (v/v) glycerol, 2 % 
SDS, 0.25 % DTT 
Equilibration Buffer B 
50 mM Tris-HCl pH 6.8, 6 M Urea, 30 % (v/v) glycerol, 2 % 
SDS, 2.5 % iodacetamide 
Fairbanks Staining Solution A 
0.05 % coomassie blue R-250, 25 % (v/v) isopropanol, 10 
% (v/v) acetic acid 
Fairbanks Staining Solution B 
0.005 % coomassie blue R-250 10 % (v/v) isopropanol, 10 
% (v/v) acetic acid 
Fairbanks Staining Solution C 0.002 % coomassie blue, 10 % (v/v) acetic acid 
Fairbanks Staining Solution D 10 % (v/v) acetic acid 
GITC 
295.4 g guanidine thiocynate, 2.5 g N-lauroyl sarcosine, 
3.9 g tri-sodium citrate, 3.6 ml 2-meracaptoethanol, 280 ml 
DEPC H2O (total volume 500 ml), pH 7.0 
Native Gel Loading Buffer 0.3 M Tris-HCl, 1 % bromophenol blue, pH 6.8 
10 x PBS 
0.2 M phosphate (0.038 M NaH2PO4, 0.162 M Na2HPO4, 
1.5 M NaCl, pH 7.4 
1 x PBS 100 ml 10 x PBS + 900 ml H2O 
Resolving Buffer 1.5 M Tris-HCl, pH 8.8 
4 x SDS loading buffer 
200 mM Tris-HCl pH 6.8, 8 % SDS, 40 % (v/v) glycerol, 0.4 
% bromophenol blue, 400 mM 2-meracaptoethanol 
SDS running buffer 25 mM Tris-HCl pH 6.8, 0.1 % SDS, 190 mM glycine 
Stacking Buffer 0.5 M Tris-HCl, pH 6.8 
10 x TAE 400 mM Tris-acetate, 20 mM EDTA 
1 x TAE 100 ml 10 x TAE + 900 ml H2O 
10 x TBE 0.89 M Tris-HCl, 0.89 M boric acid, 20mM EDTA 
1 x TBE 100 ml 10 x TBE + 900 ml H2O 
TE 10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0 
Tris-EDTA-SDS lysis solution 0.1 M Tris, 0.05 M EDTA, 1 % SDS, 0.5 M NaCl 
Tris-Glycine Running Buffer 25 mM Tris-HCl, 250 mM glycine, pH 8.5 
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Table A.7: Media used in this study 
Media Description 
7H9  
0.47 g 7H9 powder, 0.2 % (v/v) glycerol in 90 ml H2O, autoclave then 
add 10 ml ADC enrichment and 0.05 % (v/v) Tween 80 
7H10-agar  
1.9 g 7H10 powder, 0.5 % (v/v) glycerol in 90 ml H2O, autoclave then 
add 10 ml ADC enrichment and 0.05 % (v/v) Tween 80 at 50 °C 
Blood-agar 
10 % sheep blood (Life Technologies), 90 % sterile Columbia Blood 
Agar (44 g/L Columbia Blood Agar Base)  
Hartmans de 
Bont  
Components added in order given: 1 x trace metal stock*, 15 mM 
(NH4)2SO4, 0.05 % (v/v) Tween 80, 0.2 % (v/v) glycerol, 50 mM MOPS, 
pH 7.0. Autoclave, then add 1 x phosphate stock **  
LB-agar  1 % bactotryptone, 0.5 % yeast extract, 1 % NaCl, 15 g/L agar, pH 8.0  
LB  1 % bactotryptone, 0.5 % yeast extract, 1 % NaCl, pH 8.0  
LBT-agar  
1 % bactotryptone, 0.5 % yeast extract, 1 % NaCl, 15 g/L agar, 0.05 % 
(v/v) Tween 80, pH 8.0  
LBT  
1 % bactotryptone, 0.5 % yeast extract, 1 % NaCl 0.05 % (v/v) Tween 
80, pH 8.0  
Low salt LB-agar  1 % bactotryptone, 0.5 % yeast extract, 0.5 % NaCl, 15 g/L agar pH 8.0  
PA-0.5G  
50 mM Na2HPO4, 50 mM KH2PO4, 25 mM (NH4)2SO4, 1 mM MgSO4, 0.5 
% glucose, 0.1 x metals mix***, 100 μg/ml each of 17 amino acids (no 
Cys, Tyr or Met). Individual components autoclaved to sterilise  
Sauton’s 
4 g l-asparagine, 0.5 g KH2PO4, 0.5 g MgSO4, 50 mg FeNH4 citrate, 
2.4 g citric acid, and 60 ml glycerol per litre 
SOC  
2 % bactotryptone or bactopeptone, 0.55 % yeast extract, 10 mM NaCl, 
2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose  
ZYP-5052  
1 % bactotryptone, 0.5 % yeast extract, 50 mM Na2HPO4, 50 mM 
KH2PO4, 25 mM (NH4)2SO4, 1 mM MgSO4, 0.5 % glycerol, 0.05 % 
glucose, 0.2 % α-lactose, 1 x metals mix*** 
*100 x trace metals stock for Hartmans de Bont media: EDTA [0.1 g], MgCl2.6H2O [1 g], 
CaCl2.2H2O [10 mg], NaMoO4.2H2O [2 mg], CoCl2.6H2O [4 mg], MnCl2.2H2O [10 mg], 
ZnSO4.7H2O [20 mg], FeSO4.7H2O [50 mg], CuSO4.5H2O to 100 ml.  
**100 x phosphate stock for Hartmans de Bont media: K2HPO4 [15.5g], NaH2PO4.2H2O [11.1g] 
to 100 ml with dH2O. 
*** 1000 x metals mix made up from the sterile stock solutions of each component to give the 
following concentrations: 50 μM FeCl3 in 0.12 M HCl (filter sterile), 20 μM CaCl2, 10 μM MnCl2, 
10 μM ZnSO4, 2 μM CoCl2, 2 μM CuCl2, 2 μM NiCl2, 2 μM Na2MoO4, 2 μM Na2SeO3, 2 μM 
H3BO3. 
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Table A.8: Additives used in crystal additive screens 
Additive Final Concentration 
Cobalt(II) chloride hexahydrate 10 mM 
Copper(II) chloride dihydrate 10 mM 
Manganese(II) chloride tetrahydrate 10 mM 
Zinc chloride 10 mM 
Potassium chloride 100 mM 
Sodium chloride 200 mM 
Potassium sodium tartrate tetrahydrate 100 mM 
Sodium citrate tribasic dihydrate 100 mM 
Cesium chloride 100 mM 
Sodium malonate pH 7.0 100 mM 
L-Proline 10 mM 
Dimethyl sulfoxide 3 % 
Glycine 100 mM 
Sarcosine 10 mM 
Guanidine hydrochloride 100 mM 
Urea 10 mM 
Ethylenediaminetetraacetic acid disodium salt dihydrate 10 mM 
Polyethylene glycol 3,350 1 % 
D-(+)-Glucose monohydrate 3 % 
Sucrose 3 % 
D-Sorbitol 3 % 
Glycerol 3 % 
Polyethylene glycol 400 5 % 
Ethanol 3 % 
2-Propanol 3 % 
Methanol 3 % 
Acetonitrile 4 % 
Acetone 4 % 
1-Butanol 0.7 % 
2-Mercaptoethanol 10 % 
Arginine 10 mM 
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Appendix B: Gene & Protein Information  
B.1 M. smegmatis vapB, vapC & 16S Genomic Information 
Amplicon gene sequences with forward and reverse primer sequences shown in red, followed 
by the amplicons size and melt temperature (Tm) as determined by RT-qPCR using SYTO82 
dye. 
  
MS_1283 VapB (255bp) 
ATGGCTCTAAGCATCAAACACCCGGAAGCCGACCGGCTGGCCAGAGAGCTAGCGGCA
CGTACGGGGGAGACACTGACCGAGGCGGTGGTGATGGCACTGCGGGAGCGACTGGCG
CGCACTGTCGGCCGCACTCAGGTCGTTCCGCTTCGTGAGGAACTCGCCGCGATCCGT
CGTCGCTGCGCAGCCCTACCGGTGTTGGACGACCGGACAGCCGAATCGATCCTGGGC
TACGACGACCGCGGTCTGCCGTCCTGA 
 
Size:155bp 
Tm: 92.7 - 93 C 
 
MS_1284 VapC (390bp) 
ATGGTTATCGACACTTCTGCCCTCGTTGCCATCTTGACCGACGAACCCGACGCCGAG
TTGTTGGAGGGGGCGGTGGCTGACGATCCTGTTCGGACTATGTCCACCGCGTCGTAT
CTGGAGACAGCGATCGTGATCGAAAGTCGCTTCGGCGAGCCAGGTGGTCGCGAACTC
GATCTGTGGTTGCATCGCGCATCAGTGGCACTGGTCGCTGTGGATGCCGATCAGGCC
GACGCCGCCCGGTTGGCTTACCGGAGATACGGCAAGGGGCGCCATCGTGCAGGCCTG
AATTACGGCGACTGTTTTTCCTATGCGCTCGCCAAGGTCAGCGGTCAGCCTTTGTTG
TTCAAGGGCGAGGCTTTTCGGCTCACCGACGTCGCTGCGGTCCACTGA 
 
Size:231bp 
Tm: 91.8 - 92 C 
 
rrsA&B 16S (1528bp) 
TTTTTGTTTGGAGAGTTTGATCCTGGCTCAGGACGAACGCTGGCGGCGTGCTTAACA
CATGCAAGTCGAACGGAAAGGCCCTTTCGGGGGTACTCGAGTGGCGAACGGGTGAGT
AACACGTGGGTGATCTGCCCTGCACTTTGGGATAAGCCTGGGAAACTGGGTCTAATA
CCGAATACACCCTGCTGGTCGCATGGCCTGGTAGGGGAAAGCTTTTGCGGTGTGGGA
TGGGCCCGCGGCCTATCAGCTTGTTGGTGGGGTGATGGCCTACCAAGGCGACGACGG
GTAGCCGGCCTGAGAGGGTGACCGGCCACACTGGGACTGAGATACGGCCCAGACTCC
TACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGCAAGCCTGATGCAGCGACG
CCGCGTGAGGGATGACGGCCTTCGGGTTGTAAACCTCTTTCAGCACAGACGAAGCGC
AAGTGACGGTATGTGCAGAAGAAGGACCGGCCAACTACGTGCCAGCAGCCGCGGTAA
TACGTAGGGTCCGAGCGTTGTCCGGAATTACTGGGCGTAAAGAGCTCGTAGGTGGTT
TGTCGCGTTGTTCGTGAAAACTCACAGCTTAACTGTGGGCGTGCGGGCGATACGGGC
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AGACTAGAGTACTGCAGGGGAGACTGGAATTCCTGGTGTAGCGGTGGAATGCGCAGA
TATCAGGAGGAACACCGGTGGCGAAGGCGGGTCTCTGGGCAGTAACTGACGCTGAGG
AGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACG
GTGGGTACTAGGTGTGGGTTTCCTTCCTTGGGATCCGTGCCGTAGCTAACGCATTAA
GTACCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGC
CCGCACAAGCGGCGGAGCATGTGGATTAATTCGATGCAACGCGAAGAACCTTACCTG
GGTTTGACATGCACAGGACGCCGGCAGAGATGTCGGTTCCCTTGTGGCCTGTGTGCA
GGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAAC
GAGCGCAACCCTTGTCTCATGTTGCCAGCACGTTATGGTGGGGACTCGTGAGAGACT
GCCGGGGTCAACTCGGAGGAAGGTGGGGATGACGTCAAGTCATCATGCCCCTTATGT
CCAGGGCTTCACACATGCTACAATGGCCGGTACAAAGGGCTGCGATGCCGTGAGGTG
GAGCGAATCCTTTCAAAGCCGGTCTCAGTTCGGATCGGGGTCTGCAACTCGACCCCG
TGAAGTCGGAGTCGCTAGTAATCGCAGATCAGCAACGCTGCGGTGAATACGTTCCCG
GGCCTTGTACACACCGCCCGTCACGTCATGAAAGTCGGTAACACCCGAAGCCGGTGG
CCTAACCCTTGTGGAGGGAGCCGTCGAAGGTGGGATCGGCGATTGGGACGAAGTCGT
AACAAGGTAGCCGTACCGGAAGGTGCGGCTGGATCACCTCCTTTCT 
 
Size:234bp 
Tm: 89.7 C 
 
B.2 Housekeeping Gene Information 
Table B.1: HK genes tested, and the reason for their rejection as housekeepers. 
HK Gene Reason for Rejection 
Msmeg_0930 poor expression 
ftsZ variable expression 
guanylate kinase poor expression 
metC poor expression 
oxcA poor & variable expression 
rpoB variable expression 
rpsB 
variable expression & multiple 
products 
sigA variable expression 
sigH variable expression 
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B.3 Pentaprobe Sequences + Flanking Vector Sequence 
Sequences represent the RNA sequence that will be transcribed from the T7 promoter 
(excludes the T7 promoter). Yellow highlighting corresponds to the pentaprobe sequence. 
 
922 + Flanking Sequences 
AGACCCAAGCTTGGTACCGGAATTCTACGAATTTTTCTTTTGTTTATTTCCTTTCGCTTTGC 
TTCTCTTCCCTTCGGTTCTGTTCCGTTTTACCTTGTCTTGCCTTATCTTACTTTATCTAGAG 
GGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCT 
 
923 + Flanking Sequences 
AGACCCAAGCTTGGTACTATCTTACTTTAGTTTCATTTAATTGTGTTGTACTCTCCTCTGCG 
TTCACTTAGCTTAACTTGGTTTGGCTTGATTTGACTTCAGTTGCGCTCTATTCTATCTAGAG 
GGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCT 
 
924 + Flanking Sequences 
AGACCCAAGCTTGGTACCGCTCTATTCTACTGTCCTGTGCATTCAATCGTTGAGTTCGATCT 
AGTCTCGTCTAACCCTCCCCTGCTCCGCTGGTCTGGCCTCGCCTATCCTACCCATTCTAGAG 
GGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCT 
 
925 + Flanking Sequences 
AGACCCAAGCTTGGTACTATCCTACCCATTGGGCTCATCTGATCCATCCGGTCCCGTCCACT 
CGGCTATGTTATGCTGTATTGCAGTCGTGTCGCGTCGAGCTGCCCTAATCCCACCTCTAGAG 
GGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCT 
 
926 + Flanking Sequences 
AGACCCAAGCTTGGTACCGAGCTCGGATCCACTAGTAACGGCCGCCAGTGTGCTGGAATTCT 
GCAGATCCTAATCCCACCTAGCGTATCGGGTCATGTAGTGCTACGTTACGGCCCCCGCCCGG 
CATCATATTATATCACCCCAGTGTAATGTGGTGTGAGGTTGGAGCATCACACTGGCGGCCGC 
TCGAGCATGCATCTAGAGGGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCT 
 
927 + Flanking Sequences 
AGACCCAAGCTTGGTACGTGAGGTTGGAGTCCGACCTGGAATCTCAGCCTGACGTGCCATGC 
GGTGCGATGTCACGCCGCGCCACGGTATAGTATGGTACGGGATCCCGTCTAGAGGGCCCTAT 
TCTATAGTGTCACCTAAATGCTAGAGCTCGCT 
 
932 + Flanking Sequences (932 = reverse complement to 926) 
AGACCCAAGCTTGGTACCGAGCTCGGATCCACTAGTAACGGCCGCCAGTGTGCTGGAATTCT 
GCAGATCTCCAACCTCACACCACATTACACTGGGGTGATATAATATGATGCCGGGCGGGGGC 
CGTAACGTAGCACTACATGACCCGATACGCTAGGTGGGATTAGGCATCACACTGGCGGCCGC 
TCGAGCATGCATCTAGAGGGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCT 
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B.4 932 RNA Oligonucleotide Design 
 
Figure B.1: Design and predicted secondary structure of 932 RNA oligonucleotides 1 - 9. Figure taken 
from McKenzie 2011. ‘Energy’ refers to G values for each of the oligos.  
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Appendix C: Results  
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C.1 Robot Crystallisation Screen Results 
Table C.1: Promising robot screen crystalisation conditions 
 
Well # Condition 
Rv2530 
c 
Rv2530 
a/c 
Rv2530 
a/c SEC 
8 - 14 
Rv2530 
a/c SEC 
17 - 23 
C = A1 
0.02 M Calcium chloride dihydrate, 0.1 M Sodium acetate trihydrate pH 4.6, 30 % (+/-)-2-
Methyl-2,4-pentanediol 
    
C = A12 0.2 M Magnesium chloride hexahydrate, 0.1 M HEPES sodium pH 7.5, 30 % propanol     
C = B2 
0.2 M Calcium chloride dihydrate, 0.1 M HEPES sodium pH 7.5, 28 % Polyethylene glycol 
400 
    
C = B12 0.2 M Calcium chloride dihydrate, 0.1 M Sodium acetate trihydrate pH 4.6, 20 % 2-Propanol     
C = C1 0.1 M Imidazole pH 6.5, 1.0 M sodium acetate trihydrate     
C = C10 0.1 M Sodium acetate trihydrate pH 4.6, 2.0 M Sodium formate     
C = D8 0.2 M Magnesium formate dihydrate     
C = D9 0.2 M Zinc acetate dihydrate, 0.1 M sodium cacodylate trihydrate pH 6.5, 18 % PEG 8000     
C = E1 2.0 M Sodium chloride, 10 % PEG 6000    P 
C = E5 2.0 M Ammonium sulphate, 5 % propanol    P 
C = E11 
0.01 M Cobalt(II) chloride hexahydrate, 0.1 M Sodium acetate trihydrate pH 4.6, 1.0 M 1,6-
Hexanediol  
    
C = G3 
0.01 M Zinc sulfate heptahydrate, 0.1 M MES monohydrate pH 6.5, 25%  Polyethylene 
glycol monomethyl ether 550 
    
C = G5 0.5 M Ammonium sulfate, 0.1 M HEPES pH 7.5, 30% (+/-)-2-Methyl-2,4-pentanediol     
C = G7 0.1 M HEPES pH 7.5, 20% Jeffamine M-600     
I = B2 0.1 M BIS-TRIS pH 6.5, 0.5 M Magnesium formate dihydrate     
I = D12 
0.2 M Calcium chloride dihydrate, 0.1 M BIS-TRIS pH 5.5, 45% (+/-)-2-Methyl-2,4-
pentanediol    
    
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I = E1 
0.2 M Calcium chloride dihydrate, 0.1 M BIS-TRIS pH 6.5, 45 % (+/-)-2-Methyl-2,4-
pentanediol 
    
I = E2 0.2 M Ammonium acetate, 0.1 M BIS-TRIS pH 5.5, 45 % (+/-)-2-Methyl-2,4-pentanediol     
I = E3 0.2 M Ammonium acetate, 0.1 M BIS-TRIS pH 6.5, 45% (+/-)-2-Methyl-2,4-pentanediol     P   
I = F3 
5 % Tacsimate pH 7.0, 0.1 M HEPES pH 7.0, 10 % Polyethylene glycol monomethyl ether 
5,000 
    
I = H9 0.05 M Zinc acetate dihydrate, 20% Polyethylene glycol 3,350     
S = C9 1.2 M DL-Malic acid pH 7.0, 0.1 M BIS-TRIS propane pH 7.0 P    
S = E11 0.5 M Succinic acid pH 7.0, 0.1 M BIS-TRIS propane pH 7.0    P 
S = F8 0.8 M Lithium sulfate monohydrate, 0.1 M BIS-TRIS propane pH 7.0     
S = G2 1.0 M Magnesium sulphate hydrate, 0.1 M BIS-TRIS propane pH 7.0     
S = G3 1.0 M Magnesium sulfate hydrate, 0.1 M Tris pH 8.5     
S = G5 1.8 M Magnesium sulfate hydrate, 0.1 M BIS-TRIS propane pH 7.0     
S = G6 1.8 M Magnesium sulfate hydrate, 0.1 M Tris     
S = H1 0.6 M Potassium sodium tartrate tetrahydrate, 0.1 M  BIS-TRIS propane pH 7.0    P 
P = A4 0.1 M Sodium acetate trihydrate pH 4.5, 30% Polyethylene glycol 300  P   
P = A8 0.1 M MES monohydrate pH 6.0, 22 % Polyethylene glycol 400     
P = B12 0.1 M Tris pH 8.0, 30 % PEG MME 2000    P 
P = D7 0.1 M Sodium acetate trihydrate pH 4.5, 10 % PEG 10000    P 
P = E3 0.05 M Calcium chloride dihydrate, 0.1 M MES monohydrate pH 6.0, 45% PEG 200 P    
P = E7 0.2 M Ammonium acetate, 0.1 M Sodium citrate tribasic dihydrate pH 5.5, 24 % PEG 400    P 
P = E12 
0.15 M DL-Malic acid pH 7.0, 0.1 M Imidazole pH 7.0, 22% Polyethylene glycol monomethyl 
ether 550 
    
P = F5 0.2 M L-Proline, 0.1 M HEPES pH 7.5, 24 % Polyethylene glycol 1,500     
P = F7 0.1 M Sodium chloride, 0.1 M BIS-TRIS propane pH 9.0, 25 % PEG 1500    P 
P = G12 10 % 2-Propanol, 0.1 M Sodium acetate trihydrate pH 4.0, 22 % Polyethylene glycol 6,000     
Table indicates robot crystalisation screen conditions which either produced crystals () or showed promise (P) by day 49. Letters in bold indicate which crystallisation plate the 
well belonged to: Crystal, Index, Salt or PEG.  
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C.2 Confirmation of the top 10 Rangipo SNPs 
 
Figure C.1: Sequencing results of the top 10 SNPs PCR amplified from Rangipo isolate S, aligned against 
H37Rv to confirm the presence of each SNP. 
. 
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Appendix D: Raw Data 
Raw data for Chapters Three, Four and Five can be found on compact disc at the back of this 
thesis. Contents include: 
 
Chapter Three - WGS identification of putative Rangipo specific SNPs  
- Excel table of 247 putative Rangipo specific SNPs, their positions relative to the H37Rv 
genome, and findings from the database trawling 
 
Chapter Four - M. smegmatis wt vapB and vapC RT-qPCR data post DNP stress (Figure 4.5) 
- Rotor-Gene 6000 file: Syto 82 2009-04-16 (1) 2009-07-21 (1).rex 
- LinRegPCR file: Linreg output.xls 
Note, during the course of this research the nomenclature of vap genes changed from PIN to 
vap, so in the raw data, PINT = vapC and PINAT = vapB. 
 
Chapter Five - TB VapBC cloning information, and MALDI-TOF MS RNA Oligos Data 
- 47 TB VapBC gene sequences with cloning information 
- VapCRv2530c MALDI-TOF MS raw data and analysis files 
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Appendix E: Publications 
 
